

## JOINTLY SPONSORED STATEMENT

### **Accreditation Statement:**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Temple University School of Medicine and The College on Problems of Drug Dependence. Temple University School of Medicine is accredited by the ACCME to sponsor Continuing Medical Education for physicians.

### **Certification Statement:**

Temple University School of Medicine designates this live activity for a maximum of 22 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Disclosure Policy:**

It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D, Office of Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.

If you have special needs that we can address to make your participation more meaningful and enjoyable, please contact our office at (215) 707-3242.



## **TARGET AUDIENCE**

Physicians, Residents/Fellows, Physician Assistants, Nurses, Medical Students

## **OBJECTIVES**

Upon completion of this course, participants should be able to

- 1) critically evaluate current treatments for drug dependence
- 2) cite the latest findings in epidemiology, prevention and advances in treatment of drug abuse and dependence
- 3) select appropriate therapeutic approaches to dealing with issues of dependence to a variety of abused substances

## **QUALIFYING SYMPOSIA AND WORKSHOPS FOR CME CREDITS**

### **Sunday, June 16**

SI: (2:15-4:20 PM) NMDA antagonists: Therapeutic implications and abuse liability

**2 CREDITS**

SII: (2:15-4:20 PM) What do we really know about the impacts of medical marijuana?  
Research exploring policies across America

**2 CREDITS**

WI: (8-10 PM) The intertwining epidemics of drug use and HIV/AIDS: The HIV/AIDS  
workgroup

**2 CREDITS**

WII: (8-10 PM) Assessment of abuse of deterrent and tamper-resistant technologies.

Part II: New Directions

**2 CREDITS**

### **Monday, June 17**

SIII: (10 AM-12:05 PM) The interaction between alcohol and other drugs of abuse:  
From neurobiology to clinical implications

**2 CREDITS**

SIV: (10 AM-12:05 PM) New directions in the pharmacological facilitation of  
psychotherapy for drug dependence

**2 CREDITS**

SV: (1:50-2:55 PM) New science and tools to improve the diagnosis, prevention and  
treatment of hepatitis C virus and its sequelae

**1 CREDIT**

SVI: (1:50-2:55 PM) Sex hormone modulation of nicotine reward: Effects on urges,  
affect, physiological response, and brain activation

**1 CREDIT**

SVIII: (3:05-4:10 PM) Pharmacotherapeutic targeting of glutamatergic signaling in the  
reversal of addiction pathology

**1 CREDIT**

WVI: (8-10 PM) The 19th Annual Contingency Management Working Group

**2 CREDITS**

WVII: (8-10 PM) Take-home naloxone to address opioid overdose: State of the evidence  
and methods

**2 CREDITS**

WVIII: (8-10 PM) The interplay of the juvenile justice and adolescent treatment systems  
and how to use evidenced-based assessment, treatment and implementation practices to  
improve outcomes

**2 CREDITS**

WIX: (8-10 PM) Evaluating and minimizing the risk, misuse and diversion of  
prescription drug use in youth

**2 CREDITS**

## **Tuesday, June 18**

SIX: (10 AM-12:05 PM) Preclinical to clinical evidence that glia and neuroinflammation mediate drug abuse and related pathologies **2 CREDITS**

SX: (10 AM-12:05 PM) Substance use: Health and social effects in older drug users: What we know and we don't **2 CREDITS**

Animals in Research Forum (12:15-1:45 PM) **1.5 CREDITS**

WX: (8-10 PM) How to get your addiction research manuscripts published: Guidelines for emerging investigators **2 CREDITS**

WXI: (8-10 PM) Findings from introduction of reformulated opioid analgesics on patterns of abuse and diversion of prescription opioids and their surveillance **2 CREDITS**

WXIII: (8-10 PM) Novel tobacco and nicotine products and regulatory science **2 CREDITS**

WXIV: (8-10 PM) Are we missing the mark with gender differences, women substance users, and social determinants for HIV risk? Lessons from around the globe **2 CREDITS**

WXV: (8-10 PM) Approaches for screening and treating risky drug using patients in community health centers **2 CREDITS**

## **Wednesday, June 19**

SXI: (9:55 AM -12) Emerging data on efficacy and clinical applications of extended release naltrexone formulations **2 CREDITS**

SXII: (9:55 AM -12) Behavioral disinhibition, drugs of abuse, and brain dysfunction in humans and rodent models **2 CREDITS**

SXIII: (2:10- 4:15 PM) New tools provide new insights into methamphetamine's actions **2 CREDITS**

SXIV: (2:10- 3:15 PM) This is your brain before drugs: Neuroimaging high-risk youth **1 CREDIT**

SXV: (3:25- 4:30 PM) Use it AND lose it: Impact of a pharmacological pot pourri on the developing brain **1 CREDIT**

## **Thursday, June 14**

SXVI: (9:30-11:35 AM) Brain functional connectivity as a biomarker for stimulant abuse **2 CREDITS**

SXVII: (9:30-11:35 AM) Cannabis: From plants to rats, monkeys and human **2 CREDITS**

<b>REGISTRATION FOR CME CREDITS IS \$95. THE FEE INCLUDES 1-22 CREDITS MAXIMUM</b>
--

# FACULTY DISCLOSURES

It is the policy of Temple University School of Medicine, Office for Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all its individually sponsored educational programs. All faculty participating in any Temple University sponsored programs are expected to disclose to the program audience **ANY** real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturer, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. **ALL** faculty for the **CPDD 75<sup>th</sup> Annual Scientific Meeting being held June 15-20, 2013** have provided disclosure information. Listed below are those faculty who have indicated a relationship with a commercial company. Such disclosure should not be construed as a conflict of interest, but, rather as a disclosure of a current or previous financial arrangement. All other faculty have indicated they do not have a financial relationship to disclose.

Patrick M. Beardsley, Ph.D.

**GRANT/RESEARCH SUPPORT:**

**CONSULTANT:**

Reckitt-Benckiser

Eli Lilly & Co., Grunenthal

Sandra D. Comer

**GRANT/RESEARCH SUPPORT:**

**CONSULTANT:**

Reckitt Benckiser, MediciNova

Pfizer, MediciNova, Salix

Steven Shoptaw, Ph.D.

**OTHER:**

Pfizer, MediciNova

Keith Heinzerling, M.D.

**GRANT/RESEARCH SUPPORT:**

Pfizer, MediciNova

Professor Selena Bartlett

**STOCKHOLDER:**

Commonwealth Bank of Australia

Ivan Diamond, M.D., Ph.D.

**CONSULTANT:**

Gilead

**STOCKHOLDER:**

Gilead

Ingunn Hansdottir

**GRANT/RESEARCH SUPPORT:**

Alkermes

A/Prof Nicholas Lintzeris

**GRANT/RESEARCH SUPPORT:**

United Education Grant from Reckitt Benckiser

Michelle Lofwall, M.D.

**GRANT/RESEARCH SUPPORT:**

National Institute on Drug Abuse

**OTHER:**

PCM Scientific

George E. Woody, M.D.

**GRANT/RESEARCH SUPPORT:**

Alkermes

Wilson Compton, M.D., Co-Chair

**STOCKHOLDER:**

GE, Pfizer

Alain Litwin, M.D., MPH

**GRANT/RESEARCH SUPPORT:**

Vertex

**CONSULTANT:**

Janssen

Athina Markou

**GRANT/RESEARCH SUPPORT:**

Bristol-Myers-Squibb

Deborah S. Hasin, M.D.

**OTHER:**

Cathy Spatz Widom, Ph.D.

**GRANT/RESEARCH SUPPORT:**

Sidney Schnoll

**CONSULTANT:**

Theodore J. Cicero, M.D.

**GRANT/RESEARCH SUPPORT:**

Rajita Sinha, Ph.D.

**SPEAKERS' BUREAU:**

Lawrence Carter

**STOCKHOLDER:**

**OTHER:**

Jack E. Henningfield

**CONSULTANT:**

Marta Sokolowska, Ph.D.

**OTHER:**

Kerri Schoedel

**OTHER:**

Edward J. Cone

**CONSULTANT:**

Naama Levy-Cooperman

**GRANT/RESEARCH SUPPORT:**

Simon Budman, Ph.D.

**GRANT/RESEARCH SUPPORT:**

**CONSULTANT:**

Stephen F. Butler, Ph.D.

**GRANT/RESEARCH SUPPORT:**

**CONSULTANT:**

**STOCKHOLDER:**

Howard Chilcoat

**OTHER:**

Richard Dart, M.D., Ph.D.

**OTHER:**

James L. Sorensen, Ph.D.

**OTHER:**

Traci Green

**SPEAKERS' BUREAU:**

Elsevier, Publishing, Associate Editor of  
Drug & Alcohol Dependence

Eunice Kennedy Shriver, Doris Duke  
Charitable Foundation

Pinney Associates (Shire & Noven)

RADARS

Spouse Dr. Guarnaccia – TEVA,  
Accord, Pfizer, Serono, Bayer, Abbott  
Self – Scientific Advisory Board for  
Embry Neurotherapeutics

Jazz Pharmaceuticals, NPS, Orexigen,  
Theravance, Vivus, Amarin, Zogenix,  
Hemispherix  
Employee of Jazz Pharmaceuticals

Pinney Associates – GlaxoSmithKline

Employed by Grunenthal USA Inc.

Employee of Inc. Research  
Spouse – Employee of Bayer

Aegis, OraSure Technology  
**OTHER:** Consultant/Part Time  
employee Pinney Associates, Employee  
of Purdue Pharmaceuticals L.P.

Inc. Research

Endo, Purdue, NJN, Shire  
Zogenix, Pfizer

Janssen, Purdue, Endo, Shire,  
NIDA/NIH  
Janssen, Zogenix  
Inflexxion

Employee of Purdue

Employee of Denver Health

Member of Board of Directors

Association of Medical Education and  
Research in Substance Abuse

Eric Strain

**GRANT/RESEARCH SUPPORT:  
CONSULTANT:**

Fast Track Drugs, Biologics  
Transcept, Analgestic, AACTION,  
The Oak Group, Shire, Pinney  
Associates, Salix  
Starbucks, PepsiCo, var. mutual funds

**STOCKHOLDER:**

Robert L. Balster

**GRANT/RESEARCH SUPPORT:  
CONSULTANT:**

Reckitt Benckiser  
Consumer Healthcare Products  
Association, Jurox, Merz

Alexander Y. Walley

**CONSULTANT:**

Social Sciences Innovations Corp

Sheila M. Bird

**GRANT/RESEARCH SUPPORT:**

Co-principal investigator for MRC-  
funded pilot N-ALIVE Trial  
Examining the Effectiveness of  
Naloxone to reduce opiate overdose  
GSK

**SPEAKERS' BUREAU:**

**STOCKHOLDER:**

Therese A. Kosten

**CONSULTANT:**

Reckitt Benckiser

Sharon Allen, M.D.

**GRANT/RESEARCH SUPPORT:**

Please see attached Biosketch

Valgerdur Runarsdottir

**GRANT/RESEARCH SUPPORT:**

Alkermers

Mark E. Montebello, M.D.

**GRANT/RESEARCH SUPPORT:**

New South Wales Ministry of Health  
Research Grant  
Pfizer

**SPEAKERS' BUREAU:**

Jennifer M. Loftis, Ph.D.

**OTHER:**

Department of Veterans Affairs and  
Oregon Health & Science University  
own a technology to be discussed in this  
presentation (a particular MHC/  
neuroantigen peptide construct). The  
Department of Veterans Affairs, OHSU,  
and Dr. Loftis have rights to the  
royalties from the licensing agreement  
with Artielle (the company that has  
licensed the technology). These  
potential conflicts of interest have been  
reviewed and managed by the Conflict  
of Interest Committees at the Portland  
VA Medical Center and Oregon Health  
& Science University.

Rae R. Matsumoto

**GRANT/RESEARCH SUPPORT:  
CONSULTANT:**

Avanir  
Avanir

The planning committee and staff of the Office of Continuing Medical Education have provided disclosure information and indicated they do not have any financial relationships to disclose. All conflicts have been resolved.



## BOARD OF DIRECTORS

Richard De La Garza, II, PhD, President  
Scott E. Lukas, PhD, Past-President  
Frank Vocci, Jr., PhD, President-Elect  
Theodore J. Cicero, PhD, Treasurer  
Michael T. Bardo, PhD  
Lawrence S. Brown, MD, MPH  
Alan J. Budney, PhD  
Sandra D. Comer, PhD  
Andrew Coop, PhD  
Linda B. Cottler, PhD, MPH

Linda A. Dwoskin, PhD  
Linda A. Dykstra, PhD  
Carl L. Hart, PhD  
Stephen T. Higgins, PhD  
Leonard L. Howell, PhD  
Mary Jeanne Kreek, MD  
A. Thomas McLellan, PhD  
Gregory M. Miller, PhD  
Roger D. Spealman, PhD

## EXECUTIVE OFFICER

Martin W. Adler, PhD

## DIRECTOR, EXECUTIVE OFFICE

Ellen B. Geller, MA

## SCIENTIFIC PROGRAM COMMITTEE

Sandra D. Comer, PhD, Chair  
Elise Weerts, PhD, Chair-Elect  
Martin W. Adler, PhD, *ex officio*  
Ellen B. Geller, MA, *ex officio*  
Mary E. Abood, PhD  
Adam Bisaga, MD  
Linda B. Cottler, PhD, MPH  
William E. Fantegrossi, PhD  
Deborah S. Hasin, PhD  
Leonard Howell, PhD  
Wendy Lynch, PhD  
William W. Stoops, PhD  
George E. Woody, MD



## PRE-MEETING SATELLITES

*Sixth Meeting of the International Women's and Children's and Gender Group*

Chaired by Frances E. Ashe-Goins and Wendee Wechsberg

**Sapphire 410**

June 14

*The 2013 NIDA International Forum: Building International Collaborative Research on Drug Abuse*

Chaired by Steven Gust

**Sapphire 411/412 and Aqua 313/314**

June 14

**Sapphire I/J/M/N**

June 15

*The International Study Group Investigating Drugs as Reinforcers (ISGIDAR)*

Chaired by William Fantegrossi

**Sapphire 410**

June 15

*Substance Abuse and Mental Health Services Administration/ National Institute on Drug Abuse*

Chaired by Linda Kaplan

**Aqua 306**

June 15

## CPDD REGISTRATION

**Sapphire 400**

**Saturday, June 15**

**1:30 PM - 5:30 PM**

**Sunday, June 16**

**8:00 AM - 11:30 AM  
12:30 PM - 5:00 PM**

**Monday, June 17**

**8:00 AM - 12:00 PM  
1:30 PM - 5:00 PM**

**Tuesday, June 18**

**8:00 AM - 12:00 PM  
3:30 PM - 5:00 PM**

**Wednesday, June 19**

**8:00 AM - 12:00 PM  
2:00 PM - 5:00 PM**

**Thursday, June 14**

**8:00 AM - 12:00 PM**

## OPENING RECEPTION

**Promenade (Cash Bar)**

**Saturday, June 15**

**7:00 PM - 9:00 PM**  
*(Pre-registrants can pick up badges only)*

**Plenary Session**

**INDIGO BCFG  
8:15 - 11:15 AM**

- 8:15 *Welcome, CPDD President*  
Richard De La Garza, II, Baylor College of Medicine, Houston, TX
- 8:30 *Report from the National Institute on Drug Abuse*  
Nora Volkow, NIDA, Bethesda, MD
- 9:00 *Presentation of the CPDD/NIDA Media Award to David Sheff*  
Introduction By Marc Kaufman
- 9:15 *Presentation of the J. Michael Morrison Award to Redonna Chandler*  
Introduction by Michael Dennis
- 9:25 *Presentation of the Joseph Cochin Young Investigator Award to William Stoops*  
Introduction by Craig Rush
- 9:35 *Presentation of the Mentorship Award to James Sorensen*  
Introduction by Howard Newville
- 9:45 *Presentation of the Nathan B. Eddy Award to Linda Dykstra*  
Introduction by Kathryn Cunningham
- 9:55 *Nathan B. Eddy Award Lecture: In Search of a Better Analgesic*  
Linda Dykstra, University of North Carolina, Chapel Hill, NC

**CPDD Travel Awardees Luncheon**  
(By Invitation Only)

**ELEVATION  
11:30 - 1:00 PM**

**President's Lecture**

**INDIGO BCFG  
1:00 - 2:00 PM<sup>1</sup>**

- 1:00 Functional Integration: Questions and Answers*  
Nora D. Volkow, NIDA

**Symposium I**

**INDIGO A  
2:15 - 4:20 PM**

**NMDA ANTAGONISTS: THERAPEUTIC IMPLICATIONS  
AND ABUSE LIABILITY**

Chairs: William Fantegrossi and Robert Balster

- 2:15 *75th Anniversary Reflections*
- 2:20 *Rapid and sustained antidepressant effects of ketamine: Therapeutic implications*  
Mark Niciu, NIMH Intramural Program, Bethesda, MD
- 2:40 *Role of sigma receptors in antidepressant-like effects of ketamine*  
Rae R. Matsumoto, West Virginia University, Morgantown, VA
- 3:05 *The role of NMDA glutamate receptors in models of abuse vulnerability*  
J S. Beckmann, University of Kentucky, Lexington, KY
- 3:30 *Novel eticyclidine analogues as emerging drugs of abuse*  
William Fantegrossi, University of Arkansas School of Medicine, Little Rock, AR
- 3:55 *Discussant: Historical perspectives on NMDA antagonists as drugs of abuse and as therapeutics*  
Robert Balster, Virginia Commonwealth University, Richmond, VA

## **Symposium II**

**INDIGO E**  
**2:15 - 4:20 PM**

### **WHAT DO WE REALLY KNOW ABOUT THE IMPACTS OF MEDICAL MARIJUANA? RESEARCH EXPLORING POLICIES ACROSS AMERICA**

Chairs: Marsha Lopez and Bethany Deeds

- 2:15 *75th Anniversary Reflections*
- 2:20 *Medical marijuana in Denver, Colorado: Voices from the industry*  
R E. Booth, University of Colorado School of Medicine, Denver, CO
- 2:45 *Medical marijuana dispensaries and marijuana use: Evidence from 50 cities in California*  
Bridget Freisthler, UCLA Department of Social Welfare, Luskin School of Public Affairs, Los Angeles, CA
- 3:10 *Behavioral economic analysis of therapeutic and non-therapeutic marijuana use in HIV/AIDS patients*  
Mark K. Greenwald, Wayne State University School of Medicine, Detroit, MI
- 3:35 *The impact of medical marijuana policies on public health*  
Rosalie Liccardo Pacula, Rand Corporation, Santa Monica, CA
- 4:00 *Discussant*  
Deborah S. Hasin, Columbia University, New York State Psychiatric Institute, New York, NY

## **Oral Communications 1**

**INDIGO D**  
**2:15 - 4:20 PM**

### **ADDICTION AND PAIN—HARD TO EXPLAIN**

Chairs: Michelle R. Lofwall and Kelly E. Dunn

- 2:15 *75th Anniversary Reflections*
- 2:20 *Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens*  
M. Pravetoni<sup>1,2,3</sup>, M. Le Naour<sup>4</sup>, A. M. Tucker<sup>1</sup>, T. Harmon<sup>1</sup>, P. S. Portoghese<sup>4,3</sup>, P. R. Pentel<sup>1,2,3</sup>,  
<sup>1</sup>Minneapolis Medical Research Foundation, Minneapolis, MN, <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN, <sup>3</sup>Pharmacology, University of Minnesota, Minneapolis, MN, <sup>4</sup>Medicinal Chemistry, University of Minnesota, Minneapolis, MN
- 2:35 *Synergy of Group III mGluR-selective agonist and morphine in sensitized peripheral fibers*  
A. Baker<sup>1,2</sup>, S. M. Carlton<sup>1</sup>, <sup>1</sup>Neuroscience and Cell Biology, UTMB, Galveston, TX, <sup>2</sup>MD-PhD Combined Degree Program, UTMB, Galveston, TX
- 2:50 *Abuse potential and analgesic effects of oxymorphone in prescription opioid abusers*  
S. Babalonis<sup>1,2</sup>, M. R. Lofwall<sup>1,2,3</sup>, P. A. Nuzzo<sup>2</sup>, A. J. Siegel<sup>3</sup>, S. L. Walsh<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky (UK), Lexington, KY, <sup>2</sup>Center on Drug and Alcohol Research, UK, Lexington, KY, <sup>3</sup>Psychiatry, UK, Lexington, KY
- 3:05 *Is pain associated with illicit opioid use or aberrant opioid-related behaviors in opioid substitution treatment patients*  
S. Nielsen<sup>1</sup>, B. Larance<sup>2</sup>, N. Lintzeris<sup>3,1</sup>, E. Black<sup>2</sup>, R. Bruno<sup>4</sup>, B. Murnion<sup>1</sup>, A. Dunlop<sup>5</sup>, L. Degenhardt<sup>2</sup>, <sup>1</sup>University of Sydney, Sydney, NSW, Australia, <sup>2</sup>NDARC, Sydney, NSW, Australia, <sup>3</sup>SESLHD, Sydney, NSW, Australia, <sup>4</sup>University of Tasmania, Hobart, TAS, Australia, <sup>5</sup>HNEAHS, Newcastle, NSW, Australia

- 3:20 *Chronic pain and coping strategies within methadone and buprenorphine-maintained patients*  
K. E. Dunn, P. Finan, D. A. Tompkins, A. A. Chaudhry, M. Fingerhood, E. C. Strain,  
Department of Psychiatry, Johns Hopkins University, Baltimore, MD
- 3:35 *Buprenorphine/naloxone for the treatment of prescription opioid abuse and chronic pain*  
M. A. Sullivan, J. M. Manubay, S. K. Vosburg, J. D. Jones, Z. D. Cooper, J. Fogel,  
J. W. Davidson, S. D. Comer, Psychiatry, Columbia University/NYSPI, New York, NY
- 3:50 *Prevalence of psychiatric disorders among treatment-seeking individuals with co-occurring chronic pain and opioid dependence*  
D. Barry<sup>1,2</sup>, C. J. Cutter<sup>1,2</sup>, M. Beitel<sup>1,2</sup>, C. Liong<sup>2</sup>, R. S. Schottenfeld<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>APT Foundation Pain Treatment Services, New Haven, CT
- 4:05 *Sex differences in VA patients with chronic pain*  
M. B. Weimer<sup>1</sup>, T. A. Macey<sup>2</sup>, C. Nicolaidis<sup>1,3</sup>, S. Dobscha<sup>2,4,5</sup>, B. J. Morasco<sup>2,4,5</sup>, <sup>1</sup>Department of Medicine, Oregon Health and Science University, Portland, OR, <sup>2</sup>Department of Psychiatry, Oregon Health and Science University, Portland, OR, <sup>3</sup>Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, <sup>4</sup>Mental Health and Clinical Neurosciences Division, Portland VA Medical Center, Portland, OR, <sup>5</sup>Portland Center for the Study of Chronic, Comorbid Mental and Physical Disorders, Portland VA Medical Center, Portland, OR

## Oral Communications 2

**INDIGO H**  
**2:15 - 4:20 PM**

### HE SAID, SHE SAID: GENDER DIFFERENCES

Chairs: James Sorensen and Reagan R. Wetherill

- 2:15 *75th Anniversary Reflections*
- 2:20 *The impact of gender and motivation on perceptions of nonmedical use of prescription stimulants*  
S. J. Lookatch<sup>1</sup>, T. Moore<sup>1</sup>, E. C. Katz<sup>2</sup>, <sup>1</sup>Department of Psychology, University of Tennessee, Knoxville, TN, <sup>2</sup>Department of Graduate Studies and Research, Towson University, Towson, MD
- 2:35 *Gender differences in risk perceptions of very low nicotine content cigarettes*  
D. L. Joel<sup>1</sup>, D. K. Hatsukami<sup>2</sup>, L. Hertsgaard<sup>2</sup>, S. S. Dermody<sup>1</sup>, E. C. Donny<sup>1</sup>, <sup>1</sup>Psychology, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Psychiatry, University of Minnesota, Minneapolis, MN
- 2:50 *Sex differences in brain responses to smoking cues: A perfusion fMRI study*  
R. R. Wetherill, K. A. Young, K. Jagannathan, J. Shin, C. P. O'Brien, A. Childress, T. R. Franklin, University of Pennsylvania, Philadelphia, PA
- 3:05 *Gender differences in state-dependent affective brain function and motivations to smoke*  
B. Froeliger<sup>1</sup>, F. J. McClernon<sup>1</sup>, K. M. Gray<sup>2</sup>, M. E. Saladin<sup>2</sup>, <sup>1</sup>Psychiatry, Duke University Medical Center, Durham, NC, <sup>2</sup>Psychiatry, Medical University of South Carolina, Charleston, SC
- 3:20 *Gender modifying effects on the association between stress and craving*  
J. H. Kim, S. Martins, J. Santaella, D. S. Hasin, Epidemiology, Mailman School of Public Health, New York, NY

- 3:35 *Gender differences in anxiety sensitivity and sensation-seeking in relation to risk-taking on the Balloon Analogue Risk Task (BART)*  
G. Kurdziel, A. Collado-Rodriguez, J. M. Townsend, L. MacPherson, C. W. Lejuez,  
Psychology, University of Maryland, College Park, MD
- 3:50 *Poorer parental monitoring is associated with cocaine exposure in early adolescence in girls but not boys*  
E. Mansoor<sup>1</sup>, V. H. Accornero<sup>1</sup>, J. C. Anthony<sup>2</sup>, L. Xue<sup>1</sup>, C. Morrow<sup>1</sup>, E. Bandstra<sup>1</sup>, <sup>1</sup>Pediatrics,  
University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Epidemiology, Michigan State  
University, East Lansing, MI
- 4:05 *Differences by gender identity for individuals in substance abuse treatment*  
A. Flentje<sup>1</sup>, N. C. Heck<sup>2</sup>, J. L. Sorensen<sup>1</sup>, <sup>1</sup>University of California, San Francisco, San  
Francisco, CA, <sup>2</sup>The University of Montana, Missoula, MT

### Late-Breaking Research

**INDIGO BCFG**  
**4:30 - 5:30 PM**

Chair: Sandra Comer

### Primm-Singleton Travel Awardees Meeting

**AQUA 310**  
**5:30 - 7:30 PM**

### Workshop I

**INDIGO H**  
**8:00 - 10:00 PM**

#### **THE INTERTWINING EPIDEMICS OF DRUG USE AND HIV/AIDS: THE HIV/AIDS WORKGROUP**

Chairs: Don C. Des Jarlais, James Sorensen and Adam W. Carrico

*Public housing relocations and biobehavioral risks of HIV among substance misusers: A longitudinal multilevel study of African-American adults*  
Hannah L. Cooper, Emory University, Atlanta, GA

*Drug treatment experiences among female sex workers and their non-commercial partners along the Mexico-U.S. border*  
Daniel O. Hernandez, University of California at San Diego, La Jolla, CA

*Effects of HIV and cocaine on impulsive decision-making: Implications for HIV prevention*  
Christina S. Meade, Duke University, Durham, NC

*Association between substance use patterns and HIV medication adherence among HIV-positive older adults*  
Jeffrey T. Parsons, Hunter College and the Graduate Center of the City University of New York, New York, NY

*Levamisole-contaminated cocaine use is associated with lower levels of prealbumin and white blood cell count in HIV-infected homeless women*  
Elise D. Riley, University of California at San Francisco, San Francisco, CA

*Crack-cocaine and HIV: Multiple factors of a "perfect storm" in New York City*  
Don C. Des Jarlais, Beth Israel Medical Center, New York, NY

---

**Sunday, June 16, 2013**

---

*Chronic hepatitis C virus infection is associated with all-cause mortality in a cohort of HIV-infected patients with alcohol problems*

Daniel Fuster, Boston Medical Center and Boston School of Medicine, Boston, MA

## **Workshop II**

**INDIGO 202**  
**8:00 - 10:00 PM**

### **ASSESSMENT OF ABUSE-DETERRENT AND TAMPER-RESISTANT TECHNOLOGIES PART II: NEW DIRECTIONS**

Chairs: Marta Sokolowska and Kerri A. Schoedel

*Regulatory perspective on abuse-deterrent formulations*

Michael Klein, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD

*In vitro assessment of abuse-deterrent formulations*

Edward J. Cone, Pinney Associates, Johns Hopkins University, School of Medicine, Baltimore, MD

*Clinical assessment of abuse-deterrent formulations*

Naama Levy-Cooperman, INC Research, Toronto, ON, Canada

*Epidemiological confirmation of abuse deterrence*

Simon Budman, Inflexxion, Newtown, MA

*New Guidance: Two steps forward or one step back?*

Edward M. Sellers, DL Global Partners, Inc, Toronto, ON, Canada

## **Workshop III**

**INDIGO A**  
**8:00 - 10:00 PM**

### **ANIMAL MODELS OF SEX DIFFERENCES AND DRUG ABUSE: MIND THE GAPS**

Chairs: Suzette M. Evans and Cora Lee Wetherington

*Sex influences on brain and emotional memory: The burden of proof has shifted*

Larry Cahill, University of California, Irvine, Irvine, CA

*The contribution of social and environmental variables in our understanding of sex differences in substance abuse*

Michael Nader, Wake Forest University School of Medicine, Winston-Salem, NC

*Sex and phenotypic variables affecting drug abuse and its treatment*

Justin Anker, Butler Center for Research, Hazelden Foundation, Center City, MN

*Sex differences in triggers to relapse and pharmacological interventions in an animal model of addiction*

Carmela M. Reichel, Medical University of South Carolina, Charleston, SC

*The translation challenge from animals to humans and back: Successes and gaps*

Rajita Sinha, Yale University School of Medicine, New Haven, CT



---

**Sunday, June 16, 2013**

---

## **Workshop IV**

**INDIGO E  
8:00 - 10:00 PM**

### **HOW ARE WE DOING? MEASURING QUALITY OF CARE FOR ADOLESCENT SUBSTANCE ABUSE TREATMENT**

Chairs: Beth Ann Griffin and Rajeev Ramchand

*Overview to measuring quality of substance abuse treatment for adolescents*

Mady Chalk, Treatment Research Institute, Philadelphia, PA

*Washington Circle engagement performance measures' association with adolescent treatment outcomes*

Deborah W. Garnick, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, MA

*Identifying facility-level quality of care indicators that are linked to outcomes for adolescent substance abuse treatment programs*

Rajeev Ramchand, RAND Corporation, Arlington, VA

*Programs are not created equal: Using a consumer guide to adolescent treatment to assess the availability and receipt of effective treatment components among teens*

Kathleen Meyers, John S. Cacciola, Treatment Research Institute, Philadelphia, PA

*Discussant*

Hannah K. Knudsen, University of Kentucky, Lexington, KY

## **Workshop V**

**INDIGO D  
8:00 - 10:00 PM**

### **EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS**

**(IF YOU HAVE A WIRELESS-EQUIPPED OR BLUETOOTH-EQUIPPED LAPTOP  
OR SMARTPHONE, PLEASE BRING IT TO THIS WORKSHOP SESSION)**

Chairs: J. C. Anthony and Georgiy Bobashev

*Introduction*

J. C. Anthony, Michigan State University, East Lansing, MI

*Reductionist and systems methods in the analysis of complex data*

Georgiy Bobashev, RTI International, Research Triangle Park, NC

*National addiction and HIV Data Archive Program: Promise and prospects*

Amy Pienta, University of Michigan, Ann Arbor, MI

*20 years of methods for research on cannabis smoking in the Netherlands during an era of policy change*

C. Kaplan, University of Southern California School of Social Work, Los Angeles, CA

*Accessing restricted-use data from the U.S. National Survey on Drug Use and Health (NSDUH)*

Jonaki Bose, SAMHSA/CBHSQ, Rockville, MD

*Discussion*

J. C. Anthony, Michigan State University, East Lansing, MI

## Poster Session I

(Breakfast)

Odd-numbered posters manned first hour;

Even-numbered, second hour

SAPPHIRE

8:00 - 10:00 AM

Set-up time begins Sunday 1:00 PM

Must be removed by Monday 12:00 NOON

### STIMULANTS — ANIMALS I

- 1 *Rewarding effects of synthetic cathinones*  
M. McPhaul, N. Gaytan, R. Shetty, M. B. Gatch, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX
- 2 *More “bath salts”: Discriminative and locomotor effects of synthetic cathinones*  
M. J. Forster, M. Rutledge, C. Taylor, C. Elsken, E. Flores, M. B. Gatch, UNT Health Science Center, Fort Worth, TX
- 3 *Methylphenidate self-administration increases the potency and reinforcing effects of releasers through a dopamine transporter mechanism*  
E. Calipari<sup>1</sup>, M. J. Ferris<sup>1</sup>, A. Salahpour<sup>2</sup>, M. G. Caron<sup>3</sup>, D. C. Roberts<sup>1</sup>, S. R. Jones<sup>1</sup>, <sup>1</sup>Wake Forest School of Medicine, Winston-Salem, NC, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Duke University Medical Center, Durham, NC
- 4 *Methylphenidate dose response characteristics of caudate nucleus neuronal activity correlated with animal behavior*  
C. Claussen, N. Dafny, Neurobiology and Anatomy, UT Houston, Houston, TX
- 5 *Dose-response characteristics of nucleus accumbens neurons as assessed based on the animals behavioral response to chronic methylphenidate treatment*  
N. Dafny, C. Claussen, Neurobiology and Anatomy, University of Texas Health Science Center at Houston, Houston, TX
- 6 *Chronic methylphenidate and long-term effects on adult female WKY rats*  
S. Kohlleppe, T. Trinh, N. Dafny, Neurobiology and Anatomy, UT Houston, Houston, TX
- 7 *Chronic methylphenidate elicits long-term effects in adolescent female WKY rats*  
T. Trinh, N. Dafny, UT Houston, Houston, TX
- 8 *Concurrent choice between cues for social interaction and amphetamine in adolescent male and female rats*  
J. R. Yates<sup>1</sup>, F. C. Jennings<sup>1</sup>, J. S. Beckmann<sup>1</sup>, A. C. Meyer<sup>2</sup>, M. T. Bardo<sup>1</sup>, <sup>1</sup>Psychology, University of Kentucky, Lexington, KY, <sup>2</sup>Psychiatry, University of Vermont, Burlington, VT
- 9 *Dopamine systems in adolescent and adult brain respond differently to methamphetamine*  
B. K. Madras, E. J. Vallender, T. Walsh, G. M. Miller, S. Westmoreland, NEPRC, Harvard Medical School, Southborough, MA
- 10 *Stimulants as specific inducers of dopamine-independent sigma agonist self-administration*  
T. Hiranita<sup>1,2</sup>, P. L. Soto<sup>3</sup>, G. Tanda<sup>1</sup>, J. L. Katz<sup>1</sup>, <sup>1</sup>Psychobiol Sec, NIDA/IRP/NIH/DHHS, Baltimore, MD, <sup>2</sup>Dept Psychol Neurosci, Univ. Colorado at Boulder, Boulder, CO, <sup>3</sup>Behav Biol Res Center, Johns Hopkins Univ Med Sch, Baltimore, MD
- 11 *Multiple schedules as a model to test cue effects of drug and natural reinforcers*  
W. T. McCuddy, J. S. Beckmann, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY



- 12 *Effects of lipopolysaccharides on dopamine-related behavior of methamphetamine*  
M. Shibasaki, D. Masukawa, T. Imai, T. Mori, T. Suzuki, Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan
- 13 *The effects of a low and escalating dosing regimen of methamphetamine on spontaneous behaviors of rhesus macaques (Macaca mulatta)*  
J. Jiang, J. Capitanio, Department of Psychology and California National Primate Research Center, University of California, Davis, Davis, CA
- 14 *Habituation of the reinforcing effectiveness of sensory stimuli: Effects of methamphetamine and nicotine*  
D. R. LLOYD, J. B. Richards, State University of New York at Buffalo, Research Institute on Addictions, Buffalo, NY
- 15 *Rats that self-administer methamphetamine show Parkinson's disease-like inflammation and  $\alpha$ -synuclein neuropathology*  
A. Persons, S. Kousik, L. P. Kelly, S. M. Graves, T. C. Napier, Dept. of Pharmacology and Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL
- 16 *Agmatine modifies some behavioral effects of methamphetamine in rats*  
J. Li, D. A. Thorn, Pharmacology and Toxicology, University at Buffalo, Buffalo, NY
- 17 *Differential cognitive impairments induced by methamphetamine and/or HIV gp120 expression in the mouse*  
J. P. Kesby, A. Markou, S. Semenova, Psychiatry, University of California San Diego, La Jolla, CA
- 18 *Circadian disruption increases methamphetamine consumption in methamphetamine-dependent rats*  
S. E. Doyle<sup>1</sup>, H. Feng<sup>2</sup>, G. Garber<sup>1</sup>, M. Menaker<sup>1</sup>, W. J. Lynch<sup>1</sup>, <sup>1</sup>Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, <sup>2</sup>Biology, University of Virginia, Charlottesville, VA
- 19 *Combining active and passive antibody therapy to facilitate initiation and long-term treatment of methamphetamine abuse in a rat model of addiction*  
M. D. Hambuchen, D. Rüedi-Bettschen, L. J. Hennings, S. M. Owens, University of Arkansas for Medical Sciences, Little Rock, AR
- 20 *Active vaccination inhibits the acquisition of methamphetamine self-administration in rats*  
M. L. Miller<sup>1</sup>, A. Y. Moreno<sup>2</sup>, S. Aarde<sup>1</sup>, K. Creehan<sup>1</sup>, K. Janda<sup>2</sup>, M. A. Taffe<sup>1</sup>, <sup>1</sup>Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, <sup>2</sup>Chemistry, Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA
- 21 *Anti-methamphetamine vaccine attenuates brain levels and locomotor activity of methamphetamine in mice*  
X. Shen<sup>1</sup>, F. M. Orson<sup>1</sup>, T. A. Kosten<sup>2</sup>, B. M. Kinsey<sup>1</sup>, W. Yan<sup>1</sup>, X. Wang<sup>1</sup>, T. R. Kosten<sup>2</sup>, <sup>1</sup>Medicine, Baylor College of Medicine, Houston, TX, <sup>2</sup>Psychiatry, Baylor College of Medicine, Houston, TX

### SEDATIVE HYPNOTICS

- 22 *Enhancement of benzodiazepines on abused drug-induced hyperlocomotion*  
D. Masukawa, M. Shibasaki, T. Mori, T. Suzuki, Dept. Toxicol, Hoshi Univ. Sch. Pharm. Pharmaceut. Sci., Tokyo, Japan

- 23 *Role of  $\alpha 3$ GABA<sub>A</sub> receptor modulation in the anti-conflict effects of benzodiazepine-type drugs in monkeys*  
E. K. Sawyer<sup>1</sup>, B. D. Fischer<sup>2</sup>, Z. Meng<sup>1</sup>, M. M. Poe<sup>3</sup>, O. A. Namjoshi<sup>3</sup>, J. M. Cook<sup>3</sup>, J. K. Rowlett<sup>1</sup>, <sup>1</sup>New England Primate Research Center, Harvard Medical School, Southborough, MA, <sup>2</sup>Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, <sup>3</sup>Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI
- 24 *What's loneliness got to do with it? Older women's use of benzodiazepines*  
S. L. Canham, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

### PAIN

- 25 *Effect of gender on pain sensitivity and tolerance in adolescents during acute abstinence*  
K. S. Bagot<sup>1,2</sup>, R. Wu<sup>2</sup>, D. A. Cavallo<sup>2</sup>, S. Krishnan-Sarin<sup>2</sup>, <sup>1</sup>Child Study Center, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Psychiatry, Yale University School of Medicine, New Haven, CT
- 26 *Sex differences among opioid-abusing chronic pain patients in a clinical trial*  
J. M. Manubay<sup>1,2</sup>, J. W. Davidson<sup>1</sup>, S. K. Vosburg<sup>1,2</sup>, J. D. Jones<sup>1,2</sup>, Z. D. Cooper<sup>1,2</sup>, J. Fogel<sup>2</sup>, S. D. Comer<sup>1,2</sup>, M. Sullivan<sup>1,2</sup>, <sup>1</sup>Psychiatry, Columbia University, New York, NY, <sup>2</sup>Substance Abuse, NYSPI, New York, NY
- 27 *Depression, pain catastrophizing and pain tolerance in opioid-dependent patients*  
J. I. Tsui<sup>1</sup>, J. Samet<sup>1</sup>, J. M. Liebschutz<sup>1</sup>, M. Alcorn<sup>1</sup>, D. Alford<sup>1</sup>, J. Mao<sup>3</sup>, R. R. Edwards<sup>2</sup>, <sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Brigham and Womens Hospital, Boston, MA, <sup>3</sup>Massachusetts General Hospital, Boston, MA
- 28 *Content validation of the prescription opioid misuse, abuse, and diversion (MAD) instrument in the chronic pain patient population*  
B. Setnik<sup>1</sup>, C. L. Roland<sup>1</sup>, K. S. Coyne<sup>2</sup>, A. I. Barsdorf<sup>3</sup>, <sup>1</sup>Pfizer Inc, Cary, NC, <sup>2</sup>United BioSource Corporation, Bethesda, MD, <sup>3</sup>Pfizer Inc, New York, NY
- 29 *Increasing preoperative sleep reduces postoperative pain and analgesic use*  
T. Roehrs<sup>1,2</sup>, S. Randall<sup>1</sup>, T. Roth<sup>1,2</sup>, <sup>1</sup>Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI, <sup>2</sup>Psychiatry & Behavioral Neuroscience, Wayne State University, Detroit, MI
- 30 *Feasibility, acceptability, and initial efficacy of pain management groups in methadone maintenance treatment*  
M. Beitel<sup>1,2</sup>, C. J. Cutter<sup>1,2</sup>, R. S. Schottenfeld<sup>1</sup>, J. D. Savant<sup>1</sup>, B. A. Moore<sup>1</sup>, C. Liong<sup>2</sup>, D. Barry<sup>1,2</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>APT Foundation Pain Treatment Services, New Haven, CT

### SYNTHETIC COMPOUNDS FOR THERAPEUTICS

- 31 *The discovery of the first opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors*  
V. B. Journigan<sup>1</sup>, W. E. Polgar<sup>2</sup>, L. Toll<sup>3</sup>, T. V. Khroyan<sup>2</sup>, N. T. Zaveri<sup>1</sup>, <sup>1</sup>Astraea Therapeutics, Mountain View, CA, <sup>2</sup>SRI International, Menlo Park, CA, <sup>3</sup>Torrey Pines Institute, Port St. Lucie, FL

- 32 *Structural modifications to tetrahydropyridine-3-carboxylate esters towards the discovery of M5-preferring muscarinic receptor antagonists as novel treatments for drug abuse*  
L. P. Dwoskin<sup>1</sup>, A. M. Smith<sup>1</sup>, X. Huan<sup>2</sup>, K. Subramanian<sup>2</sup>, K. B. Siripurapu<sup>1</sup>, A. Deaciuc<sup>1</sup>, X. Huang<sup>1</sup>, C. G. Zhan<sup>1</sup>, G. Zheng<sup>2</sup>, <sup>1</sup>Pharmaceutical Sciences, University of Kentucky, Lexington, KY, <sup>2</sup>Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR
- 33 *KK-92A, a novel GABA B receptor positive modulator, attenuates the rewarding effects of nicotine in rat*  
X. Li<sup>1</sup>, K. Kaczanowska<sup>2</sup>, E. Sturchler<sup>3</sup>, M. Southern<sup>3</sup>, M. Cameron<sup>3</sup>, P. McDonald<sup>3</sup>, M. G. Finn<sup>2</sup>, P. Griffin<sup>3</sup>, A. Markou<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>The Scripps Research Institute, La Jolla, CA, <sup>3</sup>The Scripps Research Institute, Jupiter, FL
- 34 *Discriminative stimulus effects of a novel epibatidine analog RTI-102 in mice*  
F. B. Moura<sup>1</sup>, C. S. Cunningham<sup>1</sup>, L. McMahon<sup>1</sup>, F. I. Carroll<sup>2</sup>, P. Ondachi<sup>2</sup>, <sup>1</sup>Pharmacology, UTHSCSA, San Antonio, TX, <sup>2</sup>Center for Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC
- 35 *Synthesis of 10-fluoroalkyl-dihydrotetrabenazines as potential positron emission tomography-imaging agents for vesicular monoamine transporter type II*  
L. Hsin<sup>1,2</sup>, J. Katz<sup>3</sup>, T. Kopajtic<sup>3</sup>, C. Yang<sup>2</sup>, Y. Chen<sup>2</sup>, <sup>1</sup>Molecular Imaging Center, National Taiwan University, Taipei, Taiwan, <sup>2</sup>School of Pharmacy, National Taiwan University, Taipei, Taiwan, <sup>3</sup>Psychobiology Section, NIDA-IRP, Baltimore, MD
- 36 *Development of selective orexin-1 receptor antagonists*  
Y. Zhang<sup>1</sup>, D. Perrey<sup>1</sup>, N. German<sup>1</sup>, B. P. Gilmour<sup>1</sup>, J. Li<sup>2</sup>, B. F. Thomas<sup>1</sup>, <sup>1</sup>Research Triangle Institute, Research Triangle Park, NC, <sup>2</sup>University at Buffalo, Buffalo, NY

### CLUB DRUGS

- 37 *Efficacy of brief treatment for ecstasy use*  
M. Norberg, L. Khawar, J. Copeland, J. Olivier, University of New South Wales, Sydney, NSW, Australia
- 38 *Sex differences of MDMA metabolism in squirrel monkeys: A comparison to findings in humans*  
M. Mueller, J. Yuan, U. McCann, G. Ricaurte, Johns Hopkins, Baltimore, MD
- 39 *Age differences in (±)3,4-methylenedioxymethamphetamine (MDMA)-induced conditioned taste aversions and monoaminergic activity*  
J. L. Cobuzzi<sup>1</sup>, K. A. Siletti<sup>1</sup>, Z. E. Hurwitz<sup>1</sup>, B. Wetzell<sup>1</sup>, M. H. Baumann<sup>2</sup>, A. L. Riley<sup>1</sup>, <sup>1</sup>Psychology Department, American University, Washington, DC, <sup>2</sup>Translational Pharmacology Section, IRP, NIDA, Baltimore, MD
- 40 *Patterns and settings of 3, 4-methylenedioxymethamphetamine (MDMA) use at dance parties in Japan*  
T. Shimane<sup>1</sup>, Y. Hidaka<sup>2</sup>, K. Wada<sup>1</sup>, M. Funada<sup>1</sup>, <sup>1</sup>Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, <sup>2</sup>Takarazuka University School of Nursing, Osaka, Japan
- 41 *Role of dopamine system in expressing behavioral and cytotoxicological properties of MDPV in mice*  
M. Funada, K. Tomiyama, K. Wada, Dept. of Drug Dependence Research, NIMH, NCNP, Kodaira, Japan

- 42 *The differential expression of MDPV-induced conditioned taste aversions, thermoregulation and monoamine levels in adolescent and adult rats: A behavioral and neurochemical assessment of "bath salts"*  
A. P. Merluzzi<sup>1</sup>, Z. E. Hurwitz<sup>1</sup>, M. A. Briscione<sup>1</sup>, J. L. Cobuzzi<sup>1</sup>, B. Wetzell<sup>1</sup>, K. C. Rice<sup>2</sup>, A. L. Riley<sup>1</sup>, <sup>1</sup>Psychology, American University, Washington, DC, <sup>2</sup>Chemical Biology Research Branch, National Institute on Drug Abuse, Bethesda, MD
- 43 *The role of serotonin 2A and 2C receptors in tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine*  
T. Carbonaro<sup>1,2</sup>, M. J. Forster<sup>1</sup>, M. B. Gatch<sup>1</sup>, <sup>1</sup>Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, <sup>2</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX
- 44 *Biochemical, histopathological and behavioral changes after single and repeated inhalation of a local Egyptian glue*  
A. A. Elkoussi, M. A. Nicola, M. M. Yosry, Pharmacology, College of Medicine, University of Assiut, Assiut, Egypt
- 45 *Pharmacokinetics and subjective effects of inhaled salvinorin A, a kappa-opioid agonist hallucinogen present in the plant Salvia divinorum*  
K. A. MacLean<sup>1</sup>, M. W. Johnson<sup>1</sup>, M. Caspers<sup>2</sup>, T. Prisinzano<sup>2</sup>, R. R. Griffiths<sup>1</sup>, <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>The University of Kansas, Lawrence, KS
- 46 *Characterization of challenging experiences (i.e., bad trips) after ingesting psilocybin*  
M. P. Bradstreet<sup>1</sup>, M. W. Johnson<sup>1</sup>, K. A. MacLean<sup>1</sup>, R. R. Griffiths<sup>1,2</sup>, <sup>1</sup>Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD
- 47 *Emerging synthetic and natural psychoactive drugs in South Florida's club scene: Users' demographic and health risk profiles*  
S. P. Kurtz, M. Buttram, H. Surratt, C. L. O'Grady, ARSH: Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL

### GENETICS

- 48 *High genetic risk for methamphetamine intake in mice relates to perturbations in neurotransmission in medial prefrontal cortex and nucleus accumbens*  
K. K. Szumlanski<sup>1</sup>, D. Maliniak<sup>1</sup>, M. G. Wroten<sup>1</sup>, P. N. Ruiz<sup>1</sup>, K. D. Lominac<sup>1</sup>, T. J. Phillips<sup>2</sup>, <sup>1</sup>University of California Santa Barbara, Santa Barbara, CA, <sup>2</sup>Oregon Health Sciences University, Portland, OR
- 49 *Strain differences in measures of behavioral regulation related to drug abuse in rats*  
J. B. Richards<sup>1</sup>, D. R. Lloyd<sup>1</sup>, B. Kuehlewind<sup>1</sup>, L. Militello<sup>1</sup>, M. Paredes<sup>1</sup>, A. A. Palmer<sup>2</sup>, <sup>1</sup>Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY, <sup>2</sup>Department of Human Genetics, The University of Chicago, Chicago, IL
- 50 *Association of the prodynorphin gene promoter repeat polymorphism with basal prolactin level in normal human male volunteers*  
V. Yuferov, A. J. Brownstein, E. Ducat, M. Randesi, A. Ho, M. J. Kreek, The Rockefeller University, New York, NY
- 51 *Fatty acid amide hydrolase gene variant influences acute responses to cocaine*  
C. D. Verrico<sup>1</sup>, D. A. Nielsen<sup>1</sup>, C. J. Spellicy<sup>1</sup>, S. C. Hamon<sup>2</sup>, T. R. Kosten<sup>1</sup>, T. F. Newton<sup>1</sup>, R. De La Garza, II<sup>1</sup>, <sup>1</sup>Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine & Michael E. DeBakey V.A. Medical Center, Houston, TX, <sup>2</sup>Laboratory of Statistical Genetics, The Rockefeller University, New York, NY

- 52 *No association between crack-cocaine dependence and functional intronic polymorphism at dopamine D2 receptor gene*  
T. Roman<sup>1</sup>, A. R. Stolf<sup>2</sup>, G. C. Akutagava-Martins<sup>1</sup>, D. Müller<sup>1</sup>, J. B. Schuch<sup>1</sup>, L. S. Guimarães<sup>2</sup>, F. Pechansky<sup>2</sup>, F. H. Kessler<sup>2</sup>, <sup>1</sup>Department of Genetics, UFRGS, Porto Alegre, Brazil, <sup>2</sup>Center for Drug and Alcohol Research, UFRGS, Porto Alegre, Brazil
- 53 *Crack-cocaine users show differences in genotype frequencies of the dopamine transporter gene (DAT1/SLC6A3) 3'UTR variable number of tandem repeats*  
A. R. Stolf<sup>1</sup>, G. C. Akutagava-Martins<sup>2</sup>, D. Müller<sup>2</sup>, L. S. Guimarães<sup>1</sup>, F. H. Kessler<sup>1</sup>, F. Pechansky<sup>1</sup>, T. Roman<sup>2</sup>, <sup>1</sup>Center for Drug and Alcohol Research, UFRGS, Porto Alegre, Brazil, <sup>2</sup>Department of Genetics, UFRGS, Porto Alegre, Brazil
- 54 *Association between  $\alpha$ -1 adrenergic receptor (ADRA1A) genotype and subjective cocaine effect in cocaine-dependent individuals*  
D. Shorter<sup>1,2</sup>, D. A. Nielsen<sup>1,2</sup>, T. F. Newton<sup>1,2</sup>, R. De La Garza, II<sup>1,2</sup>, T. R. Kosten<sup>1,2</sup>, <sup>1</sup>Psychiatry, Michael E. DeBakey VA Medical Center, Houston, TX, <sup>2</sup>Menninger Department of Psychiatry and Behavioral Science, Baylor College of Medicine, Houston, TX
- 55 *Subjective effects produced by cocaine are in association with genetic variants of DAT1*  
A. Brewer<sup>1,2</sup>, D. A. Nielsen<sup>1,2</sup>, C. J. Spellicy<sup>2</sup>, S. C. Hamon<sup>3</sup>, J. Gingrich<sup>2</sup>, J. J. Mahoney<sup>2</sup>, T. R. Kosten<sup>1,2</sup>, T. F. Newton<sup>2</sup>, R. De La Garza, II<sup>1,2</sup>, <sup>1</sup>Department of Pharmacology, Baylor College of Medicine, Houston, TX, <sup>2</sup>Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, <sup>3</sup>Laboratory of Statistical Genetics, The Rockefeller University, New York, NY
- 56 *Interaction of gender and genetics in response to cocaine vaccine*  
C. J. Spellicy<sup>1,3</sup>, D. A. Nielsen<sup>1,3</sup>, S. C. Hamon<sup>2</sup>, T. R. Kosten<sup>1,3</sup>, M. J. Harding<sup>1,3</sup>, <sup>1</sup>Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, <sup>2</sup>Laboratory of Statistical Genetics, The Rockefeller University, New York, NY, <sup>3</sup>Michael E. DeBakey V.A. Medical Center, Houston, TX
- 57 *Attenuation of depressive symptoms associated with MTHFR during a cocaine vaccine trial*  
T. R. Shutter<sup>1,2</sup>, D. Shorter<sup>1,2</sup>, D. A. Nielsen<sup>1,2</sup>, T. R. Kosten<sup>1,2</sup>, <sup>1</sup>Psychiatry and Behavioral Science, Baylor College of Medicine, Houston, TX, <sup>2</sup>Psychiatry and Behavioral Science, MED-VAMC, Houston, TX
- 58 *Weaker relationships among substance use and negative consequences in a Native-American treatment-seeking sample*  
K. Venner<sup>1,3</sup>, K. Hagler<sup>1,3</sup>, B. Greenfield<sup>1,3</sup>, B. K. Guis<sup>1</sup>, J. D. Simmons<sup>1,3</sup>, D. Lupee<sup>2,4</sup>, R. Currier<sup>4,2</sup>, E. Homer<sup>2,4</sup>, Y. Yamutewa<sup>2,4</sup>, F. Lesansee<sup>4</sup>, J. S. Tonigan<sup>3,1</sup>, <sup>1</sup>Psychology, University of New Mexico, Albuquerque, NM, <sup>2</sup>Pueblo of Zuni MICRA Project, Pueblo of Zuni, NM, <sup>3</sup>Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, Albuquerque, NM, <sup>4</sup>Zuni Recovery Center, Pueblo of Zuni, NM
- 59 *Heritability of cannabis and tobacco use initiation: Findings from a genetically informative female twin cohort*  
S. A. Dinovo, M. T. Lynskey, P. Madden, K. K. Bucholz, A. C. Heath, A. Agrawal, Psychiatry, Washington University in St. Louis, St. Louis, MO

### PRESCRIPTION DRUG ABUSE

- 60 *Cue-induced craving in prescription opioid and heroin dependence*  
R. McHugh<sup>1,2</sup>, S. Park<sup>1</sup>, R. Weiss<sup>1,2</sup>, <sup>1</sup>Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA, <sup>2</sup>Department of Psychiatry, Harvard Medical School, Boston, MA
- 61 *Trauma histories of non-treatment-seeking prescription opioid-dependent individuals*  
J. McCauley, M. A. Mercer, K. T. Brady, S. E. Back, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC



- 62 *Association of mental distress and non- medical prescription drug use: Gender differences in the National Monitoring of Prescription Stimulant Study (N-MAPSS)*  
S. O. Lasopa, L. Cottler, C. Warren, Epidemiology, University of Florida, Gainesville, FL
- 63 *A longitudinal study of adolescent girls' medical misuse and non-medical use of CNS depressants*  
E. A. Meier, Q. Epstein-Ngo, P. T. Veliz, S. E. McCabe, C. J. Boyd, Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI
- 64 *Personality characteristics of young adult, non-medical prescription opioid users in central Ohio*  
R. Falck, R. W. Nahhas, R. Daniulaityte, R. G. Carlson, Community Health, Wright State University Boonshoft School of Medicine, Dayton, OH
- 65 *Chronic disease as a predictor of prescription medication misuse: Findings from a self-report study*  
S. B. Varner<sup>1</sup>, G. Villalobos<sup>1</sup>, M. Weaver<sup>2</sup>, D. Svikis<sup>3</sup>, <sup>1</sup>Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Internal Medicine, Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Psychology, Virginia Commonwealth University, Richmond, VA
- 66 *Using prescription drug monitoring data to predict prescription opioid misuse*  
D. L. Levin<sup>1,2</sup>, D. Paone<sup>2</sup>, E. Tuazon<sup>2</sup>, E. Goldmann<sup>2</sup>, G. Li<sup>1</sup>, S. Martins<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York, NY, <sup>2</sup>Bureau of Alcohol and Drug Use, Prevention, Care and Treatment, NYC Department of Health and Mental Hygiene, Long Island City, NY
- 67 *Who benefits from more intensive counseling for prescription opioid dependence?*  
R. Weiss<sup>1,2</sup>, M. L. Griffin<sup>1,2</sup>, J. A. Dreifuss<sup>1,2</sup>, D. Dodd<sup>1</sup>, J. S. Potter<sup>3,1,2</sup>, H. Connery<sup>1,2</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Harvard Medical School, Boston, MA, <sup>3</sup>University of Texas Health Science Center, San Antonio, TX
- 68 *Prescription opioid patients in addictions treatment: Characteristics and challenges for treatment providers*  
V. Slaymaker<sup>1</sup>, F. Blow<sup>2</sup>, J. Anker<sup>1</sup>, <sup>1</sup>Hazelden Graduate School of Addiction Studies, Center City, MN, <sup>2</sup>University of Michigan, Ann Arbor, MI
- 69 *Characterizing prescription opioid abusers with and without lifetime heroin use*  
A. C. Meyer, S. C. Sigmon, M. E. Patrick, S. H. Heil, S. T. Higgins, University of Vermont, Burlington, VT
- 70 *Age trends in abuse calls to poison centers involving prescription opioids*  
S. G. Severtson<sup>1</sup>, B. Bucher-Bartelson<sup>1</sup>, R. C. Dart<sup>1,2</sup>, <sup>1</sup>Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, <sup>2</sup>University of Colorado-Denver School of Medicine, Aurora, CO
- 71 *Patterns of Internet discussion associated with the release of abuse-deterrent formulations of prescription opioids*  
E. C. McNaughton, S. F. Butler, S. H. Budman, Inflexxion Inc., Newton, MA
- 72 *Abuse of prescription opioids and illegal drugs after introduction of abuse-deterrent opioid formulations in the NAVIPPRO® surveillance network*  
T. A. Cassidy, S. H. Budman, S. F. Butler, Inflexxion, Inc., Newton, MA
- 73 *Abuse of OxyContin® and immediate-release oxycodone in a rural Kentucky county following introduction of reformulated OxyContin: Results from 6-month follow-up interviews*  
A. DeVaugh-Geiss<sup>1</sup>, C. Leukefeld<sup>2</sup>, J. R. Havens<sup>2</sup>, P. Coplan<sup>1</sup>, H. Kale<sup>1</sup>, H. Chilcoat<sup>1</sup>, <sup>1</sup>Risk Management and Epidemiology, Purdue Pharma, Stamford, CT, <sup>2</sup>University of Kentucky, Lexington, KY

## EPIDEMIOLOGY I

- 74 *WITHDRAWN*
- 75 *Predictors of injection cessation and relapse among female sex workers who inject drugs in two Mexican-U.S. border cities*  
S. Strathdee<sup>1</sup>, D. Abramovitz<sup>1</sup>, G. Rangel<sup>3</sup>, H. Staines<sup>2</sup>, A. H. Vera<sup>1</sup>, M. E. Medina-Mora<sup>5</sup>, H. Amaro<sup>4</sup>, T. L. Patterson<sup>1</sup>, <sup>1</sup>UC San Diego, La Jolla, CA, <sup>2</sup>Universidad Autonoma de Cd Juarez, Cd Juarez, Mexico, <sup>3</sup>Colegio de la Frontera Norte, Tijuana, Mexico, <sup>4</sup>University of Southern California, Los Angeles, CA, <sup>5</sup>Instituto Nacional de Psiquiatria Ramon de la Fuente, Mexico City, Mexico
- 76 *Effects of drug dependence on complications in Medicare elderly prostate cancer patients treated with prostatectomy*  
S. Chhatre<sup>1</sup>, D. Metzger<sup>1</sup>, G. E. Woody<sup>1</sup>, S. B. Malkowicz<sup>2</sup>, R. Jayadevappa<sup>3</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Surgery, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Medicine, University of Pennsylvania, Philadelphia, PA
- 77 *Liver-related deaths in opioid-dependent people in New South Wales, Australia, 1997-2005: Contributions of viral hepatitis and alcohol*  
S. Larney<sup>1,2</sup>, D. Randall<sup>3</sup>, A. Gibson<sup>3</sup>, L. Degenhardt<sup>1</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, <sup>2</sup>Alpert Medical School, Brown University, Providence, RI, <sup>3</sup>Centre for Health Research, University of Western Sydney, Sydney, NSW, Australia
- 78 *Evaluating a rapidly expanding methadone system in China*  
C. Marienfeld<sup>1</sup>, P. Liu<sup>2</sup>, W. Zhou<sup>2</sup>, X. Wang<sup>2</sup>, L. Luo<sup>2</sup>, R. Schottenfeld<sup>1</sup>, M. C. Chawarski<sup>1</sup>, <sup>1</sup>Psychiatry, Yale, New Haven, CT, <sup>2</sup>China CDC, Wuhan, China
- 79 *Measurement of drug-liking in abuse potential studies: A comparison of bipolar vs. unipolar visual analog scales*  
C. L. Roland<sup>1</sup>, B. Setnik<sup>1</sup>, G. C. Pixton<sup>1</sup>, L. Webster<sup>2</sup>, <sup>1</sup>Pfizer Inc, Cary, NC, <sup>2</sup>CRI Lifetree, Salt Lake City, UT
- 80 *Medical marijuana cardholders seen in the Emergency Department*  
M. A. Ilgen<sup>1,2</sup>, A. S. Bohnert<sup>1,2</sup>, K. Barry<sup>1,2</sup>, S. Chermack<sup>1,2</sup>, R. M. Cunningham<sup>3</sup>, M. A. Walton<sup>2</sup>, F. C. Blow<sup>1,2</sup>, <sup>1</sup>VA Serious Mental Illness Treatment Research and Evaluation Center, Department of Veterans Affairs Healthcare System, Ann Arbor, MI, <sup>2</sup>Department of Psychiatry, University of Michigan, Ann Arbor, MI, <sup>3</sup>Department of Emergency Medicine, University of Michigan, Ann Arbor, MI
- 81 *Marijuana users' perceptions of health research*  
F. Webb<sup>1,2</sup>, C. W. Striley<sup>2</sup>, C. Ruktanonchai<sup>2</sup>, L. Cottler<sup>2</sup>, <sup>1</sup>Community Health and Family Medicine, University of Florida, Jacksonville, FL, <sup>2</sup>Epidemiology, University of Florida, Gainesville, FL
- 82 *Differences between younger and older medical marijuana users from a cluster-based sample of dispensaries in Los Angeles*  
C. E. Grella, L. Rodriguez, Integrated Substance Abuse Programs, University of California, Los Angeles, CA

- 83 *California smokin': Tobacco and marijuana use among young adults in California compared to the rest of the U.S*  
D. Ramo<sup>1</sup>, H. Liu<sup>1</sup>, K. Chavez<sup>1,2</sup>, J. J. Prochaska<sup>1,3</sup>, <sup>1</sup>University of California San Francisco, San Francisco, CA, <sup>2</sup>Sonoma State University, Rohnert Park, CA, <sup>3</sup>Stanford University, Stanford, CA
- 84 *Evidence from a cannabis use disorders multiple causes model for the cannabis-tobacco combination known as 'blunts'*  
B. Fairman, J. C. Anthony, Department of Epidemiology, Michigan State University, East Lansing, MI
- 85 *Big five personality traits and smoking persistence over 12 years*  
R. Goodwin<sup>1,2</sup>, A. Bono<sup>1</sup>, <sup>1</sup>Psychology, Queens College, City University of New York, Flushing, NY, <sup>2</sup>Epidemiology, Columbia University, New York, NY
- 86 *Tobacco use disorder and the risk of completed suicide in VHA*  
K. Bohnert<sup>1,2</sup>, M. A. Ilgen<sup>1,2</sup>, J. F. McCarthy<sup>1,2</sup>, R. V. Ignacio<sup>1,2</sup>, F. C. Blow<sup>1,2</sup>, <sup>1</sup>SMITREC, VA Ann Arbor, Ann Arbor, MI, <sup>2</sup>Psychiatry, University of Michigan, Ann Arbor, MI
- 87 *Cigarette smoking among a sample of urban, current and former substance-using, persons living with HIV/AIDS*  
L. R. Pacek<sup>1</sup>, C. Latkin<sup>2</sup>, A. R. Knowlton<sup>2</sup>, <sup>1</sup>Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Health, Behavior & Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
- 88 *Self-reported collision involvement associated with driving after alcohol use, cannabis use or both*  
G. Sayer<sup>1,2</sup>, R. Mann<sup>1,2</sup>, G. Stoduto<sup>1</sup>, C. Wickens<sup>1</sup>, A. Ialomiteanu<sup>1</sup>, B. Brands<sup>3,1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Health Canada, Ottawa, ON, Canada
- 89 *Participation in team sports as related to alcohol and marijuana use growth in youth*  
N. E. Lisha<sup>1</sup>, W. D. Crano<sup>2</sup>, K. Delucchi<sup>1</sup>, <sup>1</sup>Psychiatry, UCSF, San Francisco, CA, <sup>2</sup>SBOS, CGU, Claremont, CA

### PREVENTION

- 90 *Alcohol environment, perceived safety, and exposure to alcohol, tobacco, and other drugs in early adolescence*  
A. J. Milam<sup>1,2</sup>, C. D. Furr-Holden<sup>1</sup>, C. P. Bradshaw<sup>1</sup>, M. C. Cooley<sup>1</sup>, D. W. Webster<sup>1</sup>, P. J. Leaf<sup>1</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>School of Medicine, Wayne State University, Detroit, MI
- 91 *Early initiation of alcohol or marijuana use and nonmedical use of prescription drugs*  
J. D. Haddox<sup>1</sup>, R. M. Weiler<sup>2</sup>, L. N. Pealer<sup>3</sup>, T. E. Barnett<sup>3</sup>, <sup>1</sup>Health Policy, Purdue Pharma L.P., Stamford, CT, <sup>2</sup>Hlth. Educ. & Beh., University of Florida, Gainesville, FL, <sup>3</sup>Beh. Sci. & Comm. Hlth., University of Florida, Gainesville, FL
- 92 *Nationwide survey of collegiate recovery programs: Is there a single model?*  
A. B. Laudet<sup>1</sup>, K. Harris<sup>2</sup>, K. Winters<sup>3</sup>, D. Moberg<sup>4</sup>, T. Kimball<sup>2</sup>, <sup>1</sup>NDRI, NYC, NY, <sup>2</sup>Texas Tech, Lubbock, TX, <sup>3</sup>U. of Minnesota, Minneapolis, MN, <sup>4</sup>U. of Wisconsin, Madison, WI
- 93 *The marginal effects of hazardous alcohol use on the probability of behavioral healthcare utilization among National Guard members*  
C. van den Berk Clark, S. Balan, J. Scherrer, G. Widner, M. Shroff, R. K. Price, Psychiatry, Washington University, St. Louis, MO



- 94 *Current state of U.S. syringe exchange programs: Success, new tasks, the financial crisis and the Affordable Care Act*  
V. Guardino<sup>1</sup>, D. C. Des Jarlais<sup>1</sup>, A. Nugent<sup>1</sup>, D. Purchase<sup>2</sup>, <sup>1</sup>Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York, NY, <sup>2</sup>North American Syringe Exchange Network (NASEN), Tacoma, WA
- 95 *Disseminating prevention through cultural adaptation research with Latino populations*  
R. Parra-Cardona, J. C. Anthony, Michigan State University, East Lansing, MI
- 96 *The association between substance use disorder and racial discrimination in a nationally representative sample*  
S. J. Cousins, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

### HIV/AIDS

- 97 *Self-generation enhances verbal recall in HIV-infected stimulant users*  
E. Weber<sup>1,2</sup>, S. P. Woods<sup>1</sup>, I. Grant<sup>1</sup>, M. Basso<sup>3</sup>, <sup>1</sup>Psychiatry, University of California, San Diego, San Diego, CA, <sup>2</sup>SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, <sup>3</sup>Psychology, University of Tulsa, Tulsa, OK
- 98 *Differences in mood and quality of life indicators by HIV status in a group of methamphetamine-dependent individuals*  
R. Rawson<sup>1</sup>, J. Chudzynski<sup>1</sup>, R. Gonzales-Castaneda<sup>1,2</sup>, A. Ang<sup>1</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>Azuza Pacific University, Azuza, CA
- 99 *Chronic methamphetamine use heightens concurrent risk of functional dependence in persons living with HIV infection*  
K. Blackstone<sup>1</sup>, J. E. Iudicello<sup>2</sup>, E. E. Morgan<sup>2</sup>, E. Weber<sup>1</sup>, D. J. Moore<sup>2</sup>, R. J. Ellis<sup>2</sup>, I. Grant<sup>2</sup>, S. P. Woods<sup>2</sup>, <sup>1</sup>SDSU/UCSD Joint Doctoral Program, San Diego, CA, <sup>2</sup>Psychiatry, UCSD, San Diego, CA
- 100 *Patterns of methamphetamine use vary by age and HIV serostatus*  
J. Montoya<sup>1</sup>, J. Cattie<sup>1</sup>, E. E. Morgan<sup>2</sup>, S. Woods<sup>2</sup>, D. Moore<sup>2</sup>, J. Atkinson<sup>2</sup>, I. Grant<sup>2</sup>, <sup>1</sup>SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, <sup>2</sup>Psychiatry, University of California, San Diego, San Diego, CA
- 101 *Amphetamine use mediates between impulsivity and anal intercourse*  
K. L. Hess, D. G. Fisher, G. L. Reynolds, California State University, Long Beach, Long Beach, CA
- 102 *Loss aversion is associated with cocaine use and risky behavior in HIV-infected adults*  
C. S. Meade<sup>1</sup>, D. A. Young<sup>1</sup>, O. Mullette-Gillman<sup>2</sup>, S. A. Huettel<sup>1</sup>, S. Towe<sup>1</sup>, <sup>1</sup>Duke University, Durham, NC, <sup>2</sup>National University of Singapore, Singapore, Singapore
- 104 *Polydrug use and risk of blood-borne and sexually transmitted infections among heroin IDUs in Tijuana, Mexico*  
M. C. Meacham<sup>1,2</sup>, K. C. Brouwer<sup>1</sup>, M. L. Rusch<sup>1</sup>, T. L. Patterson<sup>1</sup>, M. Lozada<sup>1</sup>, A. Vera<sup>1</sup>, S. Strathdee<sup>1</sup>, S. C. Roesch<sup>2</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>San Diego State University, San Diego, CA
- 105 *Knowledge, perception and risk behaviors for HIV transmission among methadone clients in Shanghai, China*  
H. Zhang<sup>1,2</sup>, M. Chawarski<sup>1</sup>, R. Schottenfeld<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Shanghai Yangpu Mental Health Center, Shanghai, China

- 106 *Beyond sexual partner concurrency: Overlapping injection partnerships among high-risk couples in Northern Mexico*  
A. M. Robertson<sup>1</sup>, J. L. Syvertsen<sup>1</sup>, G. Martinez<sup>2</sup>, M. G. Rangel<sup>3</sup>, M. D. Ulibarri<sup>4</sup>, K. D. Wagner<sup>1</sup>, S. Strathdee<sup>1</sup>, <sup>1</sup>Medicine, UC San Diego, La Jolla, CA, <sup>2</sup>FEMAP, Ciudad Juarez, Mexico, <sup>3</sup>COLEF, Tijuana, Mexico, <sup>4</sup>Psychiatry, UC San Diego, La Jolla, CA
- 107 *Buprenorphine-naloxone vs. methadone: equal HIV risk reduction in START*  
G. E. Woody<sup>1</sup>, D. Bruce<sup>2</sup>, T. Korthuis<sup>3</sup>, S. Chhatre<sup>4</sup>, M. Hillhouse<sup>5</sup>, P. Jacobs<sup>6</sup>, J. Sorensen<sup>7</sup>, A. Saxon<sup>8</sup>, W. Ling<sup>5</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Yale University School of Medicine, New Haven, CT, <sup>3</sup>Oregon Health & Science University, Portland, OR, <sup>4</sup>Treatment Research Institute, Philadelphia, PA, <sup>5</sup>University of California, Los Angeles, CA, <sup>6</sup>National Institute on Drug Abuse, Bethesda, MD, <sup>7</sup>University of California San Francisco, San Francisco, CA, <sup>8</sup>Veterans Affairs Puget Sound Health Care, Seattle, WA
- 108 *HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment*  
E. J. Edelman<sup>1</sup>, B. A. Moore<sup>1</sup>, S. Caffrey<sup>1</sup>, K. Sikkema<sup>2</sup>, E. Jones<sup>3</sup>, R. S. Schottenfeld<sup>1</sup>, D. Fiellin<sup>1</sup>, L. E. Fiellin<sup>1</sup>, <sup>1</sup>Yale Univ, New Haven, CT, <sup>2</sup>Duke Univ, Durham, NC, <sup>3</sup>The Permanente Medical Group, Oakland, CA
- 109 *Sexual discounting among opioid-maintained women*  
E. Herrmann, S. H. Heil, D. Hand, University of Vermont, Burlington, VT
- 110 *Sex trading, substance abuse, and mental health problems among indigent HIV-positive women: Implications for HIV treatment, adherence, and diversion*  
M. A. Levi Minzi, H. Surratt, S. P. Kurtz, Nova Southeastern University, Miami, FL
- 111 *Correlates of drug use severity and HIV risk behaviors in cocaine- and opiate-dependent patients*  
A. Umbricht, O. Rass, G. Bigelow, E. C. Strain, D. A. Tompkins, M. Mintzer, Psychiatry, Johns Hopkins University, Baltimore, MD
- 112 *HIV, HCV, HBV prevalence among heroin addicts in Saudi Arabia*  
A. T. Alshomrani, Psychiatry, College of Medicine - Al Imam University, Riyadh, Saudi Arabia
- 113 *Prevalence of HIV, hepatitis C and depression among people who inject drugs in the Kinondoni Municipality in Dar es Salaam, Tanzania*  
C. Nyandindi<sup>3</sup>, J. Mbwambo<sup>3</sup>, S. McCurdy<sup>4</sup>, B. Lambdin<sup>2</sup>, M. Copenhaver<sup>5</sup>, R. Bruce<sup>1,2</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Pangaea Global AIDS Foundation, Oakland, CA, <sup>3</sup>Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania, <sup>4</sup>University of Texas, Houston, TX, <sup>5</sup>University of Connecticut, Storrs, CT
- 114 *Differences in prevalence of HIV and HCV between blacks and whites based on patterns of injection and non-injection drug users in Baltimore city*  
L. Keen, W. W. Latimer, Clinical and Health Psychology, University of Florida, Gainesville, FL
- 115 *How substance use can affect HIV test rates following a computer-based video intervention*  
I. D. Aronson<sup>1</sup>, S. Rajan<sup>2</sup>, J. Koken<sup>1</sup>, L. A. Marsch<sup>3</sup>, T. C. Bania<sup>2</sup>, <sup>1</sup>NDRI, New York, NY, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>Dartmouth College, Lebanon, NH
- 116 *Brief HIV assessment for screening CJ offenders in addiction treatment*  
G. A. Rowan-Szal, G. Joe, W. E. Lehman, N. G. Bartholomew, K. Knight, Institute of Behavioral Research, Texas Christian University, Fort Worth, TX
- 117 *Addiction and continuous HIV care for individuals with a history of incarceration*  
H. Swan, University of Delaware, Newark, DE

- 118 *Antiretroviral medication diversion in south Florida: Prescription types and motivations*  
C. L. O'Grady, S. P. Kurtz, H. L. Surratt, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL
- 119 *HIV/AIDS services in substance use disorder treatment programs within the Clinical Trials Network*  
H. K. Knudsen<sup>1</sup>, P. M. Roman<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Georgia, Athens, GA
- 120 *The impact of HIV on behavioral health services utilization among people with substance use disorder or psychiatric disorder: A propensity score matching analysis of multi-year national surveys*  
M. Chang<sup>1</sup>, L. Warner<sup>1</sup>, R. K. Price<sup>2</sup>, <sup>1</sup>School of Social Welfare, University at Albany, Albany, NY, <sup>2</sup>School of Medicine, Washington University, St. Louis, MO

### CRACK COCAINE

- 121 *Crack use mediates between impulsiveness and sex trading*  
S. Clingan<sup>1</sup>, D. G. Fisher<sup>1</sup>, G. L. Reynolds<sup>1</sup>, K. L. Hess<sup>1</sup>, D. P. MacKinnon<sup>2</sup>, <sup>1</sup>California State University, Long Beach, Long Beach, CA, <sup>2</sup>Arizona State University, Tempe, AZ
- 122 *Trajectory of treatment, hospitalization and relapse of crack users*  
R. S. Pedroso, V. M. Gonçalves, L. S. Guimarães, R. L. Rosa, M. Pettenon, F. H. Kessler, F. Pechansky, Center for Drug and Alcohol Research, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- 123 *En una pipa te cabe toda tu vida: Accessing crack users in Mexico City*  
A. Jiménez<sup>1</sup>, M. Domínguez<sup>1</sup>, E. Zafra<sup>1</sup>, J. Ramírez<sup>1</sup>, G. Natera<sup>1</sup>, A. Valdez<sup>2</sup>, A. Cepeda<sup>2</sup>, <sup>1</sup>Investigaciones Epidemiológicas y Psicosociales, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico, Mexico, <sup>2</sup>School of Social Work, University of Southern California, Los Angeles, CA
- 124 *High-risk methods and paraphernalia practices of crack smoking in Mexico City*  
A. Cepeda<sup>1</sup>, A. Valdez<sup>1</sup>, G. Natera-Rey<sup>2</sup>, <sup>1</sup>School of Social Work, University of Southern California, Los Angeles, CA, <sup>2</sup>Instituto de Psiquiatría, Ramón de la Fuente Muñiz, Distrito Federal, Mexico
- 125 *Exploring typologies of crack users among Latino immigrant day laborers in New Orleans*  
N. Negi<sup>1</sup>, A. Cepeda<sup>2</sup>, A. Valdez<sup>3</sup>, <sup>1</sup>School of Social Work, University of Maryland, Baltimore, Baltimore, MD, <sup>2</sup>School of Social Work, University of Southern California, Los Angeles, CA, <sup>3</sup>School of Social Work, University of Southern California, Los Angeles, CA
- 126 *Variation of serum BDND levels in adolescent crack-cocaine abusers after 20 days' abstinence*  
T. G. Pianca<sup>1</sup>, C. Szobot<sup>1,2</sup>, R. L. Rosa<sup>3</sup>, P. B. Ferronato<sup>1</sup>, M. C. Jensen<sup>2</sup>, R. C. Abrahão<sup>2</sup>, P. M. Lazzari<sup>2</sup>, A. P. Begnis<sup>2</sup>, R. Halpern<sup>2</sup>, B. W. de Aguiar<sup>1</sup>, K. M. Cereser<sup>1</sup>, F. H. Kessler<sup>1</sup>, F. Kapczinsky<sup>1</sup>, F. Pechansky<sup>1</sup>, L. A. Rohde<sup>1</sup>, <sup>1</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Universidade Luterana do Brasil, Canoas, Brazil, <sup>3</sup>Hospital Psiquiátrico São Pedro, Canoas, Brazil

### POLYDRUG ABUSE I

- 127 *Topiramate impairs cognitive function in cocaine-dependent individuals maintained on methadone*  
O. Rass, A. Umbricht, G. E. Bigelow, E. C. Strain, M. Mintzer, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

- 128 *A longitudinal study of organizational factors and implementation of medication-assisted treatments for addiction*  
T. R. Rieckmann<sup>1</sup>, A. Abraham<sup>2</sup>, P. Roman<sup>3</sup>, <sup>1</sup>Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR, <sup>2</sup>Health Services Policy and Management, University of South Carolina, Columbia, SC, <sup>3</sup>Sociology, University of Georgia, Athens, GA
- 129 *Daysimeter feasibility and acceptability in a polysubstance-using population*  
A. Kennedy<sup>1</sup>, M. Rea<sup>2</sup>, M. Figueiro<sup>2</sup>, M. L. Jobes<sup>1</sup>, D. Epstein<sup>1</sup>, K. L. Preston<sup>1</sup>, <sup>1</sup>National Institute on Drug Abuse, Baltimore, MD, <sup>2</sup>Rensselaer Polytechnic Institute, Troy, NY
- 130 *Early treatment drug use: Drug-positive vs. -negative patients*  
G. Cochran<sup>1</sup>, M. Stitzer<sup>1</sup>, E. V. Nunes<sup>2</sup>, M. Hu<sup>2</sup>, A. Campbell<sup>2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Johns Hopkins Medicine, Baltimore, MD, <sup>2</sup>Psychiatry, Columbia University, New York, NY
- 131 *Screening and brief intervention for drug use in primary care: The ASPIRE randomized trial*  
R. Saitz<sup>1,2</sup>, T. P. Palfai<sup>1</sup>, D. Cheng<sup>2</sup>, D. P. Alford<sup>1,2</sup>, J. A. Bernstein<sup>1</sup>, C. A. Lloyd-Travaglini<sup>1</sup>, S. M. Meli<sup>2</sup>, C. E. Chaisson<sup>1</sup>, J. H. Samet<sup>1,2</sup>, <sup>1</sup>Boston University, Boston, MA, <sup>2</sup>Boston Medical Center, Boston, MA
- 132 *Test-retest reliability of a computer self-administered Substance Use Brief Screen for tobacco, alcohol and drug use*  
J. McNeely<sup>1</sup>, P. N. Halkitis<sup>1,2</sup>, S. Strauss<sup>3</sup>, R. Khan<sup>1</sup>, M. N. Gourevitch<sup>1</sup>, <sup>1</sup>NYU School of Medicine, New York, NY, <sup>2</sup>NYU Steinhardt School, New York, NY, <sup>3</sup>NYU College of Nursing, New York, NY
- 133 *Ultra-rapid screening for substance-related problems using the alcohol smoking and substance involvement screening test (ASSIST4)*  
R. Ali<sup>1</sup>, J. Marsden<sup>2</sup>, <sup>1</sup>University of Adelaide, Adelaide, SA, Australia, <sup>2</sup>King's College London, London, United Kingdom
- 134 *Hair testing for drug use in a moderate-risk primary care population: Comparison with self-report and experiences from a clinical trial*  
J. Gryczynski<sup>1</sup>, S. G. Mitchell<sup>1</sup>, A. Gonzales<sup>2</sup>, A. Moseley<sup>2</sup>, T. Peterson<sup>2</sup>, K. E. O'Grady<sup>3</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Sangre de Cristo Community Health Partnership, Santa Fe, NM, <sup>3</sup>Psychology, University of Maryland, College Park, MD
- 135 *Comparing self report and urine drug screens for substance use*  
G. Villalobos, S. B. Varner, M. Weaver, D. Svikis, Virginia Commonwealth University, Richmond, VA
- 136 *Programmable bio-nano-chips for the quantitation of drugs of abuse in oral fluids*  
J. T. McDevitt<sup>1,2</sup>, R. De La Garza II<sup>3</sup>, T. F. Newton<sup>3</sup>, R. Smith<sup>1</sup>, J. J. Mahoney<sup>3</sup>, J. Hohenstein<sup>1</sup>, S. Gomez<sup>1</sup>, P. N. Floriano<sup>1,2</sup>, H. Talavera<sup>1</sup>, D. J. Sloan<sup>1</sup>, D. E. Moody<sup>4</sup>, D. M. Andrenyak<sup>4</sup>, T. R. Kosten<sup>4</sup>, N. Christodoulides<sup>1,2</sup>, <sup>1</sup>Bioengineering, Rice University, Houston, TX, <sup>2</sup>Chemistry, Rice University, Houston, TX, <sup>3</sup>Menninger Dept. of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, <sup>4</sup>Pharmacology and Toxicology, University of Utah, Salt Lake City, UT
- 137 *Emotion regulation predicts drug use among college binge drinkers*  
A. Pickover<sup>1</sup>, A. M. Yurasek<sup>1</sup>, C. W. Lejuez<sup>2</sup>, J. G. Murphy<sup>1</sup>, <sup>1</sup>Department of Psychology, University of Memphis, Memphis, TN, <sup>2</sup>CAPER, University of Maryland, College Park, MD
- 138 *Delay discounting rates for illicit, but not licit, drugs depend on dependency status among poly-drug recreational drug users*  
M. N. Koffarnus<sup>1,2</sup>, W. K. Bickel<sup>1,2</sup>, <sup>1</sup>Addiction Recovery Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Department of Psychology, Virginia Tech, Blacksburg, VA

- 139 *Evaluation of perceived lack of control as a moderator of the relationship between lesbian, gay, and bisexual identities and alcohol, tobacco, and other drug abuse and dependence*  
A. Flynn, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 140 *Contingency management voucher spending as an indicator of delayed gratification*  
J. B. Fletcher<sup>1</sup>, R. Dierst-Davies<sup>1,2</sup>, C. J. Reback<sup>1,3</sup>, <sup>1</sup>Friends Research Institute, Inc., Los Angeles, CA, <sup>2</sup>Public Health, University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 141 *Barriers preventing primary care patients from reducing drug use*  
H. Padwa, Y. Ni, Y. Barth-Rogers, L. Arangua, R. Andersen, L. Gelberg, UCLA, Los Angeles, CA
- 142 *The relationship between treatment for substance use disorders and stigma*  
M. Kulesza<sup>1</sup>, S. E. Ramsey<sup>2</sup>, R. Brown<sup>2</sup>, M. E. Larimer<sup>1</sup>, <sup>1</sup>Psychiatry, University of Washington, Seattle, WA, <sup>2</sup>Psychiatry, Brown University, Providence, RI
- 143 *MOVED TO WEDNESDAY POSTER SESSION #146*
- 144 *Implementing evidence-based psychosocial therapies for substance use: Aspects of measuring adherence and competence*  
A. Meier, M. P. McGovern, B. Lasko, Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH
- 145 *An exploration of childhood experiences among a sample of homeless veterans*  
L. Sawh<sup>1,2,4</sup>, J. Siegfriedt<sup>1,2,3</sup>, D. Smelson<sup>1,2,3</sup>, G. Gonzalez<sup>3</sup>, A. Kline<sup>5,6</sup>, <sup>1</sup>Edith Nourse Rogers Memorial VA, Bedford, MA, <sup>2</sup>National Center on Homelessness Among Veterans, Bedford, MA, <sup>3</sup>University of Massachusetts Medical School, Worcester, MA, <sup>4</sup>University of Massachusetts Lowell, Lowell, MA, <sup>5</sup>VA New Jersey Health Care System, Lyons, NJ, <sup>6</sup>University of Medicine and Dentistry-Robert Wood Johnson Medical School, New Brunswick, NJ
- 146 *The influence of regional location and homelessness on substance abuse treatment completion*  
M. Hawkins<sup>1</sup>, G. Stahler<sup>1</sup>, K. Eylich-Garg<sup>2</sup>, <sup>1</sup>Geography & Urban Studies, Temple University, Philadelphia, PA, <sup>2</sup>Social Work, Temple University, Philadelphia, PA
- 147 *Is primary care accessible to general population adults who use drugs?*  
B. Payne<sup>1</sup>, Y. Khodneva<sup>1</sup>, X. Wang<sup>1</sup>, M. Pletcher<sup>3</sup>, M. Stafford<sup>1</sup>, J. Richman<sup>1</sup>, S. Kertesz<sup>1,2</sup>, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>VA Medical Center, Birmingham, AL, <sup>3</sup>University of California, San Francisco, San Francisco, CA
- 148 *Using service collaboratives and implementation science for system improvement*  
D. Morisano<sup>1,2</sup>, J. A. McDonald<sup>1</sup>, H. McKee<sup>1</sup>, F. C. Thomas<sup>1</sup>, B. R. Rush<sup>1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada
- 149 *Immediate and six-month effects of project ex Russia: A smoking cessation intervention pilot program*  
B. Idrisov<sup>1</sup>, P. Sun<sup>2</sup>, L. Akhmadeeva<sup>1</sup>, T. E. Arpawong<sup>2</sup>, P. Kukhareva<sup>3</sup>, S. Sussman<sup>2</sup>, <sup>1</sup>Bashkortostan State Medical University, Ufa, Russian Federation, <sup>2</sup>University of Southern California, Los-Angeles, CA, <sup>3</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC



---

**Monday, June 17, 2013**

---

## **Symposium III**

**INDIGO A**  
**10:00 - 12:05 PM**

### **THE INTERACTION BETWEEN ALCOHOL AND OTHER DRUGS OF ABUSE: FROM NEUROBIOLOGY TO CLINICAL IMPLICATIONS**

Chairs: Markus Heilig and Eric C. Strain

- 10:00 *75th Anniversary Reflections*
- 10:05 *Developing treatments for alcohol and nicotine addiction by targeting nicotinic receptor subunits*  
Selena Bartlett, Translational Research Institute at the Institute of Health and Biomedical Innovation, Queensland University of Technology, Queensland, QLD, Australia
- 10:30 *Craving and relapse in alcoholism and cocaine addiction: Molecular medicine for a persistent malady*  
Ivan Diamond, University of California, San Francisco, Palo Alto, CA
- 10:55 *Endocannabinoid modulation of alcohol's behavioral actions*  
Andrew Holmes, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD
- 11:20 *Central opioid systems as mediators of ethanol reinforcement—A pharmacogenetic view*  
Markus Heilig, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD
- 11:45 *The interaction between alcohol and other drugs of abuse: Summary and discussion*  
Eric C. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

## **Symposium IV**

**INDIGO E**  
**10:00 - 12:05 PM**

### **NEW DIRECTIONS IN THE PHARMACOLOGICAL FACILITATION OF PSYCHOTHERAPY FOR DRUG DEPENDENCE**

Chairs: Roland R. Griffiths and Herbert D. Kleber

- 10:00 *75th Anniversary Reflections*
- 10:05 *Psilocybin and quantum change experiences: Implications for treatment of drug dependence*  
Roland R. Griffiths, Johns Hopkins University School of Medicine, Baltimore, MD
- 10:30 *Psilocybin-facilitated treatment of alcohol dependence*  
Michael Bogenschutz, University of New Mexico Health Sciences Center, Albuquerque, NM
- 10:55 *Facilitation of cognitive behavioral therapy for smoking cessation using the 5-HT<sub>2A</sub> agonist psilocybin*  
Matthew W. Johnson, Johns Hopkins University School of Medicine, Baltimore, MD
- 11:20 *Ketamine-facilitated treatment of cocaine dependence*  
Elias Dakwar, Columbia University Medical Center, New York, NY
- 11:45 *Discussant: The promise and pitfalls of drug-facilitated psychotherapy for treatment of drug dependence*  
Herbert D. Kleber, Columbia University and New York State Psychiatric Institute, New York, NY

## Oral Communications 3

INDIGO D  
10:00 - 12:05 PM

### OPIOIDS: MORE THAN MU

Chairs: Jean M. Bidlack and Kevin Freeman

- 10:00 *75th Anniversary Reflections*
- 10:05 *The kappa agonist, salvinorin A, punishes remifentanyl and cocaine self-administration in monkeys*  
K. Freeman<sup>1</sup>, T. Prisinzano<sup>2</sup>, W. Woolverton<sup>1</sup>, <sup>1</sup>Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Medicinal Chemistry, The University of Kansas, Lawrence, KS
- 10:20 *A mixed kappa/mu partial opioid agonist attenuated cocaine-induced locomotion*  
J. M. Bidlack<sup>1</sup>, B. I. Knapp<sup>1</sup>, A. Sromek<sup>2</sup>, J. L. Neumeyer<sup>2</sup>, <sup>1</sup>Pharmacology and Physiology, University of Rochester, Rochester, NY, <sup>2</sup>Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, MA
- 10:35 *Development of mixed opioid agonist/antagonists to prevent reinstatement of extinguished cocaine-seeking behavior*  
S. O. Eans<sup>1</sup>, M. L. Ganno<sup>1</sup>, E. Mizrachi<sup>1</sup>, S. Senadheera<sup>2</sup>, J. V. Aldrich<sup>2</sup>, J. P. McLaughlin<sup>1</sup>, <sup>1</sup>Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, <sup>2</sup>Dept. Med. Chem, Univ. of Kansas, Lawrence, KS
- 10:50 *Involvement of KOP-r in cocaine withdrawal-induced conditioned place aversion in rats*  
Y. Zhou, Y. Litvin, D. Pfaff, M. Kreek, Rockefeller University, New York, NY
- 11:05 *The NK1 antagonist aprepitant reduces stress-induced cocaine and alcohol craving in a human laboratory study*  
J. G. Plebani, A. L. Henninger, J. Burrell, E. Brown, K. M. Kampman, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 11:20 *Interactions between OPRK1 variants and cumulative stress are associated with basal ACTH in healthy community subjects*  
K. Xu<sup>1</sup>, D. Liu<sup>3</sup>, H. Zhang<sup>3</sup>, R. Sinha<sup>1,2</sup>, <sup>1</sup>Psychiatry, Yale University, New Haven, CT, <sup>2</sup>The Yale Stress Center, New Haven, CT, <sup>3</sup>Yale School of Public Health University, New Haven, CT
- 11:35 *Novel association of amygdala prodynorphin with addiction and negative affect-related neurocircuitry*  
S. R. Anderson<sup>1</sup>, M. Michaelides<sup>1</sup>, J. Neumaier<sup>2</sup>, M. Bannon<sup>3</sup>, Y. L. Hurd<sup>1</sup>, <sup>1</sup>Pharmacology, MSSM, NY, NY, <sup>2</sup>Psychiatry, University of Washington, Seattle, WA, <sup>3</sup>Pharmacology, Wayne State University, Detroit, MI
- 11:50 *Activation of G-protein and c-Jun N-terminal kinase by kappa opioid receptor ligands*  
B. I. Knapp, J. M. Bidlack, Pharmacology and Physiology, University of Rochester, Rochester, NY

## Oral Communications 4

INDIGO H  
10:00 - 12:05 PM

### DRUGS AND VIOLENCE—THE NEGATIVE SPIRAL

Chairs: Quyen Epstein-Ngo and Philip H. Smith

- 10:00 *75th Anniversary Reflections*
- 10:05 *Intimate partner violence victimization and cigarette smoking: A meta-analytic review*  
C. A. Crane<sup>1</sup>, S. Hawes<sup>2</sup>, A. H. Weinberger<sup>2</sup>, <sup>1</sup>Research Institute on Addictions, University at Buffalo, SUNY, Buffalo, NY, <sup>2</sup>Department of Mental Health and Addiction Services, Yale University, New Haven, CT
- 10:20 *Intimate partner violence and Iranian women with substance use disorders*  
E. Merghati-khoei<sup>1,2</sup>, J. E. Korte<sup>2</sup>, S. Rimaz<sup>1</sup>, S. E. Back<sup>2</sup>, K. T. Brady<sup>2</sup>, N. Shamsalizadeh<sup>1</sup>, <sup>1</sup>School of Public Health, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran, <sup>2</sup>Psychiatry & Behavioral Sciences, MUSC, Charleston, SC
- 10:35 *Gender-based violence, psychopathology and substance use disorders in a national sample of women*  
K. Walsh<sup>1</sup>, K. Keyes<sup>1</sup>, S. Galea<sup>1</sup>, B. Grant<sup>2</sup>, D. S. Hasin<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York, NY, <sup>2</sup>NIAAA, Bethesda, MD
- 10:50 *Substance use and motivations for violence: Event-level analyses of gender differences in antecedents to dating vs. peer violence*  
Q. Epstein-Ngo<sup>1</sup>, M. A. Walton<sup>1</sup>, S. T. Chermack<sup>1</sup>, F. C. Blow<sup>1</sup>, B. M. Booth<sup>2</sup>, M. A. Zimmerman<sup>1</sup>, R. M. Cunningham<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Arkansas, Fayetteville, AR
- 11:05 *The interaction between spouses' drug use in the prediction of intimate partner violence*  
P. H. Smith<sup>1</sup>, G. G. Homish<sup>1</sup>, K. E. Leonard<sup>1</sup>, R. L. Collins<sup>1</sup>, G. A. Giovino<sup>1</sup>, H. R. White<sup>2</sup>, <sup>1</sup>University at Buffalo, SUNY, Buffalo, NY, <sup>2</sup>Rutgers University, Piscataway, NJ
- 11:20 *Alcohol as a predictor of violence victimization among U.S. college students: An analysis of sex differences*  
R. L. Peralta, L. C. Wiley, Sociology, The University of Akron, Akron, OH
- 11:35 *The event-specific etiology of intimate partner violence: The role of alcohol use and psychiatric conditions*  
J. M. Reingle<sup>1</sup>, W. G. Jennings<sup>2</sup>, M. Businelle<sup>1</sup>, K. Chartier<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center at Houston, Dallas, TX, <sup>2</sup>Department of Criminology, University of South Florida, Tampa, FL
- 11:50 *Cuando tomo mas, siento que es un refugio: Context of alcohol use among Latino immigrant men*  
I. Ornelas<sup>1</sup>, C. Allen<sup>1</sup>, C. Vaughan<sup>1</sup>, N. Negi<sup>2</sup>, E. Williams<sup>1</sup>, <sup>1</sup>Health Services, University of Washington, Seattle, WA, <sup>2</sup>Social Work, University of Maryland, Baltimore, MD



## **Symposium V**

**INDIGO A**  
**1:50 - 2:55 PM**

### **NEW SCIENCE AND TOOLS TO IMPROVE THE DIAGNOSIS, PREVENTION AND TREATMENT OF HEPATITIS C VIRUS AND ITS SEQUELAE**

Chairs: Wilson Compton and Redonna Chandler

- 1:50 *75th Anniversary Reflections*
- 1:55 *Intensive hepatitis C treatment*  
Alain Litwin, Montefiore Medical Center, Bronx, NY
- 2:15 *Integrated vs. separate care for hepatitis C, substance abuse and HIV prevention*  
Brian Edlin, SUNY Downstate Medical College, Brooklyn, NY
- 2:35 *Economic analysis of rapid HIV, HCV testing*  
Bruce Schackman, Weill Cornell Medical College, New York, NY

## **Symposium VI**

**INDIGO E**  
**1:50 - 2:55 PM**

### **SEX HORMONE MODULATION OF NICOTINE REWARD: EFFECTS ON URGES, AFFECT, PHYSIOLOGICAL RESPONSE, AND BRAIN ACTIVATION**

Chairs: Sharon Allen and Cora Lee Wetherington

- 1:50 *75th Anniversary Reflections*
- 1:55 *Allopregnanolone and smoking-related symptomatology during smoking cessation in premenopausal women*  
Alicia Allen, Tobacco Research Programs, University of Minnesota, Minneapolis, MN
- 2:15 *Influences of gonadal hormones and sex on responses to intravenous nicotine*  
Elise E. DeVito, Yale University School of Medicine, New Haven, CT
- 2:35 *Hormonal effects on the brain's response to smoking CUES: A perfusion FMRI study*  
Teresa R. Franklin, Center for the Studies of Addiction, University of Pennsylvania, Philadelphia, PA

## **Oral Communications 5**

**INDIGO D**  
**1:50 - 2:55 PM**

### **TREATMENT OF OPIOID DEPENDENCE: SOMETHING OLD, SOMETHING NEW**

Chairs: Marc Auriacombe and Sandra Comer

- 1:50 *75th Anniversary Reflections*
- 1:55 *Effects of minocycline on oxycodone-induced responses in humans*  
S. Mogali<sup>1,2</sup>, J. D. Jones<sup>1,2</sup>, J. M. Manubay<sup>1,2</sup>, M. Sullivan<sup>1,2</sup>, S. D. Comer<sup>1,2</sup>, <sup>1</sup>Substance Abuse, Columbia University, New York, NY, <sup>2</sup>Substance Abuse, New York State Psychiatric Institute, New York, NY

- 2:10 *Using tincture of opium for treatment of opiate abusers in Iran*  
L. Seiri<sup>1</sup>, A. Mokri<sup>2</sup>, H. Dezhakam<sup>3</sup>, A. Noroozi<sup>2</sup>, <sup>1</sup>Aftab Clinic, Tehran, Islamic Republic of Iran, <sup>2</sup>Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran, <sup>3</sup>Congress 60, Tehran, Islamic Republic of Iran
- 2:25 *Opioid substitution treatment enrollment and outcomes in California:1991-2011*  
B. Nosyk<sup>1,2</sup>, E. Evans<sup>2</sup>, L. Li<sup>2</sup>, D. Urada<sup>2</sup>, M. J. Milloy<sup>1</sup>, E. Wood<sup>1</sup>, R. Rawson<sup>2</sup>, Y. Hser<sup>2</sup>, <sup>1</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, <sup>2</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 2:40 *10-years outcome of methadone- and buprenorphine-maintained patients. Mortality, quality of life and substance use*  
M. Auriacombe<sup>1,2,3</sup>, C. M. Denis<sup>1,3</sup>, V. Beltran<sup>1,2,3</sup>, J. Alexandre<sup>1,3</sup>, R. Debrabant<sup>1,3</sup>, F. Serre<sup>1,3</sup>, J. Daulouede<sup>1,2,3</sup>, M. Fatseas<sup>1,3</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>Bizia, Bayonne, France, <sup>3</sup>CH Ch. Perrens et CHU Bordeaux, Bordeaux, France

## Oral Communications 6

**INDIGO H**  
**1:50 - 2:55 PM**

### **BABY BUMPS IN THE ROAD: CONSEQUENCES OF PERINATAL DRUG ABUSE**

Chairs: Loretta P. Finnegan and Diann E. Gaalema

- 1:50 *75th Anniversary Reflections*
- 1:55 *Difference in time to treatment in neonates exposed to buprenorphine or methadone in utero*  
D. E. Gaalema<sup>1</sup>, S. H. Heil<sup>1</sup>, J. Metayer<sup>2</sup>, A. Johnston<sup>2</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>Fletcher Allen Health Care, Burlington, VT
- 2:10 *Genetic predictors of neonatal abstinence syndrome in methadone-exposed infants*  
A. L. Gordon<sup>1</sup>, M. R. Hutchinson<sup>2</sup>, R. R. Haslam<sup>3</sup>, J. K. Collier<sup>2</sup>, <sup>1</sup>University of South Australia, Adelaide, SA, Australia, <sup>2</sup>University of Adelaide, Adelaide, SA, Australia, <sup>3</sup>Women's and Children's Hospital, Adelaide, SA, Australia
- 2:25 *Favorable outcomes in newborns prenatally exposed to buprenorphine compared to methadone and slow-release oral morphine*  
V. Metz<sup>1,2</sup>, S. D. Comer<sup>2</sup>, G. Fischer<sup>1</sup>, <sup>1</sup>Medical University of Vienna, Vienna, Austria, <sup>2</sup>Columbia University NYSPI, New York, NY
- 2:40 *Longitudinal outcomes of MDMA (ecstasy)-exposed infants in the United Kingdom*  
L. Singer<sup>1</sup>, D. G. Moore<sup>2</sup>, M. O. Min<sup>1</sup>, J. Goodwin<sup>2</sup>, J. J. Turner<sup>2</sup>, S. Fulton<sup>1</sup>, A. C. Parrott<sup>3</sup>, <sup>1</sup>Case Western Reserve University, Cleveland, OH, <sup>2</sup>The University of East London, London, United Kingdom, <sup>3</sup>Swansea University, Singleton Park, United Kingdom

### Symposium VII

**INDIGO A**  
**3:05 - 4:10 PM**

#### **CHILDHOOD MALTREATMENT AND SUBSTANCE ABUSE: NEW FINDINGS ON A COMPLEX RELATIONSHIP**

Chairs: Deborah S. Hasin and Cathy Spatz Widom

- 3:05 *75th Anniversary Reflections*
- 3:10 *Pathways from childhood victimization to adult substance abuse*  
Cathy Spatz Widom, John Jay College, New York, NY
- 3:30 *Risk for alcohol use disorders: Childhood maltreatment moderates effects of genetic variation and adult war exposure*  
Katherine Keyes, Columbia University, Mailman School of Public Health, New York, NY
- 3:50 *Childhood maltreatment and psychiatric mediators: Effects on the 3-year persistence of adult substance use disorders*  
Deborah S. Hasin, Columbia University, Mailman School of Public Health, New York, NY

### Symposium VIII

**INDIGO E**  
**3:05 - 4:10 PM**

#### **PHARMACOTHERAPEUTIC TARGETING OF GLUTAMATERGIC SIGNALING IN THE REVERSAL OF ADDICTION PATHOLOGY**

Chairs: Cassandra Gipson and Erin McClure

- 3:05 *75th Anniversary Reflections*
- 3:10 *Rapid synaptic potentiation and alterations in glutamatergic signaling: New pharmacotherapeutic targets in reversing nicotine addiction*  
Cassandra Gipson, Medical University of South Carolina, Charleston, SC
- 3:30 *mGlu2 and mGlu7 receptors as targets for nicotine dependence*  
Athina Markou, University of California, San Diego, La Jolla, CA
- 3:50 *Tobacco outcomes during an N-acetylcysteine-assisted cannabis cessation trial in adolescents*  
Erin McClure, Medical University of South Carolina, Charleston, SC

### Oral Communications 7

**INDIGO D**  
**3:05 - 4:10 PM**

#### **DESIGNER MARY JANES: SYNTHETIC CANNABINOIDS**

Chair: Kenner Rice

- 3:05 *75th Anniversary Reflections*
- 3:10 *Subsecond dopamine release in cannabinoid tolerance*  
E. B. Oleson, A. Ranganath, M. Karamsetty, J. Cheer, Neurobiology and Anatomy, University of Maryland School of Medicine, Baltimore, MD
- 3:25  *$\Delta^9$ -Tetrahydrocannabinol does not substitute in rats trained to self-administer WIN55212-2*  
J. A. Marusich, T. Lefever, J. Wiley, Discovery & Analytical Sciences, RTI International, Research Triangle Park, NC

- 3:40 *Online interest in synthetic marijuana and policy implications*  
B. L. Curtis<sup>1</sup>, A. T. McLellan<sup>1,2</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA
- 3:55 *Pyrolysis studies of synthetic cannabinoids in herbal products*  
R. C. Daw, M. Grabenauer, P. G. Pande, A. O. Cox, A. L. Kovach, K. H. Davis, J. L. Wiley, P. R. Stout, B. F. Thomas, Analytical Chemistry and Pharmaceuticals, RTI International, RTP, NC

### Oral Communications 8

**INDIGO H**  
**3:05 - 4:10 PM**

#### HEALTH CARE REFORM: POLICIES TO PONDER

Chair: David Fiellin

- 3:05 *75th Anniversary Reflections*
- 3:10 *Federal parity does not lead to large increases in spending on substance use disorder treatment: Results from year 1*  
S. Busch<sup>1</sup>, A. Epstein<sup>2</sup>, M. Harhay<sup>2</sup>, D. Fiellin<sup>1</sup>, H. Un<sup>3</sup>, D. Leader<sup>3</sup>, C. Barry<sup>4</sup>, <sup>1</sup>Yale, New Haven, CT, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Aetna, Philadelphia, PA, <sup>4</sup>Johns Hopkins, Baltimore, MD
- 3:25 *Integration of substance use disorder treatment with primary care in preparation for health care reform*  
C. Teruya, D. Urada, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 3:40 *New York's Center for Excellence in Integrated Care: The system is showing significant improvement*  
S. Sacks, M. Chaple, CEIC (Center for Excellence in Integrated Care), NDRI (National Development & Research Institutes, Inc.), New York, NY
- 3:55 *Estimating capacity requirements for substance use treatment systems: Population-based approach*  
B. R. Rush<sup>1</sup>, J. Tremblay<sup>2</sup>, C. Fougere<sup>1</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada

### Marian W. Fischman Memorial Award Lecture

**INDIGO BCFG**  
**4:15 - 5:15 PM**

*Presentation of the Marian W. Fischman Award to Kathryn Cunningham*

Introduction by Sharon Walsh

*Lecture: Serotonin at the Nexus of Impulsivity and Cue Reactivity in Cocaine Addiction*  
Kathryn Cunningham

---

**Monday, June 17, 2013**

---

**Pre- and Post-Doctoral Trainees  
Networking Event**

**INDIGO TERRACE  
5:30 - 7:30 PM**

**Workshop VI**

**INDIGO H  
8:00 - 10:00 PM**

**THE 19TH ANNUAL CONTINGENCY MANAGEMENT  
WORKING GROUP**

Chairs: Kelly E. Dunn and Kathryn Saulsgiver

**Workshop VII**

**INDIGO A  
8:00 - 10:00 PM**

**TAKE-HOME NALOXONE TO ADDRESS OPIOID OVERDOSE:  
STATE OF THE EVIDENCE AND METHODS**

Chairs: Alexander Y. Walley and Phillip O. Coffin

*Opioid overdose rates in Massachusetts after the implementation of overdose education and intranasal naloxone distribution*

Alexander Y. Walley, Boston University School of Medicine/ Boston Medical Center,  
Boston, MA

*Mathematical modeling of opioid overdose and naloxone distribution: Cost-effectiveness and population outcomes*

Phillip O. Coffin, San Francisco Department of Public Health / University of California, San  
Francisco, CA

*Feasibility of prison-based overdose prevention education and prescribed naloxone at release*

Traci C. Green, Brown Medical School/Rhode Island Hospital, Providence, RI

*Design of a randomized trial of overdose education and naloxone distribution*

Caleb J. Banta-Green, Alcohol and Drug Abuse Institute, University of Washington,  
Seattle, WA

*Experimental and observational methods to determine the effectiveness of naloxone distribution for reducing opioid overdose fatalities: The N-ALIVE randomized controlled trial in England and take-home naloxone as public health policy in Scotland*

Sheila Bird, University of Cambridge Institute of Public Health, Cambridge, United Kingdom

**Workshop VIII**

**INDIGO E  
8:00 - 10:00 PM**

**THE INTERPLAY OF THE JUVENILE JUSTICE AND ADOLESCENT  
TREATMENT SYSTEMS AND HOW TO USE EVIDENCED-BASED  
ASSESSMENT, TREATMENT AND IMPLEMENTATION PRACTICES  
TO IMPROVE OUTCOMES**

Chairs: Michael L. Dennis and Redonna Chandler

*Using the GAIN Short Screener (GAIN\_SS) to predicting recidivism among of juvenile offenders in adolescent treatment*

Vinetha Belur, Chestnut Health Systems, Normal, IL

---

## Monday, June 17, 2013

---

*The changes in the pattern and cost of the crime among juveniles presenting to treatment*

Michael L. Dennis, Chestnut Health Systems, Normal, IL

*Evaluating the impact of adding the reclaiming futures approach to juvenile treatment drug courts*

Laura Nissen, Portland State University, Graduate School of Social Work, Portland, OR

*Moderator effects of gender and ethnicity across multidimensional family therapy randomized controlled trials in community and justice settings: An integrative data analysis*

Craig Henderson, Sam Houston State University, Huntsville, TX

*Overview of NIDA's new Translational Research on Interventions for Adolescents in the Legal System (TRIALS) cooperative agreement*

Redonna Chandler, National Institute on Drug Abuse, Bethesda, MD

### Workshop IX

**INDIGO D**

**8:00 - 10:00 PM**

#### **EVALUATING AND MINIMIZING THE RISK, MISUSE AND DIVERSION OF PRESCRIPTION DRUG USE IN YOUTH**

Chairs: Linda Cottler and Sidney Schnoll

*Diverters of prescription stimulants among a national sample of 11,000 10- to 18-year-olds:*

*Demographic and psychiatric risk factors*

Linda Cottler, University of Florida, Gainesville, FL

*Multicomorbid drug use among young prescription stimulant users, misusers and diverters*

Catherine W. Striley, University of Florida, Gainesville, FL

*Ideas to reduce risk for Rx opioid and stimulants among 11,000 youth: From their own voices*

C Ruktanonchai, University of Florida, Gainesville, FL

*Ongoing surveillance in real time of misuse and diversion of Rx opioids*

Theodore Cicero, Washington University School of Medicine, St. Louis, MO

*How to reduce misuse and diversion of Rx drugs among youth*

Sidney Schnoll, Pinney Associates, Inc, Bethesda, MD

**NIDA International Meeting Poster Session**

**INDIGO West Foyer  
8:00 – 10:00 PM**

Chair: Steven W. Gust

**BASIC SCIENCE**

*Modafinil maintains protective effects on methamphetamine-induced toxicity at different ambient temperatures*

V. Bisagno<sup>1</sup>, M. Raineri<sup>1</sup>, B. Gonzalez<sup>1</sup>, N. Colettis<sup>2</sup>, E. Garcia-Rill<sup>3</sup>, J.L. Cadet<sup>4</sup>, F.J. Urbano<sup>2</sup>. <sup>1</sup>Instituto de Investigaciones Farmacológicas, ININFA (UBA-CONICET), Argentina; <sup>2</sup>Instituto de Fisiología, Biología Molecular y Neurociencias, IFIByNE (UBA-CONICET), Argentina; <sup>3</sup>Center for Translational Neuroscience, University of Arkansas for Medical Sciences, United States; <sup>4</sup>Molecular Neuropsychiatry Research Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, United States

*Distinct expression profiles for cell-signaling molecules in midbrain dopamine neurons from animals showing relapse vulnerability to cocaine seeking*

A. Brown<sup>1,2,4</sup>, J. Flynn<sup>2,4</sup>, A. Dunlop<sup>1,3,4</sup>, C. Dayas<sup>2,4</sup>, D. Smith<sup>2,4</sup>. <sup>1</sup>Hunter New England Local Health District, Australia; <sup>2</sup>School of Biomedical Sciences and Pharmacy, Priority Research Centre (PRC) for Translational Neuroscience and Mental Health, University of Newcastle, Australia; <sup>3</sup>School of Medicine and Public Health, PRC for Translational Neuroscience and Mental Health, University of Newcastle, Australia; <sup>4</sup>Hunter Medical Research Institute, Australia

*Preponderant role of the glutamatergic transmission in nucleus accumbens core versus shell underlies the long-term sensitization to cocaine after a single restraint stress*

L.M. Cancela<sup>1</sup>, C. García Keller<sup>1</sup>, A. Esparza<sup>1</sup>, B. Mongi Bragato<sup>1</sup>, F. Bollati<sup>1</sup>, P.W. Kalivas<sup>2</sup>. <sup>1</sup>IFEC-CONICET, Departamento de Farmacología, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Argentina; <sup>2</sup>Department of Neurosciences, Medical University of South Carolina, United States

*High-performance liquid chromatography tandem mass spectrometry method for the determination of the serotonin 5-HT<sub>2A</sub> receptor agonists 2C-C and 25I-NBOMe in human serum*

J. Charles<sup>1,2</sup>, J.L. Poklis<sup>3</sup>, A. Poklis<sup>3,4</sup>. <sup>1</sup>Hubert H. Humphrey Fellowship Program, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States; <sup>2</sup>Trinidad and Tobago Forensic Science Centre, Trinidad and Tobago; <sup>3</sup>Department of Pharmacology and Toxicology, Virginia Commonwealth University, United States; <sup>4</sup>Department of Pathology, Virginia Commonwealth University, United States

*Increase in anxiety-like and depressive-like behaviors and long-term memory impairment after heroin self-administration in ovariectomized rats*

M. Chen, Z. Lou, W. Zhou. Laboratory of Behavioral Neuroscience, School of Medicine, Ningbo University, China



*Forensic analysis, synthesis, and characterization of new psychoactive substances of abuse*

R. Christie<sup>1</sup>, J. Fox<sup>1</sup>, C. O'Donnell<sup>1</sup>, S. McDermott<sup>2</sup>, P. Kavanagh<sup>3</sup>. <sup>1</sup>School of Chemical and Pharmaceutical Sciences, Dublin Institute of Technology, Ireland; <sup>2</sup>Forensic Science Laboratory, Garda Headquarters, Ireland; <sup>3</sup>Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James's Hospital, Ireland

*Effect of single and repeated inhalation of "kolla," a local Egyptian glue, on brain neurotransmitters, liver and kidney function, and behavior in rats*

A.A. Elkoussi, M.A. Nicola, M.M. Yosry. Department of Pharmacology, College of Medicine, University of Assiut, Egypt

*Comparison of the enzyme-multiplied immunoassay technique and gas chromatography-mass spectrometry for the detection of delta 9-THC-COOH*

Y.H. Gheat. Medico-Legal Organization, Ministry of Justice, Egypt

*Effect of nitric oxide synthase inhibitor, nitro-L-arginine, on sensitization to the operant decrement produced by naloxone in morphine-treated rats*

R. Jain. National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India

*Cue-induced brain activation in ketamine users, smokers, and controls: Functional magnetic resonance imaging study*

Y. Liao<sup>1</sup>, J. Tang<sup>1</sup>, J. Liu<sup>2</sup>, M. Yang<sup>3</sup>, M. Ma<sup>4</sup>, X. Wang<sup>1</sup>, T. Liu<sup>1</sup>, X. Chen<sup>1</sup>, H. Chen<sup>1</sup>, X. Xiang<sup>1</sup>, P.C. Fletcher<sup>5</sup>, W. Hao<sup>1</sup>. <sup>1</sup>Mental Health Institute, the Second Xiangya Hospital of Central South University, China; <sup>2</sup>Department of Radiology, The People's Hospital of Hunan Province, China; <sup>3</sup>Department of Addiction Medicine, Hunan Brain Hospital, China; <sup>4</sup>Kangda Voluntary Drug Rehabilitation Centers, China; <sup>5</sup>University of Cambridge, Department of Psychiatry, Addenbrooke's Hospital, United Kingdom

*Effect of electroacupuncture on extinction responding of heroin-seeking behavior and FosB expression in the nucleus accumbens core*

S. Liu<sup>1</sup>, M. Lai<sup>2</sup>, J. Wei<sup>1</sup>, L. Wang<sup>1</sup>, H. Mao<sup>1</sup>, W. Zhou<sup>2</sup>, A. Hu<sup>3</sup>. <sup>1</sup>Laboratory of Acupuncture and Moxibustion, Shanghai University of Traditional Chinese Medicine, China; <sup>2</sup>Ningbo Addiction Research and Treatment Center, China; <sup>3</sup>Ningbo No. 2 Hospital, China

*Self-administration of neuroactive steroids by rhesus monkeys responding under a progressive-ratio schedule*

Z. Meng, J.K. Rowlett. Department of Behavioral Biology, New England Primate Research Center, Harvard Medical School, United States

*Buspirone occupancy of D<sub>2/3</sub> dopamine receptors in humans measured by positron emission tomography*

D. Payer, I. Boileau, M. Guranda, A. Graff, S. Nakajima, J. Meyer, G. Staïos, A.A. Wilson, S. Houle, B. Le Foll. Centre for Addiction and Mental Health, University of Toronto, Canada

*Predictive pharmacology: Prediction and interpretation of putative hazardous effects from designer cannabinoid compounds*

A. Persson<sup>1</sup>, N. Stansic<sup>2</sup>, J. Gottfries<sup>2</sup>. <sup>1</sup>Swedish National Institute of Public Health, Östersund, Sweden; <sup>2</sup>Department of Chemistry and Molecular Biology, Gothenburg University, Sweden



*Variance in brain-derived neurotrophic factor levels in crack cocaine adolescent abusers after abstinence*

T. Pianca<sup>1</sup>, C. Szobot<sup>1,2</sup>, R.L. Rosa<sup>3</sup>, P.B. Ferronato<sup>1</sup>, M.C. Jensen<sup>2</sup>, R.C. Abrahão<sup>2</sup>, P.M. Lazzari<sup>2</sup>, A.P. Begnis<sup>2</sup>, R. Halpern<sup>2</sup>, B.W. de Aguiar<sup>1</sup>, K.M. Cereser<sup>1</sup>, F.H. Kessler<sup>1</sup>, F. Kapczinsky<sup>1</sup>, F. Pechansky<sup>1</sup>, L.A. Rohde<sup>1</sup>. <sup>1</sup>Programa de Pós-Graduação em Psiquiatria, Universidade Federal do Rio Grande do Sul, Brazil; <sup>2</sup>Programa de Pós-Graduação em Medicina, Universidade Luterana do Brasil, Brazil; <sup>3</sup>Hospital Psiquiátrico São Pedro, Brazil

*No association between crack cocaine dependence and dopamine D2 receptor gene in Brazil*

T. Roman<sup>1</sup>, A.R. Stolf<sup>2</sup>, G.C. Akutagava-Martins<sup>1</sup>, D. Müller<sup>1</sup>, J.B. Schuch<sup>1</sup>, L.S.P. Guimaraes<sup>2</sup>, F. Pechansky<sup>2</sup>, F.H.P. Kessler<sup>2</sup>. <sup>1</sup>Department of Genetics, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil

*Cocaine alters CREB and NR2B expression in rat hippocampus affecting learning and memory processes*

F.J. Romero<sup>1</sup>, R. López-Pedrajas<sup>2</sup>, T. Ramírez-Lamelas<sup>2</sup>, B. Muriach<sup>2</sup>, I. Almansa<sup>2</sup>, J.M. Barcia<sup>1</sup>, M. Muriach<sup>3</sup>. <sup>1</sup>Universidad Catolica de Valencia, Spain; <sup>2</sup>Universidad CEU Cardenal Herrera, Spain; <sup>3</sup>Universidad Jaume I, Spain

*Crack cocaine users show differences in genotype frequencies of the dopamine transporter gene*

A.R. Stolf<sup>1</sup>, G.C. Akutagava-Martins<sup>2</sup>, D. Müller<sup>2</sup>, L.S.P. Guimaraes<sup>1</sup>, F.H.P. Kessler<sup>1</sup>, F. Pechansky<sup>1</sup>, T. Roman<sup>2</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Department of Genetics, Federal University of Rio Grande do Sul, Brazil

*Brain-derived neurotrophic factor levels at umbilical cord blood among babies exposed to crack during pregnancy*

C. Szobot<sup>1,2</sup>, V. Mardini<sup>1,2</sup>, L. Pereira<sup>1</sup>, R. Parcianello<sup>3</sup>, L. Manna<sup>3</sup>, N. Canabarro<sup>3</sup>, L. Rohsig<sup>2</sup>, F. Pechansky<sup>1,2</sup>, L.A. Rohde<sup>1,2</sup>. <sup>1</sup>Universidade Federal do Rio Grande do Sul, Brazil; <sup>2</sup>Hospital de Clínicas de Porto Alegre, Brazil; <sup>3</sup>Lutheran University of Brazil (ULBRA), Brazil

*Identification of plasma biomarkers of chronic drug exposure in a rat model*

X. Xie<sup>1</sup>, D. Lopez-Ferrer<sup>1</sup>, G. Gil<sup>1</sup>, B. Nguyen<sup>1</sup>, Y. Karpievitch<sup>1</sup>, K. Carr<sup>2</sup>, H. Schulman<sup>1</sup>, D. Chelsky<sup>1</sup>, S.M. Roy<sup>1</sup>. <sup>1</sup>Caprion Proteomics US LLC, United States; <sup>2</sup>New York University, United States

*Evaluation of cortical thickness and white matter alterations in adolescent cannabis users with 3.0 T magnetic resonance imaging*

G. Zoccatelli<sup>1</sup>, F. Alessandrini<sup>1</sup>, G. Serpelloni<sup>2</sup>, G. Cuoghi<sup>3</sup>, E. Bellamoli<sup>3</sup>, C. Rimondo<sup>4</sup>, A. Beltramello<sup>1</sup>. <sup>1</sup>Unit of Neuroradiology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; <sup>2</sup>Department of Antidrug Policies, Presidency of the Council of Ministers, Rome, Italy; <sup>3</sup>Unit of Neuroscience, Addiction Department, Verona, Italy; <sup>4</sup>National Early Warning System, Department of Antidrug Policies, Presidency of the Council of Ministers, Rome, Italy

### EPIDEMIOLOGY

*Knowledge and attitudes of high school students in Gaza Strip toward smoking tobacco and using prescription drugs*

M.F. AlAfifi<sup>1</sup>, M. Shehada<sup>1</sup>, M. Sakka<sup>2</sup>. <sup>1</sup>Substance Abuse Research Center, Palestine; <sup>2</sup>AlAzhar University, Palestine

*Alcohol and drug use disorder in Iraqi governorates*

N.J. Al-Hemary<sup>1</sup>, M.T. Hashim<sup>2</sup>, J.K. Al-Diwan<sup>1</sup>. <sup>1</sup>College of Medicine, Baghdad University, Iraq; <sup>2</sup>Baghdad Teaching Hospital, Iraq

*Pattern of and related factors associated with khat chewing among higher education students in Jazan region, Saudi Arabia*

R.M. Alsanosy<sup>1</sup>, M.S. Mahfouz<sup>2</sup>, A.M. Gaffar<sup>2</sup>. <sup>1</sup>Substance Abuse Research Center, Jazan University, Saudi Arabia; <sup>2</sup>Department of Family and Community Medicine, Faculty of Medicine, Jazan University, Saudi Arabia

*Effect of cigarette smoking on blood sugar*

R. Aqrabi, V.M. Al-Jaf. Ministry of Health, Iraq

*Screening for DSM-5 cannabis dependence using the Cannabis Use Identification Test-Revised*

R. Bruno<sup>1</sup>, S. Marshall<sup>1</sup>, S. Adamson<sup>2</sup>. <sup>1</sup>School of Psychology, University of Tasmania, Australia; <sup>2</sup>National Addiction Centre, University of Otago, New Zealand

*Smoking prevalence and exposure to secondhand smoke during pregnancy in Mexican women*

O. Campollo<sup>1,2</sup>, F. Hernandez<sup>2</sup>, E. Angulo<sup>3</sup>, A. Guzman<sup>2</sup>, I. Navarro<sup>1</sup>, M. García<sup>3</sup>, A. Munguía<sup>1</sup>, J.K. Cunningham<sup>4</sup>. <sup>1</sup>Center of Studies on Alcohol and Addictions, Universidad de Guadalajara, Mexico; <sup>2</sup>Obstetrics Department, Hospital Civil de Guadalajara, Mexico; <sup>3</sup>Neonatology Department, Antiguo Hospital Civil de Guadalajara, Mexico; <sup>4</sup>Department of Family and Community Medicine, The University of Arizona, United States

*Epidemiological early-warning system for emerging drug use: The Medellin radar system*

G.A. Castaño Perez, G.A. Calderon Vallejo. Fundación Universitaria Luis Amigo, Colombia

*Influences of harm reduction programs on HIV knowledge and risky behaviors among injection drug users in prisons in Taiwan*

Y.J. Chang<sup>1</sup>, Y.C. Lan<sup>1</sup>, Y.I. Hser<sup>2</sup>. <sup>1</sup>China Medical University, Taiwan; <sup>2</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States

*Predictors of opioid use among women in Afghanistan: Data from the Afghanistan National Urban Drug Use Study*

A.V. Cherian<sup>1</sup>, C.W. Ruktanonchai<sup>1</sup>, K. Vaddiparti<sup>1</sup>, M.A. Ghani<sup>2</sup>, D.M. Martin<sup>3</sup>, M.S. Gold<sup>4</sup>, L.B. Cottler<sup>1</sup>. <sup>1</sup>Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, United States; <sup>2</sup>Spectre Group, Afghanistan; <sup>3</sup>JMJ Technologies, United States; <sup>4</sup>Department of Psychiatry, College of Medicine, University of Florida, United States

*Legal substance use and the development of a DSM-IV cannabis use disorder during adolescence*

H. Creemers<sup>1,2</sup>, A. Prince van Leeuwen<sup>1,3</sup>, F. Verhulst<sup>3</sup>, W. Vollebergh<sup>4</sup>, J. Ormel<sup>5</sup>, F. van Oort<sup>3</sup>, A. Huizink<sup>2</sup>. <sup>1</sup>Research Institute of Child Development and Education, University of Amsterdam, The Netherlands; <sup>2</sup>Department of Developmental Psychology, Vrije Universiteit (VU University) Amsterdam, The Netherlands; <sup>3</sup>Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, The Netherlands; <sup>4</sup>Faculty of Social and Behavioral Sciences, Utrecht University, The Netherlands; <sup>5</sup>Interdisciplinary Center for Psychiatric Epidemiology, University Medical Center Groningen, The Netherlands

*Epidemiology of engagement with the criminal justice system among opioid-dependent people: Retrospective cohort study*

L. Degenhardt<sup>1,2</sup>, J. Trevena<sup>1</sup>, S. Larney<sup>1,3</sup>, J. Kimber<sup>1</sup>, T. Butler<sup>4</sup>, R.P. Mattick<sup>1</sup>, D. Weatherburn<sup>5</sup>, L. Burns<sup>1</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>Centre for Health Policy, Programs and Economics, School of Population Health, University of Melbourne, Australia; <sup>3</sup>Brown University, United States; <sup>4</sup>Kirby Institute, University of New South Wales, Australia; <sup>5</sup>Bureau of Crime Statistics and Research, Australia

*Predictors of heroin use among opioid-dependent Afghan refugees in Iran*

A. Deylamizadeh<sup>1</sup>, Z.A. Mehrjerdi<sup>2</sup>, S. Rezaee<sup>3</sup>, A. Noroozi<sup>4</sup>, P. Higgs<sup>5</sup>. <sup>1</sup>Division of Research on Drug Use and Dependence, Rebirth Society, Iran; <sup>2</sup>Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Iran; <sup>3</sup>Department of Cultural Studies, Alame Tabata'i University, Iran; <sup>4</sup>School of Advanced Medical Technologies, INCAS, Tehran University of Medical Sciences, Iran; <sup>5</sup>Burnet Institute, Australia

*Illicit drug use in Guatemala: Critical perspectives of family and familiars*

J.B. Díaz Carranza<sup>1</sup>, B. Brands<sup>2</sup>, E. Adlaff<sup>2</sup>, N. Giesbrecht<sup>2</sup>, L. Simich<sup>2</sup>, M.G.M. Wright<sup>3</sup>. <sup>1</sup>Universidad de San Carlos, Guatemala; <sup>2</sup>Centre for Addiction and Mental Health, Canada; <sup>3</sup>Organization of American States, Inter-American Drug Abuse Control Commission, United States

*Trends in risk behavior and HIV prevalence among people who inject drugs in Ukraine: Evidence from biobehavioral surveys*

K. Dumchev<sup>1</sup>, I. Shvab<sup>2</sup>, T. Saliuk<sup>2</sup>, P. Smyrnov<sup>2</sup>, C.R. Vitek<sup>1</sup>. <sup>1</sup>Division of Global HIV/AIDS-Ukraine, U.S. Centers for Disease Control and Prevention, Ukraine; <sup>2</sup>International HIV/AIDS Alliance in Ukraine, Ukraine

*Methadone substitution treatment: Evaluation of the first experience in Morocco*

F. El Omari, N. Tarek, M. Sabir, J. Toufiq. University of Mohammed Vth Souissi, The National Center of Treatment, Prevention and Treatment on Addictions, Arrazi Psychiatric University Hospital of Rabat-Salé, Morocco

*Patterns of use of new psychoactive substances: A survey in a sample of e-psychoonauts in Spain*

M. Farre<sup>1</sup>, D. González<sup>1</sup>, M. Ventura<sup>2</sup>, F. Caudevilla<sup>3</sup>, F. Marsa<sup>1</sup>, M. Torrens<sup>1</sup>. <sup>1</sup>Hospital del Mar and Hospital del Mar Medical Research Institute-IMIM-UAB, Spain; <sup>2</sup>Energy Control, Spain; <sup>3</sup>Puerta Bonita Health Center, Spain

*Studying new trends of prescription drug use in Europe: The European opioid treatment patient survey*

F. Fonseca<sup>1,2</sup>, J.L. Green<sup>3</sup>, I. Maremmanni<sup>4</sup>, D. Touzeau<sup>5</sup>, S. Walcher<sup>6</sup>, G. Deruvo<sup>7</sup>, L. Somaini<sup>8</sup>, D. Martínez<sup>1,2</sup>, J. Roig<sup>1,2</sup>, M. Torrens<sup>1,2</sup>. <sup>1</sup>Institut de Neuropsiquiatria i Addiccions, Hospital del mar, Spain; <sup>2</sup>Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Spain; <sup>3</sup>Denver Health Rocky Mountain Poison & Drug Center, United States; <sup>4</sup>Department of Neurosciences, Santa Chiara University Hospital, Italy; <sup>5</sup>Clinique Liberté-Bagneux, France; <sup>6</sup>CONCEPT, Center for Addiction Medicine, Germany; <sup>7</sup>Drug Addiction Service-Bitonto, Italy; <sup>8</sup>Drug Addiction Service-Biella, Italy

*Drug tourism to Mexico among persons who inject drugs from the United States*

R.S. Garfein, R. Armenta, K.D. Wagner, J. Cuevas-Mota, F. Muñoz, V.D. Ojeda, J.L. Burgos, S.A. Strathdee. Division of Global Public Health, Department of Medicine, School of Medicine, University of California, San Diego, United States

*Vietnam HIV Addiction Technology Transfer Center: Training needs assessment survey results*

L.M. Giang<sup>1</sup>, R. Rawson<sup>2</sup>, B. Rutkowski<sup>2</sup>, K. Mulvey<sup>3</sup>. <sup>1</sup>Hanoi Medical University, Vietnam; <sup>2</sup>University of California, Los Angeles, United States; <sup>3</sup>Substance Abuse and Mental Health Services Administration, United States

*High proportion of undiagnosed HIV infections and high levels of methamphetamine use among men who have sex with men in Tijuana, Mexico*

D. Goodman-Meza<sup>1</sup>, J.L. Burgos<sup>1</sup>, A. Rudolph<sup>1</sup>, K.F. Torres<sup>3</sup>, D.A. Abramovitz<sup>1</sup>, S.A. Strathdee<sup>1</sup>, T.L. Patterson<sup>2</sup>. <sup>1</sup>Division of Global Public Health, University of California, San Diego, United States; <sup>2</sup>Department of Psychiatry, University of California, San Diego, United States; <sup>3</sup>Agencia Fronteriza Binacional, Mexico

*Alcohol and drug use among first- and second-generation immigrants from the former Soviet Union and Ethiopia in Israel: Toward integration or toward alienation?*

Y. Harel-Fisch<sup>1</sup>, S. Walsh<sup>2</sup>. <sup>1</sup>Israel Anti-Drugs and Alcohol Authority, Israel; <sup>2</sup>Department of Criminology, Bar Ilan University, Israel

*Perceived risk of violence at drug rehabilitation centers among people who inject drugs in Tijuana, Mexico*

A. Harvey-Vera<sup>1,2</sup>, K.D. Wagner<sup>1</sup>, P. González-Zúñiga<sup>1</sup>, M.E. Medina-Mora<sup>3</sup>, C.L. Magis-Rodríguez<sup>4</sup>, S.A. Strathdee<sup>1</sup>. <sup>1</sup>University of California, San Diego, United States; <sup>2</sup>Universidad Autónoma de Baja California, Mexico; <sup>3</sup>Instituto Nacional de Psiquiatría de México, Mexico; <sup>4</sup>Programa de SIDA de la Ciudad de México, Mexico

*Testing for amphetamine-type stimulant (ATS) use to ascertain validity of self-reported ATS use among young female sex workers in Cambodia*

V. Kab<sup>1</sup>, J. Evans<sup>2</sup>, N. Sansothy<sup>3</sup>, E. Stein<sup>2</sup>, M. Claude-Couture<sup>2</sup>, L. Maher<sup>4</sup>, and K. Page<sup>5</sup>. <sup>1</sup>School of Public Health, University of California, Berkeley, United States; <sup>2</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco, United States; <sup>3</sup>Cambodia National Center for HIV, AIDS, Dermatology and STDs, Cambodia; <sup>4</sup>The Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical Research), Australia; Young Women's Study Collaborative, Department of Epidemiology and Biostatistics, University of California, San Francisco, United States

*Suicide risks among Thai illicit drug users with and without mental disorders*

P. Kittiratanapaiboon<sup>1</sup>, S. Suttajit<sup>2</sup>, B. Junsirimongkol<sup>1</sup>, S. Likhitsathian<sup>2</sup>, M. Srisurapanont<sup>2</sup>. <sup>1</sup>Department of Mental Health, Ministry of Public Health, Thailand; <sup>2</sup>Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Thailand

*Patterns of adolescent betel nut chewing and later drug use in adults*

Y.C. Lan<sup>1,2</sup>, Y.I. Hser<sup>3</sup>, Y.K. Ho<sup>2</sup>, W.Y. Tsay<sup>4</sup>, J. Hsu<sup>4</sup>, J.J. Kang<sup>4</sup>. <sup>1</sup>Department of Health Risk Management, School of Management, China Medical University, China; <sup>2</sup>Center for Drug Abuse, China Medical University Hospital, China; <sup>3</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States; <sup>4</sup>Taiwan Food and Drug Administration, Taiwan

*Hepatitis C virus incidence and prevalence in correctional settings: Results of a global systematic review and meta-analysis*

S. Larney<sup>1,2</sup>, H. Kopinski<sup>3</sup>, C.G. Beckwith<sup>2,4</sup>, N.D. Zaller<sup>2,4</sup>, D. Des Jarlais<sup>5</sup>, H. Hagan<sup>6</sup>, J.D. Rich<sup>2,3,4</sup>, B.J. van den Bergh<sup>7</sup>, L. Degenhardt<sup>1,8</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>Alpert Medical School, Brown University, United States; <sup>3</sup>Center for Prisoner Health and Human Rights, Miriam Hospital, United States; <sup>4</sup>Division of Infectious Diseases, Miriam Hospital, United States; <sup>5</sup>Beth Israel Medical Center, United States; <sup>6</sup>College of Nursing, New York University, United States; <sup>7</sup>World Health Organization Regional Office for Europe HIV/AIDS, Sexually Transmitted Infections and Viral Hepatitis Programme, Denmark; <sup>8</sup>Centre for Health Policy, Programs and Economics, School of Population Health, University of Melbourne, Australia

*European perspective on misuse of prescription drugs: Where does Europe stand compared with the United States?*

D. Lopez. Independent Consultant, Chennai, India

*Drug-craving terminology among opiate dependents: A mixed-method study*

M. Maarefvand<sup>1</sup>, H.R. Ghiasvand<sup>2</sup>, H. Ekhtiari<sup>3</sup>. <sup>1</sup>Department of Social Work, University of Social Welfare and Rehabilitation Sciences, Iran; <sup>2</sup>Department of Educational Psychology, Islamic Azad University, Iran; <sup>3</sup>Neurocognitive Laboratory, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran

*Tobacco use during pregnancy in two different populations*

R. Magri<sup>1</sup>, J. Jones<sup>2</sup>, H. Míguez<sup>3</sup>, M. Suárez<sup>1</sup>, H. Suárez<sup>4</sup>. <sup>1</sup>Universidad de la Republica, Uruguay; <sup>2</sup>United States Drug Testing Laboratories, United States; <sup>3</sup>Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina; <sup>4</sup>Observatorio de Drogas, Uruguay

*Correlates of coabuse of methamphetamine with opioids among Afghan refugees in Iran*

Z.A. Mehrjerdi<sup>1</sup>, S. Jafari<sup>2</sup>, A. Noroozi<sup>3</sup>, M. Zarghami<sup>4</sup>, P. Higgs<sup>5</sup>. <sup>1</sup>Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Iran; <sup>2</sup>Department of Health Care and Epidemiology, Faculty of Medicine, University of British Columbia, Canada; <sup>3</sup>School of Advanced Medical Technologies, INCAS, Tehran University of Medical Sciences, Iran; <sup>4</sup>Department of Psychiatry, Faculty of Medicine, Mazandaran University of Medical Sciences, Iran; <sup>5</sup>Burnet Institute, Australia

*Molecular epidemiology of HIV in the San Diego-Tijuana Border Region*

S. Mehta<sup>1</sup>, S. Little<sup>1</sup>, J. Wertheim<sup>1</sup>, S. Pond<sup>1</sup>, R. Garfein<sup>1</sup>, T. Patterson<sup>1</sup>, S. Strathdee<sup>1</sup>, D. Smith<sup>1,2</sup>. <sup>1</sup>Department of Medicine, University of California, San Diego, United States; <sup>2</sup>San Diego Veterans Affairs Medical Center, United States



*Vocalized truths: Iranian drug-using women's narratives*

E. Merghati-Khoei<sup>1,2</sup>, F. Yadollahi<sup>1</sup>, K. Dolan<sup>3</sup>, S. Rimaz<sup>1</sup>, T.K. Killeen<sup>2</sup>. <sup>1</sup>Department of Public Health, Tehran University of Medical Sciences, Iran; <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States; <sup>3</sup>National Drug and Alcohol Research Center, University of New South Wales, Australia

*Defense mechanism styles of relapsing addicts in a Malaysian context: A new discovery*

A.H. Mohd Hussin<sup>1</sup>, F. Sabri<sup>1</sup>, M.H. Abdullah<sup>2</sup>. <sup>1</sup>Asian Centre for Research on Drug Abuse, Islamic Science University of Malaysia, Malaysia; <sup>2</sup>Faculty of Modern Languages and Communication, Universiti Putra Malaysia, Malaysia

*It takes [at least] two to share: Understanding decision-making processes influencing high-risk injecting behaviors*

M.D. Morris<sup>1</sup>, A. Bates<sup>2</sup>, K. Page<sup>1</sup>, J. Hahn<sup>3</sup>, L. Maher<sup>2</sup>. <sup>1</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco, United States; <sup>2</sup>The Kirby Institute, University of New South Wales, Australia; <sup>3</sup>Department of Medicine, University of California, San Francisco, United States

*Multicenter study of HIV infection and viral hepatitis B and C among drug users starting substance abuse treatment in Spain, 1987–2011*

R. Muga<sup>1,2</sup>, A. Sanvisens<sup>1</sup>, G. Vallecillo<sup>3</sup>, F. Bolao<sup>4,5</sup>, D. Fuster<sup>6</sup>, M. Torrens<sup>2,3</sup>, M. Fanlo<sup>4</sup>, J. Tor<sup>1,2</sup>. <sup>1</sup>Hospital Universitari Germans Trias i Pujol, Spain; <sup>2</sup>Universitat Autònoma de Barcelona, Spain; <sup>3</sup>Hospital del Mar, Spain; <sup>4</sup>Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain; <sup>5</sup>Universitat de Barcelona, Spain; <sup>6</sup>Boston University School of Medicine, United States

*Where do problematic prescription drug users acquire pharmaceuticals? Source and use patterns from a sample of people in drug treatment*

S. Nielsen<sup>1</sup>, R. Bruno<sup>2</sup>, L. Degenhardt<sup>3</sup>, M. Stoove<sup>4</sup>, J. Fischer<sup>5</sup>, S. Carruthers<sup>6</sup>, N. Lintzeris<sup>7</sup>. <sup>1</sup>University of Sydney, Australia; <sup>2</sup>University of Tasmania, Australia; <sup>3</sup>National Drug and Alcohol Centre, University of New South Wales, Australia; <sup>4</sup>Burnet Institute, Australia; <sup>5</sup>Flinders University and Queensland Health, Australia; <sup>6</sup>Curtain University, Australia; <sup>7</sup>University of Sydney and South Eastern Sydney Local Health District, Australia

*Relationship between poor self-esteem and adolescent substance use*

A.M. Ojo<sup>1</sup>, O. Akintoyese<sup>2</sup>, P. Adenibuyan<sup>1</sup>, A.A. Adegbohun<sup>3</sup>, K. Abiri<sup>3</sup>. <sup>1</sup>Substance Abuse Treatment and Research Unit, Federal Neuro-Psychiatric Hospital, Nigeria; <sup>2</sup>Drug Abuse Treatment and Research Unit, Federal Neuro-Psychiatric Hospital, Nigeria; <sup>3</sup>Substance Abuse and Treatment Unit, Federal Neuro-Psychiatric Hospital, Nigeria

*Cannabis use and criminal behavioral tendencies in young people: A study of Kaduna State, Nigeria*

M.O. Onoja, A. Okoh, J.A. Ocheh. USAID/MAPS Benue State Office, Nigeria

*Substance use among secondary school students in Calabar, Nigeria: A study in advance of establishing a school-based prevention program*

U.C. Onukogu<sup>1</sup>, C.A. Anya<sup>2</sup>, E.E. Ekpe<sup>1</sup>, B. Edet<sup>1</sup>. <sup>1</sup>Federal Psychiatric Hospital, Nigeria; <sup>2</sup>Department of Education Foundation, University of Lagos, Nigeria

*A study of quality of life of subjects with opioid and alcohol dependence*

B.N. Patra, D. Basu, S. Sarkar. Drug De-addiction and Treatment Center, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, India



*Substance use during pregnancy among women attending midwife obstetric units in the Cape Metropole, South Africa*

P. Petersen Williams<sup>1</sup>, E. Jordaan<sup>2</sup>, C. Mathews<sup>3,4</sup>, C.D.H. Parry<sup>1,5</sup>. <sup>1</sup>Alcohol and Drug Abuse Research Unit, Medical Research Council, South Africa; <sup>2</sup>Biostatistics Unit, South African Medical Research Council, South Africa; <sup>3</sup>School of Public Health and Family Medicine, University of Cape Town, South Africa; <sup>4</sup>Health Systems Research Unit, South African Medical Research Council, South Africa; <sup>5</sup>Department of Psychiatry, Stellenbosch University, South Africa

*Validity of the standardized field sobriety test in detecting drug impairment*

A. Porath-Waller, D. Beirness. Canadian Centre on Substance Abuse, Canada

*Gender and outcomes of heroin abusers admitted to a methadone maintenance program in Spain*

I. Rivas<sup>1</sup>, E. Faure<sup>1</sup>, A. Sanvisens<sup>2</sup>, D. Fuster<sup>3</sup>, M. Rubio<sup>1</sup>, T. Muñoz<sup>1</sup>, J. Tor<sup>1,4</sup>, R. Muga<sup>1,4</sup>. <sup>1</sup>Municipal Center for Substance Abuse Treatment (Centro Delta–Bus Intermunicipal de Metadona), IMSP, Spain; <sup>2</sup>Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Spain; <sup>3</sup>Section of General Internal Medicine, Boston Medical Center, Boston University School of Medicine, United States; <sup>4</sup>Universitat Autònoma de, Spain

*“Double risk–double stigma”: Characteristics of injection drug use (IDU) sex workers in comparison with non-IDU sex workers in Russia*

M. Rusakova<sup>1,2</sup>. <sup>1</sup>NGO Stellit, Social Studies, Russia; <sup>2</sup>The Sociological Institute of the Russian Academy of Sciences, Deviance and Social Control, Russia

*Factors related to the use of areca nut among families in a municipality in Cordillera Region, Philippines*

J. Sagabaen, Jr., J. Pascual, E. Castillo, I. Escartin. Postgraduate Institute of Medicine, University of the Philippines, College of Medicine, Department of Health, Philippines

*Socio-psychosocial conditions of migration and drug abuse in women*

R. Sánchez-Huesca<sup>1</sup>, J.L. Arellanez-Hernández<sup>2</sup>, V. Pérez-Islas<sup>2</sup>.

<sup>1</sup>Research and Training, Centros de Integración Juvenil, Mexico; <sup>2</sup>Psychosocial Research Department, Centros de Integración Juvenil, Mexico

*Pathways of progression from use of one substance to another in treatment seekers*

S. Sarkar<sup>1</sup>, N. Nebhinani<sup>2</sup>, S. Gupta<sup>1</sup>, P. Parakh<sup>1</sup>, D. Basu<sup>1</sup>. <sup>1</sup>Department of Psychiatry, Post Graduate Institute of Medical Education and Research–Chandigarh, India; <sup>2</sup>Department of Psychiatry, Post Graduate Institute of Medical Education and Research–Rohtak, India

*Acute intoxication cases related to methoxetamine consumption in Italy: Clinical and toxicological evidences*

G. Serpelloni<sup>1</sup>, C. Rimondo<sup>2</sup>, C. Seri<sup>3</sup>, M. Cavallini<sup>2</sup>, T. Macchia<sup>4</sup>, C. Locatelli<sup>5</sup>, P. Papa<sup>6</sup>, P. Botti<sup>7</sup>. <sup>1</sup>Department for Antidrug Policies, Presidency of the Council of Ministers, Italy; <sup>2</sup>National Early Warning System Project, Department for Antidrug Policies, Presidency of the Council of Ministers, Italy; <sup>3</sup>Department of Public Health and Community Medicine, Unit of Forensic Medicine, University of Verona, Italy; <sup>4</sup>Institute of Public Health, Drugs Department, Italy; <sup>5</sup>Poison Control Centre and National Toxicology Information Centre, Toxicology Unit, IRCCS Maugeri Foundation and University of Pavia, Italy; <sup>6</sup>Laboratory of Analytical Toxicology, Clinical Chemistry Service, IRCCS Policlinico San Matteo Foundation, Italy; <sup>7</sup>Poison Control Centre of Florence, Careggi University Hospital, Italy

*Early-onset cannabis use and young adult outcomes: An integrative data analysis of three Australasian cohorts*

E. Silins<sup>1</sup>, C. Olsson<sup>2</sup>, J. Horwood<sup>3</sup>, D. Hutchinson<sup>1</sup>, G. Patton<sup>2</sup>, D. Fergusson<sup>3</sup>, J. Toumbourou<sup>4</sup>, E. Spry<sup>2</sup>, R. Mattick<sup>1</sup>, The Cannabis Cohort Research Consortium<sup>5</sup>.

<sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia;

<sup>2</sup>Centre for Adolescent Health, Royal Children's Hospital, Australia; <sup>3</sup>Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand; <sup>4</sup>School of Psychology, Deakin University, Australia; <sup>5</sup>Cannabis Cohort Research Consortium, National Drug and Alcohol Research Center, University of New South Wales, Australia

*Characteristics of HIV-infected injection drug users at five methadone clinics in Jakarta, Indonesia*

H. Susami<sup>1</sup>, A. Nurhidayat<sup>2</sup>, D. Utami<sup>3</sup>, R. Sarasvita<sup>3</sup>, N. Hasan<sup>2</sup>, F. Wiyandani<sup>2</sup>, S. Chhatre<sup>4</sup>, M. Chawarski<sup>5</sup>, G. Woody<sup>4</sup>, D. Metzger<sup>4</sup>. <sup>1</sup>Pokdisus AIDS FKUI/RSCM, Indonesia; <sup>2</sup>Drug Dependence Hospital RSKO-Jakarta, Indonesia; <sup>3</sup>Ministry of Health, Indonesia; <sup>4</sup>University of Pennsylvania, United States; <sup>5</sup>Yale University, United States

*Prevalence and patterns of substance use among schizophrenic patients in southern Thailand*

N. Tantirangsee<sup>1</sup>, S. Assanangkornchai<sup>2</sup>. <sup>1</sup>Songkhla Rajanagarinda Psychiatric Hospital, Thailand; <sup>2</sup>Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Thailand

*Epidemiological characteristics of drug users who underwent voluntary testing for HIV in a treatment reference center in Rio De Janeiro*

P. Telles-Dias. NEPAD-State University of Rio de Janeiro and MEB-Fluminense Federal University, Brazil

*The substance and illicit drug abuser migration from an urban to rural area in Taiwan between 2005 and 2009*

W. Tsay<sup>1</sup>, J. Hsu<sup>1</sup>, J. Kang<sup>1</sup>, Y. Lan<sup>2,3</sup>, Y. Hser<sup>4</sup>, I. Ho<sup>3</sup>. <sup>1</sup>Taiwan Food and Drug Administration, Taiwan; <sup>2</sup>China Medical University, Taiwan; <sup>3</sup>China Medical University Hospital, Taiwan; <sup>4</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States

*History of abuse and depression symptoms among injection drug-using female sex workers in Mexico*

M.D. Ulibarri<sup>1</sup>, S.P. Hiller<sup>1</sup>, R. Lozada<sup>2</sup>, M.G. Rangel<sup>3</sup>, J.K. Stockman<sup>1</sup>, J.G. Silverman<sup>1</sup>, V.D. Ojeda<sup>1</sup>. <sup>1</sup>University of California, San Diego, United States; <sup>2</sup>PrevenCasa, México; <sup>3</sup>El Colegio de La Frontera Norte, México

*Quality of life among HIV-infected IDUs at five methadone clinics in Jakarta*

D. Utami<sup>1</sup>, H. Susami<sup>2</sup>, A. Nurhidayat<sup>3</sup>, E. Prayitno<sup>3</sup>, F. Murti<sup>4</sup>, I. Kusuma<sup>4</sup>, R. Sarasvita<sup>1</sup>, S. Chhatre<sup>5</sup>, M. Chawarski<sup>5</sup>, G. Woody<sup>6</sup>, D. Metzger<sup>6</sup>. <sup>1</sup>Ministry of Health, Indonesia; <sup>2</sup>Pokdisus AIDS FKUI/RSCM Indonesia; <sup>3</sup>Drug Dependence Hospital RSKO-Jakarta, Indonesia; <sup>4</sup>University of Indonesia, Indonesia; <sup>5</sup>Yale University, United States; <sup>6</sup>University of Pennsylvania, United States

*Risk factors for self-reported physical abuse of women households in Afghanistan: Data from the Afghanistan National Urban Drug Study*

K. Vaddiparti<sup>1</sup>, C. Striley<sup>1</sup>, M.A. Ghani<sup>2</sup>, D.M. Martin<sup>3</sup>, C. Ruktanonchai<sup>1</sup>, M.S. Gold<sup>4</sup>, L.B. Cottler<sup>1</sup>. <sup>1</sup>Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, United States; <sup>2</sup>Spectre Group, Afghanistan; <sup>3</sup>JMJ Technologies, United States; <sup>4</sup>Department of Psychiatry, College of Medicine, University of Florida, United States

*Drug use histories of very young drug users after 15 years: Doing well because of treatment or despite it?*

T. Zabransky<sup>1</sup>, J. Brenza<sup>1</sup>, L. Csemy<sup>1,2</sup>, K. Grohmannova<sup>1,3</sup>, B. Janikova<sup>1</sup>. <sup>1</sup>Department of Addictology, First Medical Faculty, Charles University in Prague, Czech Republic; <sup>2</sup>Prague Psychiatric Centre, Charles University in Prague, Czech Republic; <sup>3</sup>National Monitoring Centre for Drugs and Drug Addiction, Czech Republic

*Genotype diversity of hepatitis C virus among methadone maintenance treatment patients in Wuhan, China*

S. Zhou<sup>1</sup>, W. Zhou<sup>2</sup>, R.S. Schottenfeld<sup>3</sup>, W. Kong<sup>2</sup>, M. Liu<sup>2</sup>, J. Peng<sup>2</sup>, P. Liu<sup>2</sup>, M.C. Chawarski<sup>3</sup>. <sup>1</sup>Huazhong University of Science and Technology, China; <sup>2</sup>Wuhan Center for Disease Control and Prevention, China; <sup>3</sup>Yale School of Medicine, United States

## OTHER

*Israel national alcohol policy*

S. Ben-Ezra. Hubert H. Humphrey Fellowship Program, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States; Israel Anti-Drug Authority, Israel

*The Hubert H. Humphrey Fellowship Program at Virginia Commonwealth University*

J.R. Koch, R.L. Balster, A. Breland, M.E. Loos, C. Thomas. Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States

*Substance use and misuse education in Israel: Trends in higher education*

M. Lawental<sup>1</sup>, Eli Lawental<sup>2</sup>. <sup>1</sup>University of Haifa, Israel; <sup>2</sup>School of Social Work, Tel Hai College, Israel

*Virginia Commonwealth University Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment, and Policy: 1-year follow-up assessment*

L. Leonchuk<sup>1,2</sup>, J.R. Koch<sup>1</sup>, R.L. Balster<sup>1</sup>, A. Breland<sup>1</sup>. <sup>1</sup>Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States; <sup>2</sup>Department of Psychology, North Carolina State University, United States

*Guidelines for international collaboration*

C.B. McCoy<sup>1</sup>, J.M. Shultz<sup>1,2</sup>, Z. Espinel<sup>2</sup>, J.A. McCoy-Bengoa<sup>1</sup>, L.J. Hernandez<sup>3</sup>, S. Lai<sup>4</sup>, R. Achi<sup>5</sup>, M. Zhao<sup>6</sup>. <sup>1</sup>Comprehensive Drug Research Center, University of Miami, United States; <sup>2</sup>The Center for Disaster and Extreme Event Preparedness, University of Miami, United States; <sup>3</sup>Universidad de Los Andes, Colombia; <sup>4</sup>School of Medicine, Johns Hopkins University, United States; <sup>5</sup>University of Costa Rica, Costa Rica; <sup>6</sup>Shanghai Drug Abuse Treatment Center, China

### *Global addiction sciences training*

J.M. Shultz<sup>1,2</sup>, C.B. McCoy<sup>2</sup>, A.J. McCoy-Bengoa<sup>2</sup>, Z. Espinel<sup>1</sup>, M.C. Gutierrez<sup>3</sup>, S. Lai<sup>4</sup>, R. Achi<sup>5</sup>, M. Zhao<sup>6</sup>. <sup>1</sup>The Center for Disaster and Extreme Event Preparedness, University of Miami, United States; <sup>2</sup>Comprehensive Drug Research Center, University of Miami, United States; <sup>3</sup>Universidad de Los Andes, Colombia; <sup>4</sup>School of Medicine, Johns Hopkins University, United States; <sup>5</sup>University of Costa Rica, Costa Rica; <sup>6</sup>Shanghai Drug Abuse Treatment Center, China

### *Building international collaborative research on drug abuse: NIDA-Pavlov experience*

E. Zvartau. Pavlov Medical University, St. Petersburg, Russia

## PREVENTION

### *Legal environment as the risk environment: Understanding drug user experiences of law in the context of arbitrary policing*

J. Arredondo<sup>1</sup>, L. Beletsky<sup>2</sup>, K. Wagner<sup>1</sup>, C. Magis-Rodriguez<sup>3</sup>, S.A. Strathdee<sup>1</sup>.

<sup>1</sup>University of California, San Diego, United States; <sup>2</sup>Northeastern University School of Law, United States; <sup>3</sup>Centro Nacional para la Prevención y Control del VIH/SIDA—The National Center for the Prevention and Control of AIDS (CONASIDA), Mexico

### *Quality of life and substance use among school-going adolescents in India*

Y.P.S. Balhara<sup>1</sup>, D. Stevanovic<sup>2</sup>, O. Atilola<sup>3</sup>, M. Avicenna<sup>4</sup>, H. Kandemir<sup>5</sup>, P. Vostanis<sup>6</sup>.

<sup>1</sup>National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India; <sup>2</sup>Department of Psychiatry, General Hospital-Sombor, Serbia; <sup>3</sup>Department of Psychiatry, University College Hospital-Ibadan, Nigeria; <sup>4</sup>Faculty of Psychology, State Islamic University, Indonesia; <sup>5</sup>Department of Child and Adolescent Psychiatry, Harran University, Turkey; <sup>6</sup>School of Psychology, Leicester University, United Kingdom

### *Evaluation of “Education for Life Program” in preventing drug use in third-cycle and high school students*

F. Bautista-Perez. Universidad Evangélica de El Salvador, El Salvador

### *Cost of drug and HIV counseling to opiate-dependent drug users receiving methadone treatment in Jakarta, Indonesia*

J. Becher<sup>1</sup>, A.W. Nurhidayat<sup>2</sup>, F. Rahim<sup>2</sup>, E. Susami<sup>2</sup>, D. Metzger<sup>1</sup>. <sup>1</sup>University of Pennsylvania, United States; <sup>2</sup>Drug Dependence Hospital–RSKO, Indonesia

### *The influence of gender differences and engaging in romantic relationships on substance use offers among Mexican adolescents*

J. Booth<sup>1,2</sup>, F. Marsiglia<sup>1,2</sup>, B. Nuño-Gutiérrez<sup>3</sup>. <sup>1</sup>School of Social Work, Arizona State University, United States; <sup>2</sup>Southwest Interdisciplinary Research Center, Arizona State University, United States; <sup>3</sup>University of Guadalajara and Mexican Social Security Institute, Mexico

### *Cannabis and driving: Australian policy and responses*

J. Copeland. National Cannabis Prevention and Information Centre, University of New South Wales, Australia

*A comprehensive plan for inhalant misuse reduction in Mexico City*

S.L. Cruz<sup>1</sup>, F. Gutierrez-Rosse<sup>2</sup>, R. Camacho-Solis<sup>3</sup>. <sup>1</sup>Departamento de Farmacobiología, Cinvestav, Mexico; <sup>2</sup>Instituto Tecnológico de Estudios Superiores de Monterrey, Mexico; <sup>3</sup>Instituto para la Atención y Prevención de las Adicciones en la Ciudad de México, Mexico

*Comprehensive programs for children and mothers with substance abuse issues*

P. Dolezalova. Hubert H. Humphrey Fellowship Program, Bloomberg School of Public Health, Johns Hopkins University, United States; Department of Addictology, First Faculty of Medicine, Charles University–Prague, Czech Republic; General Faculty Hospital–Prague, Czech Republic

*Survey of risk and protective factors in middle school in Brazil*

C. Dos Santos. Hubert H. Humphrey Fellowship Program, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States; Military Police of São Paulo State, Brazil

*Is it possible to use new HIV testing methods among injection drug users in China?*

J. Du<sup>1</sup>, Y.Y. Meng<sup>2</sup>, M. Zhao<sup>1</sup>. <sup>1</sup>Shanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, China; <sup>2</sup>Center for Health Policy Research, University of California, Los Angeles, United States

*Management of controlled substances and dependency by pharmacists*

M. El-Sakka<sup>1</sup>, A. Azhar<sup>2</sup>. <sup>1</sup>College of Pharmacy, University of Gaza, Palestinian Territories; <sup>2</sup>Department of Pharmacognosy, University of Gaza, Palestinian Territories

*U.S.–Mexico Binational Quit Using Drugs Intervention Trial (Binational Quit)*

L. Gelberg<sup>1</sup>, G. Natera<sup>2</sup>, R.M. Andersen<sup>1</sup>, M. González<sup>3</sup>, M. Arroyo<sup>2</sup>, L. Arangua<sup>1</sup>, I. Bojórquez<sup>4</sup>, N. Baldwin<sup>1</sup>, L. Heller<sup>1</sup>, B. Leake<sup>1</sup>, M. Vahidi<sup>1</sup>, J.M. Scholtz<sup>1</sup>. <sup>1</sup>University of California, Los Angeles, United States; <sup>2</sup>Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico; <sup>3</sup>Comisión Nacional Contra las Adicciones, Mexico; <sup>4</sup>El Colegio de la Frontera Norte, Mexico

*Immediate and 6-month effects of Project EX Russia: A smoking cessation intervention pilot program*

B. Idrisov<sup>1</sup>, P. Sun<sup>2</sup>, L. Akhmadeeva<sup>1</sup>, T.E. Arpawong<sup>2</sup>, P. Kukhareva<sup>3</sup>, S. Sussman<sup>2</sup>. <sup>1</sup>Bashkortostan State Medical University, Russia; <sup>2</sup>University of Southern California, United States; <sup>3</sup>University of North Carolina at Chapel Hill, United States

*Impact of psychosocial services provided through the medication-assisted treatment program to injection drug users in the resource-poor settings of Ukraine*

Z. Islam, V. Kolomiets, S. Filippovych. International HIV/AIDS Alliance in Ukraine, Ukraine

*Harnessing the power of local civil society organizations in addressing challenges of drug use-related HIV/AIDS in Burma (Myanmar)*

N.M. Kham. Hubert H. Humphrey Fellowship Program, Bloomberg School of Public Health, Johns Hopkins University, United States

*Factors affecting overall satisfaction with HIV testing and counseling services among clients with and without injection drug use experience in Odessa, Ukraine*

T. Kiriazova<sup>1,2</sup>, O. Postnov<sup>3</sup>, I. Perehinets<sup>4</sup>, O. Neduzhko<sup>2</sup>. <sup>1</sup>Future Without AIDS Foundation, Ukraine; <sup>2</sup>Ukrainian Institute of Public Health Policy, Ukraine; <sup>3</sup>I.I. Mechnikov Ukrainian Anti-Plague Research Institute, Ukraine; <sup>4</sup>World Health Organization, Country Office, Ukraine



*Abuse of codeine-containing cough syrups and the risk of HIV among street youth in northern Nigeria*

G.A. Likpara, H. Ikenna, C. Oruete. Society Against Drug Abuse, Nigeria

*Drug policy change in Russia—origins of resistance and areas of opportunities*

K. Lunze<sup>1</sup>, N. Gnatienko<sup>1</sup>, A. Gassae<sup>2</sup>, S. Karaev<sup>2</sup>, F.I. Lunze<sup>3,4</sup>. <sup>1</sup>Boston University, United States; <sup>2</sup>Drug Treatment and Rehabilitation Center—Vladikavkaz, Russia; <sup>3</sup>North Ossetian State Medical Academy, Russia; <sup>4</sup>Harvard University, United States

*Short-term effects of the implementation of “keepin’ it REAL” on substance use in Jalisco, Mexico*

F. Marsiglia<sup>1,2</sup>, J. Booth<sup>1,2</sup>, S.L. Ayers<sup>2</sup>, B. Nuño-Gutierrez<sup>3</sup>, S. Kulis<sup>2,4</sup>, and S. Hoffman<sup>1,2</sup>. <sup>1</sup>School of Social Work, Arizona State University, United States; <sup>2</sup>Southwest Interdisciplinary Research Center, Arizona State University, United States; <sup>3</sup>University of Guadalajara and Mexican Social Security Institute, Mexico; <sup>4</sup>School of Social and Family Dynamics, Arizona State University, United States

*Risk behaviors associated with HIV infection among people who inject drugs in a rural area of Burma (Myanmar)*

R. Myint. Hubert H. Humphrey Fellowship Program, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States; Myanmar Anti-Narcotics Association—Lashio, Burma (Myanmar)

*Primary prevention of cannabis use: A systematic review of randomized controlled trials*

M.M. Norberg, S. Kezelman, N. Lim-Howe. National Cannabis Prevention and Information Centre, University of New South Wales, Australia

*Environmental tobacco smoke as a risk factor in increase of respiratory childhood infection and pneumonia in the southwest region of Nigeria*

S. Omiyefa. Youth Action on Tobacco Control and Health, Nigeria

*Long-term evaluation of the Spanish Strengthening Families Program, 8–12: Assessing the educational intervention with families*

C. Orte<sup>1</sup>, K. Kumpfer<sup>2</sup>, L. Ballester<sup>1</sup>, M.X. March<sup>1</sup>, J. Amer<sup>1</sup>, J.L. Oliver<sup>1</sup>, B. Pascual<sup>1</sup>, M. Vives<sup>1</sup>. <sup>1</sup>Department of Education and Specific Didactics, University of the Balearic Islands, Spain; <sup>2</sup>Department of Health Promotion and Education, University of Utah, United States

*Drug abuse problems among Nepalese urban youth*

L. Pokharel<sup>1</sup>, M.B. Poudyal Chhetri<sup>2</sup>. <sup>1</sup>Ministry of Home Affairs, Department of Immigration, Nepal; <sup>2</sup>Disaster Preparedness Network, Nepal

*High risk of drug abuse and HIV in urban Nepal*

M. Poudyal Chhetri. Disaster Preparedness Network, Nepal

*Ways to increase coverage of harm reduction programs in women-friendly facilities in Iran: A qualitative study*

S.R. Radfar. Thought, Culture and Health (ROOZBEH) Drug Abuse Prevention Institute, Iran

*Use of the substance abuse prevention program, CHOICE, for increase of tolerance toward HIV-positive people*

V. Ryabukha. Humanitarian Technologies Center of AHALAR, Ukraine

*Use of sex-related drugs among men who have sex with men in Jakarta, Indonesia*

I. Safika, T.P. Johnson. Survey Research Laboratory, University of Illinois at Chicago, United States



*Development of a survey on risk and protective factors for substance use among secondary school students in Lomé, Togo*

K. Sedaminou. Hubert H. Humphrey Fellowship Program, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States; Kodjoviakope Secondary School–Lomé, Togo

*Correlation between use of hard drugs, alcohol, and risky sexual behavior among youth at an international border town*

A.O. Sekoni<sup>1</sup>, A. Babatunde<sup>2</sup>, A. Adelakun<sup>2</sup>. <sup>1</sup>University of Lagos, Nigeria; <sup>2</sup>Pro-Health Initiative, Nigeria

*Motherhood and HIV: Exploring the relationship between motherhood and HIV risk behaviors among female sex workers who are also injection drug users in two Mexican–U.S. border cities*

A. Servin Aguirre<sup>1,2</sup>, J.G. Silverman<sup>2</sup>, G. Rangel<sup>3</sup>, G. Martinez<sup>4</sup>, A. Vera<sup>2</sup>, S.A. Strathdee<sup>2</sup>. <sup>1</sup>School of Medicine, Universidad Xochicalco, Campus Tijuana, Mexico; <sup>2</sup>Department of Medicine, Division of Global Public Health, University of California, San Diego, United States; <sup>3</sup>El Colegio de la Frontera Norte (COLEF), Mexico; <sup>4</sup>Salud y Desarrollo Comunitario de Ciudad Juárez A.C. (SADEC) and Federación Mexicana de Asociaciones Privadas (FEMAP), Mexico

*Development of drug use risk surveillance system for offenders in Chiang Mai and Lamphun Provinces, Thailand*

K. Thaikla<sup>1</sup>, A. Aramratana<sup>2</sup>. <sup>1</sup>Research Institute for Health Sciences, Chiang Mai University, Thailand; <sup>2</sup>Faculty of Medicine, Chiang Mai University, Thailand

*Factors of injection behavior change among participants of a peer-driven intervention in Ukraine*

T. Vasylyeva<sup>1</sup>, T. Andreeva<sup>2</sup>. <sup>1</sup>School of Public Health, State University of New York, U.S.; <sup>2</sup>School of Public Health, National University of Kyiv-Mohyla Academy, Ukraine

*Knowledge, perception, and risk behaviors for HIV transmission among methadone clients in Shanghai, China*

H. Zhang<sup>1,2</sup>, M.C. Chawarski<sup>1</sup>, R.S. Schottenfeld<sup>1</sup>. <sup>1</sup>Psychiatry Department, School of Medicine, Yale University, U.S.; <sup>2</sup>Shanghai Yangpu Mental Health Center, China

*Impaired hypothalamus-pituitary-gonadal axis in women with long-term methamphetamine use*

Y.S. Zhang<sup>1</sup>, W.W. Shen<sup>2</sup>, Y. Liu<sup>3</sup>, L.H. Li<sup>2</sup>, W.H. Zhou<sup>2,3</sup>. <sup>1</sup>Department of Gynecology, No.1 People's Hospital of Ningbo, China; <sup>2</sup>Ningbo Addiction Research and Treatment Center, China; <sup>3</sup>School of Medicine, Ningbo University, China

## TREATMENT

*Differences in antiretroviral treatment adherence in patients in opioid substitution treatment Bucharest, Romania*

A.O. Abagiu<sup>1,2</sup>, F.M. Duna<sup>1</sup>, I.T. Niculescu<sup>1</sup>, I.G. Stoica<sup>2</sup>, C.I. Fierbinteanu<sup>2</sup>, E. Apolzan<sup>2</sup>, A. Streinu-Cercel<sup>1</sup>. <sup>1</sup>National Institute for Infectious Diseases Prof. Dr. Matei Bals, Romania; <sup>2</sup>Arena MMT Center, Romania

*Cannabinoid replacement therapy (Sativex) for management of cannabis withdrawal*

D.J. Allsop<sup>1</sup>, J. Copeland<sup>1</sup>, N. Lintzeris<sup>2</sup>, I. McGregor<sup>3</sup>, A. Dunlop<sup>2</sup>, M. Norberg<sup>1</sup>, M. Montebello<sup>2</sup>, C. Saddler<sup>2</sup>. <sup>1</sup>National Cannabis Prevention and Information Centre, National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>New South Wales Health, Australia; <sup>3</sup>Sydney University, Australia

*Predictors for positive treatment outcomes of opioid dependence treatment with buprenorphine-naloxone*

S.M. Apelt. Certum Consulting-Scientific Research, Germany

*Introducing the Alcohol, Smoking, and Substance Involvement Screening Test—brief intervention for substance misuse: Acceptance and uptake in Thailand*

S. Assanangkornchai, Q. Balthip, C. Sathirapanya. Prince of Songkla University, Thailand

*Piloting a contingency management intervention among needle exchange program users in Tirana, Albania*

A. Boci<sup>1</sup>, A. Zazo<sup>2</sup>, E. Hallkaj<sup>1</sup>. <sup>1</sup>Stop AIDS NGO, Albania; <sup>2</sup>UNICEF, Albania

*Family functional treatment*

L. Caris, H. Waldron, H. Hops. University of Chile, Chile

*Relapse rate among drug users after discharge: An evaluation of the effectiveness of drug abuse programs in Taiwan*

M.C. Chang<sup>1</sup>, W.C. Kuo<sup>2</sup>. <sup>1</sup>University at Albany, State University of New York, United States; <sup>2</sup>Sindian Drug Abuse Center, Taiwan

*An evidence-based youth smoking cessation program tested in Thailand*

N. Charoenca<sup>1</sup>, P. Lapvongwatana<sup>1</sup>, N. Kungskulniti<sup>1</sup>, N. Chansatitporn<sup>1</sup>, S.L. Hamann<sup>2</sup>, T.E. Arpawong<sup>3</sup>, S. Sussman<sup>4</sup>. <sup>1</sup>Mahidol University Faculty of Public Health, Thailand; <sup>2</sup>Tobacco Control Research and Knowledge Management Center, Thailand; <sup>3</sup>Keck School of Medicine, University of Southern California, United States; <sup>4</sup>Institute for Health Promotion and Disease Prevention Research, University of Southern California, United States

*Comorbidities among injection drug users being treated with methadone in Jakarta, Indonesia*

S. Chhatre<sup>1</sup>, A. Nurhidayat<sup>2</sup>, H. Susami<sup>3</sup>, D. Utami<sup>4</sup>, R. Sarasvita<sup>4</sup>, M. Chawarski<sup>5</sup>; G. Woody<sup>1,6</sup>, D. Metzger<sup>1,6</sup>. <sup>1</sup>Department of Psychiatry, University of Pennsylvania, United States; <sup>2</sup>Drug Dependence Hospital RSKO–Jakarta, Indonesia; <sup>3</sup>Pokdisus AIDS FKUI/RSCM, Indonesia; <sup>4</sup>Ministry of Health, Indonesia; <sup>5</sup>Yale University, United States; <sup>6</sup>Treatment Research Institute, University of Pennsylvania, United States

*Correlates of buprenorphine maintenance treatment drop-out among users of homemade opioids in Ukraine*

V. Chtenguelov<sup>1</sup>, S. Dvoriak<sup>2</sup>, G. Prib<sup>3</sup>. <sup>1</sup>Department of Social Work and Applied Psychology, Academy of Labor and Social Relations, Ukraine; <sup>2</sup>Ukrainian Institute on Public Health Policy, Ukraine; <sup>3</sup>Department of Psychology, Institute of Professional Training for Public Employment Service of Ukraine

*Cochrane Reviews: Do they contribute to policy and practice?*

Cochrane Drugs and Alcohol Group. Department of Epidemiology ASL RM-E, Italy (M. Davoli, Italy; W. Ling, United States; S. Mitrova, Italy; L. Gowing, Australia; M. Farrell, Australia; D. Foxcroft, United Kingdom; F. Faggiano, Italy; P. Pier Paolo, Italy; M. Hickman, United Kingdom; M. Zhao, China; L. Amato, Italy)

*Influence of age and gender on the likelihood of endorsing cannabis use disorder criteria*

M. Delforterie<sup>1,2</sup>, H. Creemers<sup>1,2</sup>, A. Agrawal<sup>3</sup>, M. Lynskey<sup>3</sup>, A. Huizink<sup>2</sup>. <sup>1</sup>Research Institute of Child Development and Education, University of Amsterdam, The Netherlands; <sup>2</sup>Faculty of Psychology and Education and the Institute for Health and Care Research Institute, VU University, The Netherlands; <sup>3</sup>Department of Psychiatry, School of Medicine, Washington University in St. Louis, United States

*Methadone maintenance improves adherence to tuberculosis treatment for opioid addicted patients*

S. Dvoriak, O. Morozova, J. Makarenko. Ukrainian Institute on Public Health Policy, Ukraine

*Sexual activities of methamphetamine users: A qualitative study on a sample of Iranian methamphetamine users in Tehran*

H. Ekhtiari<sup>1,2</sup>, M. Maarefvand<sup>2,3</sup>, A. Danesh<sup>2</sup>, A. Mokri<sup>2</sup>. <sup>1</sup>Institute for Cognitive Science Studies, Iran; <sup>2</sup>Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; <sup>3</sup>University of Social Welfare and Rehabilitation Sciences, Iran

*Feasibility of adolescent community reinforcement approach and contingency management in a Spanish context*

S. Fernández-Artamendi, C. López-Núñez, J.R. Fernández-Hermida, R. Secades-Villa, I. Pericot-Valverde. Addictive Behaviors Research Group, University of Oviedo, Spain

*Buprenorphine and naltrexone combination in the treatment of cocaine dependence*

G. Gerra, L. Somaini, M. Amore, A. Busse, E. Saenz. United Nations Office on Drugs and Crime, Austria

*Maltreatment during childhood and its relationship to substance use among university students in Bogotá, Colombia*

J.D. Gomez<sup>1</sup>, W.R. Mann<sup>2</sup>, J. Sapag<sup>2</sup>, H. Hamilton<sup>2</sup>, P. Erickson<sup>2</sup>, A. Khenti<sup>2</sup>, B. Brands<sup>2</sup>, N. Giesbrecht<sup>2</sup>, M.G.M. Wright<sup>3</sup>, F. Cumsille<sup>3</sup>. <sup>1</sup>Pontificia Universidad Javeriana in Bogotá, Colombia; <sup>2</sup>Center for Addiction and Mental Health, Canada; <sup>3</sup>Inter-American Drug Abuse Control Commission, United States

*Motivational interviewing combined with chess improves working memory and reduces impulsivity in cocaine dependence: A pilot intervention*

P.D. Gonçalves<sup>1,2,3</sup>, M. Ometto<sup>2</sup>, A. Malbergier<sup>1</sup>, R. Amaral<sup>1</sup>, S. Nicastri<sup>1,2</sup>, P. Martins<sup>1</sup>, L. Beraldo<sup>1</sup>, D. Fuentes<sup>3</sup>, A.G. Andrade<sup>1</sup>, G.F. Busatto<sup>2</sup>, P.J. Cunha<sup>1,2</sup>. <sup>1</sup>Interdisciplinary Group of Studies on Alcohol and Drugs, Institute of Psychiatry, School of Medicine, University of São Paulo, Brazil; <sup>2</sup>Laboratory of Psychiatric Neuroimaging, Department of Psychiatry, School of Medicine, University of São Paulo, Brazil; <sup>3</sup>Psychology and Neuropsychology Service, Institute of Psychiatry, University of São Paulo, Brazil

*Meth mouth among HIV and non-HIV methamphetamine users at Drug Dependence Hospital RSKO-Jakarta*

L. Hendarmin<sup>1</sup>, A. Nurhidayat<sup>2</sup>, E. Wulandari<sup>3</sup>, A. Hapsari<sup>1</sup>, I. Fadillah<sup>1</sup>, S. Nakamura<sup>4</sup>. <sup>1</sup>Syarif Hidayatullah State Islamic University, Indonesia; <sup>2</sup>Drug Dependence Hospital RSKO-Jakarta, Indonesia; <sup>3</sup>Cipto Hospital, Indonesia; <sup>4</sup>Kyushu University, Japan

*Behavior and conditions of persons unable to give up smoking*

K. Janyam<sup>1</sup>, S. Pirasinee<sup>2</sup>. <sup>1</sup>Prince of Songkla University, Thailand; <sup>2</sup>Songkhla Rajabhat University, Thailand

*Factors associated with 1-year retention to methadone maintenance treatment program among heroin dependents in China*

H. Jiang<sup>1</sup>, Y. Han<sup>2</sup>, J. Du<sup>1</sup>, F. Wu<sup>2</sup>, R. Zhang<sup>3</sup>, H. Zhang<sup>4</sup>, J. Wang<sup>4</sup>, Z. Zhou<sup>5</sup>, Y. Hser<sup>2</sup>, M. Zhao<sup>1</sup>. <sup>1</sup>Shanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, China; <sup>2</sup>University of California, Los Angeles, United States; <sup>3</sup>Yunnan Institute on Drug Abuse, China; <sup>4</sup>Shanghai Yangpu District Mental Health Center, China; <sup>5</sup>Shanghai Xuhui District Mental Health Center, China

*Expansion of medically assisted treatment programs in Malaysia*

V.B. Kasinather<sup>1</sup>, M. Mazlan<sup>2</sup>, R.S. Schottenfeld<sup>3</sup>, M.C. Chawarski<sup>1,3</sup>. <sup>1</sup>Center for Drug Research, Universiti Sains, Malaysia; <sup>2</sup>SARC, Malaysia; <sup>3</sup>School of Medicine, Yale University, United States

*Stigma, violence, and the lack of confidentiality: The need for comprehensive, women-centered drug treatment in Georgia*

I. Kirtadze<sup>1</sup>, D. Otiashvili<sup>1</sup>, K. O'Grady<sup>2</sup>, H. Jones<sup>3</sup>, W. Zule<sup>3</sup>, E. Krupitsky<sup>4</sup>, W. Wechsberg<sup>3</sup>. <sup>1</sup>Addiction Research Center, Alternative Georgia, Republic of Georgia; <sup>2</sup>Department of Psychology, University of Maryland, United States; <sup>3</sup>RTI International, United States; <sup>4</sup>Department of Addictions, Bekhterev Research Psychoneurological Institute, Russia

*Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users: Cochrane Review*

J. Klimas<sup>1,2,3</sup>, C.A. Field<sup>2</sup>, W. Cullen<sup>1</sup>, C.S.M. O'Gorman<sup>1</sup>, L.G. Glynn<sup>4</sup>, E. Keenan<sup>5</sup>, J. Saunders<sup>1</sup>, G. Bury<sup>2</sup>, C. Dunne<sup>1</sup>. <sup>1</sup>University of Limerick, Ireland; <sup>2</sup>University College–Dublin, Ireland; <sup>3</sup>Oregon Health & Science University, United States; <sup>4</sup>National University of Ireland, Ireland; <sup>5</sup>Addiction Services, Health Service Executive, Ireland

*Injectable extended-release naltrexone for preventing relapse to opioid dependence: Findings from differing cultures, populations, and settings*

E. Krupitsky<sup>1,2</sup>, J. Zummo<sup>3</sup>, D. Gastfriend<sup>3</sup>. <sup>1</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; <sup>2</sup>Pavlov State Medical University, Russia; <sup>3</sup>Alkermes, Inc., United States

*The feasibility of delivering behavioral drug and risk counseling to methadone patients in Taiwan: An international collaborative research*

T.S.H. Lee<sup>1</sup>, M. Chawarski<sup>2</sup>, D. Metzger<sup>3</sup>, A. Nurhidayat<sup>4</sup>, C. Hung<sup>5</sup>. <sup>1</sup>Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan; <sup>2</sup>Psychiatry Department, School of Medicine Yale University, United States; <sup>3</sup>HIV/AIDS Prevention Research Division, University of Pennsylvania and the Treatment Research Institute, United States; <sup>4</sup>Drug Dependence Hospital RSKO–Jakarta, Indonesia; <sup>5</sup>Taichung Veterans General Hospital, Taiwan

*Association of marijuana use with types of crimes and mental illness in incarcerated juveniles*

G. Leveridge. Hubert H. Humphrey Fellowship Program, Bloomberg School of Public Health, Johns Hopkins University, United States

*Long-term results of psychosurgery in double addiction cocaine-nicotine smokers in Peru*

T. Llosa, L. Llosa. Coca Médica, Peru

*Initial intervention for teenagers with smoking-related pathology: Assessment of its effectiveness*

B. Lobodov<sup>1</sup>, L. Dmitrienko<sup>2</sup>. <sup>1</sup>Center Semya, Russia; <sup>2</sup>Municipal Outpatient Center #8, Russia

*Treatment outcome study among amphetamine users in Indonesia*

V.O. Lubis<sup>1,2</sup>, G.E. Woody<sup>3</sup>, D.S. Metzger<sup>3</sup>. <sup>1</sup>Drug Dependence Hospital RSKO–Jakarta, Indonesia; <sup>2</sup>NIDA INVEST/CTN Fellowship, University of Pennsylvania, United States; <sup>3</sup>Department of Psychiatry, University of Pennsylvania, United States

*Tobacco use in opioid-dependent subjects on buprenorphine-naloxone maintenance treatment*

P. Mandal<sup>1</sup>, R. Jain<sup>1</sup>, S. Jhanjee<sup>1</sup>, V. Sreenivas<sup>2</sup>. <sup>1</sup>Department of Psychiatry and National Drug Dependence and Treatment Centre, All India Institute of Medical Sciences, India; <sup>2</sup>Department of Biostatistics, All India Institute of Medical Sciences, India

*Shared injection practice among methamphetamine-dependent treatment seekers: Implications for treatment*

S. Mansoori<sup>1</sup>, Z.A. Mehrjerdi<sup>1</sup>, A. Noroozi<sup>2</sup>, R. Rawson<sup>3</sup>, A. Moradi<sup>4</sup>. <sup>1</sup>Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Iran; <sup>2</sup>School of Advanced Medical Technologies, INCAS, Tehran University of Medical Sciences, Iran; <sup>3</sup>Integrated Substance Abuse Programs, Department of Psychiatry, University of California, Los Angeles, United States; <sup>4</sup>Department of Psychology, Faculty of Psychology and Educational Sciences, Alzahra University, Iran

*Crack use and psychiatric comorbidity: Preliminary results in an outpatient setting in Brazil*

N. Marchi, F. Pechansky, F. Kessler, L. Guimarães, L. Raupp, X. Barros, S. Faller. Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Brazil

*Development of a clinical trial network to test and disseminate evidence-based practices to treat addictions and mental disorders in Mexico*

R. Marín-Navarrete<sup>1</sup>, M. Elena Medina-Mora<sup>1</sup>, V. Horigian<sup>2</sup>, R. Verdeja<sup>2</sup>, E. Alonso<sup>2</sup>, C. Berlanga-Cisneros<sup>1</sup>, R. Sánchez-Huesca<sup>3</sup>, C. Lima-Rodríguez<sup>4</sup>, A. De la Fuente-Martín<sup>1</sup>. <sup>1</sup>Instituto Nacional de Psiquiatría Ramón de la Fuente, Mexico; <sup>2</sup>Clinical Trials Network Florida Node Alliance, University of Miami, United States; <sup>3</sup>Centros de Integración Juvenil A.C., Mexico; <sup>4</sup>Consejo Estatal Contra las Adicciones Puebla, Mexico

*Chinese drug laws: Police-controlled approach to drug abuse*

J. Meng, S. Burris. Beasley School of Law, Temple University, United States

*Characteristics and treatment of opioid-addicted patients with tuberculosis and HIV in Ukraine*

O. Morozova<sup>1</sup>, S. Dvoriak<sup>2</sup>. <sup>1</sup>Pact, Inc., Ukraine; <sup>2</sup>Ukrainian Institute on Public Health Policy, Ukraine

*South African addiction treatment services assessment: Development and validation*

B. Myers<sup>1,2</sup>, J. Randy Koch<sup>3</sup>, R. Govender<sup>2</sup>, Z. Petersen<sup>1</sup>, R. Kader<sup>1</sup>, R. Manderscheid<sup>4</sup>, J. Barlett<sup>5</sup>. <sup>1</sup>South African Medical Research Council, South Africa; <sup>2</sup>University of Cape Town, South Africa; <sup>3</sup>Virginia Commonwealth University, United States; <sup>4</sup>National Association of County Behavioral Health and Developmental Disability Directors, United States; <sup>5</sup>Emory University, United States

*Early methadone maintenance outcomes analysis improved HIV and addiction treatment in Vietnam*

N.T. Nhu<sup>1</sup>, P.D. Manh<sup>2</sup>, N.T.M. Tam<sup>2</sup>, P.L. Huy<sup>1</sup>, N.C. Quoc<sup>1</sup>, T.T.T. Ha<sup>1</sup>, G. West<sup>1</sup>, C. Francis<sup>1</sup>, P. Banys<sup>1</sup>, S. Rangarajan<sup>1</sup>, P.H. Minh<sup>3</sup>, N.T.M. Ngoc<sup>3</sup>, K. Mulvey<sup>4</sup>. <sup>1</sup>FHI 360–Vietnam, Vietnam; <sup>2</sup>Vietnam Administration of HIV/AIDS Prevention and Control, Ministry of Health, Vietnam; <sup>3</sup>USAID, Vietnam Office, Vietnam; <sup>4</sup>Substance Abuse and Mental Health Services Administration, United States

*Naltrexone combined with psychosocial therapies: An experience from a treatment center in Ho Chi Minh City, Vietnam*

M. Nguyen<sup>1</sup>, H. Vu<sup>2</sup>. <sup>1</sup>Thanh Da Treatment Center, Vietnam; <sup>2</sup>Substance Abuse and Mental Health Services Administration, United States

*Methadone maintenance therapy in Vietnam: An overview and the role of policies for scaling up*

T. Nguyen<sup>1</sup>, L. Nguyen<sup>1</sup>, M. Pham<sup>1</sup>, H. Vu<sup>2</sup>, K. Mulvey<sup>2</sup>. <sup>1</sup>Vietnam Administration of HIV/AIDS Control, Ministry of Health, Vietnam; <sup>2</sup>Substance Abuse and Mental Health Services Administration, United States Embassy, Vietnam



*Methamphetamine use among females at a residential detoxification center: Implications for treatment*

A. Noroozi<sup>1</sup>, Z.A. Mehrjerdi<sup>2</sup>, S. Mansoori<sup>2</sup>, K. Dolan<sup>3</sup>, M. Zarghami<sup>4</sup>. <sup>1</sup>School of Advanced Medical Technologies, Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Iran; <sup>2</sup>INCAS, Tehran University of Medical Sciences, Iran; <sup>3</sup>Program of International Research and Training, National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>4</sup>Department of Psychiatry, Faculty of Medicine, Mazandaran University of Medical Sciences, Iran

*Monitoring and evaluation of methadone programs at 13 clinics in Jakarta*

A. Nurhidayat<sup>1,2</sup>, E. Suharjanti<sup>1</sup>, N. Nuryalis<sup>1</sup>, W. van den Brink<sup>3</sup>, D. Metzger<sup>4</sup>. <sup>1</sup>Drug Dependence Hospital RSKO–Jakarta, Indonesia; <sup>2</sup>Addiction and AIDS Research Center, Indonesia; <sup>3</sup>University of Amsterdam, the Netherlands; <sup>4</sup>University of Pennsylvania, U.S.

*Implementation by physicians and nurses of standardized Screening, Brief Intervention, and Referral to Treatment in general hospital emergency departments of Lagos State, Nigeria*

B. Ola<sup>1,2</sup>, M. Weaver<sup>3</sup>. <sup>1</sup>Hubert H. Humphrey Fellowship Program, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States; <sup>2</sup>Lagos State University, Nigeria; <sup>3</sup>Department of Psychiatry, Virginia Commonwealth University, United States

*Methadone and Suboxone<sup>®</sup> for Subutex<sup>®</sup> injectors—primary outcomes of a pilot randomized controlled trial*

D. Otiashvili<sup>1</sup>, G. Piralishvili<sup>2</sup>, Z. Sikharulidze<sup>3</sup>, G. Kamkamidze<sup>4</sup>, S. Poole<sup>5</sup>, G.E. Woody<sup>5</sup>. <sup>1</sup>Addiction Research Center, Alternative Georgia, Georgia; <sup>2</sup>Centre for Mental Health and Prevention of Addiction, Georgia; <sup>3</sup>Centre for Medical, Socio-economic and Cultural Issues–Uranti, Georgia; <sup>4</sup>Maternal and Child Care Union, Georgia; <sup>5</sup>Department of Psychiatry, School of Medicine, Treatment Research Institute, University of Pennsylvania, United States

*Prenatal cigarette smoking and readiness for change among pregnant women in Montevideo, Uruguay*

A. Pascale<sup>1</sup>, C. Bares<sup>2</sup>, D. Svikis<sup>3</sup>, E. de Souza<sup>1</sup>, F. Sarries<sup>1</sup>. <sup>1</sup>Department of Toxicology, School of Medicine, Uruguay; <sup>2</sup>School of Social Work, and; <sup>3</sup>Department of Psychology, Virginia Commonwealth University, United States

*Trajectory of treatment, hospitalization, and relapse of crack users*

R.S. Pedroso, V.M. Gonçalves, L.S.P. Guimarães, R. Lopes-Rosa, M. Pettenon, F.H.P. Kessler, F. Pechansky. Center for Drug and Alcohol Research, Universidade Federal do Rio Grande do Sul, Brazil; Hospital de Clinicas de Porto Alegre–Prof. Álvaro Alvim, Brazil

*Effect of virtual cue exposure therapy on background and cue exposure craving*

I. Pericot-Valverde, O. García-Rodríguez, S. Weidberg-López, S. Fernández-Artamendi. University of Oviedo, Spain

*Developing administrative measures to monitor the performance of South African substance abuse treatment services*

Z. Petersen<sup>1</sup>, B. Myers<sup>1</sup>, R. Kader<sup>1</sup>, J. Randy Koch<sup>2</sup>, R. Manderscheid<sup>3</sup>, J. Bartlett<sup>4</sup>. <sup>1</sup>Alcohol and Drug Abuse Research Unit, Medical Research Council, South Africa; <sup>2</sup>Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States; <sup>3</sup>National Association of County Behavioral Health and Developmental



*Drug use trends following 12 weeks of opioid substitution therapy in a randomized controlled trial in the Republic of Georgia*

G. Piralishvili<sup>1</sup>, D. Otiaishvili<sup>2</sup>, Z. Sikharulidze<sup>3</sup>, G. Kamkamidze<sup>4</sup>, S. Poole<sup>5</sup>, G.E. Woody<sup>5</sup>. <sup>1</sup>Center for Mental Health and Prevention of Addiction, Georgia; <sup>2</sup>Addiction Research Center, Alternative Georgia, Georgia; <sup>3</sup>Center for Medical, Socio-economic and Cultural Issues–Uranti, Georgia; <sup>4</sup>Maternal and Child Care Union, Georgia; <sup>5</sup>Department of Psychiatry, School of Medicine, Treatment Research Institute, University of Pennsylvania, United States

*Co-occurring methamphetamine use among heroin-dependent females: A report from a gender-specific center*

S. Rezaee<sup>1</sup>, Z.A. Mehrjerdi<sup>2</sup>, A. Mokri<sup>3</sup>, R. Rawson<sup>4</sup>, A. Noroozi<sup>5</sup>. <sup>1</sup>Department of Cultural Studies, Allameh Tabataba'i University, Iran; <sup>2</sup>Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Iran; <sup>3</sup>Department of Psychiatry, Tehran University of Medical Sciences, Iran; <sup>4</sup>Integrated Substance Abuse Programs, Department of Psychiatry, University of California, Los Angeles, United States; <sup>5</sup>School of Advanced Medical Technologies, INCAS, Tehran University of Medical Sciences, Iran

*Could quality of life measures be a middle-term relapse indicator in cocaine-dependent patients?*

C. Roncero<sup>1,2,3</sup>, S. Díaz-Morán<sup>1</sup>, C. Daigre<sup>2</sup>, L. Grau-López<sup>2,3</sup>, L. Rodríguez-Cintas<sup>2</sup>, A. Egido<sup>2</sup>, L. Miquel<sup>2</sup>, J.E. Montejó<sup>3</sup>, N. Martínez-Luna<sup>3</sup>, C. Barral<sup>2,3</sup>, M. Casas<sup>1,3</sup>.

<sup>1</sup>Department of Psychiatry and Forensic Medicine, Neuroscience Institute, Universidad Autónoma de Barcelona, Spain; <sup>2</sup>Outpatient Drug Clinic, Vall Hebron University Hospital, Vall Hebron-Public Health Agency, Spain; <sup>3</sup>Psychiatry Service, Hospital, Universitari Vall d'Hebron, Universidad Autónoma de Barcelona, CIBERSAM, Spain

*Intensive outpatient treatment center: A necessity at Kenyatta National Hospital–Nairobi, Kenya*

H.S. Ruturi. Hubert H. Humphrey Fellowship Program, Bloomberg School of Public Health, Johns Hopkins University, United States; Kenyatta National Hospital, Kenya

*Time of abstinence prior to admission to a residential rehabilitation program as a predictor of cocaine-dependence treatment completion in Lima, Peru*

M.R. Samolski, P. Ruiz-Grosso, K. Zevallos. Mental Health Research Unit, School of Public Health and Administration, Cayetano Heredia University, Peru

*Challenges in implementing structured HIV risk-reduction counseling in a methadone maintenance program*

R. Sarasvita<sup>1</sup>, P.S. Noveria<sup>2</sup>, A.W. Nurhidayat<sup>2</sup>, H. Susami<sup>3</sup>, Z.O. Syarif<sup>4</sup>, K. Vianti<sup>5</sup>, H. Ulin<sup>5</sup>, A. Kayo<sup>6</sup>, D. Metzger<sup>7</sup>, M. Chawarsky<sup>8</sup>. <sup>1</sup>Ministry of Health, Indonesia; <sup>2</sup>Drug Dependence Hospital–Jakarta, Indonesia; <sup>3</sup>Pokdisus AIDS FKUI/RSCM, Indonesia; <sup>4</sup>Koja Primary Health Care, Indonesia; <sup>5</sup>Cengkareng Primary Health Care, Indonesia; <sup>6</sup>Tebet Primary Health Care, Indonesia; <sup>7</sup>University of Pennsylvania, United States; <sup>8</sup>Yale University, United States

*Using tincture of opium for opiate abusers in Iran*

L. Seiri<sup>1</sup>, A. Mokri<sup>2</sup>, H. Dezhakam<sup>3</sup>. <sup>1</sup>Aftab Clinic, Iranian National Center for Addiction Studies (INCAS), Iran; <sup>2</sup>INCAS, Iran; <sup>3</sup>Congress 60, Nonprofit Organization, Iran

*Electronic health record system in Italian opioid agonist treatment programs*

G.S. Serpelloni<sup>1</sup>, M.G. Gomma<sup>2</sup>, B. Genetti<sup>3</sup>, M. Zermiani<sup>4</sup>, C. Rimondo<sup>1</sup>, R. Mollica<sup>5</sup>, J. Gryczynski<sup>6</sup>, K.E. O'Grady<sup>6</sup>, R.P. Schwartz<sup>6</sup>. <sup>1</sup>Dipartimento Politiche Antidroga, Presidenza del Consiglio dei Ministri, Italy; <sup>2</sup>Centro di Coordinamento Nazionale Progetto OUTCOME, Italy; <sup>3</sup>Explora—Centro di Ricerca e Analisi Statistica, Padua, Italy; <sup>4</sup>Dipartimento delle Dipendenze, Italy; <sup>5</sup>Friends Research Institute, Inc., United States; <sup>6</sup>University of Maryland at College Park, United States

*Desomorphine (“crocodile”) injection among in-treatment drug users in Tbilisi, Georgia*

Z. Sikharulidze<sup>1</sup>, N. Kapanadze<sup>1</sup>, D. Otiashvili<sup>2</sup>, S. Poole<sup>3</sup>, G.E. Woody<sup>3</sup>. <sup>1</sup>Centre for Medical, Socio-economic and Cultural Issues—Uranti, Georgia; <sup>2</sup>Addiction Research Center, Alternative Georgia, Georgia; <sup>3</sup>Department of Psychiatry, School of Medicine, Treatment Research Institute, University of Pennsylvania, United States

*Therapeutic justice in São Paulo City, Brazil: Analyzing 9 years of results*

M. Sobrinho. Public Ministry of Sao Paulo State, Brazil

*Methadone program in Burma (Myanmar): Challenges faced by methadone patients*

Z.N. Soe. University of New South Wales, Australia

*Effectiveness of problem-solving therapy to address substance use in Cape Town, South Africa*

K. Sorsdahl<sup>1</sup>, D.J. Stein<sup>1</sup>, B. Myers<sup>1,2</sup>. <sup>1</sup>University of Cape Town, South Africa; <sup>2</sup>Medical Research Council, South Africa

*Validating the American Society of Addiction Medicine Criteria Software version for the Norwegian population*

M. Stallvik<sup>1,2</sup>, D.R. Gastfriend<sup>3</sup>, H.M. Nordahl<sup>2,4</sup>. <sup>1</sup>Drug and Alcohol Treatment in Central Norway Trust, Norway; <sup>2</sup>Department of Psychology, Norwegian University of Science and Technology, Norway; <sup>3</sup>RecoverySearch, Inc., United States; <sup>4</sup>Department of Psychiatry, Levanger Hospital HF, Norway

*Incubation of alcohol craving during abstinence in human alcohol dependence: A retrospective investigation*

H. Sun<sup>1,2,3</sup>, P. Li<sup>2</sup>, X. Xin<sup>3</sup>, T.R. Koston<sup>2,4</sup>, L. Lu<sup>2,4</sup>. <sup>1</sup>Department of Alcohol and Drug Dependence, Beijing Hui-Long-Guan Hospital, Peking University, China; <sup>2</sup>National Institute on Drug Dependence, Peking University, China; <sup>3</sup>Department of Physiology, School of Basic Medical Sciences, Inner Mongolia Medical University, China; <sup>4</sup>Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, United States

*Impact of a complete smoking ban in a detoxification unit: A 6-month evaluation study*

M. Torrens<sup>1,2,3</sup>, F. Fonseca<sup>1,2</sup>, E. Francisco<sup>4</sup>, P. Rossi<sup>1,2</sup>, J.L. Pérez de Heredia<sup>1,2</sup>, S. Jornale<sup>1,2</sup>, R. Romar<sup>1,2</sup>, M. Farré<sup>2,3</sup>. <sup>1</sup>Institut de Neuropsiquiatria i Addiccions—Parc de Salut Mar, Spain; <sup>2</sup>Institut Hospital del Mar d'Investigacions Mèdiques, Spain; <sup>3</sup>Psychiatry and Pharmacology Departments, Autonomous University of Barcelona, Spain; <sup>4</sup>Parc Sanitari Sant Joan de Déu, Spain

*Private residential addiction treatment outcomes*

T. Tsarouk, G. Thompson. Sunshine Coast Health Centre, Canada

*Double-blind randomized controlled trial of acute effects of morphine at different doses of sublingual buprenorphine*

R. Verma<sup>1</sup>, R. Manohar<sup>2</sup>, A. Dhawan<sup>3</sup>, R. Ray<sup>3</sup>, R. Jain<sup>3</sup>. <sup>1</sup>Institute of Medical Education and Research, India; <sup>2</sup>Lohia Hospital, India; <sup>3</sup>National Drug Dependence Centre, Department of Psychiatry, All India Institute of Medical Sciences, India

*Fatty acid amide hydrolase gene variant influences acute responses to cocaine*

C.D. Verrico<sup>1</sup>, D.A. Nielsen<sup>1</sup>, C.J. Spellicy<sup>1</sup>, S.C. Hamon<sup>2</sup>, T.R. Kosten<sup>1</sup>, T.F. Newton<sup>1</sup>, R. De La Garza, II<sup>1</sup>. <sup>1</sup>Menninger Department of Psychiatry and Behavioral Sciences, College of Medicine, Baylor University, and Michael E. DeBakey Veterans Administration Medical Center, United States; <sup>2</sup>Laboratory of Statistical Genetics, Rockefeller University, United States

*Overcoming barriers to abstinence in methamphetamine dependence in Malaysia: A behavioral counseling approach*

S. Wahab<sup>1</sup>, M. Mazlan<sup>2</sup>, B. Vicknasingam<sup>3</sup>, M.C. Chawarski<sup>4</sup>, R.S. Schottenfeld<sup>4</sup>. <sup>1</sup>Department of Psychiatry, University Kebangsaan Malaysia Medical Centre, Malaysia; <sup>2</sup>Substance Abuse Research Centre, Malaysia; <sup>3</sup>Centre for Drug Research, Universiti Sains Malaysia, Malaysia; <sup>4</sup>Yale University School of Medicine, United States

*Effects of motivation-skills-desensitization-mental energy model on abstinence rate among heroin addicts in China: 1-year follow-up study*

Z. Wang<sup>1,2</sup>, Y. Xiao<sup>1</sup>, D. Wang<sup>1</sup>, F. Ding<sup>3</sup>, W.Q. Wei<sup>1</sup>, J. Yu<sup>1,2</sup>, H. Gu<sup>4</sup>, R. Zhong<sup>4</sup>. <sup>1</sup>Department of Epidemiology and Health Statistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, China; <sup>2</sup>Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, China; <sup>3</sup>Xiangyang Compulsory Rehabilitation Center, China; <sup>4</sup>Modern Psychology, Wuhan Shiwu Academy of Science, China

*Linking heroin users in China to drug treatment and other resources in the community: Direct and indirect effect of a recovery management intervention*

F. Wu<sup>1</sup>, L.M. Fu<sup>2</sup>, Y. Hser<sup>1</sup>. <sup>1</sup>University of California, Los Angeles, United States; <sup>2</sup>Shanghai Zi-Qiang Social Services, China

*Effects of a randomized comprehensive psychosocial intervention for heroin dependence in community in Shanghai, China*

M. Zhao, N. Zhong, Y. Yuan, H. Chen, H. Jiang, J. Du, H. Sun, W. Hao. Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, China

**Poster Session II**

**(Breakfast)**

**Odd-numbered posters manned first hour;**

**Even-numbered, second hour**

**SAPPHIRE**

**8:00 - 10:00 AM**

**Set-up time begins Monday 1 PM**

**Must be removed by Tuesday 12 NOON**

**STIMULANTS—HUMAN STUDIES**

- 1 *Current and former methamphetamine-dependent adults show attenuated brain response to pleasant interoceptive stimuli*  
A. C. May<sup>1</sup>, J. L. Stewart<sup>1</sup>, S. F. Tapert<sup>1,2</sup>, M. P. Paulus<sup>1,2</sup>, <sup>1</sup>Psychiatry, University of California, San Diego, La Jolla, CA, <sup>2</sup>Psychiatry Service, VA San Diego Healthcare System, La Jolla, CA
- 2 *Methamphetamine dependence and brain activation during risky decision-making*  
J. J. Freeman<sup>1</sup>, M. Kohno<sup>1,2</sup>, D. Ghahremani<sup>1</sup>, E. D. London<sup>1,3,4</sup>, <sup>1</sup>Dept. Psychiatry Biobehav. Sci., Univ. of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Neurosci. Interdisciplinary Prog., Univ. of California, Los Angeles, Los Angeles, CA, <sup>3</sup>Brain Res. Inst., Univ. of California, Los Angeles, Los Angeles, CA, <sup>4</sup>Dept. Molec. Med. Pharmacol., Univ. of California, Los Angeles, Los Angeles, CA
- 3 *Cognitive inconsistency in methamphetamine dependence is associated with poor everyday functioning*  
E. E. Morgan, A. Minassian, T. D. Marcotte, B. Henry, W. Perry, S. P. Woods, I. Grant, Psychiatry, University of California, San Diego, San Diego, CA
- 4 *Effects of amphetamine on retrieval of memory for emotional stimuli*  
J. Weafer, D. A. Gallo, H. de Wit, University of Chicago, Chicago, IL
- 5 *Oral d-amphetamine increases sensitivity to negative consequences on an associative learning task in cocaine users*  
N. P. Vadhan<sup>1</sup>, S. M. Evans<sup>1</sup>, C. E. Myers<sup>3</sup>, M. A. Gluck<sup>2</sup>, S. C. Reed<sup>1</sup>, <sup>1</sup>Columbia University & NYS Psychiatric Institute, New York, NY, <sup>2</sup>Rutgers University, Newark, NJ, <sup>3</sup>VA New Jersey Health Care System & New Jersey Medical School, East Orange, NJ
- 6 *Methamphetamine self-administration in humans during d-amphetamine maintenance*  
E. Pike<sup>1</sup>, W. W. Stoops<sup>1,2</sup>, P. E. Glaser<sup>3,4</sup>, L. R. Hays<sup>3</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Psychology, University of Kentucky, Lexington, KY, <sup>2</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY, <sup>4</sup>Anatomy and Neurobiology, University of Kentucky, Lexington, KY
- 7 *Aripiprazole for the treatment of methamphetamine dependence: A randomized, double-blind, placebo-controlled trial*  
P. O. Coffin<sup>1,2</sup>, G. Santos<sup>1,2</sup>, M. Das<sup>1,2</sup>, D. Santos<sup>1</sup>, T. Matheson<sup>1</sup>, J. Gasper<sup>1,2</sup>, E. Vittinghoff<sup>2</sup>, G. Colfax<sup>1,2</sup>, <sup>1</sup>San Francisco Department of Public Health, San Francisco, CA, <sup>2</sup>University of California, San Francisco, San Francisco, CA
- 8 *Randomized trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use*  
K. G. Heinzerling, T. Hall, A. Swanson, S. Shoptaw, Center for Behavioral and Addiction Medicine, UCLA, Los Angeles, CA
- 9 *A Bayesian dose-finding trial of modafinil for methamphetamine dependence*  
G. Galloway, K. Garrison, J. Mendelson, Addiction & Pharmacology Research Laboratory, California Pacific Medical Center, San Francisco, CA

- 10 *Changes in mood over time as a function of exercise among methamphetamine-dependent clients in residential treatment*  
J. Chudzynski<sup>1</sup>, R. Rawson<sup>1</sup>, J. Penate<sup>1</sup>, V. Novoa<sup>1</sup>, R. Gonzales-Castaneda<sup>1,2</sup>, A. Ang<sup>1</sup>,  
<sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>Department of Psychology, Azuza Pacific University, Azuza, CA
- 11 *Ibudilast may reduce inattention associated with methamphetamine use*  
A. Swanson<sup>1</sup>, M. Wright<sup>2,1</sup>, J. B. Birath<sup>2</sup>, J. Tsuang<sup>2,1</sup>, B. Furst<sup>2,1</sup>, K. Heinzerling<sup>1</sup>,  
L. C. Obermeit<sup>2</sup>, S. Amaya<sup>1</sup>, L. Maes<sup>2</sup>, C. McKay<sup>2,1</sup>, S. Shoptaw<sup>1</sup>, <sup>1</sup>UCLA, Los Angeles, CA,  
<sup>2</sup>LABioMed/Harbor-UCLA, Torrance, CA
- 12 *Attention-Deficit/Hyperactivity Disorder adversely impacts everyday functioning in chronic methamphetamine users*  
L. C. Obermeit, J. E. Cattie, K. Bolden, M. Marquine, E. E. Morgan, D. Franklin, I. Grant,  
S. P. Woods, Psychiatry, University of California, San Diego, San Diego, CA
- 13 *13-year outcomes of treatment for methamphetamine use: Patterns of use and correlates*  
M. Brecht, K. Lovinger, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 14 *Spatial and neighborhood-level correlates of retention in pharmacologic efficacy trials*  
D. J. Dacarett-Galeano<sup>1,2</sup>, G. M. Santos<sup>2,3</sup>, D. Santos<sup>2</sup>, M. Das<sup>2,3</sup>, P. O. Coffin<sup>2,3</sup>, <sup>1</sup>Columbia University, New York City, NY, <sup>2</sup>San Francisco Department of Public Health, San Francisco, CA, <sup>3</sup>University of California San Francisco, San Francisco, CA
- 15 *Differences in methamphetamine use patterns for treated and not-treated users*  
K. Lovinger, M. Brecht, Integrated Substance Use Programs, UCLA, Los Angeles, CA
- 16 *A qualitative study of methamphetamine users' perspectives on barriers and facilitators of drug abstinence*  
D. Herbeck, K. Lovinger, M. Brecht, D. Christou, L. Rodriguez, P. Sheaff, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 17 *Positive affect is a source of resilience among treatment-seeking methamphetamine users*  
A. W. Carrico<sup>1</sup>, M. D. Siever<sup>2</sup>, M. V. Discepolo<sup>2</sup>, N. Miller<sup>1</sup>, W. J. Woods<sup>1</sup>, S. E. Dilworth<sup>1</sup>,  
T. B. Neilands<sup>1</sup>, J. T. Moskowitz<sup>1</sup>, <sup>1</sup>University of California, San Francisco, San Francisco, CA,  
<sup>2</sup>San Francisco AIDS Foundation, San Francisco, CA
- 18 *Amphetamine-type stimulant use and unprotected sex in men who have sex with men in Vietnam*  
H. T. Bui<sup>1</sup>, P. T. Korthuis<sup>2</sup>, G. M. Le<sup>1</sup>, <sup>1</sup>Hanoi Medical University, Hanoi, Viet Nam, <sup>2</sup>Oregon Health & Science University, Portland, OR

#### **ADOLESCENT DRUG ABUSE I**

- 19 *Behavioral adjustment in prenatally cocaine-exposed adolescents*  
M. O. Min<sup>1</sup>, S. Minnes<sup>1</sup>, E. J. Short<sup>2</sup>, S. Yoon<sup>1</sup>, L. T. Singer<sup>3</sup>, <sup>1</sup>Applied Social Sciences, Case Western Reserve University, Cleveland, OH, <sup>2</sup>Psychology, Case Western Reserve University, Cleveland, OH, <sup>3</sup>Environmental Health, Case Western Reserve University, Cleveland, OH
- 20 *Evaluation of trends in abuse of stimulants in high school and college-age persons using RADARS® System data*  
K. Lowitz<sup>1</sup>, M. C. Le Lait<sup>1</sup>, S. G. Severtson<sup>1</sup>, R. C. Dart<sup>1,2</sup>, <sup>1</sup>RMPDC, Denver Health and Hospital Authority, Denver, CO, <sup>2</sup>Denver School of Medicine, University of Colorado, Denver, CO
- 21 *Initiation into drug dealing among street-involved youth in a Canadian setting*  
K. DeBeck<sup>1</sup>, C. Feng<sup>2</sup>, W. Small<sup>1</sup>, K. Chan<sup>1</sup>, T. Kerr<sup>1</sup>, E. Wood<sup>1</sup>, <sup>1</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, <sup>2</sup>University of Saskatchewan, Saskatoon, SK, Canada



- 22 *Multiple problem behaviors associated with amphetamine use among delinquent and incarcerated adolescents in Los Angeles County*  
C. M. Branson, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 23 *Perceptions about recovery needs and drug avoidance behaviors among substance-abusing youth*  
R. Gonzales-Castaneda<sup>1,2</sup>, M. D. Anglin<sup>2</sup>, D. C. Glik<sup>3</sup>, A. Moffitt<sup>1</sup>, C. Zavalza<sup>1</sup>, <sup>1</sup>Psychology, Azusa Pacific University, Azusa, CA, <sup>2</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, CA, <sup>3</sup>School of Public Health, University of California, Los Angeles, CA
- 24 *Long-term effects of Brief Strategic Family Therapy for adolescent substance users*  
V. E. Horigian<sup>1</sup>, D. J. Feaster<sup>1</sup>, M. S. Robbins<sup>2,1</sup>, A. Brincks<sup>1</sup>, M. A. Perez<sup>1</sup>, J. Szapocznik<sup>1</sup>, <sup>1</sup>University of Miami, Miami, FL, <sup>2</sup>Oregon Research Institute, Eugene, OR
- 25 *Problem behaviors and criminal thinking among adolescents in residential substance abuse treatment*  
R. Crawley, D. Knight, J. E. Becan, P. Flynn, Texas Christian University, Institute of Behavioral Research, Fort Worth, TX
- 26 *Precocious transitions and injection drug use: A longitudinal study of Mexican-American males*  
A. Valdez, A. Cepeda, S. E. Spear, C. Kaplan, Social Work, University of Southern California, Los Angeles, CA
- 27 *Lack of association of cannabis use with opioid outcomes among opioid-dependent youth*  
K. P. Hill<sup>1,2</sup>, H. E. Bennett<sup>1</sup>, M. L. Griffin<sup>1,2</sup>, H. S. Connery<sup>1,2</sup>, G. M. Fitzmaurice<sup>1,2</sup>, G. Subramaniam<sup>3</sup>, G. E. Woody<sup>4</sup>, R. Weiss<sup>1,2</sup>, <sup>1</sup>Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA, <sup>2</sup>Harvard Medical School, Boston, MA, <sup>3</sup>Center for Clinical Trials Network, National Institute on Drug Abuse, Bethesda, MD, <sup>4</sup>Department of Psychiatry, Treatment Research Institute, University of Pennsylvania, Philadelphia, PA
- 28 *A longitudinal study of marijuana use motives across emerging adulthood*  
M. Sitney<sup>1</sup>, K. G. Anderson<sup>1</sup>, H. White<sup>2</sup>, <sup>1</sup>Psychology, Reed College, Portland, OR, <sup>2</sup>Center of Alcohol Studies, Rutgers University, New Brunswick, NJ
- 29 *You started smoking weed when you were how old?*  
A. Duncan<sup>1</sup>, R. Ahmed<sup>2</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>University of Waterloo, Waterloo, ON, Canada
- 30 *Early onset cannabis use and young adult outcomes: An integrative data analysis of three Australasian cohorts*  
E. Silins<sup>1</sup>, C. Olsson<sup>2</sup>, L. J. Horwood<sup>3</sup>, D. Hutchinson<sup>1</sup>, G. Patton<sup>2</sup>, D. Fergusson<sup>3</sup>, J. Toumbourou<sup>4</sup>, E. Spry<sup>2</sup>, R. Mattick<sup>1</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>Centre for Adolescent Health, Royal Childrens Hospital, Melbourne, VIC, Australia, <sup>3</sup>Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand, <sup>4</sup>School of Psychology, Deakin University, Melbourne, VIC, Australia
- 31 *Differences in early substance use and risk factors by Asian-American Pacific Islander (AAPI) subgroups*  
R. A. Shih<sup>1</sup>, J. Tucker<sup>2</sup>, J. Miles<sup>2</sup>, B. Ewing<sup>2</sup>, E. Pedersen<sup>2</sup>, E. J. D'Amico<sup>2</sup>, <sup>1</sup>RAND, Arlington, VA, <sup>2</sup>RAND, Santa Monica, CA
- 32 *Menthol cigarette and marijuana use among adolescents*  
G. Kong, N. Singh, D. A. Cavallo, D. R. Camenga, S. Krishnan-Sarin, Psychiatry, Yale University School of Medicine, New haven, CT



- 33 *Patterns of adolescent chewing betel nut and later drug use in adults*  
Y. Lan<sup>1,3</sup>, Y. Hser<sup>2</sup>, Y. Ho<sup>3</sup>, W. Tsai<sup>4</sup>, J. Hsu<sup>4</sup>, J. Kang<sup>4</sup>, <sup>1</sup>Department of Health Risk Management, China Medical University, Taichung, Taiwan, <sup>2</sup>UCLA Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>3</sup>Center for Drug Abuse, China Medical University Hospital, Taichung, Taiwan, <sup>4</sup>Taiwan Food and Drug Administration, Taipei, Taiwan
- 34 *Parental absence and marijuana use among American youth in the latest NSDUH*  
G. Anyumba, F. A. Wagner, Prevention Sciences Research Center, Morgan State University, Baltimore, MD
- 35 *Youth in foster care use drugs too: Examining factors that influence foster parent willingness to foster substance-using youth*  
Ö. Kaynak, K. Meyers, E. Bresani, Treatment Research Institute, Philadelphia, PA
- 36 *Adolescent risk-taking among black and white adolescents: The role of parental monitoring and environmental threats*  
A. Collado-Rodriguez, G. Kurdziel, L. MacPherson, C. W. Lejuez, Clinical Psychology, University of Maryland- College Park, College Park, MD
- 37 *Exposure to stressful life events mediates the relation between family history of substance abuse and childhood adjustment*  
N. E. Charles, A. Acheson, C. W. Mathias, D. Dougherty, Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX
- 38 *Efficacy of CRAFT when modified for parents of treatment-resistant adolescents: Preliminary results*  
K. C. Kirby<sup>1,2</sup>, K. Meyers<sup>1</sup>, M. E. Kerwin<sup>1,4</sup>, B. Versek<sup>1</sup>, Y. Washio<sup>1</sup>, E. Bresani<sup>1</sup>, L. Benishek<sup>1,2</sup>, A. McNamara<sup>1</sup>, R. J. Meyers<sup>3</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>University of Pennsylvania School of Medicine, Philadelphia, PA, <sup>3</sup>University of New Mexico, Albuquerque, NM, <sup>4</sup>Rowan University, Glassboro, NJ
- 39 *A controlled evaluation of abstinence-based incentives and behavioral parent training for adolescents with cannabis use disorders*  
A. J. Budney<sup>1</sup>, C. Stanger<sup>1</sup>, S. R. Ryan<sup>2</sup>, P. C. Brown<sup>3</sup>, Z. Li<sup>1</sup>, <sup>1</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH, <sup>2</sup>University of Texas Health Science Center, San Antonio, TX, <sup>3</sup>Orlando Veterans Affairs Medical Center, Orlando, FL
- 40 *Feasibility of adolescent community reinforcement approach and contingency management in a Spanish context*  
S. Fernández-Artamendi, C. López-Núñez, J. R. Fernández-Hermida, R. Secades-Villa, I. Pericot-Valverde, Addictive Behaviors Research Group - Department of Psychology, University of Oviedo, Oviedo, Spain
- 41 *Legal substance use and the development of a DSM-IV cannabis use disorder during adolescence*  
H. Creemers<sup>1,2</sup>, A. Prince van Leeuwen<sup>1,3</sup>, F. Verhulst<sup>3</sup>, W. Vollebergh<sup>4</sup>, J. Ormel<sup>5</sup>, F. van Oort<sup>3</sup>, A. Huizink<sup>2</sup>, <sup>1</sup>University of Amsterdam, Amsterdam, Netherlands, <sup>2</sup>VU University, Amsterdam, Netherlands, <sup>3</sup>Erasmus University Medical Center, Rotterdam, Netherlands, <sup>4</sup>Utrecht University, Utrecht, Netherlands, <sup>5</sup>University Medical Center Groningen, Groningen, Netherlands
- 42 *Clearing the smoke on Canadian youths' perceptions of cannabis*  
A. Porath-Waller, Canadian Centre on Substance Abuse, Ottawa, ON, Canada

### CRAVING

- 43 *Does craving predict substance use for different substance use disorders? An Ecological Momentary Assessment study in patients with alcohol, tobacco, cannabis and heroin dependence*  
F. Serre<sup>1,3</sup>, M. Fatseas<sup>1,3</sup>, J. Swendsen<sup>2</sup>, M. Auriacombe<sup>1,3</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>CNRS UMR 5287 INCIA, Univ. Bordeaux, Bordeaux, France, <sup>3</sup>CH Ch. Perrens et CHU de Bordeaux, Bordeaux, France
- 44 *Does cue type matter for craving? Comparison of substance-specific and person-specific cues using mobile technologies*  
M. Fatseas<sup>1,3</sup>, F. Serre<sup>1,3</sup>, J. Swendsen<sup>2</sup>, M. Auriacombe<sup>1,3</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>CNRS UMR 5287 INCIA, Univ. Bordeaux, Bordeaux, France, <sup>3</sup>CH Ch. Perrens et CHU de Bordeaux, Bordeaux, France
- 45 *Reliability and validity of a substance craving scale*  
J. Mazza<sup>1,2</sup>, K. J. Conrad<sup>1,2</sup>, C. K. Scott<sup>1</sup>, M. L. Dennis<sup>1</sup>, <sup>1</sup>Chestnut Health Systems, Normal, IL, <sup>2</sup>University of Illinois at Chicago, Chicago, IL
- 46 *A prospective study of alexithymia and craving among alcohol-dependent treatment seekers*  
F. A. Thorberg<sup>1,2,3</sup>, R. Young<sup>3,5,6</sup>, M. Lyvers<sup>4</sup>, J. Connor<sup>6,5</sup>, R. Tyssen<sup>2</sup>, A. Landheim<sup>1</sup>, E. London<sup>7</sup>, G. Feeney<sup>5,6</sup>, <sup>1</sup>Natl Ctr Dual Diagnoses, Innlandet Hosp Trust, Hamar, Norway, <sup>2</sup>Fac Med, Univ Oslo, Oslo, Norway, <sup>3</sup>Qld Univ Technol, Brisbane, QLD, Australia, <sup>4</sup>Bond Univ, Gold Coast, QLD, Australia, <sup>5</sup>Princess Alexandra Hospital, Brisbane, QLD, Australia, <sup>6</sup>Univ Qld, Brisbane, QLD, Australia, <sup>7</sup>Univ Calif, Los Angeles, CA
- 47 *Cognitive regulation of cue-induced craving in alcohol-dependent and social drinkers*  
N. H. Naqvi<sup>1</sup>, H. Kober<sup>3</sup>, K. Ochsner<sup>2</sup>, J. Morgenstern<sup>1</sup>, <sup>1</sup>Psychiatry, Columbia University, New York, NY, <sup>2</sup>Psychology, Columbia University, New York, NY, <sup>3</sup>Psychiatry, Yale University, New Haven, CT
- 48 *Impaired frontostriatal white matter development in children with family histories of substance use disorders*  
A. Acheson<sup>1</sup>, P. Kochunov<sup>2,1</sup>, L. Rowland<sup>2</sup>, C. Mathias<sup>1</sup>, A. Witjtenburg<sup>2</sup>, D. Dougherty<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center at San Antonio, San Antonio, TX, <sup>2</sup>University of Maryland, School of Medicine, Baltimore, MD
- 49 *Amygdala functional connectivity during craving inhibition attempts at baseline predicts craving and cocaine use*  
J. Suh<sup>1,2</sup>, R. Ehrman<sup>1,2</sup>, K. Jagannathan<sup>1</sup>, Y. Li<sup>1</sup>, R. Fabianski<sup>1</sup>, Z. Singer<sup>1</sup>, T. R. Franklin<sup>1</sup>, Z. Wang<sup>1</sup>, K. Marquez<sup>1</sup>, R. Szucs-Reed<sup>1</sup>, M. J. Gawrysiak<sup>1,2</sup>, M. Goldman<sup>1</sup>, C. P. O'Brien<sup>1,2</sup>, A. Childress<sup>1,2</sup>, <sup>1</sup>U of Pennsylvania Perelman School of Medicine, Philadelphia, PA, <sup>2</sup>VISN4 MIRECC-VA Medical Center, Philadelphia, PA
- 50 *Frontal vs. limbic predictors of inhibitory success in addiction*  
A. Childress<sup>1</sup>, Y. Li<sup>1</sup>, M. Goldman<sup>1</sup>, J. J. Suh<sup>2,1</sup>, R. Ehrman<sup>2,1</sup>, S. Lam<sup>1</sup>, Z. Singer<sup>1</sup>, T. R. Franklin<sup>1</sup>, D. Langleben<sup>2,1</sup>, K. Young<sup>1</sup>, R. R. Wetherill<sup>1</sup>, M. J. Gawrysiak<sup>2,1</sup>, C. P. O'Brien<sup>1</sup>, <sup>1</sup>U Penn School of Medicine, Philadelphia, PA, <sup>2</sup>VAMC, Philadelphia, PA
- 51 *Effects of plasma allopregnanolone levels on drug craving in cocaine-dependent men and women*  
V. Milivojevic<sup>1</sup>, J. Covault<sup>2</sup>, R. Sinha<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Psychiatry, University of Connecticut School of Medicine, Farmington, CT
- 52 *Effects of exercise on craving and smoking in the human laboratory*  
A. N. Kurti, J. Dallery, Univ. of Florida, Gainesville, FL
- 53 *The effect of virtual cue exposure therapy on background and cue exposure craving*  
I. Pericot-Valverde, O. García-Rodríguez, S. Weidberg-López, S. Fernández-Artamendi, Psychology, University of Oviedo, Oviedo, Spain

- 54 *Virtual reality-induced craving for cigarettes among abstinent smokers*  
D. G. Thompson-Lake<sup>1,2</sup>, J. H. Yoon<sup>1,2</sup>, H. Viswanath<sup>1</sup>, A. Q. Carter<sup>1</sup>, P. S. Bordnick<sup>2</sup>, R. Salas<sup>1</sup>, T. R. Kosten<sup>1,2</sup>, J. A. Dani<sup>1</sup>, R. De La Garza, II<sup>1,2</sup>, <sup>1</sup>Psychiatry, BCM, Houston, TX, <sup>2</sup>Psychiatry, MEDVAMC, Houston, TX

### NICOTINE I

- 55 *Anatabine significantly decreases nicotine self-administration*  
N. K. Mello, P. A. Fivel, S. Kohut, Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, MA
- 56 *Locomotor response to a novel environment: Identifying a useful measure of individual differences*  
T. T. Smith, S. S. Dermody, J. N. Parrish, M. B. Schaff, M. T. Weaver, M. E. Levin, E. Thiels, D. M. Buffalari, A. F. Sved, E. C. Donny, University of Pittsburgh, Pittsburgh, PA
- 57 *Attenuation of rate-frequency intracranial self-stimulation during nicotine withdrawal in rats*  
D. M. Walentiny, K. M. Tobey, L. S. Harris, Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA
- 58 *Bidirectional changes in reward responsiveness during nicotine withdrawal and acute nicotine administration assessed in the Response Bias Probabilistic Reward Task in rats*  
A. Der-Avakian<sup>1</sup>, M. S. DSouza<sup>1</sup>, D. A. Pizzagalli<sup>2</sup>, A. Markou<sup>1</sup>, <sup>1</sup>Psychiatry, University of California, San Diego, La Jolla, CA, <sup>2</sup>Psychiatry, Harvard Medical School, Belmont, MA
- 59 *Does pregnancy alter the activity of baboon (Papio cynocephalus) hepatic cytochrome P450 2B in the biotransformation of bupropion?*  
X. Wang<sup>1</sup>, D. I. Vernikovskaya<sup>1</sup>, V. M. Fokina<sup>1</sup>, C. Bauer<sup>2</sup>, K. Rice<sup>2</sup>, G. D. Hankins<sup>1</sup>, M. S. Ahmed<sup>1</sup>, T. N. Nanovskaya<sup>1</sup>, <sup>1</sup>Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Texas Biomedical Research Institute, San Antonio, TX
- 60 *Relationships between postpartum cigarette smoking and breastfeeding duration*  
A. A. Lopez, S. T. Higgins, S. H. Heil, J. M. Skelly, M. E. Lynch, L. J. Solomon, I. M. Bernstein, University of Vermont, Burlington, VT
- 61 *Incentive-based treatment for pregnant smokers*  
S. T. Higgins<sup>1</sup>, Y. Washio<sup>2</sup>, A. A. Lopez<sup>1</sup>, S. H. Heil<sup>1</sup>, L. J. Solomon<sup>1</sup>, M. E. Lynch<sup>1</sup>, J. Hanson<sup>1</sup>, T. M. Higgins<sup>1</sup>, J. M. Skelly<sup>1</sup>, I. M. Bernstein<sup>1</sup>, <sup>1</sup>Univ. of VT, Burlington, VT, <sup>2</sup>Univ. of PA, Philadelphia, PA
- 62 *Smoking prevalence and exposure to second hand-smoke in Mexican pregnant women*  
O. Campollo<sup>1</sup>, F. Hernandez<sup>2</sup>, E. Angulo<sup>3</sup>, A. Guzman<sup>2</sup>, I. Navarro<sup>1</sup>, M. García<sup>3</sup>, A. Munguía<sup>1</sup>, J. K. Cunningham<sup>4</sup>, <sup>1</sup>Center of Studies on Alcohol and Addictions, University of Guadalajara, Guadalajara, Mexico, <sup>2</sup>Obstetrics, Hospital Civil Guadalajara, GDL, Mexico, <sup>3</sup>Neonatology, Hospital Civil Guadalajara, GDL, Mexico, <sup>4</sup>Family & Community Medicine, University of Arizona, Tucson, AZ
- 63 *The effects of menthol cigarette use on treatment outcomes in an intervention for weight-concerned smokers*  
A. M. Rojewski<sup>1</sup>, B. A. Toll<sup>1,2,3</sup>, S. S. O'Malley<sup>1,2</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Yale Cancer Center, New Haven, CT, <sup>3</sup>Smilow Cancer Hospital at Yale-New Haven, New Haven, CT
- 64 *Gender differences in withdrawal when using very low nicotine content cigarettes*  
S. S. Dermody<sup>1</sup>, D. L. Joel<sup>1</sup>, E. Donny<sup>1</sup>, L. Hertsgaard<sup>2</sup>, D. Hatsukami<sup>2</sup>, <sup>1</sup>Psychology, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Psychiatry, University of Minnesota, Minneapolis, MN

- 65 *Physiological and subjective effects of waterpipe (hookah) smoking*  
D. Howell, K. Shishani, S. McPherson, J. Roll, Washington State University, Spokane, WA
- 66 *Smoking risk perceptions of U.S. adolescents in fine-grained race-ethnicity subgroups*  
C. Lopez-Quintero, D. A. Barondess, J. C. Anthony, Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 67 *Neural correlates of reward and loss processing in adolescent smokers: Relationship with impulsivity, risk-taking and smoking cessation treatment outcome*  
S. Krishnan-Sarin, I. Balodis, H. Kober, P. Worhunsky, M. Stevens, G. Pearlson, M. Potenza, Psychiatry, Yale University School of Medicine, New Haven, CT
- 68 *Acute effect of alcohol on inhibitory control and subsequent tobacco use in young adult occasional smokers*  
D. C. Lee, C. Martin, T. H. Kelly, University of Kentucky, Lexington, KY
- 69 *Association of objective and perceived neighborhood characteristics with tobacco use among young adults*  
Q. L. Brown<sup>1</sup>, A. J. Milam<sup>1</sup>, M. J. Smart<sup>1</sup>, R. M. Johnson<sup>2</sup>, S. L. Linton<sup>1</sup>, C. D. Furr-Holden<sup>1</sup>,  
<sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Boston University School of Public Health, Boston, MA
- 70 *Smoking cessation in the elderly using nicotine replacement therapy*  
L. A. Zawertailo<sup>1,2</sup>, L. Riad-Allen<sup>2</sup>, S. Hussain<sup>2</sup>, P. Selby<sup>2,3</sup>, <sup>1</sup>Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Nicotine Dependence Service, Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>3</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 71 *Influence of bupropion on smoking abstinence in opioid-maintained smokers*  
M. E. Patrick, S. C. Sigmon, A. C. Meyer, S. H. Heil, S. T. Higgins, Psychiatry, University of Vermont, Burlington, VT
- 72 *Examining the psychological mechanisms of psilocybin-assisted smoking cessation treatment: A pilot study*  
A. P. Garcia-Romeu, M. W. Johnson, R. R. Griffiths, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

#### **OPIOIDS—HUMAN STUDIES**

- 73 *Bridging from conventional marketed immediate release formulations to new tamper-resistant alternatives*  
H. Stahlberg<sup>1</sup>, M. Brett<sup>2</sup>, J. Ossig<sup>2</sup>, S. Schwier<sup>3</sup>, A. Philipp<sup>1</sup>, <sup>1</sup>Clinical Pharmacology, Gruenthal GmbH, Aachen, Germany, <sup>2</sup>Pharmacokinetics, Gruenthal GmbH, Aachen, Germany, <sup>3</sup>Innovative Drug Delivery, Gruenthal GmbH, Aachen, Germany
- 74 *A standardized in vitro test battery to assess tamper-resistant properties of opioid formulations*  
E. Galia<sup>1</sup>, J. Bartholomaeus<sup>2</sup>, S. Schwier<sup>1</sup>, K. Strothmann<sup>1</sup>, <sup>1</sup>Gruenthal GmbH, Aachen, Germany, <sup>2</sup>Pharmakreativ Consulting, Aachen, Germany
- 75 *Is Oxycontin a special trigger for newly incident heroin use?*  
H. H. Yeh, J. C. Anthony, Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 76 *Subgroup differences in trajectories of heroin use and treatment effectiveness: An intersectionality viewpoint*  
C. Peng, Y. Hser, UCLA ISAP, Los Angeles, CA
- 77 *Dynamic modeling of initiation of nonmedical opioid use*  
A. Nielsen<sup>1</sup>, T. D. Schmidt<sup>1</sup>, D. McCarty<sup>2</sup>, W. W. Wakeland<sup>1</sup>, <sup>1</sup>Systems Science, Portland State University, Portland, OR, <sup>2</sup>PHPM, Oregon Health and Science University, Portland, OR

- 78 *Organizational factors associated with hepatitis C testing in opioid treatment programs: Results from a national study*  
J. A. Frimpong, T. D'Aunno, Columbia University, New York, NY
- 79 *The association between executive function, risky injection practices and hepatitis C virus among injection drug users*  
J. Scheidell, M. R. Khan, L. Clifford, W. W. Latimer, Clinical and Health Psychology, University of Florida, Gainesville, FL
- 80 *Identifying avenues for interventions to increase contraceptive use by opioid-maintained women*  
D. Hand<sup>1</sup>, S. H. Heil<sup>1,2</sup>, <sup>1</sup>Department of Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Department of Psychology, University of Vermont, Burlington, VT
- 81 *Improving effective contraceptive use among opioid-maintained women*  
S. H. Heil<sup>1,2</sup>, D. J. Hand<sup>1</sup>, S. C. Sigmon<sup>1,2</sup>, M. C. Meyer<sup>3</sup>, S. T. Higgins<sup>1,2</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Psychology, University of Vermont, Burlington, VT, <sup>3</sup>Obstetrics and Gynecology, University of Vermont, Burlington, VT
- 82 *Early drop-out: An indication of treatment success or difficulties?*  
J. Annon, M. P. Hillhouse, W. Ling, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 83 *Long-term follow-up of medication treatment with and without a behavioral component for opioid-dependent participants*  
M. P. Hillhouse, J. Jenkins, S. MacNicoll, S. Reed, L. Mooney, K. Miotto, M. Torrington, D. Dickerson, W. Ling, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 84 *Clinical supervision of drug counselors in Maldives*  
M. C. Chawarski<sup>1</sup>, A. Malik<sup>2</sup>, L. Hussain<sup>3</sup>, <sup>1</sup>Yale School of Medicine, New Haven, CT, <sup>2</sup>UNODC, Male, Maldives, <sup>3</sup>National Drug Agency, Male, Maldives
- 85 *Clinical supervision of drug counselors in Wuhan, China*  
R. Song<sup>3</sup>, W. Zhou<sup>2</sup>, R. S. Schottenfeld<sup>1</sup>, M. C. Chawarski<sup>1</sup>, <sup>1</sup>Yale School of Medicine, New Haven, CT, <sup>2</sup>CDC, Wuhan, China, <sup>3</sup>Huazhong University of Science and Technology, Wuhan, China
- 86 *The therapeutic workplace: A bridge to methadone treatment and drug abstinence for injection heroin users*  
A. Holtyn<sup>1</sup>, M. N. Koffarnus<sup>2</sup>, A. DeFulio<sup>1</sup>, S. O. Sigurdsson<sup>1,3</sup>, E. C. Strain<sup>1</sup>, R. P. Schwartz<sup>4</sup>, J. S. Leoutsakos<sup>1</sup>, K. Silverman<sup>1</sup>, <sup>1</sup>Johns Hopkins, Baltimore, MD, <sup>2</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>3</sup>University of Maryland Baltimore County, Baltimore, MD, <sup>4</sup>Friends Research Institute, Baltimore, MD
- 87 *Use of the BEing Safe in Treatment (BEST) feedback tool to increase counselor knowledge of patient sexual behavior*  
D. A. Calsyn, B. Hartzler, E. A. Wells, B. Beadnell, University of Washington, Seattle, WA
- 88 *Workshop training in contingency management: Initial effects on the attitudes, knowledge, self-efficacy, and adoption readiness of community addiction treatment personnel*  
B. Hartzler, Alcohol & Drug Abuse Institute, University of Washington, Seattle, WA
- 89 *Implementation of an electronic information system to enhance practice at an opioid treatment program*  
L. S. Brown, S. A. Kritz, M. Lin, Addiction Research and Treatment Corporation, Brooklyn, NY



- 90 *Concept mapping to generate items for the Patient Opioid Education Measure (POEM)*  
L. S. Wallace<sup>2</sup>, R. K. Wexler<sup>2</sup>, W. F. Miser<sup>2</sup>, L. McDougale<sup>2</sup>, J. D. Haddox<sup>1</sup>, <sup>1</sup>Health Policy, Purdue Pharma L.P., Stamford, CT, <sup>2</sup>Family Medicine, The Ohio State University, Columbus, OH

### POLICY

- 91 *Residential initiation of extended-release naltrexone and follow-up in opioid-dependent patients vs. case-matched controls*  
R. E. Meyer<sup>1</sup>, W. Milchak<sup>1</sup>, D. Leslie<sup>2</sup>, E. O. Bixler<sup>1</sup>, K. T. Brady<sup>3</sup>, P. Herschman<sup>4</sup>, G. D. Shulman<sup>5</sup>, D. R. Gastfriend<sup>6</sup>, <sup>1</sup>Psychiatry, Penn State Hershey Medical Center, Hershey, PA, <sup>2</sup>Public Health Sciences, Penn State Hershey Medical Center, Hershey, PA, <sup>3</sup>Psychiatry, MUSC, Charleston, SC, <sup>4</sup>CRC Health Group, Carlsbad, CA, <sup>5</sup>Shulman & Associates, Jacksonville, FL, <sup>6</sup>Alkermes, Inc, Waltham, MA
- 92 *Identification of data gaps that preclude evidence-based drug control policies aimed at reducing opioid analgesic abuse*  
J. G. Erensen<sup>1</sup>, J. D. Haddox<sup>1</sup>, H. Chilcoat<sup>2</sup>, <sup>1</sup>Health Policy, Purdue Pharma L.P., Stamford, CT, <sup>2</sup>Risk Mgt. & Epid., Purdue Pharma L.P., Stamford, CT
- 93 *External validation of the potential concern index model based on individual prescribing patterns*  
P. DuBose<sup>1</sup>, P. J. Burns<sup>1</sup>, J. D. Haddox<sup>2</sup>, <sup>1</sup>Principled Strategies, Inc., Encinitas, CA, <sup>2</sup>Health Policy, Purdue Pharma L.P., Stamford, CT
- 94 *Screening for substance use problems in private U.S. health plans*  
D. W. Garnick, C. M. Horgan, M. Stewart, S. Reif, E. Merrick, D. Hodgkin, A. Quinn, Institute for Behavioral Health, Heller School, Brandeis University, Waltham, MA
- 95 *Access to addiction pharmacotherapy in private U.S. health plans*  
C. M. Horgan, S. Reif, D. W. Garnick, D. Hodgkin, M. Stewart, E. Merrick, A. Quinn, Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, Waltham, MA
- 96 *Will the health care home help to reduce the health cost for drug users in medicaid?*  
K. Leung<sup>1</sup>, J. M. Topolski<sup>1</sup>, A. Ben Abdallah<sup>2</sup>, J. Parks<sup>1,3</sup>, <sup>1</sup>MIMH, University of Missouri-St. Louis, St. Louis, MO, <sup>2</sup>Washington University School of Medicine, St. Louis, MO, <sup>3</sup>Missouri's Department of Mental Health, Jefferson City, MO
- 97 *Financial capability: Standardizing assessment for adult beneficiaries with co-occurring disorders*  
A. C. Black<sup>1,2</sup>, T. J. McMahon<sup>1</sup>, R. A. Rosenheck<sup>1,2</sup>, M. I. Rosen<sup>1,2</sup>, <sup>1</sup>Psychiatry, Yale University, New Haven, CT, <sup>2</sup>Psychiatry, VA Connecticut Healthcare System, West Haven, CT
- 98 *Monitoring alcohol abuse prevention legislation*  
M. Smart, D. Jernigan, A. J. Milam, C. D. Furr-Holden, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 99 *The impact of state-level education policy, taxation, income disparity and political ideology on tobacco use in two nationally representative samples*  
A. D. Plunk, W. Tate, L. Bierut, R. Grucza, Washington University, St. Louis, MO
- 100 *Migration and tobacco smoking by race-ethnicity subgroups in the U.S.*  
W. Xue, C. Lopez-Quintero, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI



- 101 *But then what? A longitudinal analysis of child custody issues and how they impact future substance-using behavior among African-American mothers*  
K. L. Harp<sup>1</sup>, C. B. Oser<sup>1,2</sup>, B. Perry<sup>1</sup>, <sup>1</sup>Sociology, University of Kentucky, Lexington, KY, <sup>2</sup>Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 102 *A comparison of U.S. marijuana exposures calls to Poison Centers in states with and without medical marijuana laws*  
H. M. Haughey<sup>1</sup>, E. M. Martinez<sup>1</sup>, B. Bucher-Bartelson<sup>1</sup>, J. L. Green<sup>1</sup>, R. C. Dart<sup>1,2</sup>, <sup>1</sup>Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority, Denver, CO, <sup>2</sup>University of Colorado-Denver School of Medicine, Aurora, CO
- 103 *The substance and illicit drug abuser migration from urban to rural area in Taiwan population between 2005 and 2009*  
W. Tsay<sup>4</sup>, J. Hsu<sup>4</sup>, J. Kang<sup>4</sup>, Y. Lan<sup>1,2</sup>, Y. Hser<sup>3</sup>, I. Ho<sup>2</sup>, <sup>1</sup>China Medical University, Taichung, Taiwan, <sup>2</sup>China Medical University Hospital, Taichung, Taiwan, <sup>3</sup>UCLA Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>4</sup>Taiwan Food and Drug Administration, Taipei, Taiwan

### PROGRAM DESCRIPTION

- 104 *WITHDRAWN*
- 105 *Nicotine research cigarettes for the NIDA drug supply program*  
P. G. Pande, R. C. Daw, S. K. Sabharwal, K. H. Davis, B. F. Thomas, Analytical Chemistry and Pharmaceuticals, RTI International, RTP, NC
- 106 *The Medication Research Partnership*  
D. McCarty<sup>1</sup>, R. Croff<sup>1</sup>, M. Chalk<sup>2</sup>, K. Alanis-Hirsch<sup>2</sup>, J. Kemp<sup>2</sup>, J. Ford<sup>3</sup>, K. Johnson<sup>3</sup>, L. Schmidt<sup>4</sup>, <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>Treatment Research Institute, Philadelphia, PA, <sup>3</sup>NIATx, U. of Wisconsin, Madison, WI, <sup>4</sup>UC San Francisco, San Francisco, CA
- 107 *Methadone maintenance therapy in Vietnam: An overview and the role of policies for scaling up*  
T. M. Nguyen<sup>1</sup>, L. Nguyen<sup>1</sup>, M. D. Pham<sup>1</sup>, K. P. Mulvey<sup>2</sup>, H. H. Vu<sup>2</sup>, <sup>1</sup>Ministry of Health, VAAC, Hanoi, Viet Nam, <sup>2</sup>SAMHSA, US Embassy in Hanoi, Hanoi, Viet Nam
- 108 *Recovery-oriented care in American-Indian communities: A culturally legitimate practice in Indian country*  
E. Thin Elk<sup>1</sup>, A. H. Skinstad<sup>2</sup>, K. Summers<sup>2</sup>, <sup>1</sup>Sanford Health, Sioux Falls, SD, <sup>2</sup>University of Iowa, Iowa City, IA
- 109 *The spirit of communication: Motivational interviewing and Native American teachings*  
A. H. Skinstad<sup>1</sup>, K. Summers<sup>1</sup>, E. Parsells<sup>2</sup>, <sup>1</sup>University of Iowa, Iowa City, IA, <sup>2</sup>Lacota C.A.R.E., Mission, SD
- 110 *Expansion of medically assisted treatment (MAT) programs in Malaysia*  
V. B. Kasinather<sup>2</sup>, M. Mazlan<sup>3</sup>, R. S. Schottenfeld<sup>1</sup>, M. C. Chawarski<sup>1,2</sup>, <sup>1</sup>Yale School of Medicine, New Haven, CT, <sup>2</sup>Universiti Sains Malaysia, Penang, Malaysia, <sup>3</sup>SARC, Muar, Malaysia
- 111 *Themes in brief intervention sessions with substance-using emergency department patients: Interventionists' perspectives*  
C. Lizarraga, A. A. Forcehimes, M. Bogenschutz, CASAA, UNM, ABQ, NM
- 112 *A new standardised MedDRA query to address drug abuse-related safety signals*  
L. A. Love, S. Sun, FDA, Silver Spring, MD
- 113 *A videogame for substance use prevention and HIV risk reduction in young adolescents*  
L. E. Fiellin<sup>1</sup>, K. Hieftje<sup>1</sup>, L. R. Duncan<sup>1</sup>, B. G. Sawyer<sup>2</sup>, D. A. Fiellin<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Digitalmill, Portland, ME

- 114 *Using a non-inferiority trial approach to test the Holistic Health for HIV (3H+) intervention among HIV+ drug users in treatment*  
M. Copenhaver<sup>1</sup>, F. L. Altice<sup>2</sup>, <sup>1</sup>Allied Health Sciences, University of Connecticut, Storrs, CT, <sup>2</sup>Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT
- 115 *MAPIT: Development of a computer-based intervention targeting substance abuse treatment in the criminal justice system*  
S. Walters<sup>1</sup>, F. Taxman<sup>2</sup>, M. Rodriguez<sup>1</sup>, J. Lerch<sup>2</sup>, <sup>1</sup>UNT Health Science Center, Ft. Worth, TX, <sup>2</sup>George Mason University, Fairfax, VA
- 116 *Scaife Advanced Medical Student Clerkship in Alcohol and Other Drug Dependency: Description and outcome data*  
D. Lindsay, H. Hagle, P. Luongo, M. Flaherty, Institute for Research Education and Training in Addictions, Pittsburgh, PA
- 117 *Telepsychiatry for patients with co-morbid psychiatric and substance use disorders: A UCLA Integrated Substance Abuse Programs (ISAP) and Los Angeles County Department of Public Health-Substance Abuse, Prevention, and Control (SAPC) pilot*  
L. L. Denering<sup>1,2</sup>, D. A. Crevecoeur-MacPhail<sup>1</sup>, D. Dickerson<sup>1</sup>, R. Rawson<sup>1</sup>, <sup>1</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>2</sup>Health Promotion and Education, Loma Linda University School of Public Health, Loma Linda, CA
- 118 *Long-acting cocaine esterase (LACE): Assessing the treatment approach*  
E. M. Sellers, M. K. Romach, DL Global Partners Inc. and University of Toronto, Toronto, ON, Canada

**ALCOHOL**

- 119 *Taxometric analysis of DSM-IV and DSM-5 alcohol use disorders*  
B. T. Kerridge<sup>1</sup>, T. D. Saha<sup>2</sup>, G. Gmel<sup>3</sup>, J. T. Rehm<sup>4</sup>, <sup>1</sup>Epidemiology and Biostatistics, University of Maryland, College Park, College Park, MD, <sup>2</sup>LEB/DICBR, NIAAA/NIH, Rockville, MD, <sup>3</sup>Alcohol Treatment Center, Lausanne University Hospital, Lausanne, Switzerland, <sup>4</sup>SER, Centre for Addiction and Mental Health, Toronto, ON, Canada
- 120 *WITHDRAWN*
- 121 *Adolescent intermittent ethanol exposure increases risky responding in a probability discounting task in adulthood*  
N. Boutros, S. Semenova, A. Markou, Psychiatry, University of California, San Diego, La Jolla, CA
- 122 *The efficacy of topiramate at reducing ethanol's reinforcing effects is correlated with ethanol-induced extracellular glutamate concentrations in the nucleus accumbens of alcohol-preferring rats*  
W. J. Lynch<sup>1</sup>, R. W. Morgan<sup>1</sup>, C. Bond<sup>1</sup>, M. D. Lycas<sup>1</sup>, S. McIntosh<sup>2</sup>, B. A. Johnson<sup>1</sup>, S. E. Hemby<sup>2</sup>, <sup>1</sup>Univ of Virginia, Charlottesville, VA, <sup>2</sup>Wake Forest Univ, Winston-Salem, NC
- 123 *On-site ethyl glucuronide immunoassay monitoring of alcohol use in cocaine-dependent outpatients*  
T. J. White<sup>1</sup>, S. T. Higgins<sup>1,2</sup>, D. Vurbic<sup>1,2</sup>, R. Redner<sup>1</sup>, J. Skelly<sup>3</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Psychology, University of Vermont, Burlington, VT, <sup>3</sup>Medical Biostatistics, University of Vermont, Burlington, VT
- 124 *Patient motivation and 12-month treatment outcome in alcohol use disorder outpatients in France*  
B. Fleury<sup>2,4</sup>, C. M. Denis<sup>1,5</sup>, B. Nalpas<sup>2,3</sup>, M. Crapelet<sup>2</sup>, M. Auriacombe<sup>1,4,5</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>ANPAA, Paris, France, <sup>3</sup>INSERM 567, Paris, France, <sup>4</sup>CHU Bordeaux, Bordeaux, France, <sup>5</sup>CH Ch. Perrens, Bordeaux, France

- 125 *Correlation between severity of addiction and level of services received by alcohol use disorder outpatients in France*  
C. M. Denis<sup>1,5</sup>, B. Fleury<sup>2,4</sup>, B. Nalpas<sup>2,3</sup>, M. Crapelet<sup>2</sup>, M. Auriacombe<sup>1,4,5</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>ANPAA, Paris, France, <sup>3</sup>INSERM 567, Paris, France, <sup>4</sup>CHU Bordeaux, Bordeaux, France, <sup>5</sup>CH Ch. Perrens, Bordeaux, France
- 126 *HIV-1 Tat protein expression in mouse brain potentiates ethanol reward and reinstates extinguished ethanol-seeking behavior*  
J. P. McLaughlin, M. L. Ganno, S. O. Eans, J. J. Paris, H. D. Singh, Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL
- 127 *Chronic treatment with ethanol-enhanced morphine-induced hyperlocomotion*  
K. Andoh, M. Shibasaki, T. Tsuyuki, A. Otokozawa, T. Mori, T. Suzuki, Toxicology, Hoshi University, Tokyo, Japan
- 128 *WITHDRAWN*
- 129 *Context of early adolescent alcohol use: First results from a longitudinal cohort*  
R. Mattick<sup>1</sup>, M. Wadolowski<sup>1</sup>, A. Aiken<sup>1</sup>, C. Bucello<sup>1</sup>, R. Bruno<sup>2</sup>, J. Najman<sup>3</sup>, K. Kypri<sup>4</sup>, T. Slade<sup>1</sup>, D. Hutchinson<sup>1</sup>, N. McBride<sup>5</sup>, <sup>1</sup>National Drug & Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>University of Tasmania, Hobart, TAS, Australia, <sup>3</sup>University of Queensland, Brisbane, QLD, Australia, <sup>4</sup>University of Newcastle, Newcastle, NSW, Australia, <sup>5</sup>Curtin University, Perth, WA, Australia
- 130 *Television watching and alcohol expectation endorsement through late childhood in Taiwan*  
Y. Chen<sup>1</sup>, K. Chen<sup>1,2</sup>, D. T. Ding<sup>1</sup>, W. J. Chen<sup>3</sup>, C. Y. Chen<sup>1,2</sup>, <sup>1</sup>Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, <sup>2</sup>Division of Mental Health & Addiction Medicine, National Health Research Institutes, Miaoli, Taiwan, <sup>3</sup>Institute of Epidemiology, National Taiwan University, Taipei, Taiwan
- 131 *Social network drinking frequency moderates the effects of naltrexone on heavy drinking days in the COMBINE study*  
M. Worley<sup>1,3</sup>, K. Witkiewitz<sup>2</sup>, S. A. Brown<sup>3</sup>, D. Kivlahan<sup>1</sup>, R. Longabaugh<sup>4</sup>, <sup>1</sup>Puget Sound Veterans Affairs Healthcare System, Seattle, WA, <sup>2</sup>University of New Mexico, Albuquerque, NM, <sup>3</sup>University of California, San Diego, CA, <sup>4</sup>Brown University, Providence, RI
- 132 *The impact of substance use and gender on Condom Use Self-Efficacy in a rural treatment-seeking sample*  
J. Simmons<sup>1,2</sup>, D. Lupee<sup>3,4</sup>, B. Greenfield<sup>1,2</sup>, M. Romero<sup>1,2</sup>, J. S. Tonigan<sup>2,1</sup>, R. Currier<sup>4,3</sup>, E. Homer<sup>3,4</sup>, Y. Yamutewa<sup>3,4</sup>, F. Lesensee<sup>4</sup>, K. Venner<sup>1,2</sup>, <sup>1</sup>Psychology, University of New Mexico, Albuquerque, NM, <sup>2</sup>Center on Alcoholism, Substance Abuse and Addictions, University of New Mexico, Albuquerque, NM, <sup>3</sup>Pueblo of Zuni MICRA Project, Pueblo of Zuni, NM, <sup>4</sup>Zuni Recovery Center, Pueblo of Zuni, NM
- 133 *Alcohol use and related problems in the São Paulo Megacity Mental Health Survey, Brazil: Influences of neighborhood social deprivation and individual socioeconomic status*  
C. M. Silveira<sup>1</sup>, E. R. Siu<sup>1</sup>, S. Martins<sup>2</sup>, L. P. Saito<sup>1</sup>, A. G. Andrade<sup>1</sup>, M. C. Viana<sup>1</sup>, L. H. Andrade<sup>1</sup>, <sup>1</sup>University of São Paulo Medical School, Sao Paulo, Brazil, <sup>2</sup>Columbia University, New York, NY, NY
- 134 *A brief behavioral telehealth intervention for veterans with alcohol misuse problems in VA primary care*  
J. A. De Leo<sup>1,2</sup>, K. Lamb<sup>2</sup>, S. LaRowe<sup>2</sup>, E. J. Santa Ana<sup>2,1</sup>, <sup>1</sup>MUSC, Charleston, SC, <sup>2</sup>Charleston VAMC, Charleston, SC

- 135 *The impact of vivitrol on short-term outcomes post-medication*  
D. A. Crevecoeur-MacPhail, R. Rawson, S. J. Cousins, L. L. Denering, Psychiatry NPI, UCLA ISAP, Los Angeles, CA
- 136 *Patterns of recent alcohol consumption by race among a sample of urban men who have sex with men*  
E. R. Greene<sup>1,2</sup>, V. F. Frye<sup>1,2</sup>, M. Cerda<sup>2</sup>, D. C. Ompad<sup>3</sup>, V. Nandi<sup>1</sup>, D. Hoover<sup>4</sup>, B. Koblin<sup>1</sup>, <sup>1</sup>New York Blood Center, New York, NY, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>New York University, New York, NY, <sup>4</sup>Rutgers University, New Brunswick, NJ
- 137 *The influence of trait affect on the emotion-effects of alcohol*  
C. Gorey, S. D. Pressman, C. Maxwell, University of Kansas, Lawrence, KS

**PERINATAL DRUG ABUSE**

- 138 *Characteristics of perinatal women seeking treatment for marijuana abuse in a community-based clinic*  
G. K. Tzilos<sup>1</sup>, L. Hess<sup>2</sup>, J. Kao<sup>2</sup>, C. Zlotnick<sup>2</sup>, <sup>1</sup>Center for Alcohol & Addiction Studies, Brown University, Providence, RI, <sup>2</sup>Women and Infants Hospital, Brown University, Providence, RI
- 139 *BDNF levels at umbilical cord blood (UCB) among babies exposed to crack during pregnancy*  
V. Mardini<sup>1,4,5</sup>, C. Szobot<sup>5,4,2</sup>, R. Parcianello<sup>2</sup>, L. Manna<sup>2</sup>, L. Röhsig<sup>6,1</sup>, N. Canabarro<sup>2</sup>, N. Gambogi<sup>4</sup>, M. Sehbe<sup>2</sup>, M. Zavaschi<sup>1</sup>, K. M. Cereser<sup>3,1</sup>, G. Fries<sup>3</sup>, F. Kapczinsky<sup>1,3</sup>, F. Pechansky<sup>1,3</sup>, L. A. Rohde<sup>1,5</sup>, <sup>1</sup>UFRGS, Porto Alegre, Brazil, <sup>2</sup>ULBRA, Canoas, Brazil, <sup>3</sup>Laboratório de Psiquiatria Molecular, HCPA, Porto Alegre, Brazil, <sup>4</sup>Research Center on Alcohol and Drugs, HCPA, Porto Alegre, Brazil, <sup>5</sup>ADHD Outpatient Clinic, HCPA, Porto Alegre, Brazil, <sup>6</sup>Serviço de Hemoterapia, HCPA, Porto Alegre, Brazil
- 140 *Serum concentrations of BDNF during the immediate puerperium among women with crack dependence in comparison to healthy mothers: Preliminary data*  
C. Szobot<sup>4,2,3</sup>, V. Mardini<sup>4,3,1</sup>, F. Pechansky<sup>3,1</sup>, F. Kapczinski<sup>5,1</sup>, K. M. Cereser<sup>5,1</sup>, G. Fries<sup>5</sup>, N. Canabarro<sup>2</sup>, L. Manna<sup>2</sup>, R. Parcianello<sup>2</sup>, M. Zavaschi<sup>1</sup>, F. Rosa<sup>3</sup>, L. Pereira<sup>3</sup>, L. A. Rohde<sup>4,1</sup>, <sup>1</sup>UFRGS, Porto Alegre, Brazil, <sup>2</sup>ULBRA, Canoas, Brazil, <sup>3</sup>Research Center on Alcohol and Drugs, HCPA, Porto Alegre, Brazil, <sup>4</sup>ADHD Outpatient Clinic, HCPA, Porto Alegre, Brazil, <sup>5</sup>Laboratório de Psiquiatria Molecular, HCPA, Porto Alegre, Brazil
- 141 *The relationship between postpartum depression and change in perinatal alcohol use: An analysis of PRAMS data*  
S. Salimi<sup>1</sup>, M. Chisolm<sup>2</sup>, D. Cheng<sup>3</sup>, M. Terplan<sup>4</sup>, <sup>1</sup>Department of Medicine, University of Maryland, Baltimore, MD, <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Bureau for Maternal and Child Health, Maryland Department of Health and Mental Hygiene, Baltimore, MD, <sup>4</sup>Obstetrics, Gynecology and Reproductive Sciences and Epidemiology and Public Health, University of Maryland, Baltimore, MD
- 142 *Fetal Alcohol Spectrum Disorder: A growing concern in Israel?*  
Y. Neumark<sup>1</sup>, I. D. Wexler<sup>2</sup>, A. Tenenbaum<sup>2</sup>, <sup>1</sup>Braun School of Public Health, Hebrew University-Hadassah, Jerusalem, Israel, <sup>2</sup>Pediatrics, Hadassah Medical Center, Jerusalem, Israel
- 143 *Executive function in children with prenatal cocaine exposure at 12 and 15 years*  
S. Minnes<sup>1</sup>, M. O. Min<sup>1</sup>, E. Short<sup>3</sup>, M. Wu<sup>1</sup>, S. Yoon<sup>1</sup>, L. Singer<sup>2</sup>, <sup>1</sup>Applied Social Sciences, Case Western Reserve University, Cleveland, OH, <sup>2</sup>School of Medicine, Case Western Reserve University, Cleveland, OH, <sup>3</sup>Psychology, Case Western Reserve University, Cleveland, OH
- 144 *Characterization of placental efflux transporters*  
J. A. Paul, S. L. Patrikeeva, X. Wang, G. D. Hankins, T. N. Nanovskaya, M. S. Ahmed, Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX

## **Symposium IX**

**INDIGO A**  
**10:00 - 12:05 PM**

### **PRECLINICAL TO CLINICAL EVIDENCE THAT GLIA AND NEUROINFLAMMATION MEDIATE DRUG ABUSE AND RELATED PATHOLOGIES**

Chairs: Patrick Beardsley and Kurt Hauser

- 10:00 *75th Anniversary Reflections*
- 10:05 *Astroglia and microglia: Architects in opiate-mediated synaptodendritic injury and behavioral deficits in neuroAIDS*  
Kurt Hauser, Virginia Commonwealth University School of Medicine, Richmond, VA
- 10:30 *Preclinical evidence that chemically modulating glial and neuroinflammatory activity affects drug-maintained and relapse behavior with a focus on methamphetamine*  
Patrick Beardsley, Virginia Commonwealth University, Richmond, VA
- 10:55 *Effects of glial modulators (Ibuprofen, Minocycline, and Pioglitazone) on opioid-induced responses in human research volunteers*  
Sandra D. Comer, Columbia University, New York, NY
- 11:20 *Initial outcomes of a Phase IB, safety interaction trial of Ibuprofen as a medication for methamphetamine dependence*  
Steven Shoptaw, University of California Los Angeles, Los Angeles, CA
- 11:45 *Brief introduction to current research on glial/neuro-inflammatory processes and drug abuse and summary/discussion of highlights from symposium presentations*  
Keith Heinzerling, University of California Los Angeles, Los Angeles, CA

## **Symposium X**

**(Sponsored by CPDD/APSAD)**

**INDIGO E**  
**10:00 - 12:05 PM**

### **SUBSTANCE USE: HEALTH AND SOCIAL EFFECTS IN OLDER DRUG USERS: WHAT WE KNOW AND WE DON'T**

Chairs: Nicholas Lintzeris and Michelle R. Lofwall

- 10:00 *75th Anniversary Reflections*
- 10:05 *Substance use and health status in older substance users: Implications for research and practice*  
Nicholas Lintzeris, NSW Ministry of Health, Surry Hills, NSW, Australia
- 10:30 *Trends in non-alcohol substance use among older persons in the United States*  
Michelle R. Lofwall, University of Kentucky College of Medicine, Lexington, KY
- 10:55 *Hippocampal volume and cognitive function in aging cocaine smokers*  
Gillinder Bedi, Columbia University and New York State Psychiatric Institute, New York, NY
- 11:20 *Opioid use and health in older Australian women*  
Lynne Parkinson, CQ University, Queensland, QLD, Australia
- 11:45 *Health status including cognitive state of older opioid/alcohol/BZD substance users attending hospital and community health services*  
Nicholas Lintzeris, Drug and Alcohol Services, South East Sydney Local Health District and the Mental Health Drug and Alcohol Office, NSW Ministry of Health, NSW, NSW, Australia



**Oral Communications 9**

**INDIGO D  
10:00 - 12:05 PM**

**MEMORY LANE: FROM IMPAIRMENT TO IMPROVEMENT**

Chairs: Francesco Leri and Erin Cummins

- 10:00 *75th Anniversary Reflections*
- 10:05 *Evidence of a meta-memory deficit among chronic methamphetamine users*  
S. P. Woods, K. Blackstone, E. E. Morgan, D. R. Franklin, I. Grant, Psychiatry, UCSD, San Diego, CA
- 10:20 *Memory-enhancing function of drug reinforcers: The cocaine puzzle*  
F. Leri, N. Rkieh, J. Cloke, R. Filc, Psychology, University of Guelph, Guelph, ON, Canada
- 10:35 *Sex differences in associations between age of initiated cannabis use and neuropsychological performance*  
N. A. Crane<sup>1</sup>, R. M. Schuster<sup>1</sup>, R. Gonzalez<sup>2</sup>, <sup>1</sup>Department of Psychology, University of Illinois at Chicago, Chicago, IL, <sup>2</sup>Department of Psychology, Florida International University, Miami, FL
- 10:50 *Motivational Interviewing combined with chess improves working memory and reduces impulsivity in cocaine dependence: A pilot intervention*  
P. D. Goncalves<sup>1,2,3</sup>, M. Ometto<sup>2,3</sup>, A. Malbergier<sup>1</sup>, R. Amaral<sup>1</sup>, S. Nicastrì<sup>1,2</sup>, P. A. Martins<sup>2</sup>, L. Beraldo<sup>1,2</sup>, D. Fuentes<sup>3</sup>, A. Andrade<sup>1</sup>, G. Busatto<sup>2</sup>, P. J. Cunha<sup>1,2</sup>, <sup>1</sup>Interdisciplinary Group of Studies on Alcohol and Drugs (GREA), Institute of Psychiatry (IPq), School of Medicine, University of São Paulo, São Paulo, Brazil, <sup>2</sup>Laboratory of Psychiatric Neuroimaging (LIM 21/NAPNA), Department of Psychiatry (IPq), School of Medicine, University of São Paulo, São Paulo, Brazil, <sup>3</sup>Psychology & Neuropsychology Service, Institute of Psychiatry (IPq), School of Medicine, University of São Paulo, São Paulo, Brazil
- 11:05 *Effects of working-memory training in methadone maintenance patients*  
R. L. Schacht, M. W. Johnson, E. C. Strain, M. Mintzer, Johns Hopkins University School of Medicine, Baltimore, MD
- 11:20 *Correlates of impaired cognitive performance in cocaine- and opioid-dependent patients*  
A. Umbricht, M. Mintzer, O. Rass, G. E. Bigelow, M. W. Johnson, E. C. Strain, D. A. Tompkins, Psychiatry, Johns Hopkins University, Baltimore, MD
- 11:35 *Role of the noradrenergic locus coeruleus complex in memory formation underlying relapse*  
E. Cummins, E. Boughner, J. Grant, K. Kent, A. Ricchetti, F. Leri, Psychology, University of Guelph, Guelph, ON, Canada
- 11:50 *Longer abstinence from methamphetamine is associated with better neurocognitive performance in younger but not older adults*  
J. Cattie<sup>1</sup>, J. Montoya<sup>1</sup>, E. E. Morgan<sup>2</sup>, S. P. Woods<sup>2</sup>, I. Grant<sup>2</sup>, <sup>1</sup>SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, <sup>2</sup>Psychiatry, UCSD, San Diego, CA



**Oral Communications 10**

**INDIGO H  
10:00 - 12:05 PM**

**“TWEETMENT” IN THE 21ST CENTURY**

Chairs: Jan Copeland and Eric R. Pedersen

- 10:00 *75th Anniversary Reflections*
- 10:05 *A smart phone application for cannabis-related problems*  
J. Copeland, L. Albertella, M. Norberg, S. Rooke, National Cannabis Prevention and Information Centre, University of New South Wales, Sydney, NSW, Australia
- 10:20 *A randomized trial of a computerized brief intervention for drug use in primary care: 3-month outcomes*  
R. P. Schwartz<sup>1</sup>, J. Gryczynski<sup>1</sup>, S. G. Mitchell<sup>1</sup>, A. Gonzales<sup>2</sup>, T. Peterson<sup>2</sup>, A. Moseley<sup>2</sup>, K. O’Grady<sup>3</sup>, S. J. Ondersma<sup>4</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Sangre de Cristo Community Health Partnership, Santa Fe, NM, <sup>3</sup>University of Maryland, College Park, MD, <sup>4</sup>Wayne State U, Detroit, MI
- 10:35 *Place and drug craving: An Ecological Momentary Assessment study*  
P. T. Harrell<sup>1</sup>, D. H. Epstein<sup>2</sup>, K. L. Preston<sup>2</sup>, <sup>1</sup>Mental Health, Johns Hopkins University School of Public Health, Baltimore, MD, <sup>2</sup>Clinical Pharmacology and Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health School of Public Health, Baltimore, MD
- 10:50 *Comparative effectiveness and cost-effectiveness of a computer-delivered psychosocial treatment program for prisoners with substance use disorders*  
M. Chaple<sup>1</sup>, S. Sacks<sup>1</sup>, M. T. French<sup>2</sup>, B. Sayed<sup>2</sup>, L. A. Marsch<sup>3</sup>, <sup>1</sup>CIRP, NDRI, New York, NY, <sup>2</sup>Univ. of Miami, Miami, FL, <sup>3</sup>Dartmouth Med Sch, Hanover, NH
- 11:05 *A pilot study examining the efficacy of virtual-reality-based relapse prevention among alcohol-dependent veterans with traumatic brain injury*  
J. H. Yoon<sup>1</sup>, R. De La Garza, II<sup>1</sup>, P. S. Bordnick<sup>2</sup>, R. H. Hawkins<sup>1</sup>, B. A. Shapiro<sup>1</sup>, D. E. Croft<sup>1</sup>, H. E. Levin<sup>1</sup>, <sup>1</sup>Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Taiwan, <sup>2</sup>Social Work, University of Houston, Houston, TX
- 11:20 *Twitter: A window on alcohol use?*  
K. A. Ramezani<sup>1</sup>, F. Terdal<sup>1</sup>, N. Pepper<sup>2</sup>, K. G. Anderson<sup>1</sup>, <sup>1</sup>Psychology, Reed College, Portland, OR, <sup>2</sup>LuckySort, Portland, OR
- 11:35 *Evidence-based multimedia 12-Step facilitation toolkit improves counselor adherence in group counseling with minimal training: Preliminary results*  
A. C. Brooks<sup>1</sup>, A. B. Laudet<sup>2</sup>, T. Case<sup>1</sup>, C. M. Carpenedo<sup>1</sup>, D. Knoblach<sup>1</sup>, L. Benishek<sup>1</sup>, D. Carise<sup>3</sup>, K. C. Kirby<sup>1,3</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>National Development and Research Institute, New York, NY, <sup>3</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA
- 11:50 *Brief online interventions targeting risk and protective factors for increased and problematic alcohol use among American college students studying abroad*  
E. R. Pedersen<sup>1</sup>, M. E. Larimer<sup>2</sup>, D. Atkins<sup>2</sup>, C. Lee<sup>2</sup>, C. Neighbors<sup>3</sup>, <sup>1</sup>RAND Corporation, Santa Monica, CA, <sup>2</sup>University of Washington, Seattle, WA, <sup>3</sup>University of Houston, Houston, TX

---

**Tuesday, June 18, 2013**

---

**Animals in Research Forum**  
**(Brown Bag Lunch)**  
**HOW TO BE AN ANIMAL *FACTIVIST***

**INDIGO A**  
**12:15 - 1:45 PM**

Chairs: Toby K. Eisenstein and Therese A. Kosten

*Resource Person and Discussant*

Taylor Bennett, National Association for Biomedical Research, Hinsdale, IL

**Media Training Forum**  
**(Brown Bag Lunch)**  
**SCIENCE, THE PRESS, AND AN INFORMED PUBLIC**

**INDIGO E**  
**12:15 - 2:15 PM**

Chairs: Marc J. Kaufman and Kathleen T. Brady

12:15 *Introduction to media training for scientists: Why this is important and what you will learn*  
Marc J. Kaufman, Brain Imaging Center, McLean Hospital, Belmont, MA

12:40 *A scientist in the media spotlight: Converging and conflicting missions*  
Bertha K. Madras, New England Primate Research Center, Harvard Medical School,  
Southborough, MA

1:05 *Interviews with scientists: A reporter's perspective*  
Shari Roan, Freelance journalist and former medical writer for the Los Angeles Times, Los  
Angeles, CA

1:30 *Making sense of science and sound bites and mock interview sessions with coaching*  
Bertha K. Madras, New England Primate Research Primate Center, Harvard Medical School,  
Southborough, MA

1:55 *Discussant*  
Kathleen T. Brady, Medical University of South Carolina, Charleston, SC

**Grant-Writing Workshop**  
**(PRE-REGISTRANTS ONLY)**

**SAPPHIRE 410**  
**12:05 - 4:00 PM**

**Reflections on 75 Years of the**  
**CPDD Annual Scientific Meeting**

**INDIGO BCFG**  
**4:00 - 5:00 PM**

**PANEL DISCUSSION**

Chairs: Martin Adler and Charles Gorodetzky

**Business Meeting**  
**(MEMBERS ONLY)**

**INDIGO A**  
**5:00 - 6:00 PM**

## **Workshop X**

**INDIGO 202  
8:00 - 10:00 PM**

### **HOW TO GET YOUR ADDICTION RESEARCH MANUSCRIPTS PUBLISHED: GUIDELINES FOR EMERGING INVESTIGATORS**

Chairs: James Sorensen and Carmen L. Masson

*Getting published: Junior investigator issues*

Danielle Ramo, University of California, San Francisco, San Francisco, CA

*Planning, targeting, and preparing of manuscripts*

Sandra D. Comer, Columbia University and NYSPI, New York, NY

*Working with journal editors*

M P. McGovern, Dartmouth Medical School, Lebanon, NH

*Publishing: After you get your reviews*

Eric C. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

*Resources for young investigators*

Robert Balster, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA

## **Workshop XI**

**INDIGO 204  
8:00 - 10:00 PM**

### **FINDINGS FROM INTRODUCTION OF REFORMULATED OPIOID ANALGESICS ON PATTERNS OF ABUSE AND DIVERSION OF PRESCRIPTION OPIOIDS AND THEIR SURVEILLANCE**

Chairs: Edward M. Sellers and Paul Coplan

*Changing patterns of abuse reported to poison centers following introduction of reformulated extended release oxycodone*

Richard C. Dart, Denver Health and Hospital Authority, Denver, CO

*Changes in abuse patterns following introduction of reformulated opioids observed in a surveillance system of substance abuse treatment centers*

Stephen F. Butler, Inflexxion, Inc., Newtown, MA

*Impact of a rapid transition to a new opioid formulation on diversion and doctor-shopping outcomes*

Howard Chilcoat, Purdue Pharma L.P., Stamford, CT

*Using post-marketing epidemiologic studies to validate forensic and behavioral pharmacologic pre-approval research*

Edward M. Sellers, DL Global Partners Inc., Toronto, ON, Canada

*Discussant*

Theodore Cicero, Washington University, St. Louis, MO

## **Workshop XII**

**INDIGO A**  
**8:00 - 10:00 PM**

### **EARLY CAREER RESEARCH AND SECONDARY DATA ANALYSIS**

Chairs: Amy Pienta and Kaye Marz

*Benefits and challenges of using secondary data in your research*

Amy Pienta, ICPSR, University of Michigan, Ann Arbor, MI

*Seeking funding for secondary data analysis projects*

Marsha Lopez, NIDA, Rockville, MD

*Navigating the NAHDAP Website: An overview of tools and resources*

Amy Pienta, ICPSR, University of Michigan, Ann Arbor, MI

## **Workshop XIII**

**INDIGO E**  
**8:00 - 10:00 PM**

### **NOVEL TOBACCO AND NICOTINE PRODUCTS AND REGULATORY SCIENCE**

Chairs: Dorothy Hatsukami and Stacey C. Sigmon

*The Family Smoking Prevention and Tobacco Control Act and regulatory science*

David Ashley, FDA, Rockville, MD

*Emerging tobacco products: Perils and potential promise*

Jack Henningfield, Pinney Associates, Bethesda, MD

*Regulatory science: Contributions from drug abuse researchers*

Lawrence Carter, University of Arkansas for Medical Sciences, College of Medicine, Little Rock, AR

*Discussant*

David Shurtleff, National Institute on Drug Abuse, Bethesda, MD

## **Workshop XIV**

**INDIGO D**  
**8:00 - 10:00 PM**

### **ARE WE MISSING THE MARK WITH GENDER DIFFERENCES, WOMEN SUBSTANCE USERS, AND SOCIAL DETERMINANTS FOR HIV RISK? LESSONS FROM AROUND THE GLOBE**

Chairs: Wendee Wechsberg and Steffanie Strathdee

*Gender differences among couples using alcohol and drugs in disparate social settings in Cape Town, South Africa*

W Zule, RTI International, Durham, NC

*Women IDUs in Georgia: Risk and stigma in seeking care and policy implications*

Irma Kirtadze, Alternative Georgia, Tbilisi, GA

*Reconfiguring risk: Gender and injection drug-related HIV risk among female sex workers and their non-commercial partners along the Mexico-U.S. border*

Jennifer Syvertsen, University of California, San Francisco, La Jolla, CA

*Discussant*

Hendree Jones, RTI, Durham, NC

---

**Tuesday, June 18, 2013**

---

## **Workshop XV**

**INDIGO H  
8:00 - 10:00 PM**

### **APPROACHES FOR SCREENING AND TREATING RISKY DRUG- USING PATIENTS IN COMMUNITY HEALTH CENTERS**

Chairs: Lillian Gelberg and Ronald Andersen

*A conceptual model for implementing and evaluating the screening (the ASSIST) and treating (the QUIT) of risky drug users in community health centers*

Ronald Andersen, UCLA School of Public Health, Los Angeles, CA

*Implementing and evaluating the ASSIST to screen for risky untreated drug users in community health centers*

Lillian Gelberg, David Geffen School of Medicine at UCLA, Los Angeles, CA

*Barriers to reducing risky drug use by primary care patients in federally qualified health centers from reducing drug use*

Howard Padwa, University of California, Los Angeles, Los Angeles, CA

*The efficacy of the QUIT intervention for reducing risky drug use and drug-related harm behavior of patients of community health centers*

Lillian Gelberg, David Geffen School of Medicine at UCLA, Los Angeles, CA

*Applying the ASSIST/QUIT model to a collaborative Mexico/US study to reduce risky drug use of community clinic patients on both sides of the border*

Guillermina Natera, National Institute of Psychiatry Ramón de la Fuente Muñiz, Calz, Mexico

### Public Policy Forum

**INDIGO BCFG**  
**8:00 - 9:45 AM**

Chair: William L. Dewey

*Introduction*

William L. Dewey, VCU, Richmond, VA

*Speaker*

Ed Long, Van Scoyoc Associates, Washington, DC

*Speaker*

Beau Kilmer, Rand Corporation, Santa Monica, CA

*Speaker*

Rosalie Pacula, Rand Corporation, Santa Monica, CA

### Symposium XI

**INDIGO A**  
**9:55 - 12:00 PM**

#### **EMERGING DATA ON EFFICACY AND CLINICAL APPLICATIONS OF EXTENDED RELEASE NALTREXONE FORMULATIONS**

Chairs: George E. Woody and Porarinn Tyrfingsson

9:55 *75th Anniversary Reflections*

10:00 *Long-acting extended release naltrexone for opioid dependence: Implantable and injectable*  
E. Krupitsky, St. Petersburg Bekhterev Research Psychoneurological Institute and St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation

10:25 *Interest for extended-release naltrexone among opioid users evaluated for participation in the Norwegian XR-NTX vs. buprenorphine-naloxone study*  
Nikolaj Kunøe, University of Oslo, Norway, Oslo, Norway

10:50 *Using naltrexone for treating amphetamine dependence: Preliminary results of the efficacy of extended release naltrexone for treating amphetamine dependence in Iceland*  
Valgerdur Runarsdottir, Ingunn Hansdottir, National Center for Addiction Treatment, Vogur Hospital, Reykjavik, Iceland

11:15 *The efficacy and safety of the Australian sustained-release naltrexone implant for the management of opioid, amphetamine, and alcohol dependence*  
Gary Kenneth Hulse, The University of Western Australia, Nedlands, WA, Australia

11:40 *Discussant*  
Kathleen T. Brady, Medical University of South Carolina, Charleston, SC



## **Symposium XII**

**INDIGO E**  
**9:55 - 12:00 PM**

### **BEHAVIORAL DISINHIBITION, DRUGS OF ABUSE, AND BRAIN DYSFUNCTION IN HUMANS AND RODENT MODELS**

Chairs: Barry Setlow and Thomas J. Crowley

- 9:55 *75th Anniversary Reflections*
- 10:00 *Behavioral disinhibition: A continuum of risk for addiction and comorbid externalizing psychopathology*  
Susan Young, University of Colorado Denver School of Medicine, Aurora, CO
- 10:25 *Behavioral disinhibition, risk-taking, and adolescent substance use disorder*  
Thomas J. Crowley, University of Colorado Denver School of Medicine, Aurora, CO
- 10:50 *Corticostriatal serotonin 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R homeostatic imbalance links impulsivity and cue reactivity*  
Noelle C. Anastasio, Center for Addiction Research, University of Texas Medical Branch, Galveston, TX
- 11:15 *Risk-taking, dopamine signaling, and cocaine self-administration*  
Barry Setlow, University of Florida, Gainesville, FL
- 11:40 *Discussant*  
J. David Jentsch, University of California LA, Los Angeles, CA

## **Oral Communications 11**

**INDIGO D**  
**9:55 - 12:00 PM**

### **BREAKING THE CHAINS OF ADDICTION: CRIMINAL JUSTICE**

Chairs: Douglas Marlowe and Thomas Moore

- 9:55 *75th Anniversary Reflections*
- 10:00 *Gender differences in characteristics, service utilization and treatment outcomes of adult drug treatment court clients*  
D. Morse<sup>1</sup>, S. Gamble<sup>1</sup>, M. Ives<sup>3</sup>, M. Mittal<sup>1</sup>, M. T. Swogger<sup>1</sup>, E. Wang<sup>2</sup>, K. Conner<sup>1</sup>,  
<sup>1</sup>Psychiatry, University of Rochester School of Medicine, Rochester, NY, <sup>2</sup>Medicine, Yale University School of Medicine, New Haven, CT, <sup>3</sup>Lighthouse Institute, Chestnut Health Systems, Inc., Normal, IL
- 10:15 *Comparison of sentenced inmates' drug use patterns before and during incarceration*  
G. Caraballo-Correa, R. Ramírez, J. J. Ruíz, C. E. Albizu-García, Center for Evaluation and Sociomedical Center, University of Puerto Rico, San Juan
- 10:30 *Influence of organizational and staff characteristics on success in implementing process improvement goals in correctional treatment settings*  
M. Prendergast<sup>1</sup>, W. Welsh<sup>2</sup>, M. S. Shafer<sup>5</sup>, G. Melnick<sup>3</sup>, L. Stein<sup>4</sup>, J. L. Duvall<sup>6</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>Temple U, Philadelphia, PA, <sup>3</sup>NDRI, New York, NY, <sup>4</sup>U Rhode Island, Kingston, RI, <sup>5</sup>Arizona State U, Phoenix, AZ, <sup>6</sup>U Kentucky, Lexington, KY
- 10:45 *Sex/gender differences and the impact of risk factors and psychosocial functioning on the time to re-arrest among offenders treated for substance use*  
Y. Yang, K. Knight, G. W. Joe, G. A. Rowan-Szal, W. E. Lehman, P. M. Flynn, Institute of Behavioral Research, Texas Christian University, Fort Worth, TX

- 11:00 *An experimental trial of adaptive programming in drug court: Long-term outcomes*  
D. B. Marlowe<sup>1,2,3</sup>, D. S. Festinger<sup>1,3</sup>, K. L. Dugosh<sup>1</sup>, G. Fox<sup>1</sup>, K. M. Benasutti<sup>1</sup>, A. Harron<sup>1</sup>,  
<sup>1</sup>Law and Ethics, Treatment Research Institute, Philadelphia, PA, <sup>2</sup>National Association of  
Drug Court Professionals, Alexandria, VA, <sup>3</sup>Department of Psychiatry, University of  
Pennsylvania, Philadelphia, PA
- 11:15 *Contingency management intervention tailored for juveniles in drug court: Preliminary short-term substance use outcomes of a randomized controlled trial*  
P. M. Mauro<sup>1</sup>, E. J. Letourneau<sup>1</sup>, M. R. McCart<sup>2</sup>, A. J. Sheidow<sup>2</sup>, <sup>1</sup>Dept. of Mental Health,  
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Medical University of  
South Carolina, Charleston, SC
- 11:30 *Using incentives to improve parolee attendance in community treatment: Preliminary outcomes*  
E. Hall, M. Prendergast, J. Grossman, R. Veliz, U. Warda, Psychiatry and Biobehavioral  
Science, UCLA, Los Angeles, CA
- 11:45 *They tried to make me go to rehab, I said, no, no, no: Effects of legal pressure on treatment response in a multisite sample*  
T. Moore, L. A. Keyser-Marcus, L. Thacker, D. Svikis, VCU, Richmond, VA

## Oral Communications 12

**INDIGO H**  
**9:55 - 12:00 PM**

### GETTING THE DRIFT ON GENETICS AND DRUGS OF ABUSE

Chairs: Elise Weerts and F. Gerard Moeller

- 9:55 *75th Anniversary Reflections*
- 10:00 *Cocaine dependence moderates the relationship between serotonin transporter polymorphisms and measures of impulsivity*  
S. Liu<sup>1</sup>, D. A. Nielsen<sup>2</sup>, S. D. Lane<sup>1</sup>, J. Schmitz<sup>1</sup>, V. Baladandayuthapani<sup>3</sup>, K. Cunningham<sup>4</sup>,  
F. G. Moeller<sup>1</sup>, <sup>1</sup>Psychiatry, UTHSC, Houston, TX, <sup>2</sup>Psychiatry, Baylor College of Medicine,  
Houston, TX, <sup>3</sup>Biostatistics, UT MD Anderson, Houston, TX, <sup>4</sup>Pharmacology and Toxicology,  
UTMB, Galveston, TX
- 10:15 *Genetic variants of the dopaminergic system associated with subjective responses to cocaine*  
D. A. Nielsen<sup>1,2</sup>, C. J. Spellicy<sup>1,2</sup>, S. C. Hamon<sup>3</sup>, M. H. Harding<sup>1,2</sup>, J. J. Mahoney, III<sup>1,2</sup>,  
T. R. Kosten<sup>1,2</sup>, R. De La Garza, II<sup>1,2</sup>, T. F. Newton<sup>1,2</sup>, <sup>1</sup>Menninger Department of Psychiatry  
and Behavioral Sciences, Baylor College of Medicine, Houston, TX, <sup>2</sup>Michael E. DeBakey  
V.A. Medical Center, Houston, TX, <sup>3</sup>Laboratory of Statistical Genetics, The Rockefeller  
University, New York, NY
- 10:30 *Association of the A335G polymorphism with striatal dopamine D2/3 receptor availability in healthy men and women*  
E. Weerts, M. McCaul, H. Kuwabara, M. Stephens, X. Xu, D. Wong, G. S. Wand, Johns  
Hopkins University, Baltimore, MD
- 10:45 *FAAH genotype and MJ use predict executive functioning in adolescents and emerging adults*  
S. Shollenbarger, N. Wright, K. M. Lisdahl, University of WI-Milwaukee, Milwaukee, WI
- 11:00 *The impact of genetic predictors of drug dependence on neuroimmune and endocrine markers*  
S. Kershaw<sup>1</sup>, C. Della Vedova<sup>1</sup>, I. Majumder<sup>1</sup>, M. Ward<sup>1</sup>, P. Williamson<sup>2</sup>, J. White<sup>1</sup>, <sup>1</sup>School of  
Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia, <sup>2</sup>Drug  
and Alcohol Services South Australia, Adelaide, SA, Australia

- 11:15 *Examining polygenic risk of cigarette use in the Detroit Neighborhood Health Study*  
J. L. Meyers<sup>1</sup>, S. Galea<sup>1</sup>, A. Aiello<sup>2</sup>, M. Uddin<sup>2</sup>, D. Wildman<sup>3</sup>, K. Koenen<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University Medical Center, New York, NY, <sup>2</sup>Epidemiology, University of Michigan, Ann Arbor, MI, <sup>3</sup>Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI
- 11:30 *Genetics-driven animal models of addiction through next-generation sequencing*  
E. J. Vallender, L. M. Ogawa, J. M. Ward, D. B. Goswami, New England Primate Research Center, Harvard Medical School, Southborough, MA
- 11:45 *Genotype diversity of HCV among MMT patients in Wuhan, China*  
S. Zhou<sup>2</sup>, W. Zhou<sup>1</sup>, R. S. Schottenfeld<sup>3</sup>, W. Kong<sup>1</sup>, M. Liu<sup>3</sup>, J. Peng<sup>3</sup>, P. Liu<sup>3</sup>, M. C. Chawarski<sup>3</sup>, <sup>1</sup>Yale School of Medicine, New Haven, CT, <sup>2</sup>Huazhong University of Science & Technology, Wuhan, China, <sup>3</sup>CDC, Wuhan, China

### Poster Session III (Lunch)

**SAPPHIRE**  
**12:00 - 2:00 PM**

**Odd-numbered posters manned first hour;  
Even-numbered, second hour**

**Set-up time begins Tuesday 1 PM**

**Must be removed by Wednesday 2 PM**

#### EPIDEMIOLOGY II

- 1 *DSM-V alcohol use disorder symptom profile in a representative sample of the largest metropolitan area in South America*  
J. M. Castaldelli-Maia<sup>1</sup>, L. H. Andrade<sup>1</sup>, C. M. Silveira<sup>1</sup>, M. C. Viana<sup>1</sup>, A. G. Andrade<sup>1</sup>, S. S. Martins<sup>2</sup>, <sup>1</sup>Department of Psychiatry, Universidade de São Paulo, São Paulo, Brazil, <sup>2</sup>Department of Epidemiology, Columbia University, New York, NY
- 2 *User satisfaction with health care provided for alcohol and drug dependency in Brazil*  
M. C. Bozzetti<sup>1,2</sup>, F. H. Kessler<sup>2</sup>, J. B. Hilgert<sup>1</sup>, A. Bidinotto<sup>1</sup>, F. Pechansky<sup>1,2</sup>, <sup>1</sup>Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
- 3 *Alcohol and psychoactive substances abuse in Brazil: A cross-sectional study*  
F. H. Kessler<sup>1</sup>, J. B. Hilgert<sup>2</sup>, M. C. Bozzetti<sup>1,2</sup>, A. Bidinotto<sup>2</sup>, F. Pechansky<sup>1,2</sup>, <sup>1</sup>Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, <sup>2</sup>Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 4 *Testing for amphetamine-type stimulant (ATS) use to ascertain validity of self-reported ATS use among young female sex workers in Cambodia*  
V. Kab<sup>1</sup>, E. Jennifer<sup>2</sup>, S. Neth<sup>3</sup>, E. Stein<sup>2</sup>, M. Claude-Couture<sup>2</sup>, L. Maher<sup>4</sup>, K. Page<sup>2</sup>, <sup>1</sup>University of California at Berkeley, Berkeley, CA, <sup>2</sup>University of California at San Francisco, San Francisco, CA, <sup>3</sup>Cambodia National Center for HIV, AIDS, Dermatology, and STDs, Phnom Penh, Cambodia, <sup>4</sup>The Kirby Institute (formerly known as the National Centre in HIV Epidemiology and Clinical Research), Sydney, NSW, Australia

- 5 *Transition from using opioids to methamphetamine among females: A report from a residential detoxification center*  
S. Mansoori<sup>1</sup>, Z. Alam Mehrjerdi<sup>1</sup>, A. Deylamizadeh<sup>2</sup>, K. Dolan<sup>3</sup>, <sup>1</sup>Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran, <sup>2</sup>Division of Research on Drug Use and Dependence, Rebirth Society (NGO), Tehran, Islamic Republic of Iran, <sup>3</sup>Program of International Research and Training, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- 6 *Opiate use and outpatient drug treatment are associated with lack of trust in point-of-care rapid tests*  
G. L. Reynolds, D. G. Fisher, K. L. Hess, J. Brocato, Center for Behavioral Research & Services, California State University, Long Beach, Long Beach, CA
- 7 *Changes in the age distribution of admissions to substance abuse treatment for opioid abuse in the U.S. from 2000 to 2010*  
J. C. Willis, H. Chilcoat, Risk Management and Epidemiology, Purdue Pharma, L.P., Stamford, CT
- 8 *Changes in drug use frequency as a recurrent event process: Analyses on the natural history of drug abuse*  
L. Li<sup>1</sup>, B. Nosky<sup>2,1</sup>, E. Evans<sup>1</sup>, D. Y. Huang<sup>1</sup>, J. Min<sup>2</sup>, T. Kerr<sup>2</sup>, M. Brecht<sup>1</sup>, Y. Hser<sup>1</sup>, <sup>1</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>2</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 9 *Unanticipated consequences of non-drug-focused HIV prevention intervention: Changes in drug use*  
B. M. Booth, P. B. Wright, S. T. Ounpraseuth, K. E. Stewart, University of Arkansas for Medical Sciences, Little Rock, AR
- 10 *Association of childhood sexual and other physical abuse with lifetime and prenatal drug use in urban African-American women*  
M. Puia Dumitrescu<sup>1,2,3</sup>, V. H. Accornero<sup>1</sup>, L. Xue<sup>1</sup>, J. M. McKenzie<sup>1</sup>, J. C. Anthony<sup>4</sup>, E. S. Bandstra<sup>1,3</sup>, <sup>1</sup>Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Epidemiology & Public Health, University of Miami Miller School of Medicine, Miami, FL, <sup>3</sup>Department of Pediatrics, Holtz Children's Hospital UM/JMCC, Miami, FL, <sup>4</sup>Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 11 *Effects of childhood trauma on psychopathology, risky sex, aggression, and emotion dysregulation among inpatient substance users*  
A. N. Banducci, E. Hoffman, C. W. Lejuez, L. MacPherson, Psychology, University of Maryland, College Park, MD
- 12 *Association between perceived and objective measures of community violence exposure*  
S. Naeger, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 13 *Substance use disorders and poverty as prospective predictors of first-time suicide attempt in the United States*  
R. G. Thompson, D. Alonzo, M. Wall, E. Greenstein, D. S. Hasin, Columbia University, New York, NY
- 14 *Overdose experiences among patients at an urban emergency department*  
A. S. Bohnert<sup>1,2</sup>, M. A. Walton<sup>1</sup>, M. A. Ilgen<sup>1,2</sup>, R. M. Cunningham<sup>1</sup>, K. Barry<sup>1</sup>, S. Chermack<sup>1,2</sup>, F. C. Blow<sup>1,2</sup>, <sup>1</sup>University of Michigan Medical School, Ann Arbor, MI, <sup>2</sup>VA Center for Clinical Management Research, Ann Arbor, MI

- 15 *Attitudes toward and preferences for health research among drug users and non-drug users*  
C. W. Striley<sup>1</sup>, C. Ruktanonchai<sup>1</sup>, F. Webb<sup>2,1</sup>, L. Cottler<sup>1</sup>, <sup>1</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>2</sup>Department of Community Health and Family Medicine, University of Florida, Jacksonville, FL

### POLYDRUG ABUSE II

- 16 *Factors associated with time to injection initiation among drug injectors*  
R. Bluthenthal<sup>1</sup>, L. Wenger<sup>2</sup>, J. Thing<sup>1</sup>, S. Arreola<sup>2</sup>, D. Chu<sup>1</sup>, M. Y. Iguchi<sup>3</sup>, P. Bourgois<sup>4</sup>, A. Kral<sup>2</sup>, <sup>1</sup>University of Southern California, Los Angeles, CA, <sup>2</sup>RTI International, San Francisco, CA, <sup>3</sup>Georgetown University, Washington, D.C., DC, <sup>4</sup>University of Pennsylvania, Philadelphia, PA
- 17 *A brief measure assessing sexual risk behavior in women in substance abuse treatment*  
G. Thorens<sup>1</sup>, M. Hu<sup>2</sup>, M. Pavlicova<sup>2</sup>, E. V. Nunes<sup>2</sup>, A. Campbell<sup>2</sup>, S. Tross<sup>2</sup>, <sup>1</sup>Psychiatry, Geneva University Hospital, Geneva, Switzerland, <sup>2</sup>Psychiatry, Columbia University Medical Center, New York, NY
- 18 *Differences in drug use patterns and HCV among African-American adult drug users*  
N. E. Whitehead<sup>1</sup>, L. Keen<sup>1</sup>, R. Trenz<sup>2</sup>, J. Rose<sup>1</sup>, W. W. Latimer<sup>1</sup>, <sup>1</sup>Clinical and Health Psychology, University of Florida, Gainesville, FL, <sup>2</sup>Social and Behavioral Sciences, Mercy College, Dobbs Ferry, NY
- 19 *Coping style and service utilization among African-American female drug users*  
D. Stevens-Watkins<sup>1</sup>, C. B. Oser<sup>2</sup>, C. Leukefeld<sup>2</sup>, <sup>1</sup>Spalding University, Louisville, KY, <sup>2</sup>Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 20 *Adapting a women-centered intervention for injection drug users in the Republic of Georgia*  
H. Jones<sup>1</sup>, I. Kirtadze<sup>2</sup>, D. Otiashvili<sup>2,3</sup>, K. E. O'Grady<sup>4</sup>, W. Zule<sup>1</sup>, E. Krupitsky<sup>5</sup>, W. M. Wechsberg<sup>1</sup>, <sup>1</sup>SATEI, RTI International, RTP, NC, <sup>2</sup>Addiction Research Center, Alternative Georgia, Tbilisi, Georgia, <sup>3</sup>Department of Addictology, First Faculty of Medicine, Prague, Czech Republic, <sup>4</sup>Psychology, U of Maryland, College Park, MD, <sup>5</sup>Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation
- 21 *The Women's Recovery Group: Outcomes from a Stage II trial*  
S. F. Greenfield<sup>1,2</sup>, D. Sugarman<sup>1,2</sup>, J. Kaufman<sup>1</sup>, G. L. Bailey<sup>3,4</sup>, M. Crisafulli<sup>1</sup>, C. Freid<sup>1,2</sup>, H. Connery<sup>1,2</sup>, J. Rodolico<sup>1,2</sup>, S. Wigderson<sup>1</sup>, M. Rapoza<sup>3</sup>, G. Fitzmaurice<sup>1,2</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Harvard Medical School, Cambridge, MA, <sup>3</sup>Stanley Street Treatment and Resources, Fall River, MA, <sup>4</sup>Brown University, Providence, RI
- 22 *Toward quantifying the benefits of sustained addiction recovery: Findings from a national pilot survey*  
T. Hill<sup>2</sup>, A. B. Laudet<sup>1</sup>, <sup>1</sup>Center for the Study of Addictions and Recovery, NDRI, New York City, NY, <sup>2</sup>Faces and Voices of Recovery, Washington, DC
- 23 *Cost-effectiveness analysis of a randomized trial of Recovery Management Checkups for adults with chronic substance use disorders*  
K. E. McCollister<sup>1</sup>, M. T. French<sup>1,2</sup>, D. M. Freitas<sup>3</sup>, M. L. Dennis<sup>4</sup>, C. K. Scott<sup>4</sup>, R. R. Funk<sup>4</sup>, <sup>1</sup>University of Miami, Miami, FL, <sup>2</sup>University of Miami, Coral Gables, FL, <sup>3</sup>New York University, New York, NY, <sup>4</sup>Chestnut Health System, Normal & Chicago, IL
- 24 *Validation of the GAIN Self-Help Involvement Scale using the Rasch Measurement Model*  
K. M. Conrad<sup>1,2</sup>, K. J. Conrad<sup>3</sup>, L. Passetti<sup>3</sup>, R. R. Funk<sup>3</sup>, M. L. Dennis<sup>3</sup>, <sup>1</sup>Program Metrics, Oak Park, IL, <sup>2</sup>University of Illinois at Chicago, Chicago, IL, <sup>3</sup>Chestnut Health Systems, Normal, IL



- 25 *Validation of the Global Appraisal of Individual Needs' General Individual Severity Scale and its Subscales against the Rasch Measurement Model*  
K. J. Conrad<sup>1</sup>, M. L. Dennis<sup>1</sup>, K. M. Conrad<sup>2</sup>, R. R. Funk<sup>1</sup>, <sup>1</sup>Chestnut Health Systems, Normal, IL, IL, <sup>2</sup>Program Metrics, Oak Park, IL
- 26 *Comparing the ability of multiple measures of substance abuse treatment process to predict outcomes*  
M. L. Dennis, R. D. Lennox, C. K. Scott, R. R. Funk, Chestnut Health Systems, Normal & Chicago, IL
- 27 *Client reasons for poor engagement early in substance abuse treatment*  
J. S. Cacciola<sup>1,2</sup>, A. Mericle<sup>1</sup>, A. C. Brooks<sup>1</sup>, M. Ivey<sup>2</sup>, J. McKay<sup>1,2</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA
- 28 *Performance of substance use disorder treatment systems: The effect of case-mix adjustment*  
S. E. Spear<sup>1</sup>, D. Urada<sup>2</sup>, R. Rawson<sup>2</sup>, <sup>1</sup>Social Work, University of Southern California, Los Angeles, CA, <sup>2</sup>Integrated Substance Abuse Programs, University of California Los Angeles, Los Angeles, CA
- 29 *Training undergraduate students in addiction-related topics using in-person and online instructional formats: Implications for preparing the behavioral health workforce*  
N. A. Roget<sup>1</sup>, J. A. Hartje<sup>1</sup>, W. W. Woods<sup>1</sup>, M. L. Shadley<sup>1</sup>, T. E. Freese<sup>2</sup>, <sup>1</sup>Center for the Application of Substance Abuse Technologies, University of Nevada Reno, Reno, NV, <sup>2</sup>UCLA, Los Angeles, CA
- 30 *A randomized trial comparing reinforcement-based treatment with and without personalized patient feedback*  
M. Tuten<sup>1</sup>, C. Borsuk<sup>1</sup>, H. Fitzsimons<sup>1</sup>, M. S. Chisolm<sup>1</sup>, H. Jones<sup>2,1</sup>, <sup>1</sup>Psychiatry, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Research Triangle Institute International, Raleigh, NC
- 31 *Drug-using Afghan refugees and mobile unit services: A subproject report*  
Z. Alam Mehrjerdi<sup>1</sup>, A. Deylamizadeh<sup>2</sup>, A. Noroozi<sup>3</sup>, <sup>1</sup>Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran, <sup>2</sup>Division of Research on Drug Use and Dependence, Rebirth Society (NGO), Tehran, Islamic Republic of Iran, <sup>3</sup>School of Advanced Medical Technologies (SAMT), Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
- 32 *Reducing subject burden: Identifying critical measures in human abuse potential studies using factor analysis*  
N. Levy-Cooperman, C. Mills, M. J. Shram, K. A. Schoedel, Clinical Pharmacology, INC Research, Toronto, ON, Canada

### ABUSE LIABILITY

- 33 *A new graphic method for data from human abuse potential crossover studies*  
L. Chen, Y. Wang, FDA/CDER, Silver Spring, MD
- 34 *Why is a discrimination test important in human abuse liability studies?*  
M. Smith, L. R. Webster, M. Iverson, T. Theisen, J. Jenkins, M. Smollin, CRILifetree, Salt Lake City, UT
- 35 *Abuse potential of tapentadol compared to tramadol and hydromorphone in recreational opioid users*  
W. W. Stoops<sup>1,2</sup>, P. E. Glaser<sup>3,4</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY, <sup>4</sup>Anatomy and Neurobiology, University of Kentucky, Lexington, KY



- 36 *Pair housing of juvenile male rhesus macaques: A pilot study*  
M. L. Bertholomey, S. Kohut, P. Fivel, N. K. Mello, Alcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, Belmont, MA
- 37 *Opioids with lower brain uptake are less recognizable in rat drug discrimination tests and thus potentially less subject to abuse*  
S. D. Harrison<sup>1</sup>, H. Gursahani<sup>1</sup>, J. Pfeiffer<sup>1</sup>, K. Gogas<sup>1</sup>, J. Riggs<sup>1</sup>, T. Riley<sup>1</sup>, D. Gauvin<sup>2</sup>, S. Doberstein<sup>1</sup>, <sup>1</sup>Nektar Therapeutics, San Francisco, CA, <sup>2</sup>MPI Research, Inc., Mattawan, MI

### NEUROENDOCRINE STUDIES

- 38 *Hair cortisol as a biomarker of stress in cocaine-excited delirium*  
D. C. Mash<sup>1</sup>, X. B. Xie<sup>1</sup>, G. M. Vilke<sup>2</sup>, <sup>1</sup>Neurology, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Emergency Medicine, University of California, San Diego, San Diego, CA
- 39 *Progesterone treatment for cocaine-dependent women: A pilot treatment trial*  
S. M. Evans<sup>2,1</sup>, F. R. Levin<sup>1,2</sup>, D. J. Brooks<sup>2</sup>, S. C. Reed<sup>1</sup>, <sup>1</sup>Psychiatry, Columbia University, New York, NY, <sup>2</sup>Psychiatry, NYSPI, New York, NY
- 40 *A preliminary analysis of aggressive behavior under oxytocin dose*  
J. L. Alcorn, N. Dias, F. G. Moeller, S. D. Lane, Psychiatry & Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX
- 41 *Association between AAS use, muscle dysmorphia and illicit drug use among gym frequenters*  
S. Pipet<sup>1</sup>, R. Halpern<sup>1</sup>, G. E. Woody<sup>2</sup>, C. Szobot<sup>1</sup>, <sup>1</sup>Pós-graduação em saúde coletiva, ULBRA, Canoas, Brazil, <sup>2</sup>Treatment Research Institute, University of Pennsylvania, Philadelphia, PA
- 42 *Self-administration of neuroactive steroids by rhesus monkeys responding under a progressive-ratio schedule of i.v. midazolam injection*  
Z. Meng, J. K. Rowlett, Neuroscience, Harvard Medical School, New England Primate Research Center, Southborough, MA
- 43 *Handling and vehicle injections impact corticosterone but not adrenocorticotrophic hormone levels in Sprague-Dawley but not Lewis rats*  
K. Seip-Cammack, M. Buonora, M. Deutsch-Feldman, A. Brownstein, R. Picetti, M. J. Kreek, The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY

### COMORBIDITY

- 44 *Ketamine for treatment-resistant depression: Subjective effects and impact on plasma brain-derived neurotrophic factor*  
C. N. Haile<sup>1,3</sup>, J. J. Murrough<sup>2</sup>, D. V. Iosifescu<sup>2</sup>, L. C. Chang<sup>1</sup>, R. K. Al Jurdi<sup>1</sup>, A. Foulkes<sup>1</sup>, S. Iqbal<sup>1</sup>, J. J. Mahoney<sup>1,3</sup>, R. De La Garza, II<sup>1,3</sup>, D. S. Charney<sup>2</sup>, T. F. Newton<sup>1,3</sup>, S. J. Mathew<sup>3,1</sup>, <sup>1</sup>Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, <sup>2</sup>Psychiatry, Mount Sinai School of Medicine, New York, NY, <sup>3</sup>MEDVA Medical Center, Houston, TX
- 45 *Impaired nutritional status and poor diet quality among methadone maintenance patients*  
D. G. Antoine<sup>1</sup>, E. C. Strain<sup>1</sup>, A. Umbricht<sup>1</sup>, H. Geniaux<sup>2</sup>, <sup>1</sup>Psychiatry, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Département de Pharmacologie, CHU de Bordeaux, Bordeaux, France
- 46 *A randomized trial of integrated care for methadone-maintenance patients with co-occurring psychiatric disorders*  
M. S. Kidorf, J. M. Peirce, V. L. King, R. K. Brooner, Psychiatry, Johns Hopkins University, Baltimore, MD

- 47 *Reinforcing attendance to integrated psychiatric treatment: Effects on psychiatric distress*  
V. L. King, R. K. Brooner, N. Gandotra, J. Peirce, M. Kidorf, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 48 *Psychiatric diagnoses and treatment outcomes in opioid-dependent individuals receiving buprenorphine and behavioral treatment*  
L. Mooney, M. P. Hillhouse, A. Ang, K. Miotto, M. Torrington, D. Dickerson, S. MacNicoll, J. Jenkins, S. Reed, W. Ling, University of California, Los Angeles, CA
- 49 *The impact of stress and trauma on methadone-assisted treatment and initial treatment engagement in opioid dependence recovery*  
K. M. Jaremko, R. S. Sterling, E. J. Van Bockstaele, Depts. of Psychiatry and Neuroscience, Thomas Jefferson University, Philadelphia, PA
- 50 *Integrated Cognitive Enhancement Therapy and Personal Therapy for substance misusing schizophrenia patients: Interim results on the first 6 months of treatment*  
S. M. Eack<sup>1,2</sup>, S. S. Hogarty<sup>2</sup>, D. P. Greenwald<sup>2</sup>, A. L. Bahorik<sup>1,2</sup>, M. Y. Litschge<sup>2</sup>, S. S. Bangalore<sup>2</sup>, M. F. Pogue-Geile<sup>3</sup>, J. R. Cornelius<sup>2</sup>, <sup>1</sup>School of Social Work, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Psychiatry, University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Psychology, University of Pittsburgh, Pittsburgh, PA
- 51 *Effects of walking on cigarette craving, nicotine withdrawal symptoms and affect in smokers with schizophrenia*  
J. W. Tidey, D. Williams, C. Goodwin, Brown University, Providence, RI
- 52 *Contingency management targeting psycho-stimulant use results in secondary decreases in smoking for severely mentally ill adults*  
M. G. McDonell<sup>1</sup>, S. McPherson<sup>2</sup>, R. Vilardaga<sup>1</sup>, D. Srebnik<sup>1</sup>, F. Angelo<sup>1</sup>, E. Leickly<sup>1</sup>, A. Saxon<sup>1</sup>, J. Roll<sup>2</sup>, R. Ries<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, <sup>2</sup>School of Nursing, Washington State University Spokane, Spokane, WA
- 53 *WITHDRAWN*
- 54 *ADHD subtype differences in smoking to regulate affect and ADHD symptoms using ecological momentary assessment*  
J. Mitchell<sup>1</sup>, M. Dennis<sup>1</sup>, J. English<sup>1</sup>, A. Brightwood<sup>1</sup>, J. Beckham<sup>1,2</sup>, S. H. Kollins<sup>1</sup>, <sup>1</sup>Duke University Medical Center, Durham, NC, <sup>2</sup>Veterans Affairs Medical Center, Durham, NC
- 55 *Adult ADHD subtypes, autistic traits, and substance use*  
D. De Alwis, A. Todorov, A. Agrawal, A. Reiersen, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 56 *The modifying effects of regular alcohol use on perceived social support and depression in Israel*  
J. Kane<sup>1</sup>, B. Hall<sup>1</sup>, D. Canetti<sup>2</sup>, C. Rapaport<sup>2</sup>, S. Hobfoll<sup>3</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>School of Political Science, University of Haifa, Haifa, Israel, <sup>3</sup>Department of Behavioral Sciences, Rush University, Chicago, IL
- 57 *Post-retrieval propranolol may alter reconsolidation of trauma memory in individuals with PTSD and comorbid alcohol dependence*  
M. E. Saladin<sup>1</sup>, K. Gray<sup>1</sup>, T. Abbott<sup>1</sup>, S. LaRowe<sup>1,2</sup>, A. McRae-Clark<sup>1</sup>, S. DeSantis<sup>1</sup>, N. Baker<sup>1</sup>, S. Back<sup>1</sup>, K. Hartwell<sup>1,2</sup>, K. T. Brady<sup>1,2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Ralph H. Johnson VAMC, Charleston, SC

- 58 *Substance abuse treatment-seeking and barriers to care in persons with alcohol use disorders and comorbid mood or anxiety disorders*  
C. N. Kaufmann<sup>1</sup>, R. Crum<sup>1,2,3</sup>, L. Chen<sup>1</sup>, R. Mojtabai<sup>1</sup>, <sup>1</sup>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>3</sup>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 59 *PTSD and substance abuse comorbidity from a behavioral economic perspective*  
J. Tripp<sup>1,2</sup>, M. McDevitt-Murphy<sup>1,2</sup>, J. Murphy<sup>1,2</sup>, M. Avery<sup>1,2</sup>, <sup>1</sup>Department of Psychology, The University of Memphis, Memphis, TN, <sup>2</sup>Veterans Affairs Medical Center, Memphis, TN
- 60 *Trauma exposure and PTSD is associated with attenuation in fronto-limbic functional connectivity among cocaine users*  
M. J. Gawrysiak<sup>1,2</sup>, J. Suh<sup>1,2</sup>, Y. Li<sup>2</sup>, K. Jagannathan<sup>2</sup>, R. Fabianski<sup>2</sup>, A. Childress<sup>2</sup>, <sup>1</sup>Philadelphia VA Medical Center, VISN 4 MIRECC, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
- 61 *The effect of the Life Enhancement Treatment for Substance Use (LETS ACT) on cocaine relapse: Results from a randomized control trial*  
C. Seitz-Brown<sup>1</sup>, J. F. Magidson<sup>1</sup>, K. Anderson<sup>1</sup>, A. Wilson<sup>1</sup>, A. Alberto<sup>1</sup>, C. W. Lejuez<sup>1</sup>, S. B. Daughters<sup>2</sup>, <sup>1</sup>University of Maryland, College Park, MD, <sup>2</sup>University of North Carolina, Chapel Hill, Chapel Hill, NC
- 62 *Understanding module effects in open-enrollment group therapy studies*  
S. M. Paddock<sup>1</sup>, T. Leininger<sup>2</sup>, S. B. Hunter<sup>1</sup>, <sup>1</sup>RAND Corporation, Santa Monica, CA, <sup>2</sup>Duke University, Durham, NC
- 63 *DSM-5 criteria for gambling disorders and its effects on the association with other psychiatric disorders*  
J. Santaella, M. Cerdá, J. H. Kim, S. S. Martins, Epidemiology, Columbia University, New York, NY
- 64 *Gender as a predictor of past treatment in dual-diagnosed patients presenting for detoxification*  
A. Harrington, G. Gonzalez, Psychiatry, University of Massachusetts, Worcester, MA
- 65 *Association of cognitive functioning with treatment outcomes of substance-dependent adults with major depression*  
S. Glasner-Edwards<sup>1</sup>, M. Brecht<sup>1</sup>, A. Bellows<sup>1</sup>, H. Chokron Garneau<sup>1</sup>, S. A. Brown<sup>2</sup>, R. Rawson<sup>1</sup>, <sup>1</sup>Psychiatry, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>2</sup>Psychology, UCSD, San Diego, CA
- 66 *Maternal mental health and children's internalizing and externalizing behaviors: Beyond mother's substance use disorder*  
Y. Hser, I. Lanza, L. Li, E. Kahn, Integrated Substance Abuse Programs (ISAP), University of California Los Angeles, Los Angeles, CA
- 67 *Specific maternal substance use behaviors linked to child co-occurring externalizing and internalizing symptoms*  
H. Lanza, Y. Hser, N. Glick, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA

### STIMULANTS—ANIMALS

- 68 *Strain differences in sign-tracking and goal-tracking as an indicator of abuse vulnerability in rats*  
J. J. Chow, M. T. Bardo, J. S. Beckmann, Psychology, University of Kentucky, Lexington, KY

- 69 *A tonic-phasic model of  $\Delta$ FosB action and relevance to environmental enrichment*  
Y. Zhang<sup>1</sup>, D. Li<sup>1</sup>, E. J. Nestler<sup>3</sup>, M. K. Lobo<sup>2</sup>, X. Fan<sup>1</sup>, T. Green<sup>1</sup>, <sup>1</sup>Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, <sup>3</sup>Neuroscience, Mount Sinai School of Medicine, New York, NY
- 70 *A predisposition toward inherent impulsivity is associated with elevated 5-HT<sub>2A</sub>R expression*  
L. H. Fink<sup>1,2</sup>, N. C. Anastasio<sup>1,2</sup>, R. G. Fox<sup>1,2</sup>, F. G. Moeller<sup>3</sup>, K. A. Cunningham<sup>1,2</sup>, <sup>1</sup>Ctr Addiction Res, UTMB, Galveston, TX, <sup>2</sup>Dept Pharm & Tox, UTMB, Galveston, TX, <sup>3</sup>Dept Psych & Behav Sci, UTHSC, Houston, TX
- 71 *Maladaptive cortical serotonin (5-HT) 5-HT<sub>2A</sub>:5-HT<sub>2C</sub> receptor balance generates aberrant impulsivity and elevated cocaine cue reactivity*  
N. C. Anastasio<sup>1,2</sup>, S. J. Stutz<sup>1,2</sup>, L. H. Fink<sup>1,2</sup>, R. G. Fox<sup>1,2</sup>, R. M. Sears<sup>3</sup>, T. A. Green<sup>2</sup>, R. J. DiLeone<sup>3</sup>, F. G. Moeller<sup>4</sup>, K. A. Cunningham<sup>1,2</sup>, <sup>1</sup>Ctr Addiction Res, UTMB, Galveston, TX, <sup>2</sup>Pharm & Tox, UTMB, Galveston, TX, <sup>3</sup>Psych, Yale Univ, New Haven, CT, <sup>4</sup>Psych & Behav Sci, UTHSC, Houston, TX
- 72 *Lower serotonin 2C receptor (5-HT<sub>2CR</sub>) expression in the ventral tegmental area (VTA) associates with elevated cue reactivity following extended forced abstinence from cocaine-taking*  
S. E. Swinford, N. C. Anastasio, R. G. Fox, S. J. Stutz, K. A. Cunningham, Ctr Addiction Res, UTMB, Galveston, TX
- 73 *Adolescent risk taking, dopamine, and cocaine: A vicious cycle*  
M. R. Mitchell<sup>1</sup>, V. G. Weiss<sup>2</sup>, D. Morgan<sup>3</sup>, J. L. Bizon<sup>4</sup>, B. Setlow<sup>3</sup>, <sup>1</sup>Psychiatry, Yale University, New Haven, CT, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Florida, Gainesville, FL, <sup>4</sup>Neuroscience, University of Florida, Gainesville, FL
- 74 *Individual differences in negative urgency behavior: Relationship with dopamine transporter function*  
M. Darna<sup>1</sup>, J. R. Yates<sup>2</sup>, M. T. Bardo<sup>2</sup>, L. P. Dwoskin<sup>1</sup>, <sup>1</sup>College of Pharmacy, University of Kentucky, Lexington, KY, <sup>2</sup>Department of Psychology, University of Kentucky, Lexington, KY
- 75 *Increased myelin protein expression within the ventromedial prefrontal cortex following extended access to cocaine self-administration in adult male rats*  
S. M. Webb, M. McCloskey, M. Wroten, O. Ben-Shahar, K. Szumlinski, University of California Santa Barbara, Santa Barbara, CA
- 77 *The effects of strength training on cocaine self-administration*  
M. A. Smith, J. C. Strickland, M. A. Witte, Department of Psychology, Davidson College, Davidson, NC
- 78 *Evidence for the contribution of D<sub>4</sub> receptors to cocaine self-administration in monkeys*  
J. B. Acri, MDTB/DPMC, NIDA/NIH, Bethesda, MD
- 79 *Differential alteration in  $\alpha$ 3-containing GABA A receptors after long-term cocaine self-administration in rhesus monkeys*  
N. M. Shinday<sup>1,2</sup>, S. Westmoreland<sup>1</sup>, W. D. Yao<sup>1,2</sup>, J. K. Rowlett<sup>1,2</sup>, <sup>1</sup>Neuroscience, NEPRC-Harvard Med School, Southborough, MA, <sup>2</sup>Neuroscience and Behavior, University of Massachusetts, Amherst, MA
- 80 *Time-dependent impact of traumatic brain injury on the behavioral effects of cocaine*  
S. L. Sell, S. Leavitt, D. S. Prough, D. S. DeWitt, Anesthesiology, University of Texas Medical Branch, Galveston, TX
- 81 *Comparative effects of raclopride in two models of cocaine-induced reinstatement*  
C. Froger-Colleaux, V. Castagné, D. J. Virley, Pharmacology, Porsolt, Le Genest-Saint-Isle, France

- 82 *Effects of the short-acting KOP-r antagonist [D-Trp]CJ-15,208 on cocaine self-administration, locomotor activity, and food intake in male C57/BL6 mice*  
A. J. Brownstein<sup>1</sup>, Y. Zhang<sup>1</sup>, R. Picetti<sup>1</sup>, E. Butelman<sup>1</sup>, S. D. Schlussman<sup>1</sup>, A. Ho<sup>1</sup>, J. V. Aldrich<sup>2</sup>, M. J. Kreek<sup>1</sup>, <sup>1</sup>The Laboratory of the Addictive Diseases, The Rockefeller University, New York, NY, <sup>2</sup>Department of Medicinal Chemistry, University of Kansas, Lawrence, KS
- 83 *The effects of tropisetron on cocaine-induced conditioned taste aversions*  
M. A. Briscione<sup>1</sup>, K. M. Serafine<sup>2</sup>, A. P. Merluzzi<sup>1</sup>, K. C. Rice<sup>3</sup>, A. L. Riley<sup>1</sup>, <sup>1</sup>Psychology, American University, Washington, DC, <sup>2</sup>Pharmacology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, <sup>3</sup>Chemical Biology Research Branch, NIAAA, NIDA, Baltimore, MD
- 84 *A microdialysis and behavioural investigation of modafinil in freely moving rats*  
H. L. Rowley<sup>1</sup>, R. S. Kulkarni<sup>1</sup>, D. Hackett<sup>2</sup>, D. J. Heal<sup>1</sup>, <sup>1</sup>RenaSci Ltd, Nottingham, United Kingdom, <sup>2</sup>Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom
- 85 *Subjective and reinforcing effects of modafinil in rats*  
D. J. Heal<sup>1</sup>, N. W. Buckley<sup>1</sup>, J. Gosden<sup>1</sup>, D. Hackett<sup>2</sup>, <sup>1</sup>RenaSci Ltd, Nottingham, United Kingdom, <sup>2</sup>Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom
- 86 *Gene transfer of engineered cocaine hydrolase: Lifetime expression with no immune response*  
L. Geng, Y. Gao, S. Brimijoin, Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN
- 87 *High level expression of cocaine hydrolase based on mammalian cholinesterase blocks cocaine responses with no sign of toxicity*  
Y. Gao, L. Geng, S. Brimijoin, Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN
- 88 *Distinct expression profiles for cell-signaling molecules in midbrain dopamine neurons from animals showing relapse vulnerability to cocaine-seeking*  
A. L. Brown<sup>1,2,4</sup>, J. Flynn<sup>2,4</sup>, A. Dunlop<sup>1,3,4</sup>, C. Dayas<sup>2,4</sup>, D. Smith<sup>2,4</sup>, <sup>1</sup>Hunter New England Local Health District, Newcastle, NSW, Australia, <sup>2</sup>School of Biomedical Sciences & Pharmacy, PRC for Translational Neuroscience & Mental Health, University of Newcastle, Newcastle, NSW, Australia, <sup>3</sup>School of Medicine & Public Health, PRC for Translational Neuroscience & Mental Health, University of Newcastle, Newcastle, NSW, Australia, <sup>4</sup>Hunter Medical Research Institute, Newcastle, NSW, Australia
- 89 *Cocaine-seeking is dose dependently enhanced by HIV-1 Tat protein expression in male and female mice*  
J. J. Paris<sup>1</sup>, A. N. Carey<sup>2</sup>, J. P. McLaughlin<sup>1</sup>, <sup>1</sup>Pharmacology and Neuroscience, Torrey Pines Institute for Molecular Studies, Port Saint Lucie, FL, <sup>2</sup>Psychology, Simmons College, Boston, MA
- 90 *Humanized mouse models to study effects of anti-cocaine vaccine*  
R. A. Singh<sup>1,2</sup>, B. M. Kinsey<sup>1,2</sup>, Z. Huang<sup>3</sup>, T. R. Kosten<sup>1,2</sup>, F. M. Orson<sup>1,2</sup>, <sup>1</sup>Medicine, BCM, Houston, TX, <sup>2</sup>Immunology, VA Hospitals, Houston, TX, <sup>3</sup>Walvax Biotechnology Co., Ltd, Kunming, China

#### OPIOIDS—ANIMALS

- 91 *Morphine prevents LPS-induced TNF secretion in mast cells blocking IKK activation and SNAP-23 phosphorylation. Correlation with the formation of a  $\beta$ -arrestin/TRAF-6 complex*  
S. Cruz, I. Madera-Salcedo, C. Gonzalez-Espinosa, Farmacobiología, Centro de Investigación y de Estudios Avanzados del IPN, México City, Mexico



- 92 *Chronic morphine administration and withdrawal cause tolerance to the suppressive effects of morphine on LPS- induced TNF and corticosterone production in mice*  
L. Molina, C. Gonzalez-Espinosa, S. Cruz, Farmacobiología, Centro de Investigación y de Estudios Avanzados del IPN, México City, Mexico
- 93 *Effects of a morphine-conjugate vaccine on heroin self-administration in rats*  
M. G. LeSage<sup>1,2</sup>, M. D. Raleigh<sup>1,2</sup>, M. Pravetoni<sup>1,2</sup>, L. Tally<sup>1</sup>, P. R. Pentel<sup>1,2</sup>, <sup>1</sup>Minneapolis Medical Research Foundation, Minneapolis, MN, <sup>2</sup>University of Minnesota, Minneapolis, MN
- 94 *Delay discounting of remifentanyl under a drug-drug choice procedure*  
D. R. Maguire, L. R. Gerak, C. P. France, Pharmacology, UTHSCSA, San Antonio, TX
- 95 *Role of proenkephalin and beta-endorphin in sucrose palatability*  
I. A. Mendez, A. R. Kosheleff, S. B. Ostlund, N. P. Murphy, N. T. Maidment, Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA
- 96 *Conditioned taste aversion predicts morphine, but not cocaine, self-administration: A role of drug aversion in drug-taking*  
A. Verendeey, B. J. Tunstall, D. N. Kearns, A. L. Riley, Psychology, American University, Washington, DC
- 97 *Adolescent Fischer 344 and Lewis rats differ in morphine-induced taste aversions*  
Z. E. Hurwitz, J. L. Cobuzzi, B. Wetzell, A. P. Merluzzi, A. L. Riley, Psychology, American University, Washington, DC
- 98 *Long-lasting sensitization induced by a single exposure to morphine: Age-related differences in mice*  
W. Koek, Psychiatry and Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX
- 99 *Different sensitivity for oxycodone-induced conditioned place preference and sensitization of locomotor activity in adolescent and adult mice*  
K. Niikura, Y. Zhang, A. Ho, M. J. Kreek, Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY
- 100 *Tamper-resistant properties of Oxycodone DETERx: Intranasal administration and in vitro tampering studies*  
E. A. Kopecky, A. B. Fleming, R. K. Varanasi, S. P. Mayock, S. Saim, Collegium Pharmaceutical, Cumberland, RI

### ADOLESCENT DRUG ABUSE II

- 101 *A qualitative study of young adults' perceptions of modified-risk tobacco products for smoking cessation*  
D. Camenga, D. A. Cavallo, G. Kong, A. Palmer, K. Carroll, S. O'Malley, S. Krishnan-Sarin, Yale School of Medicine, New Haven, CT
- 102 *The role of parental smoking in adolescent impulsivity*  
A. Herrick, S. Thamocharan, M. S. Sferra, K. Lange, S. Fields, Psychology, Texas A&M University, College Station, TX
- 103 *Approach-bias and impulsivity among adolescent smokers and non-smokers: A bi-national study*  
H. Larsen<sup>1</sup>, G. Kong<sup>2</sup>, D. Becker<sup>1</sup>, J. Cousijn<sup>1</sup>, S. Krishnan-Sarin<sup>2</sup>, R. Wiers<sup>1</sup>, <sup>1</sup>Psychology, ADAPT-Lab, University of Amsterdam, Amsterdam, Netherlands, <sup>2</sup>Psychiatry, Yale University School of Medicine, New Haven, CT
- 104 *Liability for risk behaviors: Racial differences*  
M. D. Reynolds, T. A. Ridenour, L. Kirisci, M. Vanyukov, R. E. Tarter, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA



- 105 *Differential risk of racial admixture for substance abuse: A longitudinal analysis*  
R. K. Price<sup>1,2</sup>, S. Balan<sup>1</sup>, C. van den Berk-Clark<sup>1</sup>, M. V. Shroff<sup>1</sup>, <sup>1</sup>Washington Univ. School of Medicine, St. Louis, MO, <sup>2</sup>VA St. Louis Health Care System, St. Louis, MO
- 106 *A Web-based contingency management program with adolescent smokers in rural Appalachia*  
B. Reynolds<sup>1</sup>, J. Dallery<sup>2</sup>, W. W. Stoops<sup>1</sup>, M. Harris<sup>3</sup>, J. Weiser<sup>4</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Florida, Gainesville, FL, <sup>3</sup>Nationwide Children's Hospital, Columbus, OH, <sup>4</sup>University of Cincinnati, Cincinnati, OH
- 107 *MOVED TO MONDAY POSTER SESSION #149*
- 108 *Validity of a brief screener for adolescent tobacco, alcohol, and drug use*  
S. M. Kelly<sup>1</sup>, K. E. O'Grady<sup>2</sup>, J. Gryczynski<sup>1</sup>, S. G. Mitchell<sup>1</sup>, A. Kirk<sup>3</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Univ. of MD, College Park, MD, <sup>3</sup>Total Health Care, Baltimore, MD
- 109 *Negative affect, emotional awareness and substance use in adolescents and young adults*  
A. Desrosiers<sup>1</sup>, H. Sipsma<sup>2</sup>, T. Kershaw<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>University of Illinois, Chicago, IL
- 110 *Adolescent and emerging adult marijuana triers and non-users: The difference in potential HIV risk*  
S. Thamocharan, K. Lange, A. Herrick, M. Sferra, S. Fields, Psychology, Texas A&M University, College Station, TX
- 111 *The association between ADHD and nicotine in a prospective sample of youth*  
K. Winters, S. Lee, A. Symmes, Psychiatry, University of Minnesota, Minneapolis, MN
- 112 *Impulsivity moderates the relation between age and increases in adolescent alcohol use*  
K. R. Hamilton, J. W. Felton, G. Kurdziel, L. MacPherson, C. W. Lejuez, Psychology, University of Maryland, College Park, MD
- 113 *Implementing screening and brief intervention in public schools: Feasibility and proof of concept*  
A. T. McLellan<sup>1</sup>, B. L. Curtis<sup>1</sup>, H. Meitiner<sup>2</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Phoenix House, New York, NY
- 114 *The natural history of adolescent binge drinking: Findings from a 15-year prospective cohort study*  
L. Degenhardt<sup>1,2</sup>, C. O'Loughlin<sup>3</sup>, W. Swift<sup>1</sup>, H. Romaniuk<sup>3,5,6</sup>, J. Carlin<sup>5,6</sup>, C. Coffey<sup>3</sup>, W. Hall<sup>4</sup>, G. Patton<sup>3,5</sup>, <sup>1</sup>NDARC, UNSW, Sydney, NSW, Australia, <sup>2</sup>School of Population Health, University of Melbourne, Melbourne, VIC, Australia, <sup>3</sup>Centre for Adolescent Health, MCRI, Melbourne, VIC, Australia, <sup>4</sup>Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia, <sup>5</sup>Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia, <sup>6</sup>CEBU, MCRI, Melbourne, VIC, Australia
- 115 *Childhood physical abuse, sensitive periods, and problematic alcohol use in young adulthood*  
S. H. Shin<sup>1</sup>, S. Jeon<sup>1</sup>, M. Teicher<sup>2</sup>, <sup>1</sup>Boston University, Boston, MA, <sup>2</sup>Harvard Medical School, Boston, MA
- 116 *Alcohol demand indices predict outcomes among heavy-drinking young adults receiving a brief intervention*  
M. Bernstein<sup>2,1</sup>, J. Murphy<sup>3</sup>, J. MacKillop<sup>4</sup>, S. Colby<sup>1</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>University of Rhode Island, Kingston, RI, <sup>3</sup>University of Memphis, Memphis, TN, <sup>4</sup>University of Georgia, Athens, GA

- 117 *Frequency of alcohol use and reported engagement in risky behaviors*  
K. Lange, S. Thamotharan, M. Sferra, A. Herrick, S. Fields, Psychology, Texas A&M University, College Station, TX
- 118 *Substance use in adolescents with environmental lead exposure in childhood*  
A. Pascale<sup>1</sup>, C. B. Bares<sup>2</sup>, A. Sosa<sup>1</sup>, M. J. Moll<sup>1</sup>, S. Couto<sup>1</sup>, D. Pose<sup>1</sup>, A. Laborde<sup>1</sup>, <sup>1</sup>Department of Toxicology, School of Medicine, Montevideo, Uruguay, <sup>2</sup>School of Social Work, Virginia Commonwealth University, Richmond, VA
- 119 *Adolescent patients in substance abuse treatment: Examining callous-unemotional traits*  
J. Sakai<sup>1</sup>, S. K. Mikulich-Gilbertson<sup>1</sup>, S. E. Young<sup>1,2</sup>, S. H. Rhee<sup>2</sup>, S. K. McWilliams<sup>1</sup>, R. Dunn<sup>3</sup>, S. Salomonsen-Sautel<sup>1</sup>, C. Thurstone<sup>4,1</sup>, C. J. Hopfer<sup>1</sup>, <sup>1</sup>University of Colorado School of Medicine, Aurora, CO, <sup>2</sup>Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO, <sup>3</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Denver Health & Hospital Authority, Denver, CO
- 120 *Callous and unemotional traits as early indicators of poor treatment performance in a behavioral activation treatment for substance-using adolescents*  
K. Long<sup>1</sup>, J. W. Felton<sup>1</sup>, J. Jacobs<sup>3</sup>, A. K. Matusiewicz<sup>1</sup>, M. DiMeo<sup>2</sup>, R. Subbiah<sup>4</sup>, C. W. Lejuez<sup>1</sup>, <sup>1</sup>Psychology, University of Maryland, College Park, College Park, MD, <sup>2</sup>Psychology, University of North Carolina, Greensboro, Greensboro, NC, <sup>3</sup>Psychology, Saint Mary's College of Maryland, Saint Mary's City, MD, <sup>4</sup>Daytop, Pittsgrove, NJ
- 121 *Modeling inter-relationships among longitudinal non-normal outcomes: Trajectories of daily use of different drugs during treatment*  
S. K. Mikulich-Gilbertson, G. O. Zerbe, P. D. Riggs, Psychiatry, University of Colorado, Aurora, CO
- 122 *Addressing time-varying confounding when assessing the causal effects of cumulative treatments for adolescents with substance use problems*  
B. Griffin<sup>1</sup>, D. McCaffrey<sup>2</sup>, R. Ramchand<sup>1</sup>, D. Almirall<sup>3</sup>, M. Slaughter<sup>2</sup>, L. Burgette<sup>1</sup>, <sup>1</sup>RAND Corporation, Washington, DC, <sup>2</sup>RAND Corporation, Pittsburgh, PA, <sup>3</sup>Institute for Social Research, University of Michigan, Ann Arbor, MI
- 123 *Effectiveness of the Treatment Retention and Induction Program (TRIP) for increasing adolescent motivation for change*  
J. E. Becan, D. Knight, G. Joe, R. Crawley, P. Flynn, Institute of Behavioral Research, Texas Christian University, Fort Worth, TX
- 124 *The effectiveness of the Treatment Retention and Induction Program (TRIP) for improving adolescent decision-making*  
D. Knight, J. Becan, D. Dansereau, R. Crawley, P. Flynn, Institute of Behavioral Research, Texas Christian University, Fort Worth, TX
- 125 *Risk and protective factors of transactional sex involvement among substance using adolescents in an urban emergency room (ED)*  
L. S. Massey<sup>1</sup>, R. Patton<sup>1</sup>, M. A. Walton<sup>1</sup>, R. M. Cunningham<sup>1</sup>, F. Blow<sup>1</sup>, M. Zimmerman<sup>1</sup>, B. M. Booth<sup>2</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Arkansas, Little Rock, AR

### TREATMENT

- 126 *Organizational dynamics, learning environments, and integration of technology in substance abuse treatment*  
E. Klemperer, T. R. Rieckmann, Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR

- 127 *A RCT of long-term recovery management (LTRM) for opioid or stimulant dependence*  
G. S. Brigham<sup>1,2</sup>, R. Falck<sup>3</sup>, R. W. Nahhas<sup>3</sup>, B. M. Booth<sup>4</sup>, X. Han<sup>3</sup>, R. Carlson<sup>3</sup>, <sup>1</sup>Maryhaven Addiction Research Institute, Columbus, OH, <sup>2</sup>University of Cincinnati, Cincinnati, OH, <sup>3</sup>Wright State University Boonshoft School of Medicine, Dayton, OH, <sup>4</sup>University of Arkansas for Medical Sciences, Little Rock, AR
- 128 *Integrating substance use disorder services into primary care settings: Current status in California*  
E. Tran, B. T. Oeser, V. P. Antonini, D. Urada, D. Ramirez, R. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 129 *Vital signs: A national study of the addiction treatment profession*  
O. Ryan<sup>1</sup>, K. Summers<sup>3</sup>, M. S. Shafer<sup>2</sup>, H. J. Gotham<sup>1</sup>, M. Cruz<sup>4</sup>, <sup>1</sup>UMKC, Kansas City, MO, <sup>2</sup>Arizona State University, Phoenix, AZ, <sup>3</sup>University of Iowa, Iowa City, IA, <sup>4</sup>Universidad Central del Caribe, Bayamon
- 130 *Women and entry to residential detoxification treatment: Motivations and barriers*  
A. Noroozi<sup>1</sup>, Z. Alam Mehrjerdi<sup>2</sup>, A. Deylamizadeh<sup>3</sup>, S. Moradi<sup>3</sup>, <sup>1</sup>School of Advanced Medical Technologies (SAMT), Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran, <sup>2</sup>Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran, <sup>3</sup>Division of Research on Drug Use and Dependence, Rebirth Society (NGO), Tehran, Islamic Republic of Iran

### CRIMINAL JUSTICE

- 131 *Severity, frequency and variety of crime in heroin-dependent prisoners enrolled in a buprenorphine study*  
M. S. Gordon<sup>1</sup>, T. W. Kinlock<sup>1</sup>, R. P. Schwartz<sup>1</sup>, K. E. O'Grady<sup>2</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Psychology, University of Maryland, College Park, MD
- 132 *Profile of substance use risk by race and rurality among re-entering offenders*  
M. Staton-Tindall<sup>2</sup>, M. Webster<sup>1</sup>, C. Leukefeld<sup>1</sup>, C. B. Oser<sup>3</sup>, J. L. Duvall<sup>1</sup>, J. R. Havens<sup>1</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Social Work, University of Kentucky, Lexington, KY, <sup>3</sup>Sociology, University of Kentucky, Lexington, KY
- 133 *Prescription opioid abuse and related behavior among prisoners*  
C. Leukefeld<sup>1</sup>, M. Webster<sup>1</sup>, M. Staton-Tindall<sup>2</sup>, C. B. Oser<sup>3</sup>, H. K. Knudsen<sup>1</sup>, J. L. Duvall<sup>1</sup>, J. R. Havens<sup>1</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Social Work, University of Kentucky, Lexington, KY, <sup>3</sup>Sociology, University of Kentucky, Lexington, KY
- 134 *Brief screening for alcohol and drug problems among prisoners*  
M. Webster, C. Leukefeld, M. Staton-Tindall, J. L. Duvall, C. B. Oser, J. R. Havens, Center on Drug & Alcohol Research, University of Kentucky, Lexington, KY
- 135 *Opioid treatment and criminal charges: A comparison of methadone and buprenorphine*  
A. A. Chaudhry<sup>1</sup>, V. L. King<sup>2</sup>, E. Harris<sup>4</sup>, S. Kawasaki<sup>3</sup>, D. Rastegar<sup>1</sup>, <sup>1</sup>Medicine, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, <sup>3</sup>Family Medicine, University of California Los Angeles, Los Angeles, CA, <sup>4</sup>Medicine, Montefiore Medical Center, Bronx, NY
- 136 *Examining perceived coercion among incarcerated substance abusers participating in research*  
K. L. Dugosh, D. Festinger, J. S. Cacciola, Section on Law and Ethics, Treatment Research Institute, Philadelphia, PA

- 137 *Feasibility of a visual performance feedback during judicial status hearings in drug court*  
D. S. Festinger<sup>1,2</sup>, K. L. Dugosh<sup>1</sup>, C. M. Denis<sup>2</sup>, D. B. Marlowe<sup>1,2,3</sup>, <sup>1</sup>Law and Ethics, Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>National Association of Drug Court Professionals, Alexandria, VA
- 138 *Individual influences on change team member attrition in the CJDATS2 assessment study*  
M. Hiller<sup>1</sup>, W. Ulasek<sup>2</sup>, J. Cartier<sup>3</sup>, S. Abdel-Salam<sup>4</sup>, M. Clair<sup>5</sup>, T. Litwicki<sup>6</sup>, M. Prendergast<sup>3</sup>, G. Melnick<sup>7</sup>, G. Zajac<sup>1</sup>, <sup>1</sup>Criminal Justice, Temple U., Philadelphia, PA, <sup>2</sup>Mental Health & Addiction Services, U. Connecticut, Hartford, CT, <sup>3</sup>ISAP, UCLA, Los Angeles, CA, <sup>4</sup>Center on Drug and Alcohol Studies, U Delaware, Newark, DE, <sup>5</sup>Cancer Prevention Research Center, U. Rhode Island, Kingston, RI, <sup>6</sup>Social Work, Arizona State U., Phoenix, AZ, <sup>7</sup>NDRI, New York, NY
- 139 *Pre-custody HIV risks as a factor in the effectiveness of the Way Safe intervention*  
W. E. Lehman, G. A. Rowan-Szal, N. G. Bartholomew, G. Joe, K. Knight, Institute of Behavioral Research, Texas Christian University, Fort Worth, TX
- 140 *CJDATS2 Local Change Team initiatives for improving assessment for drug treatment in correctional systems*  
L. R. Taylor<sup>1</sup>, G. Stahler<sup>2</sup>, M. Hiller<sup>3</sup>, <sup>1</sup>Department of Criminal Justice, Temple University, Philadelphia, PA, <sup>2</sup>Geography & Urban Studies, Temple University, Philadelphia, PA, <sup>3</sup>Department of Criminal Justice, Temple University, Philadelphia, PA
- 141 *Are former prisoners with drug disorders ready for mutual-help?*  
D. Howard, L. Baldini, D. Blonigen, C. Timko, Center for Health Care Evaluation, Dept of Veterans Affairs and Stanford University, Menlo Park, CA
- 142 *Childhood abuse is associated with alcohol use outcomes after gender responsive treatment for women in prison*  
P. Saxena, N. P. Messina, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 143 *The association between incarceration history and HIV-related drug risk behaviors*  
L. Hearn<sup>1</sup>, N. EnnisWhitehead<sup>1</sup>, M. Khan<sup>2</sup>, W. Latimer<sup>1</sup>, <sup>1</sup>Clinical and Health Psychology, University of Florida, Gainesville, FL, <sup>2</sup>Epidemiology, University of Florida, Gainesville, FL
- 144 *Arrest for violent offenses in early adulthood: Predictions from prenatal and adolescent cocaine exposure*  
D. C. Vidot<sup>1,2</sup>, V. H. Accornero<sup>2</sup>, L. Xue<sup>2</sup>, J. C. Anthony<sup>3</sup>, E. S. Bandstra<sup>2</sup>, <sup>1</sup>Epidemiology & Public Health, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Pediatrics, University of Miami Miller School of Medicine, Miami, FL, <sup>3</sup>Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 145 *Influences of harm reduction programs on HIV knowledge and risky behaviors among injection drug users in prisons in Taiwan*  
Y. Chang<sup>1,2</sup>, Y. Lan<sup>1</sup>, Y. Hser<sup>2</sup>, <sup>1</sup>China Medical University, Taichung, Taiwan, <sup>2</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 146 *Not ashamed anymore: Longitudinal changes in barriers to treatment entry for online treatment seekers*  
A. Jaffe<sup>1,2</sup>, D. Murphy<sup>1</sup>, T. Shaheed<sup>2</sup>, A. Coleman<sup>2</sup>, Y. Hser<sup>1</sup>, <sup>1</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>California Treatment Services, LLC, Beverly Hills, CA

## **Symposium XIII**

**INDIGO A  
2:10 - 4:15 PM**

### **NEW TOOLS PROVIDE NEW INSIGHTS INTO METHAMPHETAMINE'S ACTIONS**

Chairs: David Grandy and David Shurtleff

- 2:10 *75th Anniversary Reflections*
- 2:15 *Meth/amphetamine modulation of intracellular signaling pathways: More about DAT*  
Susan G. Amara, University of Pittsburgh School of Medicine, Pittsburgh, PA
- 2:40 *Trace amine-associated receptor 1 is a methamphetamine receptor that differentially controls DAT and NET internalization*  
Gregory M. Miller, Harvard Medical School, Southborough, MA
- 3:05 *Partial MHC/neuroantigen peptide constructs: A potential neuroimmune- based treatment for methamphetamine addiction*  
Jennifer M. Loftis, Portland VA Medical Center, Portland, OR
- 3:30 *Trace amine-associated receptor 1 is a methamphetamine receptor in mice*  
David Grandy, Oregon Health and Science University, Portland, OR
- 3:55 *Discussant*  
David Shurtleff, National Institute on Drug Abuse, Bethesda, MD

## **Symposium XIV**

**INDIGO E  
2:10 - 3:15 PM**

### **THIS IS YOUR BRAIN BEFORE DRUGS: NEUROIMAGING HIGH-RISK YOUTH**

Chairs: Leslie A. Hulvershorn and Joanna Jacobus

- 2:10 *75th Anniversary Reflections*
- 2:15 *Functional correlates of impulse control deficits in high-risk youth*  
Mary Heitzeg, University of Michigan, Ann Arbor, MI
- 2:35 *Functional neuroimaging of emotion processing and regulation in high-risk 10 - 14-year-olds*  
Leslie A. Hulvershorn, Indiana University School of Medicine, Indianapolis, IN
- 2:55 *Structural brain predictors of adolescent substance use*  
Joanna Jacobus, University of California at San Diego, San Diego, CA

## **Symposium XV**

**INDIGO E  
3:25 - 4:30 PM**

### **USE IT AND LOSE IT: IMPACT OF A PHARMACOLOGICAL POT POURRI ON THE DEVELOPING BRAIN**

Chairs: Scott E. Lukas and Staci A. Gruber

- 3:25 *75th Anniversary Reflections*
- 3:30 *Worth the wait: Early marijuana use is related to alterations in neurocognitive, functional and structural brain correlates*  
Staci A. Gruber, McLean Hospital/Harvard Medical School, Belmont, MA



- 3:45 *Why we need to delay age of alcohol & marijuana use onset: Neurocognitive studies in youth*  
Krista M. Lisdahl, University of Wisconsin-Milwaukee, Milwaukee, WI
- 4:00 *Smoking and prefrontal cortex function in late adolescence*  
Edythe London, Brain Research Institute, University of California, Los Angeles, Los Angeles, CA
- 4:15 *Challenges of detecting and predicting the consequences of early drug use by adolescents*  
Scott E. Lukas, McLean Hospital/Harvard Medical School, Belmont, MA

### Oral Communications 13

**INDIGO D**  
**2:10 - 4:15 PM**

#### DEPENDENT DEFENDERS: THE VETERANS' STORY

Chairs: Philip T. Korthuis and Elizabeth J. Santa Ana

- 2:10 *75th Anniversary Reflections*
- 2:15 *Quality of HIV care and mortality in HIV-infected patients who use drugs and alcohol*  
P. T. Korthuis<sup>1</sup>, K. L. Kraemer<sup>2</sup>, K. A. McGinnis<sup>3</sup>, M. Skanderson<sup>3</sup>, A. J. Gordon<sup>2,3</sup>, A. C. Justice<sup>4</sup>, D. A. Fiellin<sup>4</sup>, <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>VA Pittsburgh Healthcare System, Pittsburgh, PA, <sup>4</sup>Yale School of Medicine, New Haven, CT
- 2:30 *Missed opportunity for alcohol intervention among Army members returning from deployment*  
M. Larson<sup>1</sup>, B. Mohr<sup>1</sup>, N. R. Wooten<sup>2</sup>, R. Sayko Adams<sup>1</sup>, E. Merrick<sup>1</sup>, L. Lorenz<sup>1</sup>, T. V. Williams<sup>3</sup>, <sup>1</sup>Institute for Behavioral Health Heller School, Brandeis University, Waltham, MA, <sup>2</sup>College of Social Work, University of South Carolina, Columbia, SC, <sup>3</sup>Defense Health Cost and Program Evaluation, TRICARE Management Activity Dept of Defense, Falls Church, VA
- 2:45 *Impact of group motivational interviewing (GMI) on dually diagnosed veterans with alcohol use disorders*  
E. J. Santa Ana<sup>1</sup>, K. Lamb<sup>1</sup>, A. Morgan-Lopez<sup>2</sup>, S. LaRowe<sup>1</sup>, <sup>1</sup>Charleston VAMC, Charleston, SC, <sup>2</sup>RTI International, Research Triangle Park, NC
- 3:00 *Comparing the prevalence of concurrent benzodiazepine prescription among Veterans receiving methadone vs. buprenorphine maintenance therapies*  
T. Park<sup>1,2</sup>, A. S. Bohnert<sup>3</sup>, K. Austin<sup>3</sup>, R. Saitz<sup>2</sup>, S. Pizer<sup>1,2</sup>, <sup>1</sup>VA Boston, Boston, MA, <sup>2</sup>Boston University, Boston, MA, <sup>3</sup>VA Ann Arbor, Ann Arbor, MI
- 3:15 *Gender differences in substance use treatment utilization the year prior to deployment in Army service members*  
N. R. Wooten<sup>1</sup>, B. A. Mohr<sup>2</sup>, L. M. Lundgren<sup>3</sup>, R. S. Adams<sup>2</sup>, E. Merrick<sup>4</sup>, D. D. Jeffery<sup>4</sup>, T. V. Williams<sup>2</sup>, M. Larson<sup>2</sup>, <sup>1</sup>College of Social Work, University of South Carolina, Columbia, SC, <sup>2</sup>Institute of Behavioral Health, Heller School, Brandeis University, Waltham, MA, <sup>3</sup>School of Social Work, Boston University, Boston, MA, <sup>4</sup>Health Affairs, TRICARE Management Activity, Defense Health Costs and Program Evaluation (DHCAPE), Department of Defense, Falls Church, VA
- 3:30 *What medical care needs of homeless and housed Veterans are served by the VA?*  
A. H. Yuan<sup>1</sup>, S. Gabrielian<sup>1</sup>, R. Andersen<sup>2</sup>, J. McGuire<sup>1</sup>, L. Rubenstein<sup>1</sup>, L. Gelberg<sup>2</sup>, <sup>1</sup>Veterans Affairs, Los Angeles, CA, <sup>2</sup>UCLA, Los Angeles, CA



- 3:45 *Incorporating addiction treatment into medical homes for homeless Veterans: A 3-site comparison*  
S. Gabrielian<sup>1,2</sup>, A. J. Gordon<sup>3,4</sup>, L. Gelberg<sup>2,1</sup>, B. Patel<sup>1</sup>, R. Manchanda<sup>1</sup>, L. Altman<sup>1,2</sup>,  
R. M. Andersen<sup>2,1</sup>, A. Campbell<sup>5</sup>, S. Kertesz<sup>5</sup>, <sup>1</sup>VA Greater Los Angeles, Los Angeles, CA,  
<sup>2</sup>UCLA, Los Angeles, CA, <sup>3</sup>VA Pittsburgh, Pittsburgh, PA, <sup>4</sup>U. Pittsburgh, Pittsburgh, PA, <sup>5</sup>VA  
Birmingham, Birmingham, AL
- 4:00 *Whose post-traumatic stress affects drinking levels? Couple-dyad modeling of National Guard service members and their partners*  
S. Balan, C. van den Berk-Clark, M. Shroff, G. Widner, J. Scherrer, R. K. Price, Washington  
University School of Medicine, Saint Louis, MO

## Oral Communications 14

**INDIGO H**  
**2:10 - 4:15 PM**

### MECHANISMS OF MALADAPTATION: BRAIN AND BEHAVIOR

Chairs: Taline Khroyan and Mark K. Greenwald

- 2:10 *75th Anniversary Reflections*
- 2:15 *Impulsive choice behavior and sensorimotor function in adult rats exposed to chronic intermittent ethanol during adolescence and adulthood*  
J. Mejia-Toiber, A. Markou, S. Semenova, Psychiatry, University of California San Diego, La Jolla, CA
- 2:30 *Nicotine vapor inhalation escalates nicotine self-administration*  
N. W. Gilpin, Physiology, Louisiana State University Health Sciences Center, New Orleans, LA
- 2:45 *Effects of N-acetylcysteine (NAC) vs. placebo maintenance on frontal-cortical glutamate, motor-cortical excitability and cocaine seeking*  
M. K. Greenwald, J. A. Stanley, D. Khatib, K. Gjini, N. N. Boutros, L. H. Lundahl,  
C. L. Steinmiller, Psychiatry, Wayne State University, Detroit, MI
- 3:00 *Wheel running dose dependently attenuates cocaine-seeking and associated neuroadaptations in the prefrontal cortex*  
A. B. Peterson<sup>1</sup>, J. L. Abel<sup>2</sup>, W. J. Lynch<sup>1</sup>, <sup>1</sup>Psychiatry and Neurobehavioral Sciences,  
University of Virginia, Charlottesville, VA, <sup>2</sup>Biochemistry and Molecular Genetics, University  
of Virginia, Charlottesville, VA
- 3:15 *Individual differences in controllability of social defeat stress as a predictor for escalated cocaine self-administration*  
C. O. Boyson, A. R. Burke, K. A. Miczek, Psychology, Tufts University, Medford, MA
- 3:30 *Adaptation of the hippocampus-accumbens pathway following repeated cocaine*  
J. L. Barr<sup>1</sup>, G. L. Forster<sup>2</sup>, E. M. Unterwald<sup>1</sup>, <sup>1</sup>Department of Pharmacology and Center for  
Substance Abuse Research, Temple University, Philadelphia, PA, <sup>2</sup>Division of Basic  
Biomedical Sciences, The University of South Dakota, Vermillion, SD
- 3:45 *The role of alpha3beta4 nicotinic receptors in cocaine-induced reward acquisition and behavioral sensitization*  
T. Khroyan<sup>1</sup>, L. Toll<sup>2</sup>, W. E. Polgar<sup>1</sup>, D. Yasuda<sup>3</sup>, N. Zaveri<sup>3</sup>, <sup>1</sup>SRI International, Menlo  
Park, CA, <sup>2</sup>Torrey Pines, Port St. Lucie, FL, <sup>3</sup>Astraea Therapeutics, Mountain View, CA

---

## Wednesday, June 19, 2013

---

4:00 *DNA methylation is altered with extended access to cocaine during abstinence*

K. Ploense<sup>1,2</sup>, A. Carr<sup>1</sup>, T. Bredy<sup>2</sup>, Y. Sun<sup>3</sup>, T. E. Kippin<sup>1</sup>, <sup>1</sup>Psychological and Brain Sciences, UCSB, Santa Barbara, CA, <sup>2</sup>Queensland Brain Institute, Saint Lucia, QLD, Australia, <sup>3</sup>Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA

### **Dinner and Dancing**

**INDIGO BALLROOM**  
**7:00 - 10:00 PM**

**BADGES MUST BE WORN FOR ADMISSION**

**Poster Session IV  
(Breakfast)**

**SAPPHIRE  
7:30 - 9:30 AM**

**Odd-numbered posters manned first hour;  
Even-numbered, second hour**

**Set-up time begins Wednesday 3 PM**

**Must be removed by Thursday 12 NOON**

**LITERATURE REVIEW**

- 1 *A systematic review of studies exploring craving, its moderators, and the link with substance use in daily life using Ecological Momentary Assessment (EMA)*  
J. Swendsen<sup>2</sup>, F. Serre<sup>1,3</sup>, M. Fatseas<sup>1,3</sup>, M. Auriacombe<sup>1,3</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>CNRS UMR 5287 INCIA, Univ. Bordeaux, Bordeaux, France, <sup>3</sup>CH Ch. Perrens et CHU Bordeaux, Bordeaux, France
- 2 *Impulsivity in substance dependence: A meta-analysis*  
C. G. Schütz, S. Sahoo, M. Krausz, Psychiatry, Institute of Mental Health, Vancouver, BC, Canada
- 3 *The role of gender in the association between child maltreatment and substance use behavior: A systematic review of longitudinal research from 1995 to 2011*  
A. Kristman-Valente, E. A. Wells, Social Work, University of Washington, Seattle, WA
- 4 *Literature review of substance abuse "treatment as usual" for psychosocial interventions*  
D. C. Wendt, Department of Psychology, University of Michigan, Ann Arbor, MI
- 5 *Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users: Cochrane review*  
J. Klimas<sup>1,2,5</sup>, C. A. Field<sup>2</sup>, W. Cullen<sup>1</sup>, C. S. O'Gorman<sup>1</sup>, L. G. Glynn<sup>3</sup>, E. Keenan<sup>4</sup>, J. Saunders<sup>1</sup>, G. Bury<sup>2</sup>, C. Dunne<sup>1</sup>, <sup>1</sup>University of Limerick, Limerick, Ireland, <sup>2</sup>University College Dublin, Dublin, Ireland, <sup>3</sup>National University of Ireland, Galway, Ireland, <sup>4</sup>Addiction Services, Health Service Executive, Dublin, Ireland, <sup>5</sup>Oregon Health & Science University, Portland, OR
- 6 *Quantitative review of psychosocial and ethical contents of home drug testing for parents on the Internet*  
Y. Washio<sup>1</sup>, K. C. Kirby<sup>1</sup>, J. Fairfax-Columbo<sup>2</sup>, E. Ball<sup>1</sup>, H. Cassey<sup>3</sup>, E. Bresani<sup>1</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Drexel University, Philadelphia, PA, <sup>3</sup>Temple University, Philadelphia, PA
- 7 *Insight and motivation in drug treatment for offenders: A content analysis*  
R. Linn-Walton, BST Program, National Development and Research Institutes, New York, NY
- 8 *Prevalence of smokeless tobacco use among individuals with comorbid other substance dependence*  
R. Redner<sup>1</sup>, S. T. Higgins<sup>1,2</sup>, T. J. White<sup>1</sup>, J. M. Skelly<sup>3</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Psychology, University of Vermont, Burlington, VT, <sup>3</sup>Biomedical Statistics, University of Vermont, Burlington, VT
- 9 *Data on the diversion, nonmedical use and adverse outcomes associated with pharmaceutical opioids*  
A. Zimam, T. D. Schmidt, A. Nielsen, W. Wakeland, Systems Science Graduate Program, Portland State University, Portland, OR

- 10 *Systematic evidence review on methadone harms and comparative harms*  
R. Chou<sup>1,2</sup>, M. B. Weimer<sup>1</sup>, D. Fiellin<sup>3</sup>, <sup>1</sup>Department of Medicine, Oregon Health and Science University, Portland, OR, <sup>2</sup>Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, OR, <sup>3</sup>Department of Medicine, Yale University, New Haven, CT
- 11 *Retention of participants in opiate substitution programs in low and middle-income countries: An international systematic review*  
D. C. Des Jarlais<sup>1</sup>, J. P. Feelemyer<sup>1</sup>, K. Arasteh<sup>1</sup>, H. Hagan<sup>2</sup>, <sup>1</sup>The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York, NY, <sup>2</sup>College of Nursing, NYU, New York, NY
- 12 *HIV risk behaviors among returnee male migrant workers in Nepal*  
R. Shrestha<sup>1</sup>, M. Copenhaver<sup>2</sup>, <sup>1</sup>Allied Health Sciences, University of Connecticut, Storrs, CT, <sup>2</sup>Allied Health Sciences, University of Connecticut, Storrs, CT
- 13 *Review of human abuse potential study methodology for abuse-deterrent formulations*  
K. A. Schoedel<sup>1</sup>, B. Setnik<sup>2</sup>, C. L. Roland<sup>2</sup>, G. C. Pixton<sup>2</sup>, M. Shram<sup>1</sup>, N. Levy-Cooperman<sup>1</sup>, <sup>1</sup>INC Research, Toronto, ON, Canada, <sup>2</sup>Pfizer Inc., Cary, NC

### THEORETICAL/COMMENTARY

- 15 *The Dual Diagnosis Capability and Medically Integrated Care (DDMICE) instrument*  
G. Melnick, CIRP, NDRI, New York, NY
- 16 *Research issues in executive functioning: Implications for addictions treatment*  
A. M. Horton, Neuropsychology Section, Psych Associates of Maryland, Bethesda, MD
- 17 *Advanced methods for causal inference in drug abuse observational data*  
R. L. Stout<sup>1,2</sup>, J. M. Braciszewski<sup>2,1</sup>, W. Zywiak<sup>1,2</sup>, <sup>1</sup>Pacific Institute for Research and Evaluation, Pawtucket, RI, <sup>2</sup>Brown University, Providence, RI
- 18 *Brain surgery and agonist oral cocaine: Two therapeutic modalities originating and applied in Peru for cocaine addiction*  
T. Llosa, COCAMEDICA, Lima, Peru
- 19 *Drop-the-Loser: An innovative design for a clinical trial of citalopram for cocaine dependence*  
C. Green, S. D. Lane, F. G. Moeller, J. Schmitz, Psychiatry and Behavioral Sciences, University of Texas - Houston, Houston, TX
- 20 *Numerators and denominators to quantify the abuse of prescription opioids: A review of data sources and metrics*  
A. M. Secora, C. Dormitzer, J. Staffa, Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, MD
- 21 *Abuse potential assessment of novel opioid analgesic NKTR-181: Implications for labeling and scheduling*  
L. R. Webster<sup>1</sup>, S. Smith<sup>2</sup>, J. Silowsky<sup>2</sup>, K. Gogas<sup>2</sup>, A. Odinecs<sup>2</sup>, M. Eldon<sup>2</sup>, N. Abrouk<sup>2</sup>, R. Medve<sup>2</sup>, J. Henningfield<sup>3</sup>, A. Buchhalter<sup>3</sup>, E. Cone<sup>3</sup>, R. Fant<sup>3</sup>, S. Schnoll<sup>3</sup>, <sup>1</sup>CRI Lifetree, Salt Lake City, UT, <sup>2</sup>Nektar, San Francisco, CA, <sup>3</sup>PinneyAssociates, Bethesda, MD
- 22 *Changes in understanding of opioid-induced hyperalgesia-clinical implications*  
P. Athanasos<sup>1</sup>, R. Neild<sup>2,3</sup>, <sup>1</sup>Discipline of Psychiatry, Flinders University, Adelaide, SA, Australia, <sup>2</sup>School of Public Health, Flinders University, Adelaide, SA, Australia, <sup>3</sup>Drug and Alcohol Services, Adelaide, SA, Australia

### OPIOIDS II—HUMAN STUDIES

- 23 *Desomorphine (Crocodile) injection among in-treatment drug users in Tbilisi, Georgia*  
Z. Sikharulidze<sup>1</sup>, N. Kapanadze<sup>1</sup>, D. Otiashvili<sup>2</sup>, S. Poole<sup>3</sup>, G. E. Woody<sup>3</sup>, <sup>1</sup>Centre for Medical, Socio-economic and Cultural Issues Uranti, Tbilisi, Georgia, <sup>2</sup>Addiction Research Center, Alternative Georgia, Tbilisi, Georgia, <sup>3</sup>Department of Psychiatry, School of Medicine, University of Pennsylvania, Treatment Research Institute, Philadelphia, PA
- 24 *Drug use trends following the 12-weeks OST in the Republic of Georgia (RCT)*  
G. Piralishvili<sup>1</sup>, D. Otiashvili<sup>2</sup>, Z. Sikharulidze<sup>3</sup>, G. Kamkamidze<sup>4</sup>, S. Poole<sup>5</sup>, G. E. Woody<sup>5</sup>, <sup>1</sup>Centre for Mental Health and Prevention of Addiction, Tbilisi, Georgia, <sup>2</sup>Addiction Research Center, Alternative Georgia, Tbilisi, Georgia, <sup>3</sup>Centre for Medical, Socio-economic and Cultural Issues Uranti, Tbilisi, Georgia, <sup>4</sup>Maternal and Child Care Union, Tbilisi, Georgia, <sup>5</sup>Psychiatry, University of Pennsylvania, Phila, PA
- 25 *Latent class analysis of non-opioid dependent illegal pharmaceutical opioid users in Ohio*  
R. Carlson<sup>1</sup>, R. W. Nahhas<sup>1</sup>, R. Daniulaityte<sup>1</sup>, S. S. Martins<sup>2</sup>, R. Falck<sup>1</sup>, <sup>1</sup>Wright State University Boonshoft School of Medicine, Dayton, OH, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY
- 26 *Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal*  
M. R. Lofwall<sup>1,2,3</sup>, S. Babalonis<sup>2</sup>, P. A. Nuzzo<sup>3</sup>, A. Siegel<sup>1</sup>, C. L. Campbell<sup>4</sup>, S. L. Walsh<sup>1,2,3</sup>, <sup>1</sup>Psychiatry, University of Kentucky College of Medicine (UK COM), Lexington, KY, <sup>2</sup>Behavioral Science, UK COM, Lexington, KY, <sup>3</sup>Center on Drug and Alcohol Research, UK COM, Lexington, KY, <sup>4</sup>Cardiology, UK COM, Lexington, KY
- 27 *Evaluation of opioid withdrawal after maintenance on extended-release tramadol*  
P. A. Nuzzo<sup>1</sup>, S. L. Walsh<sup>1,2,3</sup>, S. Babalonis<sup>1,3</sup>, A. Siegel<sup>2</sup>, C. L. Campbell<sup>4</sup>, M. R. Lofwall<sup>1,2,3</sup>, <sup>1</sup>Center on Drug and Alcohol Research, University of Kentucky College of Medicine (UK COM), Lexington, KY, <sup>2</sup>Psychiatry, UK COM, Lexington, KY, <sup>3</sup>Behavioral Science, UK COM, Lexington, KY, <sup>4</sup>Cardiology, UK COM, Lexington, KY
- 28 *Relations between craving and withdrawal and time to first opioid use among prescription opioid abusers initiating buprenorphine detoxification*  
A. Stotts<sup>1</sup>, T. Northrup<sup>1</sup>, J. S. Potter<sup>2</sup>, E. N. Marino<sup>2</sup>, R. Walker<sup>3</sup>, M. Trivedi<sup>3</sup>, R. Weiss<sup>4</sup>, <sup>1</sup>UT Medical School-Houston, Houston, TX, <sup>2</sup>UT Health Science Center-San Antonio, San Antonio, TX, <sup>3</sup>UT Southwestern, Dallas, TX, <sup>4</sup>Harvard Medical School, Boston, MA
- 29 *Buprenorphine for inpatient medically assisted withdrawal in prescription opioid and heroin users*  
B. Sproule<sup>1,2</sup>, H. Badalato<sup>1</sup>, A. Kalvik<sup>1,2</sup>, B. Brands<sup>1,2,3</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Health Canada, Ottawa, ON, Canada
- 30 *A mechanistic PK/PD model of buprenorphine*  
W. I. Li, R. Turncliff, Translational Medicine, Alkermes Inc., Waltham, MA
- 31 *Buprenorphine vs. morphine withdrawal: A controlled comparison*  
D. A. Tompkins, M. T. Smith, C. Campbell, M. Mintzer, E. C. Strain, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 32 *Treatment outcomes by patterns of methadone and buprenorphine induction strategies: Does higher dose and faster induction improve outcomes?*  
P. Jacobs<sup>1</sup>, A. Ang<sup>2</sup>, M. P. Hillhouse<sup>2</sup>, L. Mooney<sup>2</sup>, A. Saxon<sup>3</sup>, J. S. Potter<sup>4</sup>, S. Nielsen<sup>5</sup>, P. Wakim<sup>1</sup>, J. Blaine<sup>1</sup>, <sup>1</sup>Center for the Clinical Trials Network, Rockville, MD, <sup>2</sup>UCLA, Los Angeles, CA, <sup>3</sup>VA Puget Sound Health Care, Seattle, WA, <sup>4</sup>University Texas Health Science Center, San Antonio, TX, <sup>5</sup>University of Sydney, Sydney, NSW, Australia

- 33 *Buprenorphine and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: Findings from Starting Treatment with Agonist Replacement Therapies (START)*  
J. S. Potter<sup>1</sup>, E. N. Marino<sup>1</sup>, M. P. Hillhouse<sup>2</sup>, S. Nielsen<sup>3</sup>, K. Wiest<sup>4</sup>, C. Canamar<sup>2</sup>, J. Martin<sup>5</sup>, A. Ang<sup>2</sup>, R. Baker<sup>4</sup>, A. Saxon<sup>6</sup>, W. Ling<sup>2</sup>, <sup>1</sup>University of Texas Health Science Center, San Antonio, TX, <sup>2</sup>University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>University of Sydney, Sydney, NSW, Australia, <sup>4</sup>CODA, Inc., Portland, OR, <sup>5</sup>City and County of San Francisco, Dept of Public Health, San Francisco, CA, <sup>6</sup>Veteran's Affairs Puget Sound Health Care System, Seattle, WA
- 34 *What happens when stabilized methadone-maintained dose must be changed ?*  
E. Peles, S. Schreiber, A. Sason, M. Adelson, Adelson Clinic for Drug Abuse Treatment & Research, Psychiatric Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- 35 *Low incidence of cardiac diagnoses in methadone patients: No association with QTc*  
G. Bart<sup>1,2</sup>, S. Lenz<sup>1</sup>, Z. Wyman<sup>2</sup>, B. Bart<sup>1</sup>, <sup>1</sup>Hennepin County Medical Center, Minneapolis, MN, <sup>2</sup>College of Pharmacy, University of Minnesota, Minneapolis, MN
- 36 *Initiating buprenorphine maintenance for opiate-dependent hospitalized patients: A randomized trial*  
J. M. Liebschutz<sup>1</sup>, M. Stein<sup>2</sup>, D. Crooks<sup>1</sup>, D. Herman<sup>2</sup>, B. Anderson<sup>2</sup>, L. Meshesha<sup>1</sup>, S. Dossabhoy<sup>1</sup>, <sup>1</sup>Boston Medical Center, Boston, MA, <sup>2</sup>Butler Hospital, Providence, RI
- 37 *RCT of drug counseling and abstinence contingent buprenorphine in Malaysia*  
R. S. Schottenfeld<sup>1</sup>, M. C. Chawarski<sup>1</sup>, M. Mazlan<sup>2</sup>, <sup>1</sup>Psychiatry, Yale University Medical School, New Haven, CT, <sup>2</sup>Substance Abuse Center Muar, Muar, Malaysia
- 38 *Methadone and suboxone® for subutex® injectors: Primary outcomes of pilot RCT*  
D. Otiashvili<sup>1</sup>, G. Piralishvili<sup>2</sup>, Z. Sikharulidze<sup>3</sup>, G. Kamkamidze<sup>4</sup>, S. Poole<sup>5</sup>, G. E. Woody<sup>5</sup>, <sup>1</sup>Addiction Research Center, Tbilisi, Georgia, <sup>2</sup>Centre for Mental Health and Prevention of Addiction, Tbilisi, Georgia, <sup>3</sup>Centre for Medical, Socio-economic and Cultural Issues Uranti, Tbilisi, Georgia, <sup>4</sup>Maternal and Child Care Union, Tbilisi, Georgia, <sup>5</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA
- 39 *Indicators of treatment success: Comparing urine drug screening outcomes with quality of life for buprenorphine patients*  
S. G. Mitchell<sup>1</sup>, J. Gryczynski<sup>1</sup>, C. P. Myers<sup>2</sup>, K. E. O'Grady<sup>3</sup>, R. P. Schwartz<sup>1</sup>, Y. K. Olsen<sup>4</sup>, J. H. Jaffe<sup>1,5</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Patrick Myers & Assoc, Baltimore, MD, <sup>3</sup>Univ. of MD, College Park, MD, <sup>4</sup>IBR REACH, Baltimore, MD, <sup>5</sup>UMD Med School, Baltimore, MD
- 40 *Community-based buprenorphine treatment program in Baltimore City: Reaching an underserved population*  
M. Fingerhood<sup>1</sup>, P. M. Mauro<sup>2</sup>, D. Agus<sup>3,2</sup>, A. A. Chaudhry<sup>1</sup>, <sup>1</sup>Johns Hopkins Medical Institutions, Baltimore, MD, <sup>2</sup>Dept. of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>3</sup>Behavioral Health Leadership Institute, Baltimore, MD
- 41 *Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone vs. buprenorphine*  
T. Huynh, A. Bisaga, K. Mishlen, E. Nunes, M. Sullivan, Psychiatry, Columbia University/ New York State Psychiatric Institute, New York, NY
- 42 *Buprenorphine-naloxone induction-dosing predicts treatment outcome*  
S. M. Apelt, Certum Consulting - Scientific Research, Oberbergkirchen, Germany



- 43 *Open-label 24-month study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence*  
D. Gastfriend<sup>1</sup>, P. Earley, MD<sup>2</sup>, B. Silverman, MD<sup>1</sup>, A. Memisoglu<sup>1</sup>, <sup>1</sup>Alkermes, Inc., Waltham, MA, <sup>2</sup>Earley Consultancy LLP, Smyrna, GA
- 44 *Injectable extended-release naltrexone (XR-NTX) for preventing relapse to opioid dependence: Findings from differing cultures, populations & settings*  
E. Krupitsky<sup>1,2</sup>, J. Zummo<sup>3</sup>, D. Gastfriend<sup>3</sup>, <sup>1</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation, <sup>2</sup>Pavlov State Medical University, St. Petersburg, Russian Federation, <sup>3</sup>Alkermes, Inc., Waltham, MA
- 45 *The injection of buprenorphine-naloxone film among people who inject drugs: Findings from the Australian post-marketing surveillance studies, 2012*  
B. Larance<sup>1</sup>, L. Degenhardt<sup>1</sup>, R. Mattick<sup>1</sup>, R. Ali<sup>4</sup>, N. Lintzeris<sup>2,3</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>South Eastern Sydney Local Health District, Sydney, NSW, Australia, <sup>3</sup>University of Sydney, Sydney, NSW, Australia, <sup>4</sup>University of Adelaide, Adelaide, SA, Australia

### NICOTINE II

- 46 *Comparing results from two smoking cessation trials that used participatory research methods*  
P. Sheikhattari<sup>1,2</sup>, F. A. Wagner<sup>1,2</sup>, C. E. Cease<sup>1</sup>, <sup>1</sup>Prevention Sciences Research Center, Morgan State University, Baltimore, MD, <sup>2</sup>School of Community Health and Policy, Morgan State University, Baltimore, MD
- 47 *Statistical models, measurement and nicotine dependence theory*  
B. P. Flaherty, Psychology, University of Washington, Seattle, WA
- 48 *Correlates of lifetime cigarette use and dependence by mid-adulthood in a non-Western (Mauritian) sample*  
M. N. Sargeant, N. Gupta, C. A. Prescott, L. M. Yarnell, A. Raine, P. H. Venables, S. A. Mednick, S. E. Luczak, Psychology, University of Southern California, Los Angeles, CA
- 49 *A cross-lagged analysis of five intrapersonal determinants of smoking abstinence*  
Y. Castro<sup>1</sup>, M. A. Cano<sup>2</sup>, M. S. Businelle<sup>3</sup>, V. Correa-Fernandez<sup>2</sup>, D. W. Wetter<sup>2</sup>, <sup>1</sup>The University of Texas at Austin, Austin, TX, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>3</sup>The University of Texas School of Public Health, Dallas, TX
- 50 *Impact of a 12-Step Facilitation intervention on tobacco smoking outcomes in community treatment programs*  
T. Killeen<sup>1</sup>, J. E. Korte<sup>1</sup>, G. S. Brigham<sup>2</sup>, V. E. Horigian<sup>3</sup>, B. Carlini<sup>4</sup>, D. Donovan<sup>4</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Maryhaven, Columbus, OH, <sup>3</sup>University of Miami Miller School of Medicine, Miami, OH, <sup>4</sup>University of Washington, Seattle, WA
- 51 *Financial incentives for smoking abstinence in patients diagnosed with pulmonary disease*  
S. C. Sigmon, M. E. Patrick, A. C. Meyer, C. Teneback, A. Dixon, Psychiatry, University of Vermont, Burlington, VT
- 52 *Investigating group contingencies to promote brief abstinence from cigarette smoking*  
S. Meredith<sup>1</sup>, J. Dallery<sup>2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Psychology, University of Florida, Gainesville, FL
- 53 *Make your own cigarette smoking: Toxicant exposure and behavioral changes*  
W. Pickworth, L. Canlas, Z. Rosenberry, J. L. Potts, Battelle, CAPH, Baltimore, MD

- 54 *Impact of a complete smoking ban in a Detoxification Unit: 6-months evaluation study*  
F. Fonseca<sup>1,2</sup>, E. Francisco<sup>3</sup>, P. Rossi<sup>1,2</sup>, J. L. Pérez de Heredia<sup>1,2</sup>, S. Jornale<sup>1,2</sup>, R. Romar<sup>1,2</sup>,  
M. Farre<sup>2,4</sup>, M. Torrens<sup>1,2,4</sup>, <sup>1</sup>Institut de Neuropsiquiatria i Addiccions (INAD), Hospital del  
Mar, Barcelona, Spain, <sup>2</sup>IMIM (Institut Hospital del Mar d'Investigacions Mèdiques),  
Barcelona, Spain, <sup>3</sup>Parc Sanitari Sant Joan de Deu, Sant Boi del Llobregat, Spain, <sup>4</sup>Psychiatry  
and Pharmacology Departments, Autonomous University of Barcelona, Barcelona, Spain
- 55 *Smoking-related psychopathology across cultures*  
M. Lyvers, C. Carlopio, M. Edwards, Psychology, Bond University, Gold Coast, QLD,  
Australia

### SEX DIFFERENCES

- 56 *Nicotine, HPA axis hormones and mood states in women*  
N. Goletiani<sup>1</sup>, A. Siegel<sup>2</sup>, J. Hudson<sup>3,1</sup>, <sup>1</sup>MIC, McLean Hospital, Belmont, MA, <sup>2</sup>Internal  
Medicine, McLean Hospital, Belmont, MA, <sup>3</sup>Psychiatry, McLean Hospital, Belmont, MA
- 57 *Childhood stressors differentially affect age of first use and telescoping across women and men*  
L. Oberleitner, A. H. Weinberger, C. M. Mazure, S. A. McKee, Psychiatry, Yale University  
School of Medicine, New Haven, CT
- 58 *Gender, problem-gambling severity, and the incidence of substance use disorders*  
C. E. Pilver, D. J. Libby, R. A. Hoff, M. N. Potenza, Yale School of Medicine, New Haven, CT
- 59 *The influence of age and gender on the likelihood of endorsing cannabis use disorder criteria*  
M. Delforterie<sup>1,2</sup>, H. Creemers<sup>1,2</sup>, A. Agrawal<sup>3</sup>, M. Lynskey<sup>3</sup>, A. Huizink<sup>2</sup>, <sup>1</sup>Child Development  
and Education, University of Amsterdam, Amsterdam, Netherlands, <sup>2</sup>Developmental  
Psychology and the EMGO institute for Health and Care Research, VU University,  
Amsterdam, Netherlands, <sup>3</sup>Psychiatry, Washington University School of Medicine, St.  
Louis, MO
- 60 *Alcohol, moods, and male-female differences: A six-month daily process study using interactive  
voice response*  
V. Harder, L. Ayer, G. Rose, M. Naylor, J. Helzer, Psychiatry, University of Vermont,  
Burlington, VT
- 61 *Sex modulates approach systems and impulsivity in substance dependence*  
R. I. Perry<sup>1</sup>, T. D. Krmpotich<sup>1</sup>, L. L. Thompson<sup>1</sup>, S. K. Mikulich-Gilbertson<sup>1</sup>, M. T. Banich<sup>2,1</sup>,  
J. Tanabe<sup>1</sup>, <sup>1</sup>University of Colorado Denver, Aurora, CO, <sup>2</sup>University of Colorado Boulder,  
Boulder, CO
- 62 *Contraception continuation among female exotic dancers seeking mobile reproductive health  
services concurrent with syringe exchange*  
C. E. Martin<sup>1</sup>, M. Terplan<sup>2</sup>, J. Han<sup>3</sup>, P. Chaulk<sup>4</sup>, C. Serio-Chapman<sup>3</sup>, <sup>1</sup>Johns Hopkins Schools of  
Medicine and Public Health, Baltimore, MD, <sup>2</sup>Departments of Obstetrics, Gynecology, and  
Reproductive Sciences & Epidemiology and Public Health, University of Maryland School of  
Medicine, Baltimore, MD, <sup>3</sup>Community Risk Reduction Services, Baltimore City Health  
Department, Baltimore, MD, <sup>4</sup>Bureau of HIV/STD Services, Baltimore City Health  
Department, Baltimore, MD
- 63 *Exploring gender differences among people who inject drugs in Australia: Findings from the  
2012 Illicit Drug Reporting System*  
J. Stafford, L. Burns, National Drug and Alcohol Research Centre, Sydney, NSW, Australia

- 64 *Gender differences in sexual abuse history and HIV prevention outcomes among treatment-seeking substance abusers*  
L. Skalski<sup>1</sup>, N. Gottfredson<sup>1</sup>, D. A. Calsyn<sup>2</sup>, A. Campbell<sup>3</sup>, M. Hatch-Maillette<sup>2</sup>, S. Tross<sup>3</sup>, C. S. Meade<sup>1</sup>, <sup>1</sup>Duke University, Durham, NC, <sup>2</sup>Alcohol & Drug Abuse Institute, University of Washington, Seattle, WA, <sup>3</sup>Psychiatry, Columbia University, New York, NY
- 65 *Gender differences in HIV risk and mental health among methamphetamine users*  
K. F. Corsi, C. Garver-Apgar, R. E. Booth, Psychiatry, University of Colorado Denver, Denver, CO

### FEEDING AND BODY WEIGHT

- 66 *Sugar dependence: Association with psychiatric disorders, gender and obesity*  
M. C. Rosa<sup>1</sup>, C. M. Gomes<sup>2</sup>, F. Kessler<sup>1</sup>, E. F. Ferreira<sup>2</sup>, F. Pechansky<sup>1</sup>, <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Federal University of Minas Gerais, Belo Horizonte, Brazil
- 67 *Delay discounting by monkeys in a drug vs. non-drug choice paradigm*  
S. L. Huskinson<sup>1</sup>, K. B. Freeman<sup>1</sup>, J. Myerson<sup>2</sup>, L. Green<sup>2</sup>, W. Woolverton<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Washington University, St. Louis, MO
- 68 *Blockade of N-methyl-D-aspartate receptors in the nucleus accumbens shell increased nicotine self-administration but had no effect on nicotine-induced conditioned taste aversion*  
M. S. DSouza, A. Markou, Psychiatry, University of California San Diego, La Jolla, CA
- 69 *A novel 5HT2 modulator as a potential antipsychotic medication*  
D. Morgan<sup>1</sup>, K. Kondabolu<sup>1</sup>, C. Ajufu<sup>1</sup>, P. Orza<sup>1</sup>, J. Nwokolo<sup>1</sup>, R. Sakhuja<sup>1</sup>, K. Robertson<sup>1</sup>, D. Felsing<sup>1</sup>, C. Canal<sup>2</sup>, N. Rowland<sup>1</sup>, R. Booth<sup>2,1</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>Northeastern University, Boston, MA
- 70 *Insulin, dopamine D2 receptors, and monetary reward discounting: A common pathway for food and drug addiction*  
D. M. Gredysa, S. Eisenstein, J. Antenor-Dorsey, A. Arbelaez, J. Koller, K. Black, S. Klein, J. Perlmutter, S. Moerlein, A. Agrawal, T. Hershey, Washington University School of Medicine, St. Louis, MO
- 71 *Effects of gender and weight on errors of omission during an inattention task*  
S. Fields, K. Lange, M. S. Sferra, S. Thamotharan, A. Herrick, Texas A&M University, College Station, TX
- 72 *The effects of the interaction between body weight and depression on adolescent and emerging adult alcohol use*  
M. S. Sferra, A. Herrick, K. Lange, S. Thamotharan, S. Fields, Psychology, Texas A&M University, College Station, TX
- 73 *Body mass index (BMI) and obesity prevalence among substance abuse participants from NIDA's Clinical Trials Network*  
A. Matthews<sup>1</sup>, L. Hu<sup>1</sup>, L. Lu<sup>1</sup>, P. VanVeldhuisen<sup>1</sup>, B. Tai<sup>2</sup>, N. Volkow<sup>2</sup>, <sup>1</sup>The EMMES Corporation, Rockville, MD, <sup>2</sup>National Institute on Drug Abuse, Bethesda, MD
- 74 *Eating high fat chow increases sensitivity of female rats to indirect-acting but not direct-acting dopamine receptor agonists*  
K. M. Serafine<sup>1</sup>, T. A. Bentley<sup>1</sup>, A. E. Grenier<sup>1</sup>, C. P. France<sup>1,2</sup>, <sup>1</sup>Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, <sup>2</sup>Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX

### STIMULANTS II—HUMAN STUDIES

- 75 *Executive functioning deficits in cocaine-dependent individuals*  
L. Moody<sup>1</sup>, C. Franck<sup>2,1</sup>, D. P. Jarmolowicz<sup>3,2</sup>, E. T. Mueller<sup>1</sup>, A. Carter<sup>1</sup>, K. Gatchalian<sup>1</sup>, M. N. Koffarnus<sup>1</sup>, W. Bickel<sup>1</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Virginia Tech, Blacksburg, VA, <sup>3</sup>University of Kansas, Lawrence, KS
- 76 *State versus trait: Evaluating the stability of neurocognitive functioning over time in cocaine-dependent participants*  
J. J. Mahoney<sup>1,2</sup>, A. D. Kalechstein<sup>1,2</sup>, T. F. Newton<sup>1,2</sup>, S. Meyer<sup>1,2</sup>, C. Verrico<sup>1,2</sup>, R. Bennett<sup>1,2</sup>, L. Chang<sup>1,2</sup>, R. De La Garza, II<sup>1,2</sup>, <sup>1</sup>Psychiatry, BCM, Houston, TX, <sup>2</sup>Psychiatry, MEDVAMC, Houston, TX
- 77 *Development and testing of a Web-enabled cognitive/neuropsychological evaluation system for substance abusers*  
J. Mendelson<sup>1</sup>, O. Clavier<sup>2</sup>, R. Pal<sup>1</sup>, B. Kline-Shroder<sup>2</sup>, M. Baggott<sup>1</sup>, J. Coyle<sup>1</sup>, G. Galloway<sup>1</sup>, <sup>1</sup>Addiction and Pharmacology Research, California Pacific Medical Center, San Francisco, CA, <sup>2</sup>Creare, Inc, Hanover, NH
- 78 *The neuropsychological assessment battery (S-NAB) in cocaine-dependent patients*  
E. Aharonovich<sup>1,2</sup>, E. V. Nunes<sup>1,2</sup>, D. Cannizzaro<sup>2</sup>, M. Stohl<sup>2</sup>, D. S. Hasin<sup>1,2</sup>, <sup>1</sup>Psychiatry, Columbia University, New York, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY
- 79 *Eye-tracking measures of attentional bias in cocaine-dependent subjects*  
N. Dias, J. Schmitz, N. Rathnayaka, F. G. Moeller, S. D. Lane, The University of Texas Health Science Center, Houston, TX
- 80 *Choice to view cocaine images predicts concurrent and prospective drug use in cocaine addiction*  
S. J. Moeller<sup>1</sup>, N. Beebe-Wang<sup>1</sup>, P. A. Woicik<sup>1</sup>, A. B. Konova<sup>1,2</sup>, T. Maloney<sup>1</sup>, R. Z. Goldstein<sup>1</sup>, <sup>1</sup>Brookhaven National Laboratory, Upton, NY, <sup>2</sup>Stony Brook University, Stony Brook, NY
- 81 *Gaze time as a sensitive measure of cocaine-related attentional bias*  
K. R. Marks<sup>1</sup>, W. W. Stoops<sup>1,2</sup>, E. Pike<sup>1</sup>, W. Roberts<sup>1</sup>, M. T. Fillmore<sup>1,2,3</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Psychology, University of Kentucky, Lexington, KY, <sup>2</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY
- 82 *Are personality disorders or ADHD linked to cocaine-induced psychosis in cocaine-dependent patients?*  
C. Roncero<sup>1,2,3</sup>, C. Daigre<sup>1,2</sup>, L. Grau-López<sup>1,2</sup>, N. Martínez-Luna<sup>1,2</sup>, L. Rodríguez-Cintas<sup>1,2</sup>, L. Miquel<sup>1,2</sup>, C. Barral<sup>1,2</sup>, D. Bachiller<sup>1,2</sup>, O. Esculies<sup>4</sup>, A. Egido<sup>2</sup>, N. Voltes<sup>2</sup>, J. Pérez-Pazos<sup>1</sup>, J. Alvarós<sup>2</sup>, B. Gonzalvo<sup>1</sup>, M. Casas<sup>1,3</sup>, <sup>1</sup>Psychiatry, Hospital Vall Hebron, CIBERSAM, Barcelona, Spain, <sup>2</sup>Outpatient Drug Clinic Vall Hebron, Hospital Vall Hebron-ASPB, Barcelona, Spain, <sup>3</sup>Psychiatry, Universidad Autònoma de Barcelona, Barcelona, Spain, <sup>4</sup>Mental Health, Proyecto Hombre, Barcelona, Spain
- 83 *The association of impulsivity and distress tolerance with PTSD symptom severity: A test among trauma-exposed, cocaine-dependent adults*  
N. Rathnayaka, S. Ahmed, C. Green, J. Schmitz, A. Vujanovik, Psychiatry and Behavioral Sciences, University of Texas, Houston, TX
- 84 *Sleep and clinical outcomes in the placebo arm of a randomized clinical trial of modafinil treatment for cocaine dependence*  
G. A. Angarita<sup>1,2</sup>, S. V. Canavan<sup>1,2</sup>, E. Forselius<sup>1,2</sup>, A. Bessette<sup>1,2</sup>, B. Pittman<sup>1</sup>, P. Morgan<sup>1,2</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Clinical Neuroscience Research Unit of the Connecticut Mental Health Center, New Haven, CT

- 85 *Paradoxical normalization of risk-taking by modafinil in chronic cocaine users*  
S. V. Canavan, E. L. Forselius, A. Bessette, P. Morgan, Psychiatry, Yale University, New Haven, CT
- 86 *Challenges to recruitment of cocaine-using women for a medication development trial*  
D. Metzger, C. P. O'Brien, C. Dackis, G. E. Woody, S. Chhatre, University of Pennsylvania, Philadelphia, PA
- 87 *Mediators of response to sertraline vs. placebo among recently abstinent, cocaine-dependent patients*  
A. Oliveto<sup>1</sup>, J. Thostenson<sup>1</sup>, T. R. Kosten<sup>2</sup>, M. Mancino<sup>1</sup>, <sup>1</sup>UAMS, Little Rock, AR, <sup>2</sup>Baylor College of Medicine, Houston, TX
- 88 *Induction onto extended-release naltrexone in 302 cocaine-dependent opioid users*  
R. Lindblad<sup>1</sup>, J. McCormack<sup>1</sup>, A. Saxon<sup>2,3</sup>, M. P. Hillhouse<sup>4</sup>, C. Thomas<sup>4</sup>, A. Hasson<sup>4</sup>, L. Mooney<sup>4</sup>, P. VanVeldhuisen<sup>1</sup>, W. Ling<sup>4</sup>, <sup>1</sup>The EMMES Corporation, Rockville, MD, <sup>2</sup>VA Puget Sound HCS, Seattle, WA, <sup>3</sup>University of Washington, Seattle, WA, <sup>4</sup>UCLA ISAP, Los Angeles, CA
- 89 *Success in cocaine treatment trials: Which drug use outcome is most associated with clinical improvement?*  
K. M. Kampman, A. L. Henninger, L. Rennert, J. Plebani, J. E. Vernace, H. Pettinati, Psychiatry, Perelman School of Medicine, Philadelphia, PA
- 90 *A randomized clinical trial evaluating the impact of concurrent outpatient smoking-cessation and substance use disorder (SUD) treatment on substance use outcomes*  
T. Winhusen<sup>1</sup>, D. Lewis<sup>1</sup>, G. S. Brigham<sup>1</sup>, G. Sharma<sup>2</sup>, U. Ghitza<sup>3</sup>, <sup>1</sup>University of Cincinnati, Cincinnati, OH, <sup>2</sup>EMMES Corp., Rockville, MD, <sup>3</sup>NIDA, Bethesda, MD
- 91 *Use of a sliding schedule enhances cocaine self-administration in a human laboratory setting: Relevance for relapse prevention*  
K. Grasing, V. Panwar, A. Morani, R. Singh, Substance Abuse Research Laboratory, VA Medical Center, Kansas City, MO
- 92 *Cocaine use reduction with buprenorphine (CURB): Study methods and participant characteristics*  
W. Ling<sup>1</sup>, M. P. Hillhouse<sup>1</sup>, C. Thomas<sup>1</sup>, A. Hasson<sup>1</sup>, J. Annon<sup>1</sup>, L. Mooney<sup>1</sup>, A. Saxon<sup>2</sup>, D. Blumberg<sup>3</sup>, W. Weimer<sup>4</sup>, E. Koosis<sup>10</sup>, G. S. Brigham<sup>5</sup>, G. E. Woody<sup>6</sup>, M. Trivedi<sup>7</sup>, K. Drexler<sup>8</sup>, M. A. Dawes<sup>9</sup>, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>VA Puget Sound Health Care System, University of Washington, Seattle, WA, <sup>3</sup>The EMMES Corporation, Rockville, MD, <sup>4</sup>CODA, Inc., Portland, OR, <sup>5</sup>Maryhaven, Columbus, OH, <sup>6</sup>Treatment Research Institute, University of Pennsylvania, Philadelphia, PA, <sup>7</sup>University of Texas Southwestern Medical Center, Dallas, TX, <sup>8</sup>Atlanta VA Medical Center, Atlanta, GA, <sup>9</sup>University of Texas Health Science Center, San Antonio, TX, <sup>10</sup>BAART, San Francisco, CA
- 93 *Growth mixture modeling of stimulant use treatment effects and differential trajectories: Evidence from two contingency management clinical trials*  
S. McPherson<sup>1</sup>, C. Barbosa-Leiker<sup>1</sup>, M. G. McDonnell<sup>2</sup>, J. M. Roll<sup>1,2</sup>, <sup>1</sup>Program of Excellence in the Addictions, Washington State University College of Nursing, Spokane, WA, <sup>2</sup>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA
- 94 *ASI changes sustained over 12 months in two contingency managed treatments*  
L. Hayes<sup>1</sup>, A. Davidson<sup>1</sup>, J. B. Milby<sup>1</sup>, J. E. Schumacher<sup>1</sup>, D. Wallace<sup>2</sup>, S. Mennemeyer<sup>1</sup>, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>RTI International, Durham, NC



- 95 *A comparison of long-term treatment outcomes for cocaine dependence: Abstinence, homelessness, and employment*  
A. L. Davidson<sup>1</sup>, L. Hayes<sup>1</sup>, J. B. Milby<sup>1</sup>, D. Wallace<sup>2</sup>, J. Schumacher<sup>1</sup>, S. Mennemeyer<sup>1</sup>,  
<sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>RTI International, Durham, NC
- 96 *Time of abstinence prior admission to a residential rehabilitation program as a predictor of cocaine dependence treatment completion in Lima, Peru*  
M. R. Samolski, P. Ruiz-Grosso, K. Zevallos, Facultad de Salud Pública y Administración,  
Universidad Peruana Cayetano Heredia, Lima, Peru

### IMAGING

- 97 *Striatal gating effect and prediction of treatment response in cocaine dependence*  
L. Ma<sup>1</sup>, J. L. Steinberg<sup>1</sup>, S. D. Lane<sup>1</sup>, J. Schmitz<sup>1</sup>, C. Green<sup>1</sup>, P. A. Narayana<sup>2</sup>, L. A. Kramer<sup>2</sup>,  
F. G. Moeller<sup>1</sup>, <sup>1</sup>Department of Psychiatry & Behavioral Sciences, University of Texas Health  
Science Center, Houston, TX, <sup>2</sup>Department of Diagnostic & Interventional Imaging,  
University of Texas Health Science Center, Houston, TX
- 98 *Neural basis of modulating cognitive control in young adults at risk for stimulant dependence: Failure to expect when to stop*  
K. Harle<sup>1</sup>, P. Shenoy<sup>2</sup>, S. Tapert<sup>1,3</sup>, A. Yu<sup>2</sup>, M. P. Paulus<sup>1,3</sup>, <sup>1</sup>Department of Psychiatry, UCSD,  
San Diego, CA, <sup>2</sup>Department of Cognitive Science, UCSD, San Diego, CA, <sup>3</sup>Psychiatry, VA  
San Diego Healthcare System, San Diego, CA
- 99 *Hypoactive BOLD response to general emotional stimuli among cocaine-dependent women*  
M. Canterberry, W. DeVries, K. T. Brady, C. A. Hanlon, Medical University of South Carolina,  
Charleston, SC
- 100 *Resting-state brain networks are related to cocaine use in chronic cocaine smokers*  
S. Ray<sup>1</sup>, S. Gohel<sup>2,4</sup>, M. Haney<sup>3</sup>, B. Biswal<sup>2</sup>, S. J. Hanson<sup>1</sup>, <sup>1</sup>Rutgers University, Piscataway, NJ,  
<sup>2</sup>NJIT, Newark, NJ, <sup>3</sup>Columbia University, New York, NY, <sup>4</sup>UMDNJ-Newark, Newark, NJ
- 101 *Resting-state activity in the left executive control network is associated with behavioral approach and is increased in substance dependence*  
T. D. Krmpotich<sup>1</sup>, J. R. Tregillas<sup>1</sup>, L. L. Thompson<sup>1</sup>, M. T. Banich<sup>2,1</sup>, A. Klenk<sup>1</sup>, J. Tanabe<sup>1</sup>,  
<sup>1</sup>University of Colorado Denver, Aurora, CO, <sup>2</sup>University of Colorado Boulder, Boulder, CO
- 102 *Baclofen, a GABA B agonist, reduces risk-taking and reveals the relationship between brain responses to drug cues and risk-taking in cocaine-addicted patients*  
K. A. Young<sup>1</sup>, Y. Li<sup>1</sup>, D. C. S. Roberts<sup>2</sup>, C. Lejuez<sup>3</sup>, T. R. Franklin<sup>1</sup>, J. Suh<sup>1</sup>, M. Goldman<sup>1</sup>,  
K. M. Kampman<sup>1</sup>, R. R. Wetherill<sup>1</sup>, C. P. O'Brien<sup>1</sup>, A. Childress<sup>1</sup>, <sup>1</sup>University of Pennsylvania,  
Philadelphia, PA, <sup>2</sup>Wake Forest, Winston, NC, <sup>3</sup>U of Maryland, College Park, MD
- 103 *Altered processing of risk-taking in the insula predicts relapse in recently abstinent methamphetamine-dependent individuals*  
J. Gowin<sup>1</sup>, S. Tapert<sup>1,2</sup>, M. Paulus<sup>1,3</sup>, <sup>1</sup>Psychiatry, UCSD, La Jolla, CA, <sup>2</sup>Psychology Service,  
VA San Diego Healthcare System, La Jolla, CA, <sup>3</sup>Psychiatry, VA San Diego Healthcare  
System, La Jolla, CA
- 104 *Recently abstinent methamphetamine users show increased recruitment of prefrontal cortex during valuation: An fMRI study*  
J. Parnass, S. Mackey, A. C. May, M. Paulus, University of California San Diego, San  
Diego, CA



- 105 *Diffusion tensor imaging of major white matter tracts in active and recently abstinent methamphetamine users*  
J. C. Lin<sup>1,2</sup>, R. K. Jan<sup>1,2</sup>, T. A. Woudes<sup>3</sup>, R. R. Kydd<sup>2,3</sup>, B. R. Russell<sup>1,2</sup>, <sup>1</sup>School of Pharmacy, University of Auckland, Auckland, New Zealand, <sup>2</sup>Centre for Brain Research, University of Auckland, Auckland, New Zealand, <sup>3</sup>Department of Psychological Medicine, University of Auckland, Auckland, New Zealand
- 106 *Medial prefrontal cortex gray matter volume is associated with lifetime substance use severity in abstinent addiction treatment patients*  
M. L. Copersino<sup>1,2</sup>, B. D. Frederick<sup>1,2</sup>, A. Janes<sup>1,2</sup>, K. H. Frost<sup>1</sup>, W. M. Hurley-Dorof<sup>1</sup>, J. Faberman<sup>1,2</sup>, R. Weiss<sup>1,2</sup>, S. E. Lukas<sup>1,2</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Harvard Medical School, Boston, MA
- 107 *Neural correlates of cross-commodity discounting in cocaine users and controls*  
W. K. Bickel, M. J. Wesley, J. Shin, M. N. Koffarnus, T. Lohrenz, P. R. Montague, Virginia Tech Carilion Research Institute, Roanoke, VA
- 108 *Monetary delay discounting in a behavioral addiction sample: An fMRI pilot study*  
D. M. Ledgerwood<sup>1</sup>, B. Knezevic<sup>2</sup>, R. White<sup>1</sup>, D. Khatib<sup>1</sup>, N. M. Petry<sup>3</sup>, V. A. Diwadkar<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Neurosciences, Wayne State School of Medicine, Detroit, MI, <sup>2</sup>Psychology, University of Windsor, Windsor, ON, Canada, <sup>3</sup>Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, MI
- 109 *Neural tracking of prediction error (PE) is reduced in substance-dependent individuals*  
J. Tanabe<sup>1</sup>, J. Reynolds<sup>3</sup>, T. Krmpotich<sup>1</sup>, E. Claus<sup>4</sup>, L. Thompson<sup>1</sup>, Y. Du<sup>1</sup>, M. Banich<sup>2</sup>, <sup>1</sup>University of Colorado Denver School of Medicine, Denver, CO, <sup>2</sup>University of Colorado Boulder, Boulder, CO, <sup>3</sup>University of Denver, Denver, CO, <sup>4</sup>The Mind Research Network, Albuquerque, NM
- 110 *The effect of methylphenidate (MPH) on cognitive control in active methamphetamine (MA) dependence using functional magnetic resonance imaging (fMRI)*  
R. K. Jan<sup>1,2</sup>, J. C. Lin<sup>1,2</sup>, N. A. McNair<sup>2</sup>, I. J. Kirk<sup>2</sup>, D. G. McLaren<sup>3,4</sup>, R. R. Kydd<sup>2</sup>, B. R. Russell<sup>1,2</sup>, <sup>1</sup>School of Pharmacy, University of Auckland, Auckland, New Zealand, <sup>2</sup>Centre for Brain Research, University of Auckland, Auckland, New Zealand, <sup>3</sup>Athinoula A. Martinos Center for Biomedical Imaging, MGH, Boston, MA, <sup>4</sup>Harvard Medical School, Boston, MA
- 111 *MDMA use is associated with lower gray matter volume in widespread cortical regions*  
A. J. Dornan, T. J. Watkins, M. S. Dietrich, M. M. Benningfield, J. U. Blackford, R. M. Salomon, R. L. Cowan, Vanderbilt University, Nashville, TN
- 112 *Evaluated iron in the globus pallidus of methamphetamine users: MRI susceptibility imaging*  
W. Deng, L. Chang, V. Stenger, Medicine, University of Hawaii JABSOM, Honolulu, HI
- 113 *The effect of tobacco use on brain phosphocreatine levels in female methamphetamine users*  
Y. Sung<sup>1</sup>, D. Yurgelun-Todd<sup>1,2,3</sup>, D. Kondo<sup>1,2</sup>, X. Shi<sup>1</sup>, K. Lundberg<sup>1</sup>, T. Hellem<sup>1</sup>, R. Huber<sup>1</sup>, E. McGlade<sup>1,2</sup>, E. Jeong<sup>1</sup>, P. Renshaw<sup>1,2,3</sup>, <sup>1</sup>University of Utah, SLC, UT, <sup>2</sup>VISN 19 MIRECC, SLC, UT, <sup>3</sup>USTAR, SLC, UT
- 114 *Lower GABA levels in the dorsal anterior cingulate cortex impair ability to ignore smoking-related cues in tobacco-dependent volunteers*  
A. Janes, J. E. Jensen, S. Farmer, B. Frederick, D. Pizzagalli, S. E. Lukas, McLean Hospital/Harvard Medical School, Belmont, MA
- 115 *Sex differences in functional connectivity during smoking cue exposure*  
T. R. Franklin, R. Wetherill, K. Jagannathan, J. Shin, C. P. O'Brien, A. R. Childress, Psychiatry, University of Pennsylvania, Phila, PA

- 116 *Binge alcohol consumption in emerging adults: Altered anterior cingulate cortical thickness is associated with alcohol use consequences*  
Y. Mashhoon<sup>1,3,4</sup>, C. Czerkawski<sup>2</sup>, D. J. Crowley<sup>1,2,4</sup>, J. E. Cohen-Gilbert<sup>1,2,4</sup>, J. T. Sneider<sup>1,2,4</sup>, M. M. Silveri<sup>1,2,4</sup>, <sup>1</sup>McLean Imaging Center, McLean Hospital/HMS, Belmont, MA, <sup>2</sup>Neurodevelopmental Lab, McLean Hospital/HMS, Belmont, MA, <sup>3</sup>Behavioral Psychopharmacology Research Lab, McLean Hospital/HMS, Belmont, MA, <sup>4</sup>Psychiatry, Harvard Medical School, Boston, MA
- 117 *Neural markers for recovery in cannabis withdrawal*  
D. J. Allsop, D. Alperstein, J. Copeland, NCPIC, UNSW, Sydney, NSW, Australia

### CANNABINOIDS

- 118 *Behavioral effects of synthetic cannabinoids marketed as "Spice"*  
M. B. Gatch, M. Forster, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX
- 119 *Separate and combined effects of gabapentin and  $\Delta^9$ -THC doses in cannabis users discriminating  $\Delta^9$ -THC*  
J. A. Lile, T. Kelly, L. Hays, University of Kentucky, Lexington, KY
- 120 *Preclinical investigation of the abused synthetic cannabinoid CP47,497*  
K. L. Samano<sup>1</sup>, A. Poklis<sup>2</sup>, A. H. Lichtman<sup>1</sup>, <sup>1</sup>Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Pathology, Virginia Commonwealth University, Richmond, VA
- 121 *Dose-dependent physiological and subjective effects of marijuana in daily marijuana smokers*  
D. Ramesh, M. Haney, Z. D. Cooper, Psychiatry, College of Physicians and Surgeons of Columbia University and New York State Psychiatric Institute, New York, NY
- 122 *Effect of dronabinol (oral THC) maintenance on cannabis self-administration*  
R. Vandrey, M. L. Stitzer, Johns Hopkins University, Baltimore, MD
- 123 *Citicoline alters impulsivity in marijuana smokers*  
S. A. Gruber<sup>1</sup>, K. Sagar<sup>1</sup>, M. Dahlgren<sup>1</sup>, D. Penetar<sup>2</sup>, S. E. Lukas<sup>2</sup>, N. E. Conn<sup>2</sup>, <sup>1</sup>CCNC, McLean Hospital, Belmont, MA, <sup>2</sup>BPRL, McLean Hospital, Belmont, MA
- 124 *The impact of Sativex® on cognitive function during treatment for cannabis withdrawal*  
R. Bruno<sup>1</sup>, D. J. Allsop<sup>2</sup>, J. Copeland<sup>3</sup>, N. Lintzeris<sup>3,4</sup>, I. McGregor<sup>3</sup>, M. Norberg<sup>2</sup>, A. Dunlop<sup>4</sup>, M. Montebello<sup>4</sup>, C. Sadler<sup>4</sup>, R. Holland<sup>4</sup>, G. Rivas<sup>4</sup>, <sup>1</sup>University of Tasmania, Hobart, TAS, Australia, <sup>2</sup>National Cannabis Prevention and Information Centre, University of New South Wales, Sydney, NSW, Australia, <sup>3</sup>University of Sydney, Sydney, NSW, Australia, <sup>4</sup>New South Wales Health, Sydney, NSW, Australia
- 125 *Differences in cannabis withdrawal symptoms between individuals with and without attention deficit hyperactivity disorder*  
K. Hartwell<sup>1,2</sup>, E. Chauchard<sup>3,4</sup>, D. A. Gorelick<sup>3</sup>, A. McRae-Clark<sup>1</sup>, <sup>1</sup>Dept of Psychiatry, MUSC, Charleston, SC, <sup>2</sup>Ralph H. Johnson VAMC, Charleston, SC, <sup>3</sup>Intramural Research Program, NIDA, Bethesda, MD, <sup>4</sup>Toulouse University Octogone-CERPP, Toulouse, France
- 126 *Marijuana normalizes sleep efficiency in marijuana-dependent volunteers*  
L. H. Lundahl<sup>1</sup>, T. Roehrs<sup>2</sup>, C. L. Steinmiller<sup>1,3</sup>, S. Randall<sup>2</sup>, T. Roth<sup>2</sup>, <sup>1</sup>Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, <sup>2</sup>Henry Ford Hospital, Detroit, MI, <sup>3</sup>University of Toledo, Toledo, OH
- 127 *Sleep quality among cannabis users seeking treatment*  
M. A. Khalil, M. L. Stitzer, R. Vandrey, Johns Hopkins University, Baltimore, MD

- 128 *The impact of sleep disturbance on cannabis quit attempts*  
J. Johnston<sup>1</sup>, N. Lintzeris<sup>1,2</sup>, I. McGregor<sup>1</sup>, D. J. Allsop<sup>3</sup>, D. Bartlett<sup>4</sup>, D. Helliwell<sup>5</sup>, <sup>1</sup>University of Sydney, Sydney, NSW, Australia, <sup>2</sup>South Eastern Sydney Local Health District, Sydney, NSW, Australia, <sup>3</sup>University of NSW, Sydney, NSW, Australia, <sup>4</sup>Woolcock Institute of Medical Research, Sydney, NSW, Australia, <sup>5</sup>Riverlands Drug and Alcohol Centre, Lismore, NSW, Australia
- 129 *Cannabis use motives and frequency of use: Combined and distinct associations with cannabis-use problems*  
M. Hiles<sup>1</sup>, Z. Walsh<sup>1</sup>, K. Crosby<sup>1</sup>, M. T. Swogger<sup>2</sup>, <sup>1</sup>Psychology, University of British Columbia, Kelowna, BC, Canada, <sup>2</sup>Medical Center, University of Rochester, Rochester, NY
- 130 *Development and evaluation of the Marijuana Reduction Strategies Self-efficacy Scale*  
A. K. Davis, J. Leith, L. A. Osborn, H. Rosenberg, E. Bannon, S. Jesse, L. Ashrafioun, A. Hawley, S. Kraus, E. Kryszak, N. Cross, K. Lauritsen, Psychology, BGSU, Bowling Green, OH
- 131 *Development and initial validation of a marijuana cessation expectancy scale*  
J. Metrik, N. S. Spillane, C. W. Kahler, Center for Alcohol and Addiction Studies, Brown University, Providence, RI
- 132 *Predicting adolescent marijuana use: The role of school support and positive marijuana expectancies*  
C. M. Risco, J. W. Felton, L. MacPherson, C. W. Lejuez, Psychology, University of Maryland, College Park, MD
- 133 *Treatment outcomes for MJ dependence among adolescents attending an urban intensive outpatient treatment program*  
A. Estreet, K. Rai, M. Fishman, Adolescent Outpatient Services, Mountain Manor Treatment Center, Baltimore, MD
- 134 *Development of an adolescent marijuana educational presentation: Preliminary findings*  
D. A. Cavallo, G. Kong, S. Krishnan-Sarin, Psychiatry, Yale University, New Haven, CT
- 135 *Evaluation of self-efficacy to use harm reduction strategies among marijuana-using university students*  
L. Ashrafioun, S. W. Kraus, E. Kryszak, N. Cross, A. R. Hawley, A. K. Davis, J. Leith, L. A. Osborn, H. Rosenberg, E. E. Bannon, S. R. Jesse, K. Baik, Psychology, Bowling Green State University, Bowling Green, OH
- 136 *Substance use among medical cannabis users: Substituting cannabis for alcohol and other substances*  
P. Lucas<sup>1</sup>, K. Crosby<sup>2</sup>, M. Hiles<sup>2</sup>, M. T. Swogger<sup>3</sup>, Z. Walsh<sup>2</sup>, <sup>1</sup>Centre for Addiction Research of BC, Victoria, BC, Canada, <sup>2</sup>Psychology, University of British Columbia, Kelowna, BC, Canada, <sup>3</sup>Psychiatry, University of Rochester, Rochester, NY
- 137 *Cannabis and alcohol: Is there a relationship for drivers?*  
J. C. Maxwell, Addiction Research Institute, The University of Texas at Austin, Austin, TX
- 138 *Marijuana as a predictor of concurrent substance use among motor vehicle operators*  
M. Scherer<sup>1</sup>, C. D. Furr-Holden<sup>1</sup>, R. Voas<sup>2</sup>, <sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>Pacific Institute for Research and Evaluation, Calverton, MD
- 139 *The impact of personalized feedback on marijuana use: Examining a brief intervention delivered via the Internet*  
S. Towe<sup>1</sup>, R. S. Stephens<sup>2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Duke University, Durham, NC, <sup>2</sup>Psychology, Virginia Tech, Blacksburg, VA

- 140 *Impact of race and age on treatment completion among adult marijuana users*  
E. N. Peters<sup>1,2</sup>, P. S. Hendricks<sup>3</sup>, C. B. Clark<sup>3</sup>, K. L. Cropsey<sup>3</sup>, F. Vocci<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Yale School of Medicine, New Haven, CT, <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL
- 141 *Moderating effects of race in clinical trial participation and outcomes among marijuana-dependent young adults*  
L. Montgomery<sup>1,4</sup>, N. Petry<sup>2</sup>, K. Carroll<sup>1,3</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>University of Connecticut Health Center, Farmington, CT, <sup>3</sup>VA Connecticut Healthcare System, West Haven, CT, <sup>4</sup>University of Cincinnati, Cincinnati, OH

### Symposium XVI

**INDIGO A**  
**9:30 - 11:35 AM**

#### **BRAIN FUNCTIONAL CONNECTIVITY AS A BIOMARKER FOR STIMULANT ABUSE**

Chairs: Leonard Howell and Anna Rose Childress

- 9:30 *75th Anniversary Reflections*
- 9:35 *Functional brain networks as predictors of cocaine self-administration in nonhuman primates*  
Kevin Murnane, Yerkes National Primate Research Center, Emory University, Atlanta, GA
- 10:00 *What happens to the addicted brain during recovery? Functional connectivity changes during abstinence*  
Kelvin Lim, University of Minnesota, Minneapolis, MN
- 10:25 *Differentiating mesocortical and mesolimbic circuitry in cocaine users through interleaved TMS-BOLD imaging: A 'hybrid' approach to functional connectivity*  
Colleen A. Hanlon, Medical University of South Carolina, Charleston, SC
- 10:50 *Resting-state functional connectivity pathways from dopaminergic regions: Disruption in addiction and effects of methylphenidate*  
Dardo Tomasi, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health and Brookhaven National Laboratory, Upton, NY
- 11:15 *Heightened intra-limbic connectivity during cocaine cues as treatment target: Modulation by candidate medications*  
Anna Rose Childress, University of Pennsylvania School of Medicine, Philadelphia, PA

### Symposium XVII

**(Sponsored by CPDD/APSAD)**

#### **CANNABIS: FROM PLANTS TO RATS, MONKEYS AND HUMANS**

**INDIGO E**  
**9:30 - 11:35 AM**

Chairs: Iain McGregor and Margaret Haney

- 9:30 *75th Anniversary Reflections*
- 9:35 *Cannabis and the cannabinoids: Plants, rats, detox and reintox*  
Iain McGregor, The University of Sydney, Sydney, NSW, Australia
- 10:00 *The impact of regular cannabis use on cognitive functioning, brain volume and connectivity: Implications for understanding the neural basis of psychosis*  
Murat Yucel, The University of Melbourne, Parkville, VIC, Australia

- 10:25 *THC-induced working memory impairments in adolescent rhesus monkeys; translating findings into therapies for cannabis dependence*  
Christopher D. Verrico, Baylor College of Medicine, Houston, TX
- 10:50 *Cannabis: Pharmacotherapies, psychosocial interventions and DSM 5*  
Mark Montebello, Drug and Alcohol Service, South East Sydney Local Health District, Surry Hills, NSW, Australia
- 11:15 *Pharmacological treatment of cannabis dependence*  
Margaret Haney, Columbia University, New York State Psychiatric Institute, New York, NY

### Oral Communications 15

**INDIGO D**  
**9:30 - 11:35 AM**

#### **TEENAGE WASTELAND: ADOLESCENT PRESCRIPTION DRUG ABUSE**

Chairs: Carol J. Boyd and Robert M. Weiler

- 9:30 *75th Anniversary Reflections*
- 9:35 *Changing patterns of onset of nonmedical prescription opioid use relative to other drugs from adolescence to early adulthood*  
G. Biondo<sup>1,2</sup>, H. Chilcoat<sup>1</sup>, <sup>1</sup>Risk Management and Epidemiology, Purdue Pharma, L.P., Stamford, CT, <sup>2</sup>Yale School of Public Health, New Haven, CT
- 9:50 *Adolescent substance use and the identification of subgroups*  
C. J. Boyd<sup>1,2</sup>, S. E. McCabe<sup>2</sup>, J. Cranford<sup>3</sup>, <sup>1</sup>School of Nursing, University of Michigan, Ann Arbor, MI, <sup>2</sup>Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI, <sup>3</sup>Department of Psychiatry, University of Michigan, Ann Arbor, MI
- 10:05 *Nonmedical use of prescription stimulants to help study among U.S. high school seniors*  
S. E. McCabe<sup>1,2</sup>, C. G. DiRaimo<sup>3</sup>, J. P. Grayson<sup>3</sup>, B. T. West<sup>4</sup>, C. J. Teter<sup>3</sup>, <sup>1</sup>Substance Abuse Research Center, University of Michigan, Ann Arbor, MI, <sup>2</sup>Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI, <sup>3</sup>College of Pharmacy, University of New England, Portland, ME, <sup>4</sup>Survey Research Center, Institute for Survey Research, University of Michigan, Ann Arbor, MI
- 10:20 *Medical use, medical misuse, and diversion of opioids among adolescents involved in organized sport*  
P. T. Veliz, C. J. Boyd, S. E. McCabe, E. A. Meier, Q. Epstein-Ngo, P. L. Ross-Durow, Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI
- 10:35 *Motive-specific differences in nonmedical use of prescription pain relievers among adolescents*  
R. M. Weiler<sup>2</sup>, J. D. Haddox<sup>3</sup>, L. N. Pealer<sup>1</sup>, T. E. Barnett<sup>1</sup>, <sup>1</sup>Beh. Sci. & Comm. Hlth., University of Florida, Gainesville, FL, <sup>2</sup>Hlth Educ. & Behav., University of Florida, Gainesville, FL, <sup>3</sup>Hlth Policy, Purdue Pharma L.P., Stamford, CT
- 10:50 *Patterns of prescription and illicit drug use among young adults: The significance of housing status and injection drug use*  
S. Lankenau, A. Kecojovic, Community Health and Prevention, Drexel University, Philadelphia, PA
- 11:05 *Prevalence and correlates of nonmedical prescription opiate and nonmedical prescription sedative use among a group of adolescents and young adults with current drug use in an urban Emergency Department*  
L. K. Whiteside<sup>1</sup>, A. S. Bohnert<sup>2</sup>, M. A. Walton<sup>2</sup>, F. C. Blow<sup>2</sup>, M. Zimmerman<sup>2</sup>, R. M. Cunningham<sup>2,3</sup>, <sup>1</sup>Division of Emergency Medicine, University of Washington, Seattle, WA, <sup>2</sup>Injury Center, University of Michigan, Ann Arbor, MI, <sup>3</sup>Emergency Medicine, Hurley Medical Center, Flint, MI



- 11:20 *Association between nonmedical use of prescription drugs and suicidality among adolescents*  
K. J. Zullig<sup>1</sup>, R. M. Weiler<sup>2</sup>, J. D. Haddox<sup>3</sup>, A. L. Divin<sup>4</sup>, L. N. Pealer<sup>5</sup>, T. E. Barnett<sup>5</sup>, <sup>1</sup>Soc. & Beh. Sci., West Virginia University, Morgantown, WV, <sup>2</sup>Hlth. Educ. & Beh., University of Florida, Gainesville, FL, <sup>3</sup>Hlth. Policy, Purdue Pharma L.P., Stamford, CT, <sup>4</sup>Hlth. Sci., Western Illinois University, Macomb, IL, <sup>5</sup>Beh. Sci. & Comm. Hlth., University of Florida, Gainesville, FL

## Oral Communications 16

**INDIGO H**  
**9:30 - 11:35 AM**

### **THE LOWS OF OPIATE HIGHS: RISKS OF DEPENDENCE AND OVERDOSE**

Chairs: Howard Chilcoat and Alexander Y. Walley

- 9:30 *75th Anniversary Reflections*
- 9:35 *Nasal naloxone rescue kits in an emergency department overdose education program*  
A. Y. Walley, A. Sorensen-Alawad, K. Dwyer, B. Langlois, P. Mitchell, S. Lin, J. Cromwell, S. Strobel, E. Bernstein, Boston University School of Medicine/ Boston Medical Center, Boston, MA
- 9:50 *Trends in overdose deaths after release from state prison, 1999-2009*  
I. A. Binswanger<sup>1</sup>, P. J. Blatchford<sup>1</sup>, T. E. Yamashita<sup>1</sup>, S. Mueller<sup>1</sup>, M. F. Stern<sup>2</sup>, <sup>1</sup>University of Colorado School of Medicine, Aurora, CO, <sup>2</sup>University of Washington, Seattle, WA
- 10:05 *Feasibility of prison-based overdose prevention education and prescribed naloxone at release*  
T. C. Green<sup>1,3</sup>, S. Bowman<sup>1</sup>, M. Ray<sup>1</sup>, M. McKenzie<sup>2,3</sup>, J. Rich<sup>2,3</sup>, <sup>1</sup>Rhode Island Hospital, Providence, RI, <sup>2</sup>The Miriam Hospital, Providence, RI, <sup>3</sup>Center for Prisoner Health and Human Rights, Providence, RI
- 10:20 *Extended-release naltrexone opioid treatment at release from jail*  
J. D. Lee<sup>1</sup>, D. Selling<sup>2</sup>, R. McDonald<sup>1</sup>, N. Santana-Correa<sup>1</sup>, E. Grossman<sup>1</sup>, J. Rotrosen<sup>3</sup>, M. N. Gourevitch<sup>1</sup>, <sup>1</sup>Population Health, NYU, New York, NY, <sup>2</sup>NYC Department of Health and Mental Hygiene, New York, NY, <sup>3</sup>Psychiatry, NYU, New York, NY
- 10:35 *Which comes first, prescription opiate medications or heroin?*  
A. Kral<sup>1</sup>, S. P. Novak<sup>1</sup>, L. Wenger<sup>1</sup>, D. Chu<sup>2</sup>, M. Y. Iguchi<sup>3</sup>, R. Bluthenthal<sup>2</sup>, <sup>1</sup>RTI International, San Francisco, CA, <sup>2</sup>University of Southern California, Los Angeles, CA, <sup>3</sup>Georgetown University, Washington, DC
- 10:50 *Prescription opioid use and risk of cardiovascular disease among older adults from a community sample*  
Y. Khodneva, P. Muntner, S. Kertesz, M. M. Safford, University of Alabama Birmingham, Birmingham, AL
- 11:05 *Changes in prescriptions of OxyContin and OPANA after introduction of tamper-resistant formulations among potentially problematic and comparator prescribers*  
H. Chilcoat, R. Abrams, S. Natarajan, P. Coplan, Purdue Pharma, L.P., Stamford, CT
- 11:20 *Current thinking on the premarketing evaluation of abuse-deterrent opioid formulations*  
S. N. Calderon, J. M. Tolliver, M. Klein, Controlled Substance Staff, Food and Drug Administration, Silver Spring, MD

**Brunch with Champions  
(PRE-REGISTRANTS ONLY)**

**AQUA 310  
11:45 - 1:00 PM**

**Oral Communications 17**

**INDIGO A  
1:00 - 3:05 PM**

**POLYDRUG ABUSE: INCIDENCE AND CONSEQUENCE**

Chairs: Jermaine D. Jones and Margaret Haney

- 1:00 *75th Anniversary Reflections*
- 1:05 *An objective study of concomitant drug use among heroin and prescription opioid abusers*  
J. D. Jones, S. D. Comer, Division on Substance Abuse, Columbia University, College of Physicians and Surgeons, New York, NY
- 1:20 *Non-opioid substance use among opioid-dependent patients enrolling in opioid treatment programs: A latent class analysis*  
A. Rosenblum<sup>1</sup>, C. Fong<sup>1</sup>, C. Cleland<sup>2</sup>, <sup>1</sup>ITSR, NDRI, New York, NY, <sup>2</sup>College of Nursing, NYU, New York, NY
- 1:35 *Pathways of progression from one substance use to another in treatment seekers*  
S. Sarkar<sup>1</sup>, N. Nebhinani<sup>2</sup>, S. Gupta<sup>1</sup>, P. Parakh<sup>1</sup>, D. Basu<sup>1</sup>, <sup>1</sup>Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India, <sup>2</sup>Department of Psychiatry, Pt. Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
- 1:50 *Behavioral and physiological effects of cocaine smoked with marijuana*  
Z. D. Cooper, R. W. Foltin, M. Haney, Psychiatry, 1NYSPI and Columbia University, New York, NY
- 2:05 *Differences in illicit drug use among medical, illicit, and non-users of marijuana*  
H. Newville<sup>1</sup>, C. E. Grella<sup>2</sup>, J. L. Sorensen<sup>1</sup>, <sup>1</sup>University of California, San Francisco, San Francisco, CA, <sup>2</sup>University of California, Los Angeles, Los Angeles, CA
- 2:20 *Use of synthetic drugs among people who inject drugs in San Diego, CA*  
K. D. Wagner, J. Cuevas-Mota, R. F. Armenta, S. Strathdee, R. S. Garfein, University of California San Diego, San Diego, CA
- 2:35 *The relationships between smoking abstinence-related expectancies and illicit substance use*  
P. S. Hendricks<sup>1</sup>, E. N. Peters<sup>2</sup>, S. M. Hall<sup>3</sup>, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Friends Research Institute, Baltimore, MD, <sup>3</sup>University of California, San Francisco, San Francisco, CA
- 2:50 *Polydrug use among emergency department patients receiving SBIRT services*  
J. Akin<sup>1</sup>, N. Tarantino<sup>1</sup>, J. A. Johnson<sup>2</sup>, G. Kuperminc<sup>1</sup>, <sup>1</sup>Department of Psychology, Georgia State University, Atlanta, GA, <sup>2</sup>Mercer University School of Medicine, Macon, GA

## Oral Communications 18

INDIGO E  
1:00 - 3:05 PM

### GLOBAL CURRENCIES: SEX, DRUGS, AND MONEY

Chairs: Steven Shoptaw and Kathleen T. Brady

- 1:00 *75th Anniversary Reflections*
- 1:05 *Transactional sex among an emergency department sample: Exploring gender, substance abuse and HIV risk*  
R. Patton<sup>1,2</sup>, F. C. Blow<sup>2</sup>, A. S. Bohnert<sup>2</sup>, E. E. Bonar<sup>2</sup>, K. L. Barry<sup>2</sup>, M. A. Walton<sup>2</sup>, <sup>1</sup>Substance Abuse Research Center, University of Michigan, Ann Arbor, MI, <sup>2</sup>Department of Psychiatry, University of Michigan, Ann Arbor, MI
- 1:20 *Drug use among patients at public clinics treating sexually transmitted infections (STI)*  
L. Haynes<sup>1</sup>, K. T. Brady<sup>1</sup>, D. J. Feaster<sup>2</sup>, L. R. Metsch<sup>2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Miller School of Medicine, University of Miami, Miami, FL
- 1:35 *Women who trade sex for drugs only as a high-risk subgroup of sex workers: An exploratory analysis*  
E. M. Dunne, M. Khan, W. Latimer, Clinical and Health Psychology, University of Florida, Gainesville, FL
- 1:50 *Changes in substance use and sexual risk over time among black MSM and black MSMW in 6 U.S. cities*  
T. V. Penniman<sup>1</sup>, R. Regan<sup>2</sup>, L. Wang<sup>3</sup>, S. Ou<sup>3</sup>, S. Shoptaw<sup>2</sup>, <sup>1</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>2</sup>Family Medicine, UCLA, Los Angeles, CA, <sup>3</sup>Statistical Center for HIV/AIDS Research & Prevention, Seattle, WA
- 2:05 *Hazardous drinking and HIV risk-related behavior among male clients of female sex workers in Tijuana, Mexico*  
D. Goodman-Meza, E. V. Ptpitan, S. Strathdee, S. J. Semple, K. D. Wagner, C. Chavarin, T. L. Patterson, University of California San Diego, San Diego, CA
- 2:20 *Substance use and high-risk sexual behavior among men who have sex with men in Hanoi*  
D. B. Nguyen<sup>1</sup>, P. T. Korthuis<sup>2</sup>, H. M. Nguyen<sup>3</sup>, G. M. Le<sup>1</sup>, <sup>1</sup>Hanoi Medical University, Hanoi, Viet Nam, <sup>2</sup>Oregon Health & Science University, Portland, OR, <sup>3</sup>Center for Community Health Research and Development, Hanoi, Viet Nam
- 2:35 *Increased condom use with psychological abuse among drug-abusing women in Tehran*  
J. E. Korte<sup>1</sup>, E. Merghati-Khoie<sup>2</sup>, S. Rimaz<sup>2</sup>, K. T. Brady<sup>1,3</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran, <sup>3</sup>Ralph H. Johnson VA Medical Center, Charleston, SC
- 2:50 *Substance use and sexual behavior among women in Prague*  
S. M. Stemmler<sup>1</sup>, T. M. Hall<sup>1</sup>, P. Prokopik<sup>2</sup>, S. Shoptaw<sup>1</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>Charles University, Prague, Czech Republic

## Oral Communications 19

INDIGO D  
1:00 - 3:05 PM

### FIGHTING THE TWO-HEADED MONSTER: COMORBIDITY

Chairs: Teresa Franklin and Kelly Young-Wolff

- 1:00 *75th Anniversary Reflections*
- 1:05 *Trauma-informed treatment decreases PTSD among women offenders*  
N. P. Messina<sup>1</sup>, S. Calhoun<sup>1,2</sup>, J. Braithwaite<sup>2</sup>, <sup>1</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>2</sup>Department of Criminology, Law and Society, University of California, Irvine, Irvine, CA
- 1:20 *Substances viewed through the lens of trauma: Substance expectancies in women with PTSD/SUD*  
J. Utley<sup>1,2</sup>, L. Najavits<sup>1,2</sup>, N. Capezza<sup>3</sup>, <sup>1</sup>Boston University, Boston, MA, <sup>2</sup>VA, Boston, MA, <sup>3</sup>University of Massachusetts, Worcester, MA
- 1:35 *Substance use and PTSD among smokers with serious mental illness*  
K. C. Young-Wolff<sup>1</sup>, S. Fromont<sup>2</sup>, K. Delucchi<sup>2</sup>, S. Hall<sup>2</sup>, S. Hall<sup>2</sup>, J. Prochaska<sup>1</sup>, <sup>1</sup>Stanford University, Stanford, CA, <sup>2</sup>University of California, San Francisco, San Francisco, CA
- 1:50 *Underreporting of drug use among individuals with schizophrenia: Prevalence and predictors*  
A. Bahorik<sup>1</sup>, C. E. Newhill<sup>1</sup>, C. Queen<sup>1</sup>, J. R. Cornelius<sup>3,4</sup>, S. Eack<sup>1,2</sup>, <sup>1</sup>Social Work, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA, <sup>3</sup>Psychiatry, University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA
- 2:05 *Trajectories of daily cigarette use from mid-adolescence to young adulthood: The role of depressive symptoms*  
C. B. Bares<sup>1</sup>, A. Pascale<sup>2</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Universidad de la Republica, Montevideo, Uruguay
- 2:20 *Methylphenidate for ADHD in adults with substance dependence: A 24-week randomized placebo-controlled trial*  
M. Konstenius<sup>1</sup>, N. Jayaram-Lindström<sup>1</sup>, J. Guterstam<sup>1</sup>, O. Beck<sup>2</sup>, B. Philips<sup>3</sup>, J. Franck<sup>1</sup>, <sup>1</sup>Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, <sup>2</sup>Medicine, Karolinska Institutet, Stockholm, Sweden, <sup>3</sup>Psychology, Linköping University, Linköping, Sweden
- 2:35 *Synthesizing outcomes of evidence-based practices in a multi-site clinical trial for women with trauma and addictions*  
D. A. Hien<sup>1,2</sup>, A. Campbell<sup>2</sup>, G. Miele<sup>2</sup>, <sup>1</sup>Psychology, City University of NY, New York, NY, <sup>2</sup>Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY
- 2:50 *SMART Recovery®: An effective group method for co-occurring conditions in community treatment*  
P. Penn<sup>1</sup>, A. J. Brooks<sup>3</sup>, S. M. Gallagher<sup>2</sup>, D. Brooke<sup>1</sup>, <sup>1</sup>Research, La Frontera Arizona, Tucson, AZ, <sup>2</sup>Psychology, Veterans Administration, Tucson, AZ, <sup>3</sup>Psychology, University of Arizona, Tucson, AZ

## Oral Communications 20

INDIGO H  
1:00 - 3:05 PM

### NEW HORIZONS IN STIMULANT PHARMACOTHERAPY DEVELOPMENT

Chairs: Leonard Howell and Stephen Kohut

- 1:00 *75th Anniversary Reflections*
- 1:05 *Metabotropic glutamate receptor 7 activation with AMN082 attenuates the reinforcing and motivational effects of nicotine in rats*  
A. K. Stoker, X. Li, A. Markou, University of California San Diego, La Jolla, CA
- 1:20 *Anti-methamphetamine vaccine attenuates reinstatement of conditioned place preference in mice*  
T. A. Kosten<sup>1,2</sup>, X. Shen<sup>1,2</sup>, P. W. O'Malley<sup>1,2</sup>, B. M. Kinsey<sup>1,2</sup>, Z. Huang<sup>3</sup>, F. M. Orson<sup>1,2</sup>, T. R. Kosten<sup>1,2</sup>, <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>ME Deakey VAMC, Houston, TX, <sup>3</sup>Walvax Biotechnology, Kunming, China
- 1:35 *Chronic treatment with varenicline decreases concurrent cocaine + nicotine self-administration*  
S. Kohut<sup>1</sup>, P. A. Fivel<sup>1</sup>, F. I. Carroll<sup>2</sup>, N. K. Mello<sup>1</sup>, <sup>1</sup>Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>The Research Triangle Institute, Research Triangle Park, NC
- 1:50 *Effects of a mutant bacterial cocaine esterase on cocaine brain levels measured with PET neuroimaging in rhesus monkeys*  
L. Howell<sup>1</sup>, J. Nye<sup>1</sup>, J. Stehouwer<sup>1</sup>, R. Voll<sup>1</sup>, J. Mun<sup>1</sup>, D. Narasimhan<sup>2</sup>, J. Nichols<sup>2</sup>, R. Sunahara<sup>2</sup>, M. Goodman<sup>1</sup>, F. I. Carroll<sup>3</sup>, J. Woods<sup>2</sup>, <sup>1</sup>Emory University, Atlanta, GA, <sup>2</sup>University of Michigan, Ann Arbor, MI, <sup>3</sup>Research Triangle Institute, Research Triangle Park, NC
- 2:05 *Preclinical evaluation of JPC-077 as a novel treatment for methamphetamine abuse*  
J. R. Nickell<sup>1</sup>, J. S. Beckmann<sup>2</sup>, E. D. Denehy<sup>2</sup>, K. B. Siripurapu<sup>2</sup>, J. P. Culver<sup>1</sup>, M. T. Bardo<sup>2</sup>, P. A. Crooks<sup>3</sup>, L. P. Dwoskin<sup>1</sup>, <sup>1</sup>Pharmaceutical Sciences, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Pharmaceutical Sciences, University of Arkansas, Fayetteville, AR
- 2:20 *Dopamine D3 receptors underlie cocaine-induced conditioned place preference in mice*  
E. L. Gardner<sup>1</sup>, H. Y. Zhang<sup>1</sup>, X. Q. Peng<sup>1</sup>, R. B. Su<sup>2</sup>, R. F. Yang<sup>2</sup>, J. Li<sup>2</sup>, Z. X. Xi<sup>1</sup>, R. Song<sup>1,2</sup>, <sup>1</sup>Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, <sup>2</sup>Beijing Institute of Pharmacology and Toxicology, Beijing, China
- 2:35 *Tranlycypromine enhances propensity to acquire self-administration of a low dose of nicotine*  
M. B. Schaff<sup>1</sup>, T. T. Smith<sup>2</sup>, D. M. Buffalari<sup>1</sup>, A. F. Sved<sup>1</sup>, E. C. Donny<sup>2</sup>, <sup>1</sup>Neuroscience, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Psychology, University of Pittsburgh, Pittsburgh, PA
- 2:50 *Effects of orexin receptor antagonism on methamphetamine-seeking in male and female adolescent and adult rats*  
N. Zlebnik, N. Holtz, M. E. Carroll, Psychiatry, University of MN, Minneapolis, MN



---

**Thursday, June 20, 2013**

---

**SWEEPSTAKES DRAWING**

**INDIGO A  
3:10 - 3:30 PM**

***YOU MUST BE SEATED IN ONE OF THE SESSIONS STARTING  
AT 1:00 PM IN ORDER TO HAVE YOUR BADGE COLLECTED***

HAVE A SAFE TRIP HOME!

SEE YOU IN SAN JUAN, PUERTO RICO, JUNE 14-19, 2014

# AUTHOR INDEX

- Aarde, S. 8  
 Abbott, T. 81  
 Abdel-Salam, S. 89  
 Abel, J.L. 92  
 Abraham, A. 19  
 Abrahão, R.C. 18  
 Abramovitz, D. 14  
 Abrams, R. 109  
 Abrouk, N. 95  
 Accornero, V.H. 4, 77, 89  
 Acheson, A. 56, 57  
 Acri, J.B. 83  
 Adams, R.S. 91  
 Adelson, M. 97  
 Adler, M. 69  
 Agrawal, A. 12, 81, 99, 100  
 Agus, D. 97  
 Aharonovich, E. 101  
 Ahmed, M.S. 58, 65  
 Ahmed, R. 55  
 Ahmed, S. 101  
 Aiello, A. 76  
 Aiken, A. 64  
 Ajufo, C. 100  
 Akhmadeeva, L. 86  
 Akin, J. 110  
 Akutagava-Martins, G.C. 12  
 Al Jurdi, R.K. 80  
 Alam Mehrjerdi, Z. 77, 79, 88  
 Alanis-Hirsch, K. 62  
 Albertella, L. 68  
 Alberto, A. 82  
 Albizu-García, C.E. 74  
 Alcorn, J.L. 80  
 Alcorn, M. 9  
 Aldrich, J.V. 22, 84  
 Alexandre, J. 25  
 Alford, D.P. 9, 19  
 Ali, R. 19, 98  
 Allen, A. 24  
 Allen, C. 23  
 Allen, S. 24  
 Allsop, D.J. 105, 106  
 Almirall, D. 87  
 Alonzo, D. 77  
 Alperstein, D. 105  
 Alshomrani, A.T. 17  
 Altice, F.L. 63  
 Altman, L. 92  
 Alvarós, J. 101  
 Amara, S.G. 90  
 Amaral, R. 67  
 Amaro, H. 14  
 Amaya, S. 54  
 Anastasio, N.C. 74, 83  
 Andersen, R.M. 20, 72, 91, 92  
 Anderson, B. 97  
 Anderson, K. 82  
 Anderson, K.G. 55, 68  
 Anderson, S.R. 22  
 Andoh, K. 64  
 Andrade, A.G. 64, 67, 76  
 Andrade, L.H. 64, 76  
 Andrenyak, D.M. 19  
 Ang, A. 16, 54, 81, 96, 97  
 Angarita, G.A. 101  
 Angelo, F. 81  
 Anglin, M.D. 55  
 Angulo, E. 58  
 Anker, J. 5, 13  
 Annon, J. 60, 102  
 Antenor-Dorsey, J. 100  
 Anthony, J.C. 4, 6, 15, 16, 59, 61, 77, 89  
 Antoine, D.G. 80  
 Antonini, V.P. 88  
 Anyumba, G. 56  
 Apelt, S.M. 97  
 Arangua, L. 20  
 Arasteh, K. 95  
 Arbelaez, A. 100  
 Armenta, R.F. 110  
 Aronson, I.D. 17  
 Arpawong, T.E. 86  
 Arreola, S. 78  
 Ashley, D. 71  
 Ashrafioun, L. 106  
 Athanasos, P. 95  
 Atkins, D. 68  
 Atkinson, J. 16  
 Auriacombe, M. 24, 25, 57, 63, 64, 94  
 Austin, K. 91  
 Avery, M. 82  
 Ayer, L. 99  
 Babalonis, S. 2, 96  
 Bachiller, D. 101  
 Back, S.E. 12, 23, 81  
 Badalato, H. 96  
 Baggott, M. 101  
 Bagot, K.S. 9  
 Bahorik, A.L. 81, 112  
 Baik, K. 106  
 Bailey, G.L. 78  
 Baker, A. 2  
 Baker, N. 81  
 Baker, R. 97  
 Baladandayuthapani, V. 75  
 Balan, S. 15, 86, 92  
 Baldini, L. 89  
 Ball, E. 94  
 Balodis, I. 59  
 Balster, R. 1, 70  
 Bandstra, E.S. 4, 77, 89  
 Banducci, A.N. 77  
 Bangalore, S.S. 81  
 Bania, T.C. 17  
 Banich, M.T. 99, 103, 104  
 Bannon, E.E. 106  
 Bannon, M. 22  
 Banta-Green, C.J. 28  
 Barbosa-Leiker, C. 102  
 Bardo, M.T. 7, 82, 83, 113  
 Bares, C.B. 87, 112  
 Barnett, T.E. 15, 108, 109  
 Barondess, D.A. 59  
 Barr, J.L. 92  
 Barral, C. 101  
 Barry, C. 27  
 Barry, D. 3, 9  
 Barry, K.L. 14, 77, 111  
 Barsdorf, A.I. 9  
 Bart, B. 97  
 Bart, G. 97  
 Barth-Rogers, Y. 20  
 Bartholomaeus, J. 59  
 Bartholomew, N.G. 17, 89  
 Bartlett, D. 106  
 Bartlett, S. 21  
 Basso, M. 16

# AUTHOR INDEX

- Basu, D. 110  
 Bauer, C. 58  
 Baumann, M.H. 10  
 Beadnell, B. 60  
 Beardsley, P. 66  
 Becan, J.E. 55, 87  
 Beck, O. 112  
 Becker, D. 85  
 Beckham, J. 81  
 Beckmann, J.S. 1, 7, 82, 113  
 Bedi, G. 66  
 Beebe-Wang, N. 101  
 Begnis, A.P. 18  
 Beitel, M. 3, 9  
 Bellows, A. 82  
 Beltran, V. 25  
 Belur, V. 28  
 Ben Abdallah, A. 61  
 Ben-Shahar, O. 83  
 Benasutti, K.M. 75  
 Benishek, L. 56, 68  
 Bennett, H.E. 55  
 Bennett, R. 101  
 Bennett, T. 69  
 Benningfield, M.M. 104  
 Bentley, T.A. 100  
 Beraldo, L. 67  
 Bernstein, E. 109  
 Bernstein, I.M. 58  
 Bernstein, J.A. 19  
 Bernstein, M. 86  
 Bertholomey, M.L. 80  
 Bessette, A. 101, 102  
 Bickel, W.K. 19, 101, 104  
 Bidinotto, A. 76  
 Bidlack, J.M. 22  
 Bierut, L. 61  
 Bigelow, G.E. 17, 18, 67  
 Binswanger, I.A. 109  
 Biondo, G. 108  
 Birath, J.B. 54  
 Bird, S. 28  
 Bisaga, A. 97  
 Biswal, B. 103  
 Bixler, E.O. 61  
 Bizon, J.L. 83  
 Black, A.C. 61  
 Black, E. 2  
 Black, K. 100  
 Blackford, J.U. 104  
 Blackstone, K. 16, 67  
 Blaine, J. 96  
 Blatchford, P.J. 109  
 Blonigen, D. 89  
 Blow, F.C. 13, 14, 15, 23, 77, 87, 108, 111  
 Blumberg, D. 102  
 Bluthenthal, R. 78, 109  
 Bobashev, G. 6  
 Bogenschutz, M. 21, 62  
 Bohnert, A.S. 14, 77, 91, 108, 111  
 Bohnert, K. 15  
 Bolden, K. 54  
 Bonar, E.E. 111  
 Bond, C. 63  
 Bono, A. 15  
 Booth, B.M. 23, 77, 87, 88  
 Booth, R.E. 2, 100  
 Bordnick, P.S. 58, 68  
 Borsuk, C. 79  
 Bose, J. 6  
 Boughner, E. 67  
 Bourgois, P. 78  
 Boutros, N. 63  
 Boutros, N.N. 92  
 Bowman, S. 109  
 Boyd, C.J. 13, 108  
 Boyson, C.O. 92  
 Bozzetti, M.C. 76  
 Braciszewski, J.M. 95  
 Bradshaw, C.P. 15  
 Bradstreet, M.P. 11  
 Brady, K.T. 12, 23, 61, 69, 81, 103, 111  
 Braithwaite, J. 112  
 Brands, B. 15, 96  
 Branson, C.M. 55  
 Brecht, M. 54, 77, 82  
 Bredy, T. 93  
 Bresani, E. 56, 94  
 Brett, M. 59  
 Brewer, A. 12  
 Brigham, G.S. 88, 98, 102  
 Brightwood, A. 81  
 Brimijoin, S. 84  
 Brincks, A. 55  
 Briscione, M.A. 11, 84  
 Brocato, J. 77  
 Brooke, D. 112  
 Brooks, A.C. 68, 79  
 Brooks, A.J. 112  
 Brooks, D.J. 80  
 Brooner, R.K. 80, 81  
 Brouwer, K.C. 16  
 Brown, A.L. 84  
 Brown, E. 22  
 Brown, L.S. 60  
 Brown, P.C. 56  
 Brown, Q.L. 59  
 Brown, R. 20  
 Brown, S.A. 64, 82  
 Brownstein, A.J. 11, 80, 84  
 Bruce, D. 17  
 Bruce, R. 17  
 Bruno, R. 2, 64, 105  
 Bucello, C. 64  
 Bucher-Bartelson, B. 13, 62  
 Buchhalter, A. 95  
 Bucholz, K.K. 12  
 Buckley, N.W. 84  
 Budman, S. 5  
 Budman, S.H. 13  
 Budney, A.J. 56  
 Buffalari, D.M. 58, 113  
 Bui, H.T. 54  
 Buonora, M. 80  
 Burgette, L. 87  
 Burke, A.R. 92  
 Burns, L. 99  
 Burns, P.J. 61  
 Burrell, J. 22  
 Bury, G. 94  
 Busatto, G. 67  
 Busch, S. 27  
 Businelle, M.S. 23, 98  
 Butelman, E. 84  
 Butler, S.F. 13, 70  
 Buttram, M. 11  
 Cacciola, J.S. 6, 79, 88

## AUTHOR INDEX

- Caffrey, S. 17  
 Cahill, L. 5  
 Calderon, S.N. 109  
 Calhoun, S. 112  
 Calipari, E. 7  
 Calsyn, D.A. 60, 100  
 Camenga, D.R. 55, 85  
 Cameron, M. 10  
 Campbell, A. 19, 78, 92, 100, 112  
 Campbell, C. 96  
 Campbell, C.L. 96  
 Campollo, O. 58  
 Canabarro, N. 65  
 Canal, C. 100  
 Canamar, C. 97  
 Canavan, S.V. 101, 102  
 Canetti, D. 81  
 Canham, S.L. 9  
 Canlas, L. 98  
 Cannizzaro, D. 101  
 Cano, M.A. 98  
 Canterberry, M. 103  
 Capezza, N. 112  
 Capitanio, J. 8  
 Caraballo-Correa, G. 74  
 Carbonaro, T. 11  
 Carey, A.N. 84  
 Carise, D. 68  
 Carlin, J. 86  
 Carlini, B. 98  
 Carlopio, C. 99  
 Carlson, R.G. 13, 88, 96  
 Carlton, S.M. 2  
 Caron, M.G. 7  
 Carpenedo, C.M. 68  
 Carr, A. 93  
 Carrico, A.W. 4, 54  
 Carroll, F.I. 10, 113  
 Carroll, K. 85, 107  
 Carroll, M.E. 113  
 Carter, A. 101  
 Carter, A.Q. 58  
 Carter, L. 71  
 Cartier, J. 89  
 Casas, M. 101  
 Case, T. 68  
 Caspers, M. 11  
 Cassey, H. 94  
 Cassidy, T.A. 13  
 Castagné, V. 83  
 Castaldelli-Maia, J.M. 76  
 Castro, Y. 98  
 Cattie, J.E. 16, 54, 67  
 Cavallo, D.A. 9, 55, 85, 106  
 Cease, C.E. 98  
 Cepeda, A. 18, 55  
 Cerdá, M. 65, 82  
 Cereser, K.M. 18, 65  
 Chaisson, C.E. 19  
 Chalk, M. 6, 62  
 Chan, K. 54  
 Chandler, R. 24, 28, 29  
 Chang, L.C. 80, 101, 104  
 Chang, M. 18  
 Chang, Y. 89  
 Chaple, M. 27, 68  
 Charles, N.E. 56  
 Charney, D.S. 80  
 Chartier, K. 23  
 Chauchard, E. 105  
 Chaudhry, A.A. 3, 88, 97  
 Chaulk, P. 99  
 Chavarin, C. 111  
 Chavez, K. 15  
 Chawarski, M.C. 14, 16, 60, 62, 76, 97  
 Cheer, J. 26  
 Chen, C.Y. 64  
 Chen, K. 64  
 Chen, L. 79, 82  
 Chen, W.J. 64  
 Chen, Y. 10, 64  
 Cheng, D. 19, 65  
 Chermack, S.T. 14, 23, 77  
 Chhatre, S. 14, 17, 102  
 Chilcoat, H. 13, 61, 70, 77, 108, 109  
 Childress, A.R. 3, 57, 82, 103, 104, 107  
 Chisolm, M.S. 65, 79  
 Chokron Garneau, H. 82  
 Chou, R. 95  
 Chow, J.J. 82  
 Christodoulides, N. 19  
 Christou, D. 54  
 Chu, D. 78, 109  
 Chudzynski, J. 16, 54  
 Cicero, T. 29, 70  
 Clair, M. 89  
 Clark, C.B. 107  
 Claude-Couture, M. 76  
 Claus, E. 104  
 Claussen, C. 7  
 Clavier, O. 101  
 Cleland, C. 110  
 Clifford, L. 60  
 Clingan, S. 18  
 Cloke, J. 67  
 Cobuzzi, J.L. 10, 11, 85  
 Cochran, G. 19  
 Coffey, C. 86  
 Coffin, P.O. 28, 53, 54  
 Cohen-Gilbert, J.E. 105  
 Colby, S. 86  
 Coleman, A. 20  
 Colfax, G. 53  
 Collado-Rodriguez, A. 4, 56  
 Collier, J.K. 25  
 Collins, R.L. 23  
 Comer, S.D. 3, 4, 9, 24, 25, 66, 70, 110  
 Compton, W. 24  
 Cone, E.J. 5, 95  
 Conn, N.E. 105  
 Conner, K. 74  
 Connery, H.S. 13, 55, 78  
 Connor, J. 57  
 Conrad, K.J. 57, 78, 79  
 Conrad, K.M. 78, 79  
 Cook, J.M. 9  
 Cooley, M.C. 15  
 Cooper, H.L. 4  
 Cooper, Z.D. 3, 9, 105, 110  
 Copeland, J. 10, 68, 105  
 Copenhagen, M. 17, 63, 95  
 Copersino, M.L. 104  
 Coplan, P. 13, 70, 109  
 Cornelius, J.R. 81, 112  
 Correa-Fernandez, V. 98  
 Corsi, K.F. 100

# AUTHOR INDEX

- Cottler, L. 13, 14, 29, 78  
 Cousins, S.J. 65  
 Cousijn, J. 85  
 Cousins, S.J. 16  
 Couto, S. 87  
 Covault, J. 57  
 Covey, L. 81  
 Cowan, R.L. 104  
 Cox, A.O. 27  
 Coyle, J. 101  
 Coyne, K.S. 9  
 Crane, C.A. 23  
 Crane, N.A. 67  
 Cranford, J. 108  
 Crano, W.D. 15  
 Crapelet, M. 63, 64  
 Crawley, R. 55, 87  
 Creehan, K. 8  
 Creemers, H. 56, 99  
 Crevecœur-MacPhail, D.A. 63, 65  
 Crisafulli, M. 78  
 Croff, R. 62  
 Croft, D.E. 68  
 Cromwell, J. 109  
 Crooks, D. 97  
 Crooks, P.A. 113  
 Cropsey, K.L. 107  
 Crosby, K. 106  
 Cross, N. 106  
 Crowley, D.J. 105  
 Crowley, T.J. 74  
 Crum, R. 82  
 Cruz, M. 88  
 Cruz, S. 84, 85  
 Cuevas-Mota, J. 110  
 Cullen, W. 94  
 Culver, J.P. 113  
 Cummins, E. 67  
 Cunha, P.J. 67  
 Cunningham, C.S. 10  
 Cunningham, J.K. 58  
 Cunningham, K.A. 1, 75, 83  
 Cunningham, R.M. 14, 23, 77, 87, 108  
 Currier, R. 12, 64  
 Curtis, B.L. 27, 86  
 Cutter, C.J. 3, 9  
 Czerkawski, C. 105  
 D'Amico, E.J. 55  
 D'Aunno, T. 60  
 Dacarett-Galeano, D.J. 54  
 Dackis, C. 102  
 Dafny, N. 7  
 Dahlgren, M. 105  
 Daigre, C. 101  
 Dakwar, E. 21  
 Dallery, J. 57, 86, 98  
 Dani, J.A. 58  
 Daniulaityte, R. 13, 96  
 Dansereau, D. 87  
 Darna, M. 83  
 Dart, R.C. 13, 54, 62, 70  
 Das, M. 53, 54  
 Daughters, S.B. 82  
 Daulouede, J. 25  
 Davidson, A.L. 102, 103  
 Davidson, J.W. 3, 9  
 Davis, A.K. 106  
 Davis, K.H. 27, 62  
 Daw, R.C. 27, 62  
 Dawes, M.A. 102  
 Dayas, C. 84  
 de Aguiar, B.W. 18  
 De Alwis, D. 81  
 De La Garza, II, R. 1, 11, 12, 19, 58, 68, 75, 80, 101  
 De Leo, J.A. 64  
 de Wit, H. 53  
 Deaciuc, A. 10  
 DeBeck, K. 54  
 Debrabant, R. 25  
 Deeds, B. 2  
 DeFulio, A. 60  
 Degenhardt, L. 2, 14, 86, 98  
 Delforterie, M. 99  
 Della Vedova, C. 75  
 Delucchi, K. 15, 112  
 Denehy, E.D. 113  
 Denering, L.L. 63, 65  
 Deng, W. 104  
 Denis, C.M. 25, 63, 64, 89  
 Dennis, M. 1, 81  
 Dennis, M.L. 28, 29, 57, 78, 79  
 Der-Avakian, A. 58  
 Dermody, S.S. 3, 58  
 Des Jarlais, D.C. 4, 16, 95  
 DeSantis, S. 81  
 Desrosiers, A. 86  
 Deutsch-Feldman, M. 80  
 DeVeugh-Geiss, A. 13  
 DeVito, E.E. 24  
 DeVries, W. 103  
 Dewey, W.L. 73  
 DeWitt, D.S. 83  
 Deylamizadeh, A. 77, 79, 88  
 Dezhakam, H. 25  
 Diamond, I. 21  
 Dias, N. 80, 101  
 Dickerson, D. 60, 63, 81  
 Dierst-Davies, R. 20  
 Dietrich, M.S. 104  
 DiLeone, R.J. 83  
 Dilworth, S.E. 54  
 DiMeo, M. 87  
 Ding, D.T. 64  
 Dinovo, S.A. 12  
 DiRaimo, C.G. 108  
 Discepolo, M.V. 54  
 Divin, A.L. 109  
 Diwadkar, V.A. 104  
 Dixon, A. 98  
 Doberstein, S. 80  
 Dobscha, S. 3  
 Dodd, D. 13  
 Dolan, K. 77  
 Domínguez, M. 18  
 Donny, E.C. 3, 58, 113  
 Donovan, D. 98  
 Dormitzer, C. 95  
 Dornan, A.J. 104  
 Dossabhoy, S. 97  
 Dougherty, D. 56, 57  
 Doyle, S.E. 8  
 Dreifuss, J.A. 13  
 Drexler, K. 102  
 DSouza, M.S. 58, 100  
 Du, Y. 104  
 DuBose, P. 61  
 Ducat, E. 11



# AUTHOR INDEX

- Dugosh, K.L. 75, 88, 89  
Duncan, A. 55  
Duncan, L.R. 62  
Dunlop, A. 2, 84, 105  
Dunn, K.E. 2, 3, 28  
Dunn, R. 87  
Dunne, C. 94  
Dunne, E.M. 111  
Duvall, J.L. 74, 88  
Dwoskin, L.P. 10, 83, 113  
Dwyer, K. 109  
Dykstra, L. 1
- Eack, S.M. 81, 112  
Eans, S.O. 22, 64  
Earley, MD, P. 98  
Edelman, E.J. 17  
Edlin, B. 24  
Edwards, M. 99  
Edwards, R.R. 9  
Egido, A. 101  
Ehrman, R. 57  
Eisenstein, S. 100  
Eisenstein, T.K. 69  
Eldon, M. 95  
Elkoussi, A.A. 11  
Ellis, R.J. 16  
Elsken, C. 7  
English, J. 81  
EnnisWhitehead, N. 89  
Epstein-Ngo, Q. 13, 23, 108  
Epstein, A. 27  
Epstein, D.H. 19, 68  
Erensen, J.G. 61  
Esculies, O. 101  
Estreet, A. 106  
Evans, E. 25, 77  
Evans, S.M. 5, 53, 80  
Ewing, B. 55  
Eyrich-Garg, K. 20
- Faberman, J. 104  
Fabianski, R. 57, 82  
Fairfax-Columbo, J. 94  
Fairman, B. 15  
Falck, R. 13, 88, 96  
Fan, X. 83
- Fant, R. 95  
Fantegrossi, W. 1  
Farmer, S. 104  
Farre, M. 99  
Fatseas, M. 25, 57, 94  
Feaster, D.J. 55, 111  
Feelemyer, J.P. 95  
Feeney, G. 57  
Felsing, D. 100  
Felton, J.W. 86, 87, 106  
Feng, C. 54  
Feng, H. 8  
Fergusson, D. 55  
Fernández-Artamendi, S. 56, 57  
Fernández-Hermida, J.R. 56  
Ferreira, E.F. 100  
Ferris, M.J. 7  
Ferronatto, P.B. 18  
Festinger, D.S. 75, 88, 89  
Field, C.A. 94  
Fields, S. 85, 86, 87, 100  
Fiellin, D.A. 17, 27, 62, 91, 95  
Fiellin, L.E. 17, 62  
Figueiro, M. 19  
Filc, R. 67  
Fillmore, M.T. 101  
Finan, P. 3  
Fingerhood, M. 3, 97  
Fink, L.H. 83  
Finn, M.G. 10  
Finnegan, L.P. 25  
Fischer, B.D. 9  
Fischer, G. 25  
Fisher, D.G. 16, 18, 77  
Fishman, M. 106  
Fitzmaurice, G.M. 55, 78  
Fitzsimons, H. 79  
Fivel, P.A. 58, 80, 113  
Flaherty, B.P. 98  
Flaherty, M. 63  
Fleming, A.B. 85  
Flentje, A. 4  
Fletcher, J.B. 20  
Fleury, B. 63, 64  
Flores, E. 7  
Floriano, P.N. 19  
Flynn, A. 20
- Flynn, J. 84  
Flynn, P.M. 55, 74, 87  
Fogel, J. 3, 9  
Fokina, V.M. 58  
Foltin, R.W. 110  
Fong, C. 110  
Fonseca, F. 99  
Forcehimes, A.A. 62  
Ford, J. 62  
Forselius, E.L. 101, 102  
Forster, G.L. 92  
Forster, M.J. 7, 11, 105  
Fougere, C. 27  
Foulkes, A. 80  
Fox, G. 75  
Fox, R.G. 83  
France, C.P. 85, 100  
Francisco, E. 99  
Franck, C. 101  
Franck, J. 112  
Franklin, D.R. 54, 67  
Franklin, T.R. 3, 24, 57, 103, 104, 112  
Frederick, B.D. 104  
Freeman, J.J. 53  
Freeman, K.B. 22, 100  
Freese, T.E. 79  
Freid, C. 78  
Freisthler, B. 2  
Freitas, D.M. 78  
French, M.T. 68, 78  
Fries, G. 65  
Frimpong, J.A. 60  
Froeliger, B. 3  
Froger-Colleaux, C. 83  
Fromont, S. 112  
Frost, K.H. 104  
Frye, V.F. 65  
Fuentes, D. 67  
Fulton, S. 25  
Funada, M. 10  
Funk, R.R. 78, 79  
Furr-Holden, C.D. 15, 59, 61, 106  
Furst, B. 54  
Fuster, D. 5

# AUTHOR INDEX

- Gaalema, D.E. 25  
 Gabrielian, S. 91, 92  
 Galea, S. 23, 76  
 Galia, E. 59  
 Gallagher, S.M. 112  
 Gallo, D.A. 53  
 Galloway, G. 53, 101  
 Gamble, S. 74  
 Gambogi, N. 65  
 Gandotra, N. 81  
 Ganno, M.L. 22, 64  
 Gao, Y. 84  
 Garber, G. 8  
 García-Rodríguez, O. 57  
 Garcia-Romeu, A.P. 59  
 García, M. 58  
 Gardner, E.L. 113  
 Garfein, R.S. 110  
 Garnick, D.W. 6, 61  
 Garrison, K. 53  
 Garver-Apgar, C. 100  
 Gasper, J. 53  
 Gastfriend, D.R. 61, 98  
 Gatch, M.B. 7, 11, 105  
 Gatchalian, K. 101  
 Gauvin, D. 80  
 Gawrysiak, M.J. 57, 82  
 Gaytan, N. 7  
 Gelberg, L. 20, 72, 91, 92  
 Geng, L. 84  
 Geniaux, H. 80  
 Gerak, L.R. 85  
 German, N. 10  
 Ghahremani, D. 53  
 Ghitza, U. 102  
 Gibson, A. 14  
 Gilmour, B.P. 10  
 Gilpin, N.W. 92  
 Gingrich, J. 12  
 Giovino, G.A. 23  
 Gipson, C. 26  
 Gjini, K. 92  
 Glaser, P.E. 53, 79  
 Glasner-Edwards, S. 82  
 Glick, N. 82  
 Glik, D.C. 55  
 Gluck, M.A. 53  
 Glynn, L.G. 94  
 Gmel, G. 63  
 Gogas, K. 80, 95  
 Gohel, S. 103  
 Goldman, M. 57, 103  
 Goldmann, E. 13  
 Goldstein, R.Z. 101  
 Goletiani, N. 99  
 Gomes, C.M. 100  
 Gomez, S. 19  
 Goncalves, P.D. 67  
 Gonçalves, V.M. 18  
 Gonzales-Castaneda, R. 16, 54, 55  
 Gonzales, A. 19, 68  
 Gonzalez-Espinosa, C. 84, 85  
 Gonzalez, G. 20, 82  
 Gonzalez, R. 67  
 Gonzalvo, B. 101  
 Goodman-Meza, D. 111  
 Goodman, M. 113  
 Goodwin, C. 81  
 Goodwin, J. 25  
 Goodwin, R. 15  
 Gordon, A.J. 91, 92  
 Gordon, A.L. 25  
 Gordon, M.S. 88  
 Gorelick, D.A. 105  
 Gorey, C. 65  
 Gorodetzky, C. 69  
 Gosden, J. 84  
 Goswami, D.B. 76  
 Gotham, H.J. 88  
 Gottfredson, N. 100  
 Gourevitch, M.N. 19, 109  
 Gowin, J. 103  
 Grabenauer, M. 27  
 Grandy, D. 90  
 Grant, B. 23  
 Grant, I. 16, 53, 54, 67  
 Grant, J. 67  
 Grasing, K. 102  
 Grau-López, L. 101  
 Graves, S.M. 8  
 Gray, K.M. 3, 81  
 Grayson, J.P. 108  
 Gredysa, D.M. 100  
 Green, C. 95, 101, 103  
 Green, J.L. 62  
 Green, L. 100  
 Green, T.A. 83  
 Green, T.C. 28, 109  
 Greene, E.R. 65  
 Greenfield, B. 12, 64  
 Greenfield, S.F. 78  
 Greenstein, E. 77  
 Greenwald, D.P. 81  
 Greenwald, M.K. 2, 92  
 Grella, C.E. 14, 110  
 Grenier, A.E. 100  
 Griffin, B. 6, 87  
 Griffin, M.L. 13, 55  
 Griffin, P. 10  
 Griffiths, R.R. 11, 21, 59  
 Grossman, E. 109  
 Grossman, J. 75  
 Gruber, S.A. 90, 105  
 Grucza, R. 61  
 Gryczynski, J. 19, 68, 86, 97  
 Guardino, V. 16  
 Guimarães, L.S. 12, 18  
 Guis, B.K. 12  
 Gupta, N. 98  
 Gupta, S. 110  
 Gursahani, H. 80  
 Guterstam, J. 112  
 Guzman, A. 58  
 Hackett, D. 84  
 Haddox, J.D. 15, 61, 108, 109  
 Hagan, H. 95  
 Hagle, H. 63  
 Hagler, K. 12  
 Haile, C.N. 80  
 Halkitis, P.N. 19  
 Hall, B. 81  
 Hall, E. 75  
 Hall, S. 112  
 Hall, S.M. 110  
 Hall, T.M. 53, 111  
 Hall, W. 86  
 Halpern, R. 18, 80  
 Hambuchen, M.D. 8  
 Hamilton, K.R. 86

# AUTHOR INDEX

- Hamon, S.C. 11, 12, 75  
 Han, J. 99  
 Han, X. 88  
 Hand, D.J. 17, 60  
 Haney, M. 103, 105, 107, 108, 110  
 Hankins, G.D. 58, 65  
 Hanlon, C.A. 103, 107  
 Hansdottir, I. 73  
 Hanson, J. 58  
 Hanson, S.J. 103  
 Harder, V. 99  
 Harding, M.H. 75  
 Harding, M.J. 12  
 Harhay, M. 27  
 Harle, K. 103  
 Harmon, T. 2  
 Harp, K.L. 62  
 Harrell, P.T. 68  
 Harrington, A. 82  
 Harris, E. 88  
 Harris, K. 15  
 Harris, L.S. 58  
 Harris, M. 86  
 Harrison, S.D. 80  
 Harron, A. 75  
 Hartje, J.A. 79  
 Hartwell, K. 81, 105  
 Hartzler, B. 60  
 Hasin, D.S. 2, 3, 23, 26, 77, 101  
 Haslam, R.R. 25  
 Hasson, A. 102  
 Hatch-Maillette, M. 100  
 Hatsukami, D.K. 3, 58, 71  
 Haughey, H.M. 62  
 Hauser, K. 66  
 Havens, J.R. 13, 88  
 Hawes, S. 23  
 Hawkins, M. 20  
 Hawkins, R.H. 68  
 Hawley, A.R. 106  
 Hayes, L. 102, 103  
 Haynes, L. 111  
 Hays, L.R. 53, 105  
 Heal, D.J. 84  
 Hearn, L. 89  
 Heath, A.C. 12  
 Heck, N.C. 4  
 Heil, S.H. 13, 17, 25, 58, 59, 60  
 Heilig, M. 21  
 Heinzerling, K.G. 53, 54, 66  
 Heitzeg, M. 90  
 Hellem, T. 104  
 Helliwell, D. 106  
 Helzer, J. 99  
 Hemby, S.E. 63  
 Henderson, C. 29  
 Hendricks, P.S. 107, 110  
 Henninger, A.L. 22, 102  
 Henningfield, J. 71, 95  
 Hennings, L.J. 8  
 Henry, B. 53  
 Herbeck, D. 54  
 Herman, D. 97  
 Hernandez, D.O. 4  
 Hernandez, F. 58  
 Herrick, A. 85, 86, 87, 100  
 Herrmann, E. 17  
 Herschman, P. 61  
 Hershey, T. 100  
 Hertsgaard, L. 3, 58  
 Hess, K.L. 16, 18, 77  
 Hess, L. 65  
 Hidaka, Y. 10  
 Hieftje, K. 62  
 Hien, D.A. 112  
 Higgins, S.T. 13, 58, 59, 60, 63, 94  
 Higgins, T.M. 58  
 Hiles, M. 106  
 Hilgert, J.B. 76  
 Hill, K.P. 55  
 Hill, T. 78  
 Hiller, M. 89  
 Hillhouse, M.P. 17, 60, 81, 96, 97, 102  
 Hiranita, T. 7  
 Ho, A. 11, 84, 85  
 Ho, I. 62  
 Ho, Y. 56  
 Hobfoll, S. 81  
 Hodgkin, D. 61  
 Hoff, R.A. 99  
 Hoffman, E. 77  
 Hogarty, S.S. 81  
 Hohenstein, J. 19  
 Holland, R. 105  
 Holmes, A. 21  
 Holtyn, A. 60  
 Holtz, N. 113  
 Homer, E. 12, 64  
 Homish, G.G. 23  
 Hoover, D. 65  
 Hopfer, C.J. 87  
 Horgan, C.M. 61  
 Horigian, V.E. 55, 98  
 Horton, A.M. 95  
 Horwood, L.J. 55  
 Howard, D. 89  
 Howell, D. 59  
 Howell, L. 107, 113  
 Hser, Y. 20, 25, 56, 59, 62, 77, 82, 89  
 Hsin, L. 10  
 Hsu, J. 56, 62  
 Hu, L. 100  
 Hu, M. 19, 78, 81  
 Huan, X. 10  
 Huang, D.Y. 77  
 Huang, X. 10  
 Huang, Z. 84, 113  
 Huber, R. 104  
 Hudson, J. 99  
 Huettel, S.A. 16  
 Huizink, A. 56, 99  
 Hulse, G. 73  
 Hulvershorn, L.A. 90  
 Hunter, S.B. 82  
 Hurd, Y.L. 22  
 Hurley-Dorof, W.M. 104  
 Hurwitz, Z.E. 10, 11, 85  
 Huskinson, S.L. 100  
 Hussain, L. 60  
 Hussain, S. 59  
 Hutchinson, D. 55, 64  
 Hutchinson, M.R. 25  
 Huynh, T. 97  
 Ialomiteanu, A. 15  
 Idrisov, B. 86  
 Ignacio, R.V. 15

# AUTHOR INDEX

- Iguchi, M.Y. 78, 109  
 Ilgen, M.A. 14, 15, 77  
 Imai, T. 8  
 Iosifescu, D.V. 80  
 Iqbal, S. 80  
 Iudicello, J.E. 16  
 Iverson, M. 79  
 Ives, M. 74  
 Ivey, M. 79  
  
 Jacobs, J. 87  
 Jacobs, P. 17, 96  
 Jacobus, J. 90  
 Jaffe, A. 20  
 Jaffe, J.H. 97  
 Jagannathan, K. 3, 57, 82, 104  
 Jan, R.K. 104  
 Janda, K. 8  
 Janes, A. 104  
 Jaremko, K.M. 81  
 Jarmolowicz, D.P. 101  
 Jayadevappa, R. 14  
 Jayaram-Lindström, N. 112  
 Jeffery, D.D. 91  
 Jenkins, J. 60, 79, 81  
 Jennifer, E. 76  
 Jennings, F.C. 7  
 Jennings, W.G. 23  
 Jensen, J.E. 104  
 Jensen, M.C. 18  
 Jentsch, J. 74  
 Jeon, S. 86  
 Jeong, E. 104  
 Jernigan, D. 61  
 Jesse, S.R. 106  
 Jiang, J. 8  
 Jiménez, A. 18  
 Jobes, M.L. 19  
 Joe, G.W. 17, 74, 87, 89  
 Joel, D.L. 3, 58  
 Johnson, B.A. 63  
 Johnson, J.A. 110  
 Johnson, K. 62  
 Johnson, M.W. 11, 21, 59, 67  
 Johnson, R.M. 59  
 Johnston, A. 25  
 Johnston, J. 106  
  
 Jones, E. 17  
 Jones, H. 71, 78, 79  
 Jones, J.D. 3, 9, 24, 110  
 Jones, S.R. 7  
 Jornalé, S. 99  
 Journigan, V.B. 9  
 Justice, A.C. 91  
  
 Kab, V. 76  
 Kaczanowska, K. 10  
 Kahler, C.W. 106  
 Kahn, E. 82  
 Kale, H. 13  
 Kalechstein, A.D. 101  
 Kalvik, A. 96  
 Kamkamidze, G. 96, 97  
 Kampman, K.M. 22, 102, 103  
 Kane, J. 81  
 Kang, J. 56, 62  
 Kao, J. 65  
 Kapanadze, N. 96  
 Kapczinski, F. 18, 65  
 Kaplan, C. 6, 55  
 Karamsetty, M. 26  
 Kasinather, V.B. 62  
 Katz, E.C. 3  
 Katz, J. 10  
 Katz, J.L. 7  
 Kaufman, J. 78  
 Kaufman, M.J. 1, 69  
 Kaufmann, C.N. 82  
 Kawasaki, S. 88  
 Kaynak, Ö. 56  
 Kearns, D.N. 85  
 Kecojevic, A. 108  
 Keen, L. 17, 78  
 Keenan, E. 94  
 Kelly, L.P. 8  
 Kelly, S.M. 86  
 Kelly, T.H. 59, 105  
 Kemp, J. 62  
 Kennedy, A. 19  
 Kent, K. 67  
 Kerr, T. 54, 77  
 Kerridge, B.T. 63  
 Kershaw, S. 75  
 Kershaw, T. 86  
  
 Kertesz, S. 20, 92, 109  
 Kerwin, M.E. 56  
 Kesby, J.P. 8  
 Kessler, F.H. 12, 18, 76, 100  
 Keyes, K. 23, 26  
 Keyser-Marcus, L.A. 75  
 Khalil, M.A. 105  
 Khan, M.  
 Khan, M.R. 60, 89, 111  
 Khan, R. 19  
 Khatib, D. 92, 104  
 Khawar, L. 10  
 Khodneva, Y. 20, 109  
 Khroyan, T.V. 9, 92  
 Kidorf, M.S. 80, 81  
 Killeen, T. 98  
 Kilmer, B. 73  
 Kim, J.H. 3, 82  
 Kimball, T. 15  
 King, V.L. 80, 81, 88  
 Kinlock, T.W. 88  
 Kinsey, B.M. 8, 84, 113  
 Kippin, T.E. 93  
 Kirby, K.C. 56, 68, 94  
 Kirisci, L. 85  
 Kirk, A. 86  
 Kirk, G.D. 14  
 Kirk, I.J. 104  
 Kirtadze, I. 71, 78  
 Kivlahan, D. 64  
 Kleber, H.D. 21  
 Klein, M. 5, 109  
 Klein, S. 100  
 Klemperer, E. 87  
 Klenk, A. 103  
 Klimas, J. 94  
 Kline-Shroder, B. 101  
 Kline, A. 20  
 Knapp, B.I. 22  
 Knezevic, B. 104  
 Knight, D. 55, 87  
 Knight, K. 17, 74, 89  
 Knoblach, D. 68  
 Knowlton, A.R. 15  
 Knudsen, H.K. 6, 18, 88  
 Kober, H. 57, 59  
 Koblin, B. 65

# AUTHOR INDEX

- Kochunov, P. 57  
 Koek, W. 85  
 Koenen, K. 76  
 Koffarnus, M.N. 19, 60, 101, 104  
 Kohlleppe, S. 7  
 Kohno, M. 53  
 Kohut, S. 58, 80, 113  
 Koken, J. 17  
 Koller, J. 100  
 Kollins, S.H. 81  
 Kondabolu, K. 100  
 Kondo, D. 104  
 Kong, G. 55, 85, 106  
 Kong, W. 76  
 Konova, A.B. 101  
 Konstenius, M. 112  
 Koosis, E. 102  
 Kopajtic, T. 10  
 Kopecky, E.A. 85  
 Korte, J.E. 23, 98, 111  
 Korthuis, P.T. 17, 54, 91, 111  
 Kosheleff, A.R. 85  
 Kosten, T.A. 8, 69, 113  
 Kosten, T.R. 8, 11, 12, 19, 58, 75, 84, 102, 113  
 Kousik, S. 8  
 Kovach, A.L. 27  
 Kraemer, K.L. 91  
 Kral, A. 78, 109  
 Kramer, L.A. 103  
 Kraus, S.W. 106  
 Krausz, M. 94  
 Kreek, M.J. 11, 22, 80, 84, 85  
 Krishnan-Sarin, S. 9, 55, 59, 85, 106  
 Kristman-Valente, A. 94  
 Kritz, S.A. 60  
 Krmpotich, T.D. 99, 103, 104  
 Krupitsky, E. 73, 78, 98  
 Kryczak, E. 106  
 Kryszak, E. 106  
 Kuehlewind, B. 11  
 Kukhareva, P. 86  
 Kulesza, M. 20  
 Kulkarni, R.S. 84  
 Kunøe, N. 73  
 Kuperminc, G. 110  
 Kurdziel, G. 4, 56, 86  
 Kurti, A.N. 57  
 Kurtz, S.P. 11, 17, 18  
 Kuwabara, H. 75  
 Kydd, R.R. 104  
 Kypri, K. 64  
 Laborde, A. 87  
 Lam, S. 57  
 Lamb, K. 64, 91  
 Lambdin, B. 17  
 Lan, Y. 56, 62, 89  
 Landheim, A. 57  
 Lane, S.D. 75, 80, 95, 101, 103  
 Lange, K. 85, 86, 87, 100  
 Langleben, D. 57  
 Langlois, B. 109  
 Lankenau, S. 108  
 Lanza, H. 82  
 Lanza, I. 82  
 Larance, B. 2, 98  
 Larimer, M.E. 20, 68  
 Larney, S. 14  
 LaRowe, S. 64, 81, 91  
 Larsen, H. 85  
 Larson, M. 91  
 Lasko, B. 20  
 Lasopa, S.O. 13  
 Latimer, W.W. 17, 60, 78, 89, 111  
 Latkin, C. 15  
 Laudet, A.B. 15, 68, 78  
 Lauritsen, K. 106  
 Lazzari, P.M. 18  
 Le Lait, M.C. 54  
 Le Naour, M. 2  
 Le, G.M. 54, 111  
 Leader, D. 27  
 Leaf, P.J. 15  
 Leavitt, S. 83  
 Ledgerwood, D.M. 104  
 Lee, C. 68  
 Lee, D.C. 59  
 Lee, J.D. 109  
 Lee, S. 86  
 Lefever, T. 26  
 Lehman, W.E. 17, 74, 89  
 Leickly, E. 81  
 Leininger, T. 82  
 Leith, J. 106  
 Lejuez, C.W. 4, 19, 56, 77, 82, 86, 87, 103, 106  
 Lennox, R.D. 79  
 Lenz, S. 97  
 Leonard, K.E. 23  
 Leoutsakos, J.S. 60  
 Lerch, J. 63  
 Leri, F. 67  
 LeSage, M.G. 85  
 Lesansee, F. 12, 64  
 Leslie, D. 61  
 Letourneau, E.J. 75  
 Leukefeld, C. 13, 78, 88  
 Leung, K. 61  
 Levi Minzi, M.A. 17  
 Levin, D.L. 13  
 Levin, F.R. 80, 81  
 Levin, H.E. 68  
 Levin, M.E. 58  
 Levy-Cooperman, N. 5, 79, 95  
 Lewis, D. 102  
 Li, D. 83  
 Li, G. 13  
 Li, J. 8, 10, 113  
 Li, L. 25, 77, 82  
 Li, W.I. 96  
 Li, X. 10, 113  
 Li, Y. 57, 82, 103  
 Li, Z. 56  
 Libby, D.J. 99  
 Liccardo Pacula, R. 2  
 Lichtman, A.H. 105  
 Liebschutz, J.M. 9, 97  
 Lile, J.A. 105  
 Lim, K. 107  
 Lin, J.C. 104  
 Lin, M. 60  
 Lin, S. 109  
 Lindblad, R. 102  
 Lindsay, D. 63  
 Ling, W. 17, 60, 81, 97, 102  
 Linn\_Walton, R. 94  
 Linton, S.L. 14, 59



# AUTHOR INDEX

- Lintzeris, N. 2, 66, 98, 105, 106  
 Liong, C. 3, 9  
 Lisdahl, K.M. 75, 91  
 Lisha, N.E. 15  
 Litschge, M.Y. 81  
 Litvin, Y. 22  
 Litwicki, T. 89  
 Litwin, A. 24  
 Liu, D. 22  
 Liu, H. 15  
 Liu, M. 76  
 Liu, P. 14, 76  
 Liu, S. 75  
 Lizarraga, C. 62  
 Llosa, T. 95  
 Lloyd-Travaglini, C.A. 19  
 LLoyd, D.R. 8, 11  
 Lobo, M.K. 83  
 Loftis, J.M. 90  
 Lofwall, M.R. 2, 66, 96  
 Lohrenz, T. 104  
 Lominac, K.D. 11  
 London, E.D. 53, 57, 91  
 Long, E. 73  
 Long, K. 87  
 Longabaugh, R. 64  
 Lookatch, S.J. 3  
 López-Núñez, C. 56  
 Lopez-Quintero, C. 59, 61  
 Lopez, A.A. 58  
 Lopez, M. 2, 71  
 Lorenz, L. 91  
 Love, L.A. 62  
 Lovinger, K. 54  
 Lowitz, K. 54  
 Lozada, M. 16  
 Lu, L. 100  
 Lucas, P. 106  
 Luczak, S.E. 98  
 Lukas, S.E. 90, 91, 104, 105  
 Lundahl, L.H. 92, 105  
 Lundberg, K. 104  
 Lundgren, L.M. 91  
 Luo, L. 14  
 Luo, S. 81  
 Luongo, P. 63  
 Lupee, D. 12, 64  
 Lycas, M.D. 63  
 Lynch, M.E. 58  
 Lynch, W.J. 8, 63, 92  
 Lynskey, M.T. 12, 99  
 Lyvers, M. 57, 99  
 Ma, L. 103  
 Macey, T.A. 3  
 Mackey, S. 103  
 MacKillop, J. 86  
 MacKinnon, D.P. 18  
 MacLean, K.A. 11  
 MacNicoll, S. 60, 81  
 MacPherson, L. 4, 56, 77, 86, 106  
 Madden, P. 12  
 Madera-Salcedo, I. 84  
 Madras, B.K. 7, 69  
 Maes, L. 54  
 Magidson, J.F. 82  
 Maguire, D.R. 85  
 Maher, L. 76  
 Mahoney, III, J.J. 12, 19, 75, 80, 101  
 Maidment, N.T. 85  
 Majumder, I. 75  
 Malbergier, A. 67  
 Malik, A. 60  
 Maliniak, D. 11  
 Malkowicz, S.B. 14  
 Maloney, T. 101  
 Manchanda, R. 92  
 Mancino, M. 102  
 Mann, R. 15  
 Manna, L. 65  
 Mansoor, E. 4  
 Mansoori, S. 77  
 Manubay, J.M. 3, 9, 24  
 Mao, J. 9  
 Marcotte, T.D. 53  
 Mardini, V. 65  
 Marienfeld, C. 14  
 Marino, E.N. 96, 97  
 Markou, A. 8, 10, 26, 58, 63, 92, 100, 113  
 Marks, K.R. 101  
 Marlowe, D.B. 74, 75, 89  
 Marquez, K. 57  
 Marquine, M. 54  
 Marsch, L.A. 17, 68  
 Marsden, J. 19  
 Martin, C. 59  
 Martin, C.E. 99  
 Martin, J. 97  
 Martínez-Luna, N. 101  
 Martinez, E.M. 62  
 Martinez, G. 17  
 Martins, P.A. 67  
 Martins, S.S. 3, 13, 64, 76, 82, 96  
 Marusich, J.A. 26  
 Marz, K. 71  
 Mash, D.C. 80  
 Mashhoon, Y. 105  
 Massey, L.S. 87  
 Masson, C.L. 70  
 Masukawa, D. 8  
 Matheson, T. 53  
 Mathew, S.J. 80  
 Mathias, C.W. 56, 57  
 Matsumoto, R.R. 1  
 Matthews, A. 100  
 Mattick, R. 55, 64, 98  
 Matusiewicz, A.K. 87  
 Mauro, P.M. 75, 97  
 Maxwell, C. 65  
 Maxwell, J.C. 106  
 May, A.C. 53, 103  
 Mayock, S.P. 85  
 Mazlan, M. 62, 97  
 Mazure, C.M. 99  
 Mazza, J. 57  
 Mbwambo, J. 17  
 McBride, N. 64  
 McCabe, S.E. 13, 108  
 McCaffrey, D. 87  
 McCann, U. 10  
 McCart, M.R. 75  
 McCarthy, J.F. 15  
 McCarty, D. 59, 62  
 McCaul, M. 75  
 McCauley, J. 12  
 McClernon, F.J. 3  
 McCloskey, M. 83

# AUTHOR INDEX

- McClure, E. 26  
 McCollister, K.E. 78  
 McCormack, J. 102  
 McCuddy, W.T. 7  
 McCurdy, S. 17  
 McDevitt-Murphy, M. 82  
 McDevitt, J.T. 19  
 McDonald, J.A. 20  
 McDonald, P. 10  
 McDonald, R. 109  
 McDonell, M.G. 81, 102  
 McDougle, L. 61  
 McGinnis, K.A. 91  
 McGlade, E. 104  
 McGovern, M.P. 20, 70  
 McGregor, I. 105, 106, 107  
 McGuire, J. 91  
 McHugh, R. 12  
 McIntosh, S. 63  
 McKay, C. 54  
 McKay, J. 79  
 McKee, H. 20  
 McKee, S.A. 99  
 McKenzie, J.M. 77  
 McKenzie, M. 109  
 McLaren, D.G. 104  
 McLaughlin, J.P. 22, 64, 84  
 McLellan, A.T. 27, 86  
 McMahan, L. 10  
 McMahan, T.J. 61  
 McNair, N.A. 104  
 McNamara, A. 56  
 McNaughton, E.C. 13  
 McNeely, J. 19  
 McPhaul, M. 7  
 McPherson, S. 59, 81, 102  
 McRae-Clark, A. 81, 105  
 McWilliams, S.K. 87  
 Meacham, M.C. 16  
 Meade, C.S. 4, 16, 100  
 Medina-Mora, M.E. 14  
 Mednick, S.A. 98  
 Medve, R. 95  
 Mehta, S.H. 14  
 Meier, A. 20  
 Meier, E.A. 13, 108  
 Meitner, H. 86  
 Mejia-Toiber, J. 92  
 Meli, S.M. 19  
 Mello, N.K. 58, 80, 113  
 Melnick, G. 74, 89, 95  
 Memisoglu, A. 98  
 Menaker, M. 8  
 Mendelson, J. 53, 101  
 Mendez, I.A. 85  
 Meng, Z. 9, 80  
 Menemeyer, S. 102, 103  
 Mercer, M.A. 12  
 Meredith, S. 98  
 Merghati-khoei, E. 23  
 Merghati-Khoie, E. 111  
 Mericle, A. 79  
 Merluzzi, A.P. 11, 84, 85  
 Merrick, E. 61, 91  
 Meshesha, L. 97  
 Messina, N.P. 89, 112  
 Metayer, J. 25  
 Metrik, J. 106  
 Metsch, L.R. 111  
 Metz, V. 25  
 Metzger, D. 14, 102  
 Meyer, A.C. 7, 13, 59, 98  
 Meyer, M.C. 60  
 Meyer, R.E. 61  
 Meyer, S. 101  
 Meyers, J.L. 76  
 Meyers, K. 6, 56  
 Meyers, R.J. 56  
 Michaelides, M. 22  
 Miczek, K.A. 92  
 Miele, G. 112  
 Mikulich-Gilbertson, S.K. 87, 99  
 Milam, A.J. 15, 59, 61  
 Milby, J.B. 102, 103  
 Milchak, W. 61  
 Miles, J. 55  
 Militello, L. 11  
 Milivojevic, V. 57  
 Miller, G.M. 7, 90  
 Miller, M.L. 8  
 Miller, N. 54  
 Milloy, M.J. 25  
 Mills, C. 79  
 Min, J. 77  
 Min, M.O. 25, 54, 65  
 Minassian, A. 53  
 Minnes, S. 54, 65  
 Mintzer, M. 17, 18, 67, 96  
 Miotto, K. 60, 81  
 Miquel, L. 101  
 Miser, W.F. 61  
 Mishlen, K. 97  
 Mitchell, J. 81  
 Mitchell, M.R. 83  
 Mitchell, P. 109  
 Mitchell, S.G. 19, 68, 86, 97  
 Mittal, M. 74  
 Mizrachi, E. 22  
 Moberg, D. 15  
 Moeller, F.G. 75, 80, 83, 95, 101, 103  
 Moeller, S.J. 101  
 Moerlein, S. 100  
 Moffitt, A. 55  
 Mogali, S. 24  
 Mohr, B.A. 91  
 Mojtabai, R. 82  
 Mokri, A. 25  
 Molina, L. 85  
 Moll, M.J. 87  
 Montague, P.R. 104  
 Montebello, M. 105, 108  
 Montgomery, L. 107  
 Montoya, J. 16, 67  
 Moody, D.E. 19  
 Moody, L. 101  
 Mooney, L. 60, 81, 96, 102  
 Moore, B.A. 9, 17  
 Moore, D.G. 16, 25  
 Moore, D.J. 16  
 Moore, T. 3, 74, 75  
 Moradi, S. 88  
 Morani, A. 102  
 Morasco, B.J. 3  
 Moreno, A.Y. 8  
 Morgan-Lopez, A. 91  
 Morgan, D. 83, 100  
 Morgan, E.E. 16, 53, 54, 67  
 Morgan, P. 101, 102  
 Morgan, R.W. 63  
 Morgenstern, J. 57

# AUTHOR INDEX

- Mori, T. 8, 64  
 Morisano, D. 20  
 Morrow, C. 4  
 Morse, D. 74  
 Moseley, A. 19, 68  
 Moskowitz, J.T. 54  
 Moura, F.B. 10  
 Mueller, E.T. 101  
 Mueller, M. 10  
 Mueller, S. 109  
 Müller, D. 12  
 Mullette-Gillman, O. 16  
 Mulvey, K.P. 62  
 Mun, J. 113  
 Munguía, A. 58  
 Muntner, P. 109  
 Murnane, K. 107  
 Murnion, B. 2  
 Murphy, D. 20  
 Murphy, J.G. 19, 82, 86  
 Murphy, N.P. 85  
 Murrough, J.J. 80  
 Myers, C.E. 53  
 Myers, C.P. 97  
 Myerson, J. 100  
  
 Nader, M. 5  
 Naeger, S. 77  
 Nahhas, R.W. 13, 88, 96  
 Najavits, L. 112  
 Najman, J. 64  
 Nalpas, B. 63, 64  
 Namjoshi, O.A. 9  
 Nandi, V. 65  
 Nanovskaya, T.N. 58, 65  
 Napier, T.C. 8  
 Naqvi, N.H. 57  
 Narasimhan, D. 113  
 Narayana, P.A. 103  
 Natarajan, S. 109  
 Natera-Rey, G. 18  
 Natera, G. 18, 72  
 Navarro, I. 58  
 Naylor, M. 99  
 Nebhinani, N. 110  
 Negi, N. 18, 23  
 Neighbors, C. 68  
  
 Neilands, T.B. 54  
 Neild, R. 95  
 Nestler, E.J. 83  
 Neth, S. 76  
 Neumaier, J. 22  
 Neumark, Y. 65  
 Neumeyer, J.L. 22  
 Newhill, C.E. 112  
 Newton, T.F. 11, 12, 19, 75, 80, 101  
 Newville, H. 1, 110  
 Nguyen, D.B. 111  
 Nguyen, H.M. 111  
 Nguyen, L. 62  
 Nguyen, T.M. 62  
 Ni, Y. 20  
 Nicastri, S. 67  
 Nichols, J. 113  
 Niciu, M. 1  
 Nickell, J.R. 113  
 Nicola, M.A. 11  
 Nicolaidis, C. 3  
 Nielsen, A. 59, 94  
 Nielsen, D.A. 11, 12, 75  
 Nielsen, S. 2, 96, 97  
 Niikura, K. 85  
 Nissen, L. 29  
 Norberg, M. 10, 68, 105  
 Noroozi, A. 25, 79, 88  
 Northrup, T. 96  
 Nosky, B. 77  
 Nosyk, B. 25  
 Novak, S.P. 109  
 Novoa, V. 54  
 Nugent, A. 16  
 Nunes, E.V. 19, 73, 78, 81, 97, 101  
 Nuzzo, P.A. 2, 96  
 Nwokolo, J. 100  
 Nyandindi, C. 17  
 Nye, J. 113  
  
 O'Brien, C.P. 3, 57, 102, 103, 104  
 O'Gorman, C.S. 94  
 O'Grady, C.L. 11, 18  
  
 O'Grady, K.E. 19, 68, 78, 86, 88, 97  
 O'Loughlin, C. 86  
 O'Malley, P.W. 113  
 O'Malley, S.S. 58, 85  
 Oberleitner, L. 99  
 Obermeit, L.C. 54  
 Ochsner, K. 57  
 Odinecs, A. 95  
 Oeser, B.T. 88  
 Ogawa, L.M. 76  
 Oleson, E.B. 26  
 Oliveto, A. 102  
 Olivier, J. 10  
 Olsen, Y.K. 97  
 Olsson, C. 55  
 Ometto, M. 67  
 Ompad, D.C. 65  
 Ondachi, P. 10  
 Ondersma, S.J. 68  
 Ormel, J. 56  
 Ornelas, I. 23  
 Orson, F.M. 8, 84, 113  
 Orza, P. 100  
 Osborn, L.A. 106  
 Oser, C.B. 62, 78, 88  
 Ossig, J. 59  
 Ostlund, S.B. 85  
 Otiashvili, D. 78, 96, 97  
 Otokozaawa, A. 64  
 Ou, S. 111  
 Ounpraseuth, S.T. 77  
 Owens, S.M. 8  
  
 Pacek, L.R. 15  
 Pacula, R. 73  
 Paddock, S.M. 82  
 Padwa, H. 20, 72  
 Page, K. 76  
 Pal, R. 101  
 Palfai, T.P. 19  
 Palmer, A. 85  
 Palmer, A.A. 11  
 Pande, P.G. 27, 62  
 Panwar, V. 102  
 Paone, D. 13  
 Parakh, P. 110

# AUTHOR INDEX

- Parcianello, R. 65  
 Paredez, M. 11  
 Paris, J.J. 64, 84  
 Park, S. 12  
 Park, T. 91  
 Parkinson, L. 66  
 Parks, J. 61  
 Parnass, J. 103  
 Parra-Cardona, R. 16  
 Parrish, J.N. 58  
 Parrott, A.C. 25  
 Parsells, E. 62  
 Parsons, J.T. 4  
 Pascale, A. 87, 112  
 Passetti, L. 78  
 Patel, B. 92  
 Patrick, M.E. 13, 59, 98  
 Patrikeeva, S.L. 65  
 Patterson, T.L. 14, 16, 111  
 Patton, G. 55, 86  
 Patton, R. 87, 111  
 Paul, J.A. 65  
 Paulus, M.P. 53, 103  
 Pavlicova, M. 78  
 Payne, B. 20  
 Pealer, L.N. 15, 108, 109  
 Pearlson, G. 59  
 Pechansky, F. 12, 18, 65, 76, 100  
 Pedersen, E.R. 55, 68  
 Pedroso, R.S. 18  
 Peirce, J.M. 80, 81  
 Peles, E. 97  
 Penate, J. 54  
 Penetar, D. 105  
 Peng, C. 59  
 Peng, J. 76  
 Peng, X.Q. 113  
 Penn, P. 112  
 Penniman, T.V. 111  
 Pentel, P.R. 2, 85  
 Pepper, N. 68  
 Peralta, R.L. 23  
 Pereira, L. 65  
 Pérez de Heredia, J.L. 99  
 Pérez-Pazos, J. 101  
 Perez, M.A. 55  
 Pericot-Valverde, I. 56, 57  
 Perlmutter, J. 100  
 Perrey, D. 10  
 Perry, B. 62  
 Perry, R.I. 99  
 Perry, W. 53  
 Persons, A. 8  
 Peters, E.N. 107, 110  
 Peterson, A.B. 92  
 Peterson, T. 19, 68  
 Petry, N.M. 104, 107  
 Pettenon, M. 18  
 Pettinati, H. 102  
 Pfaff, D. 22  
 Pfeiffer, J. 80  
 Pham, M.D. 62  
 Philipp, A. 59  
 Philips, B. 112  
 Phillips, T.J. 11  
 Pianca, T.G. 18  
 Picetti, R. 80, 84  
 Pickover, A. 19  
 Pickworth, W. 98  
 Pienta, A. 6, 71  
 Pike, E. 53, 101  
 Pilver, C.E. 99  
 Pipet, S. 80  
 Piralishvili, G. 96, 97  
 Pittman, B. 101  
 Pixton, G.C. 14, 95  
 Pizer, S. 91  
 Pizzagalli, D.A. 58, 104  
 Plebani, J.G. 22, 102  
 Pletcher, M. 20  
 Ploense, K. 93  
 Plunk, A.D. 61  
 Poe, M.M. 9  
 Pogue-Geile, M.F. 81  
 Poklis, A. 105  
 Polgar, W.E. 9, 92  
 Poole, S. 96, 97  
 Porath-Waller, A. 56  
 Portoghese, P.S. 2  
 Pose, D. 87  
 Potenza, M.N. 59, 99  
 Potter, J.S. 13, 96, 97  
 Potts, J.L. 98  
 Pravetoni, M. 2, 85  
 Prendergast, M. 74, 75, 89  
 Prescott, C.A. 98  
 Pressman, S.D. 65  
 Preston, K.L. 19, 68  
 Price, R.K. 15, 18, 86, 92  
 Prince van Leeuwen, A. 56  
 Prinszano, T. 11, 22  
 Prochaska, J.J. 15, 112  
 Prokopik, P. 111  
 Prough, D.S. 83  
 Ptpitan, E.V. 111  
 Puia Dumitrescu, M. 77  
 Purchase, D. 16  
  
 Queen, C. 112  
 Quinn, A. 61  
  
 Rai, K. 106  
 Raine, A. 98  
 Rajan, S. 17  
 Raleigh, M.D. 85  
 Ramchand, R. 6, 87  
 Ramesh, D. 105  
 Ramezani, K.A. 68  
 Ramirez, D. 88  
 Ramírez, J. 18  
 Ramírez, R. 74  
 Ramo, D. 15, 70  
 Ramsey, S.E. 20  
 Randall, D. 14  
 Randall, S. 9, 105  
 Randesi, M. 11  
 Ranganath, A. 26  
 Rangel, G. 14  
 Rangel, M.G. 17  
 Rapaport, C. 81  
 Rapoza, M. 78  
 Rass, O. 17, 18, 67  
 Rastegar, D. 88  
 Rathnayaka, N. 101  
 Rawson, R. 16, 25, 54, 63, 65,  
 79, 82, 88  
 Ray, M. 109  
 Ray, S. 103  
 Rea, M. 19  
 Reback, C.J. 20  
 Redner, R. 63, 94

# AUTHOR INDEX

- Reed, S. 60, 81  
 Reed, S.C. 53, 80  
 Regan, R. 111  
 Rehm, J.T. 63  
 Reichel, C.M. 5  
 Reiersen, A. 81  
 Reif, S. 61  
 Reingle, J.M. 23  
 Rennert, L. 102  
 Renshaw, P. 104  
 Reynolds, B. 86  
 Reynolds, G.L. 16, 18, 77  
 Reynolds, J. 104  
 Reynolds, M.D. 85  
 Rhee, S.H. 87  
 Riad-Allen, L. 59  
 Ricaurte, G. 10  
 Ricchetti, A. 67  
 Rice, K. 26, 58  
 Rice, K.C. 11, 84  
 Rich, J. 109  
 Richards, J.B. 8, 11  
 Richman, J. 20  
 Ridenour, T.A. 85  
 Rieckmann, T.R. 19, 87  
 Ries, R. 81  
 Riggs, J. 80  
 Riggs, P.D. 87  
 Riley, A.L. 10, 11, 84, 85  
 Riley, E.D. 4  
 Riley, T. 80  
 Rimaz, S. 23, 111  
 Risco, C.M. 106  
 Rivas, G. 105  
 Rkieh, N. 67  
 Roan, S. 69  
 Robbins, M.S. 55  
 Roberts, D.C. 7  
 Roberts, D.C.S. 103  
 Roberts, W. 101  
 Robertson, A.M. 17  
 Robertson, K. 100  
 Rodolico, J. 78  
 Rodríguez-Cintas, L. 101  
 Rodriguez, L. 14, 54  
 Rodriguez, M. 63  
 Roehrs, T. 9, 105  
 Roesch, S.C. 16  
 Roget, N.A. 79  
 Rohde, L.A. 18, 65  
 Röhsig, L. 65  
 Rojewski, A.M. 58  
 Roland, C.L. 9, 14, 95  
 Roll, J. 59, 81  
 Roll, J.M. 102  
 Romach, M.K. 63  
 Roman, P. 19  
 Roman, P.M. 18  
 Roman, T. 12  
 Romaniuk, H. 86  
 Romar, R. 99  
 Romero, M. 64  
 Roncero, C. 101  
 Rooke, S. 68  
 Rosa, F. 65  
 Rosa, M.C. 100  
 Rosa, R.L. 18  
 Rose, G. 99  
 Rose, J. 78  
 Rosen, M.I. 61  
 Rosenberg, H. 106  
 Rosenberry, Z. 98  
 Rosenblum, A. 110  
 Rosenheck, R.A. 61  
 Ross-Durow, P.L. 108  
 Rossi, P. 99  
 Roth, T. 9, 105  
 Rotrosen, J. 109  
 Rowan-Szal, G.A. 17, 74, 89  
 Rowland, L. 57  
 Rowland, N. 100  
 Rowlett, J.K. 9, 80, 83  
 Rowley, H.L. 84  
 Rubenstein, L. 91  
 Rüedi-Bettschen, D. 8  
 Ruiz-Grosso, P. 103  
 Ruíz, J.J. 74  
 Ruiz, P.N. 11  
 Ruktanonchai, C. 14, 29, 78  
 Runarsdottir, V. 73  
 Rusch, M.L. 16  
 Rush, B.R. 20, 27  
 Rush, C.R. 1, 53, 79, 101  
 Russell, B.R. 104  
 Rutledge, M. 7  
 Ryan, O. 88  
 Ryan, S.R. 56  
 Sabharwal, S.K. 62  
 Sacks, S. 27, 68  
 Sadler, C. 105  
 Safford, M.M. 109  
 Sagar, K. 105  
 Saha, T.D. 63  
 Sahoo, S. 94  
 Saim, S. 85  
 Saito, L.P. 64  
 Saitz, R. 19, 91  
 Sakai, J. 87  
 Sakhuja, R. 100  
 Saladin, M.E. 3, 81  
 Salahpour, A. 7  
 Salas, R. 58  
 Salimi, S. 65  
 Salomon, R.M. 104  
 Salomonsen-Sautel, S. 87  
 Samano, K.L. 105  
 Samet, J.H. 9, 19  
 Samolski, M.R. 103  
 Santa Ana, E.J. 64, 91  
 Santaella, J. 3, 82  
 Santana-Correa, N. 109  
 Santos, D. 53, 54  
 Santos, G.M. 53, 54  
 Sargeant, M.N. 98  
 Sarkar, S. 110  
 Sason, A. 97  
 Saulsgiver, K. 28  
 Saunders, J. 94  
 Savant, J.D. 9  
 Sawh, L. 20  
 Sawyer, B.G. 62  
 Sawyer, E.K. 9  
 Saxena, P. 89  
 Saxon, A. 17, 81, 96, 97, 102  
 Sayed, B. 68  
 Sayer, G. 15  
 Sayko Adams, R. 91  
 Schacht, R.L. 67  
 Schackman, B. 24  
 Schaff, M.B. 58, 113



# AUTHOR INDEX

- Scheidell, J. 60  
 Scherer, M. 106  
 Scherrer, J. 15, 92  
 Schlussman, S.D. 84  
 Schmidt, L. 62  
 Schmidt, T.D. 59, 94  
 Schmitz, J. 75, 95, 101, 103  
 Schnoll, S. 29, 95  
 Schoedel, K.A. 5, 79, 95  
 Schottenfeld, R.S. 3, 9, 14, 16, 17, 60, 62, 76, 97  
 Schreiber, S. 97  
 Schuch, J.B. 12  
 Schumacher, J.E. 102, 103  
 Schuster, R.M. 67  
 Schütz, C.G. 94  
 Schwartz, R.P. 19, 60, 68, 86, 88, 97  
 Schwier, S. 59  
 Scott, C.K. 57, 78, 79  
 Sears, R.M. 83  
 Secades-Villa, R. 56  
 Secora, A.M. 95  
 Sehbe, M. 65  
 Seip-Cammack, K. 80  
 Seiri, L. 25  
 Seitz-Brown, C. 82  
 Selby, P. 59  
 Sell, S.L. 83  
 Sellers, E.M. 5, 63, 70  
 Selling, D. 109  
 Semenova, S. 8, 63, 92  
 Semple, S.J. 111  
 Senadheera, S. 22  
 Serafine, K.M. 84, 100  
 Serio-Chapman, C. 99  
 Serre, F. 25, 57, 94  
 Setlow, B. 74, 83  
 Setnik, B. 9, 14, 95  
 Severtson, S.G. 13, 54  
 Sferra, M.S. 85, 86, 87, 100  
 Shadley, M.L. 79  
 Shafer, M.S. 74, 88  
 Shaheed, T. 20  
 Shamsalizadeh, N. 23  
 Shapiro, B.A. 68  
 Sharma, G. 102  
 Sheaff, P. 54  
 Sheidow, A.J. 75  
 Sheikhattari, P. 98  
 Shen, X. 8, 113  
 Shenoy, P. 103  
 Shetty, R. 7  
 Shi, X. 104  
 Shibasaki, M. 8, 64  
 Shih, R.A. 55  
 Shimane, T. 10  
 Shin, J. 3, 104  
 Shin, S.H. 86  
 Shinday, N.M. 83  
 Shishani, K. 59  
 Shollenbarger, S. 75  
 Shoptaw, S. 53, 54, 66, 111  
 Shoptaw, W. 111  
 Short, E.J. 54, 65  
 Shorter, D. 12  
 Shram, M.J. 79, 95  
 Shrestha, R. 95  
 Shroff, M.V. 15, 86, 92  
 Shulman, G.D. 61  
 Shurtleff, D. 71, 90  
 Shutter, T.R. 12  
 Siegel, A. 96, 99  
 Siegel, A.J. 2  
 Siegfriedt, J. 20  
 Siever, M.D. 54  
 Sigmon, S.C. 13, 59, 60, 71, 98  
 Sigurdsson, S.O. 60  
 Sikharulidze, Z. 96, 97  
 Sikkema, K. 17  
 Siletti, K.A. 10  
 Silins, E. 55  
 Silowsky, J. 95  
 Silveira, C.M. 64, 76  
 Silveri, M.M. 105  
 Silverman, K. 60  
 Silverman, B. 98  
 Simmons, J. 64  
 Simmons, J.D. 12  
 Singer, L.T. 25, 54, 65  
 Singer, Z. 57  
 Singh, H.D. 64  
 Singh, N. 55  
 Singh, R. 102  
 Singh, R.A. 84  
 Sinha, R. 5, 22, 57  
 Sipsma, H. 86  
 Siripurapu, K.B. 10, 113  
 Sitney, M. 55  
 Siu, E.R. 64  
 Skalski, L. 100  
 Skanderson, M. 91  
 Skelly, J.M. 58, 63, 94  
 Skinstad, A.H. 62  
 Slade, T. 64  
 Slaughter, M. 87  
 Slaymaker, V. 13  
 Sloan, D.J. 19  
 Small, W. 54  
 Smart, M. 61  
 Smart, M.J. 59  
 Smelson, D. 20  
 Smith, A.M. 10  
 Smith, D. 84  
 Smith, M. 79  
 Smith, M.A. 83  
 Smith, M.T. 96  
 Smith, P.H. 23  
 Smith, R. 19  
 Smith, S. 95  
 Smith, T.T. 58, 113  
 Smollin, M. 79  
 Sneider, J.T. 105  
 Sokolowska, M. 5  
 Solomon, L.J. 58  
 Song, R. 60, 113  
 Sorensen-Alawad, A. 109  
 Sorensen, J.L. 3, 4, 17, 70, 110  
 Sosa, A. 87  
 Soto, P.L. 7  
 Southern, M. 10  
 Spatz Widom, C. 26  
 Spear, S.E. 55, 79  
 Spellicy, C.J. 11, 12, 75  
 Spillane, N.S. 106  
 Sproule, B. 96  
 Spry, E. 55  
 Srebnik, D. 81  
 Sromek, A. 22  
 Staffa, J. 95  
 Stafford, J. 99



## AUTHOR INDEX

- Stafford, M. 20  
 Stahlberg, H. 59  
 Stahler, G. 20, 89  
 Staines, H. 14  
 Stanger, C. 56  
 Stanley, J.A. 92  
 Staton-Tindall, M. 88  
 Stehouwer, J. 113  
 Stein, E. 76  
 Stein, L. 74  
 Stein, M. 97  
 Steinberg, J.L. 103  
 Steinmiller, C.L. 92, 105  
 Stemmler, S.M. 111  
 Stenger, V. 104  
 Stephens, M. 75  
 Stephens, R.S. 106  
 Sterling, R.S. 81  
 Stern, M.F. 109  
 Stevens-Watkins, D. 78  
 Stevens, M. 59  
 Stewart, J.L. 53  
 Stewart, K.E. 77  
 Stewart, M. 61  
 Stitzer, M.L. 19, 105  
 Stoduto, G. 15  
 Stohl, M. 101  
 Stoker, A.K. 113  
 Stolf, A.R. 12  
 Stoops, W.W. 53, 79, 86, 101  
 Stotts, A. 96  
 Stout, P.R. 27  
 Stout, R.L. 95  
 Strain, E.C. 3, 17, 18, 21, 60, 67, 70, 80, 96  
 Strathdee, S. 14, 16, 17, 71, 110, 111  
 Strauss, S. 19  
 Strickland, J.C. 83  
 Striley, C.W. 14, 29, 78  
 Strobel, S. 109  
 Strothmann, K. 59  
 Sturchler, E. 10  
 Stutz, S.J. 83  
 Su, R.B. 113  
 Subbiah, R. 87  
 Subramaniam, G. 55  
 Subramanian, K. 10  
 Sugarman, D. 78  
 Suh, J.J. 57, 82, 103  
 Sullivan, M.A. 3, 9, 24, 97  
 Summers, K. 62, 88  
 Sun, P. 86  
 Sun, S. 62  
 Sun, Y. 93  
 Sunahara, R. 113  
 Sung, Y. 104  
 Surratt, H.L. 11, 17, 18  
 Sussman, S. 86  
 Suzuki, T. 8, 64  
 Sved, A.F. 58, 113  
 Svikis, D. 13, 19, 75  
 Swan, H. 17  
 Swanson, A. 53, 54  
 Swendsen, J. 57, 94  
 Swift, W. 86  
 Swinford, S.E. 83  
 Swogger, M.T. 74, 106  
 Symmes, A. 86  
 Syvertsen, J.L. 17, 71  
 Szapocznik, J. 55  
 Szobot, C. 18, 65, 80  
 Szucs-Reed, R. 57  
 Szumlinski, K.K. 11, 83  
 Taffe, M.A. 8  
 Tai, B. 100  
 Talavera, H. 19  
 Tally, L. 85  
 Tanabe, J. 99, 103, 104  
 Tanda, G. 7  
 Tapert, S.F. 53, 103  
 Tarantino, N. 110  
 Tarter, R.E. 85  
 Tate, W. 61  
 Taxman, F. 63  
 Taylor, C. 7  
 Taylor, L.R. 89  
 Teicher, M. 86  
 Teneback, C. 98  
 Tenenbaum, A. 65  
 Terdal, F. 68  
 Terplan, M. 65, 99  
 Teruya, C. 27  
 Teter, C.J. 108  
 Thacker, L. 75  
 Thamotharan, S. 85, 86, 87, 100  
 Theisen, T. 79  
 Thiels, E. 58  
 Thin Elk, E. 62  
 Thing, J. 78  
 Thomas, B.F. 10, 27, 62  
 Thomas, C. 102  
 Thomas, F.C. 20  
 Thompson-Lake, D.G. 58  
 Thompson, L.L. 99, 103, 104  
 Thompson, R.G. 77  
 Thorberg, F.A. 57  
 Thorens, G. 78  
 Thorn, D.A. 8  
 Thostenson, J. 102  
 Thurstone, C. 87  
 Tidey, J.W. 81  
 Timko, C. 89  
 Tobey, K.M. 58  
 Todorov, A. 81  
 Toll, B.A. 58  
 Toll, L. 9, 92  
 Tolliver, J.M. 109  
 Tomasi, D. 107  
 Tomiyama, K. 10  
 Tompkins, D.A. 3, 17, 67, 96  
 Tonigan, J.S. 12, 64  
 Topolski, J.M. 61  
 Torrens, M. 99  
 Torrington, M. 60, 81  
 Toumbourou, J. 55  
 Towe, S. 16, 106  
 Townsend, J.M. 4  
 Tran, E. 88  
 Tregllas, J.R. 103  
 Tremblay, J. 27  
 Trenz, R. 78  
 Trinh, T. 7  
 Tripp, J. 82  
 Trivedi, M. 96, 102  
 Tross, S. 78, 100  
 Tsai, W. 56  
 Tsay, W. 62  
 Tsuang, J. 54  
 Tsui, J.I. 9

# AUTHOR INDEX

- Tsuyuki, T. 64  
 Tuazon, E. 13  
 Tucker, A.M. 2  
 Tucker, J. 55  
 Tunstall, B.J. 85  
 Turncliff, R. 96  
 Turner, J.J. 25  
 Tuten, M. 79  
 Tyrfingsson, P. 73  
 Tyssen, R. 57  
 Tzilos, G.K. 65  
  
 Uddin, M. 76  
 Ulasek, W. 89  
 Ulibarri, M.D. 17  
 Umbricht, A. 17, 18, 67, 80  
 Un, H. 27  
 Unterwald, E.M. 92  
 Urada, D. 25, 27, 79, 88  
 Utley, J. 112  
  
 Vadhan, N.P. 53  
 Valdez, A. 18, 55  
 Vallender, E.J. 7, 76  
 Van Bockstaele, E.J. 81  
 van den Berk-Clark, C. 15, 86, 92  
 van Oort, F. 56  
 Vandrey, R. 105  
 VanVeldhuisen, P. 100, 102  
 Vanyukov, M. 85  
 Varanasi, R.K. 85  
 Varner, S.B. 13, 19  
 Vaughan, C. 23  
 Veliz, P.T. 13, 108  
 Veliz, R. 75  
 Venables, P.H. 98  
 Venner, K. 12, 64  
 Vera, A. 16  
 Vera, A.H. 14  
 Verendeef, A. 85  
 Verhulst, F. 56  
 Vernace, J.E. 102  
 Vernikovskaya, D.I. 58  
 Verrico, C.D. 11, 101, 108  
 Versek, B. 56  
 Viana, M.C. 64, 76  
  
 Vidot, D.C. 89  
 Vilardaga, R. 81  
 Vilke, G.M. 80  
 Villalobos, G. 13, 19  
 Virley, D.J. 83  
 Viswanath, H. 58  
 Vittinghoff, E. 53  
 Voas, R. 106  
 Vocci, F. 107  
 Volkow, N. 1, 100  
 Voll, R. 113  
 Vollebergh, W. 56  
 Voltes, N. 101  
 Vosburg, S.K. 3, 9  
 Vu, H.H. 62  
 Vujanovik, A. 101  
 Vurbic, D. 63  
  
 Wada, K. 10  
 Wadolowski, M. 64  
 Wagner, F.A. 56, 98  
 Wagner, K.D. 17, 110, 111  
 Wakeland, W.W. 59, 94  
 Wakim, P. 96  
 Walentiny, D.M. 58  
 Walker, R. 96  
 Wall, M. 77  
 Wallace, D. 102, 103  
 Wallace, L.S. 61  
 Walley, A.Y. 28, 109  
 Walsh, K. 23  
 Walsh, S.L. 2, 96  
 Walsh, T. 7  
 Walsh, Z. 106  
 Walters, S. 63  
 Walton, M.A. 14, 23, 77, 87, 108, 111  
 Wand, G.S. 75  
 Wang, E. 74  
 Wang, L. 111  
 Wang, X. 8, 14, 20, 58, 65  
 Wang, Y. 79  
 Wang, Z. 57  
 Ward, J.M. 76  
 Ward, M. 75  
 Warda, U. 75  
 Warner, L. 18  
  
 Warren, C. 13  
 Washio, Y. 56, 58, 94  
 Watkins, T.J. 104  
 Weafer, J. 53  
 Weaver, M.T. 13, 19, 58  
 Webb, F. 14, 78  
 Webb, S.M. 83  
 Weber, E. 16  
 Webster, D.W. 15  
 Webster, L. 14  
 Webster, L.R. 79, 95  
 Webster, M. 88  
 Wechsberg, W.M. 71, 78  
 Weerts, E. 75  
 Weidberg-López, S. 57  
 Weiler, R.M. 15, 108, 109  
 Weimer, M.B. 3, 95  
 Weimer, W. 102  
 Weinberger, A.H. 23, 99  
 Weiser, J. 86  
 Weiss, R. 12, 13, 55, 96, 104  
 Weiss, V.G. 83  
 Wells, E.A. 60, 94  
 Welsh, W. 74  
 Wendt, D.C. 94  
 Wenger, L. 78, 109  
 Wesley, M.J. 104  
 West, B.T. 108  
 Westmoreland, S. 7, 83  
 Wetherill, R.R. 3, 57, 103, 104  
 Wetherington, C. 5, 24  
 Wetter, D.W. 98  
 Wetzell, B. 10, 11, 85  
 Wexler, I.D. 65  
 Wexler, R.K. 61  
 White, H. 55  
 White, H.R. 23  
 White, J. 75  
 White, R. 104  
 White, T.J. 63, 94  
 Whitehead, N.E. 78  
 Whiteside, L.K. 108  
 Wickens, C. 15  
 Widner, G. 15, 92  
 Wiers, R. 85  
 Wiest, K. 97  
 Wigderson, S. 78

# AUTHOR INDEX

- Wildman, D. 76  
 Wiley, J. 26  
 Wiley, J.L. 27  
 Wiley, L.C. 23  
 Williams, D. 81  
 Williams, E. 23  
 Williams, T.V. 91  
 Williamson, P. 75  
 Willis, J.C. 77  
 Wilson, A. 82  
 Winhusen, T. 102  
 Winters, K. 15, 86  
 Witjtenburg, A. 57  
 Witkiewitz, K. 64  
 Witte, M.A. 83  
 Woicik, P.A. 101  
 Wong, D. 75  
 Wood, E. 25, 54  
 Woods, J. 113  
 Woods, S. 16  
 Woods, S.P. 16, 53, 54, 67  
 Woods, W.J. 54  
 Woods, W.W. 79  
 Woody, G.E. 14, 17, 55, 73, 80, 96, 97, 102  
 Woolverton, W. 22, 100  
 Wooten, N.R. 91  
 Worhunsky, P. 59  
 Worley, M. 64  
 Wouldes, T.A. 104  
 Wright, M. 54  
 Wright, N. 75  
 Wright, P.B. 77  
 Wroten, M.G. 11, 83  
 Wu, M. 65  
 Wu, R. 9  
 Wyman, Z. 97  
 Xi, Z.X. 113  
 Xie, X.B. 80  
 Xu, K. 22  
 Xu, X. 75  
 Xue, L. 4, 77, 89  
 Xue, W. 61  
 Yamashita, T.E. 109  
 Yamutewa, Y. 12, 64  
 Yan, W. 8  
 Yang, C. 10  
 Yang, R.F. 113  
 Yang, Y. 74  
 Yao, W.D. 83  
 Yarnell, L.M. 98  
 Yasuda, D. 92  
 Yates, J.R. 7, 83  
 Yeh, H.H. 59  
 Yoon, J.H. 58, 68  
 Yoon, S. 54, 65  
 Yosry, M.M. 11  
 Young-Wolff, K.C. 112  
 Young, D.A. 16  
 Young, K.A. 3, 57, 103  
 Young, R. 57  
 Young, S. 74  
 Young, S.E. 87  
 Yu, A. 103  
 Yuan, A.H. 91  
 Yuan, J. 10  
 Yucel, M. 107  
 Yuferov, V. 11  
 Yurasek, A.M. 19  
 Yurgelun-Todd, D. 104  
 Zafra, E. 18  
 Zajac, G. 89  
 Zavalza, C. 55  
 Zavaschi, M. 65  
 Zaveri, N.T. 9, 92  
 Zawertailo, L.A. 59  
 Zerbe, G.O. 87  
 Zevallos, K. 103  
 Zhan, C.G. 10  
 Zhang, H.Y. 16, 22, 113  
 Zhang, Y. 10, 83, 84, 85  
 Zheng, G. 10  
 Zhou, S. 76  
 Zhou, W. 14, 60, 76  
 Zhou, Y. 22  
 Zimam, A. 94  
 Zimmerman, M.A. 23, 87, 108  
 Zlebnik, N. 113  
 Zlotnick, C. 65  
 Zule, W. 71, 78  
 Zullig, K.J. 109  
 Zummo, J. 98  
 Zywiak, W. 95

## SYMPOSIA

Sunday, June 16

### I. *NMDA antagonists: Therapeutic implications and abuse liability*

Chairs: William Fantegrossi and Robert Balster

Drugs currently available for treatment of unipolar major depressive disorder target monoaminergic systems, have a delayed onset of action, sexual and metabolic side-effects, and possess rather unimpressive efficacy. Novel antidepressant medications with primary pharmacological targets outside the monoamine system may offer the potential for more rapid activity with improved therapeutic benefit. The glutamate system has been studied as a target for antidepressant drug discovery, but the known abuse liability of glutamatergic antagonists may limit the clinical utility of these compounds. This comprehensive series of talks will focus on glutamatergic NMDA antagonists (such as PCP, ketamine, and their analogues), both as drugs of abuse and as potential therapeutics. In this regard, recent data suggest that the NMDA antagonist ketamine is an efficacious and fast-acting antidepressant, even in otherwise treatment-resistant patients. Mechanistic explanations for these remarkable therapeutic effects are still incomplete, but likely involve more than just glutamatergic antagonism. On the other hand, the recent emergence of novel eticyclidine analogues as drugs of abuse (for example, methoxetamine), coupled with mounting evidence of the involvement of NMDA receptors in vulnerability to psychostimulant abuse, reminds us that there is significant abuse liability associated with these compounds. Finally, a historical perspective will be applied to the study of NMDA antagonists, weighing their therapeutic promise against their potential for abuse. This timely symposium will likely be of interest to clinicians and basic scientists alike.

### II. *What do we really know about the impacts of medical marijuana? Research exploring policies across America*

Chairs: Marsha Lopez and Bethany Deeds

Seventeen U.S. states and the District of Columbia have passed laws to decriminalize the use of medical marijuana in some form and other states are now considering similar changes. How is the public's health impacted by these medical marijuana policies? Does it influence local crime rates or increase recreational drug use? A great deal of heterogeneity exists among states regarding implementation and regulation of medical marijuana policy, including zoning regulations on numbers and locations of dispensaries; licensing of dispensaries; prescriber practices and compliance monitoring; identification systems for patients to obtain medical marijuana; inspections and oversight of cultivation; price and purity medical marijuana requirements; wait lists to accommodate patient demand for prescriptions; prescriber licensing; law enforcement policies and personnel to enforce restrictions on sales; and insurance regulations and requirements for cases of medical malpractice, prescription fraud, product contamination, adverse reactions, etc. This symposium highlights new research on the effects of and attitudes surrounding medical marijuana laws, regulations, and policies as they are rapidly evolving. Presentations will range from sharing preliminary local analyses of the cross-sectional

## SYMPOSIA

relationship of marijuana use with medical marijuana dispensary density across 30 cities in California; describing the beliefs and customs surrounding the medical marijuana industry in Denver, Colorado; and evaluating therapeutic and non-therapeutic marijuana use among HIV/AIDS patients in Detroit, Michigan; to an investigation of how specific dimensions of state medical marijuana laws influence recreational use and other public health harms nationally, followed by discussion of the opportunities and challenges in this emerging body of research.

Monday, June 17

### *III. The interaction between alcohol and other drugs of abuse: From neurobiology to clinical implications*

Chairs: Markus Heilig and Eric Strain

There is a considerable overlap between alcohol and other addictive drugs, both with regard to genetic risk factors, neurobiological mechanisms, and clinical manifestations. As an example, therapeutics targeting opioid (naltrexone, nalmefene), or nicotinic transmission (varenicline) have various levels of support for efficacy in alcoholism, while endocannabinoid systems are profoundly influenced by alcohol use. Similarly, clinical populations affected by alcohol and other substance use disorders overlap. This overlap is perhaps most striking between alcohol and nicotine addiction, but is increasingly also found with illicit drug use disorders. This symposium brings together scientists with expertise in complementary areas of alcohol and other drug use disorders, in order to review commonalities and differences in neurobiological mechanisms as well as clinical features of alcohol and nicotine, stimulant, cannabis and opioids use disorders. The symposium consists of four talks, each of which addresses alcohol use, and considers commonalities between alcohol and another drug class: nicotine, cocaine, cannabinoids, and opioids. While there are cultural distinctions made between licit drugs (such as alcohol) and illicit drugs (such as cocaine and cannabis), the symposium will highlight the commonalities across all drugs of abuse.

### *IV. New directions in the pharmacological facilitation of psychotherapy for drug dependence*

Chairs: Roland Griffiths and Herbert Kleber

This symposium will present new research investigating pharmacological facilitation of psychotherapy and behavior change for treatment of drug dependence. In the 1950s through early 1970s a series of studies and case reports explored whether classic 5-HT<sub>2A</sub>-mediated hallucinogens (e.g. LSD) had efficacy in treatment of alcohol and other drug dependence. Human research was subsequently halted for decades because of concern about increasing recreational abuse, media sensationalism, and an undermining of scientific credibility of research by the misadventures of Timothy Leary which resulted in regulatory and funding challenges as well as professional marginalization of clinical investigators. Although methodological limitations and procedural differences across the older studies precluded drawing any definitive conclusions about efficacy in drug dependence treatment, recent reviews and a meta-analysis suggest possible efficacy. In



## SYMPOSIA

the 1990s, research with 5-HT<sub>2A</sub> agonists (e.g. psilocybin) and NMDA antagonists (i.e. ketamine) hallucinogens was renewed. Four presentations will summarize ongoing research with these compounds with regard to drug dependence treatment for alcoholism, tobacco and cocaine dependence.

### *V. New science and tools to improve the diagnosis, prevention and treatment of hepatitis C virus and its sequelae*

Chairs: Wilson Compton and Redonna Chandler

In the United States, an estimated 5 million persons are infected with the hepatitis C virus (HCV). Most will suffer clinical sequelae, which in many cases leads to liver disease, which is the most common cause of death for this population. Hepatitis C is also the leading indication for liver transplantation in the U.S. Deaths from HCV have been increasing each year, until they surpassed the deaths from HIV/AIDS in 2007. This fact makes HCV not only the most prevalent blood-borne viral disease in the U.S., but the deadliest. Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). Up to 90% of HIV-infected IDUs are also infected with HCV. To more accurately identify persons infected with HCV, point of care testing has recently been approved by the FDA. This will allow providers to provide rapid HCV testing and initiation into care. Additional testing that will be able to distinguish between acute and chronic infections could assist in tracking infections, and may be available relatively soon. This symposium will update participants on the new developments in the three main areas of HCV care; prevention, diagnosis, and treatment. The Viral Hepatitis Action Plan, which is part of the Healthy People 2020 goals, will also be discussed briefly. The changes brought about by the Affordable Care Act should further improve the status of diagnosis, prevention, and treatment of the Hepatitis C virus.

### *VI. Sex hormone modulation of nicotine reward: Effects on urges, affect, physiological response, and brain activation*

Chairs: Sharon Allen and Cora Lee Wetherington

Women tend to respond less favorably to smoking cessation pharmacotherapy. Evidence for an association between sex hormones and drug abuse behaviors continues to accumulate. Preclinical and clinical studies suggest that sex hormones may modulate the reward system and related nicotine response. Animal studies provide strong evidence that progesterone is protective against, whereas estrogen promotes, drug abuse behaviors. The clinical literature is less clear but recent work provides support for this theory. Specifically, high levels of estrogen are associated with a heightened response to nicotine, whereas high levels of progesterone are associated with a blunted nicotine response. This symposium will present the latest research on this association of sex hormones with neural, subjective, physiological and affective responses to nicotine cues, acute nicotine administration and nicotine withdrawal. Presentations include associations between allopregnanolone, a progesterone metabolite, and affect during short-term smoking cessation in premenopausal women; menstrual phase differences in fMRI response during smoking cue exposure; and associations between sex hormone levels on subjective and physiological responses to intravenous nicotine with overnight abstinence.

## SYMPOSIA

Overall, these findings further our understanding of roles for sex hormones in nicotine dependence. To improve cessation rates it is crucial that we continue to explore the role of sex hormones with the ultimate goal of developing directed interventions to promote cessation and prevent relapse for women.

### VII. *Childhood maltreatment and substance abuse: New findings on a complex relationship*

Chairs: Deborah Hasin and Cathy Spatz Widom

Childhood maltreatment has long been associated with substance abuse problems, but many questions about this relationship remain. Cross-sectional studies indicate strong associations, but prospective longitudinal studies are not as consistent, suggesting that these relationships may be more complex than previously assumed. Three presentations draw on very different sources of information. The first presentation is a prospective cohort study from a US Midwestern county in which documented cases of childhood physical and sexual abuse and neglect were compared to a demographically matched control group, both followed up over 30 years in several waves of interviews and data collection efforts (most recently in 2010). Trajectories are examined for drug use and abuse from the first to last interviews when the participants were approximately 47 years old. The second is a presentation from a survey of Israeli adults that examines childhood maltreatment as a sensitizer to genetic and other environmental risk factors for heavy drinking and alcohol disorders. These include (a) a genetic variant (ADH1B) that influences the risk of alcohol disorders, and (b) level of exposure to the 2006 Lebanon War. The third is a presentation from a prospective study of a large national sample of U.S. adults (NESARC), examining the relationship of childhood maltreatment to the *persistence* of adult substance use disorders (alcohol, drug and nicotine) across three years of follow-up, and potential mediators of this relationship through other psychopathology, e.g., personality disorders and PTSD. Implications for prevention and intervention will be discussed.

### VIII. *Pharmacotherapeutic targeting of glutamatergic signaling in the reversal of addiction pathology*

Chairs: Cassandra Gipson and Erin McClure

In the search for effective pharmacotherapeutic medications to treat addiction, a number of promising agents have been identified throughout the years. However, these agents tend to be specific to the substance of abuse or addictive disorder, and do not always show long-term efficacy in the treatment of addiction. Thus, new targets for pharmacotherapy that span multiple addictive behaviors would be beneficial and would help to demonstrate potentially overlapping mechanisms in addiction. This translational symposium will include preclinical and clinical components and has two specific aims: (1) Present data on novel preclinical mechanisms of addiction, and demonstrate preclinical efficacy of pharmacotherapies including N-acetylcysteine (NAC), a widely available glutamatergic agent, in reversing alterations in glutamatergic signaling in addiction and relapse, and (2) Demonstrate clinical efficacy of NAC in the treatment of smoking, cannabis dependence, and pathological gambling. Specifically, preclinical data

## SYMPOSIA

will establish novel alterations in synaptic plasticity involved in nicotine withdrawal and relapse, and will focus on potential new glutamatergic targets that may be important pharmacotherapeutic avenues in reducing nicotine addiction and relapse. Clinical data will then be presented on tobacco outcomes during a NAC-assisted cannabis cessation clinical trial in adolescents, as well as outcomes on pathological gambling behavior in a randomized controlled trial using NAC. Thus, the goal of this symposium is to inform both preclinical and clinical researchers on the translational efficacy of glutamatergic agents in the treatment of various types of addictive behaviors.

Tuesday, June 18

### *IX. Preclinical to clinical evidence that glia and neuroinflammation mediate drug abuse and related pathologies*

Chairs: Patrick Beardsley and Kurt Hauser

Accumulating evidence has promoted an elevated level of importance of the activity of glial cells and neuroinflammatory processes in pathologies associated with drug abuse. The extensiveness of these data, and their implications, have now justified initial evaluations of glial cell modulators in the treatment of opiate and methamphetamine abuse. The overall aim of this symposium is to provide preclinical examples of the range of drug-abuse-associated effects in which the glia may be involved, while providing recent clinical results involving glial modulators in participants who abuse drugs. The first presentation will highlight the concept that neuroAIDS is principally a glial-driven disease, and that opiate abuse acts through multiple glial cell types to disrupt neuronal function. The second presentation will provide an introduction to the emerging preclinical evidence that pharmacologically manipulating glial and neuroinflammatory activity affect behaviors predictive of continued drug seeking with an emphasis on methamphetamine-associated behaviors. The third and forth presentations will review recent clinical data involving the effects of glial cell modulators. The third presentation will describe preliminary results of studies examining the ability of three glial inhibitors (ibudilast, minocycline, and pioglitazone) to modify the pharmacodynamic effects of opioids in opioid abusers. The final presentation will show the results of an interim analysis that supports advancement to Phase II testing with the glial modulator, ibudilast, in the treatment of methamphetamine abuse. The symposium will conclude with a brief discussion of implications of the presented research on the future development of anti-addiction medications targeting glial dysfunction

### *X. Substance use: Health and social effects in older drug users: What we know and we don't*

Chairs: Nicholas Lintzeris and Michelle Lofwall

The number of adults aged 50+ with substance use disorders (SUD) is projected to double by 2020 in many western societies due to the ageing population and high levels of substance use among 'baby boomers'. Despite this expected increase in older people with a history of SUD, little is known about the physical, psychiatric, cognitive and social

## SYMPOSIA

implications of SUD in the elderly – the theme of this symposium. Data on recent and lifetime substance use, mood, cognition, medical history, health status, psychosocial function, medication history, and recent health service use from two concurrent studies of aging patients in the South East Sydney, Australia will be presented. Trends over the last decade in non-alcohol substance use, including illicit drugs and non-medical use of prescription therapeutics, among older people from the National Survey on Drug Use and Health, Treatment Episode Data Set and Drug Abuse Warning Network and related mortality in older people will be discussed. In addition there will be a discussion of epidemiological data from the Australian Longitudinal Study on Women's Health using data linkage to describe substance use in Australian women and prevalence of prescription opioid use in the three birth cohorts in the study. Data on cognitive, social, neural function and brain structure in long-term, aging cocaine smokers relative to age-, other drug-, and demographically matched controls and data related to hippocampal volume and associated cognitive function in cocaine users and controls will also be presented.

Wednesday, June 19

### *XI. Emerging data on efficacy and clinical applications of extended release naltrexone formulations*

Chairs: George Woody and Porarinn Tyrfingsson

Agonist maintenance with methadone and buprenorphine-naloxone is a highly effective treatment for opioid dependence but not always available, and some patients reject it while others accept it but continue using opioids or other drugs, notably benzodiazepines and stimulants. Naltrexone could be a meaningful alternative for some patients because it blocks opioid effects and does not interact with benzodiazepines or stimulants to produce a “high”, however early studies found that low patient interest and poor adherence to the oral formulation limited its effects. Extended release formulations, both injectable and implantable, were developed to address the adherence problem, and much of the work has been done outside the U.S. This symposium will present the results of these international studies by individuals who did them, along with findings from more recent studies exploring the efficacy of naltrexone for treating amphetamine dependence. Work on the efficacy of oral, implantable and injectable naltrexone for opioid dependence in Russia, and data from a study evaluating patient interest in extended release-injectable naltrexone (XR-NTX) vs. buprenorphine-naloxone for opioid addiction treatment in Norway will be reviewed. Data on the efficacy of XR-NTX on treating amphetamine addiction in a recently completed study in Iceland, and on the safety and efficacy of the Australian naltrexone implant for treating alcohol, amphetamine, and opioid addiction, will be presented.

## SYMPOSIA

### XII. *Behavioral disinhibition, drugs of abuse, and brain dysfunction in humans and rodent models*

Chairs: Barry Setlow and Thomas Crowley

Shared genetic mechanisms underlie the strong comorbidity of antisocial behavior, substance use disorders (SUD), impulsivity, and Attention-Deficit/Hyperactivity disorder; considered together as "behavioral disinhibition" (BD), the joint heritability for these disorders is 0.8. BD-related behaviors and P300 abnormalities in children (before drug exposure) predict SUD and antisocial problems in adulthood, suggesting that BD begins with underlying, early-onset, persisting brain abnormalities. Then, when SUD develops in persons with BD, the drugs may further alter brain function, worsening BD. Fortunately, animal models of BD can help disentangle antecedent brain abnormalities from subsequent drug-induced abnormalities. This panel addresses BD-related brain dysfunction in both humans and rodent models. Topics include the conceptual framework of BD in human research and findings from longitudinal twin studies; whole brain fMRI data showing profoundly impaired neural decision-making as adolescent patients with severe antisocial and substance problems (*i.e.*, BD) contemplate cautious or risky behaviors; individual differences in impulsivity resulting from a homeostatic imbalance in nucleus accumbens 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors and novel pharmacotherapeutic strategies; individual differences in risk-taking linked to corticostriatal dopamine signaling that predict later cocaine self-administration; and chronic cocaine self-administration causing lasting elevations in risk-taking and impulsivity.

### XIII. *New tools provide new insights into methamphetamine's actions*

Chairs: David K. Grandy and David Shurtleff

Worldwide, the number of people abusing methamphetamine (METH) continues to increase. METH burdens communities with its demands on healthcare, criminal justice, and child welfare services while taking its toll on the emotional and psychological wellbeing of users and their families. Although a vast experimental literature implicates the dopamine and vesicular monoamine transporters as *the* important targets of AMPH and METH, this knowledge has not led to the development of a single FDA-approved treatment. In 2001 *in vitro* experiments revealed AMPH and METH are potent full agonists of trace amine-associated receptor 1 (TAAR1), a G protein-coupled receptor that is expressed in a variety of cell types, including neurons and leukocytes. This finding revealed a previously unrecognized fundamental gap in our knowledge about how these drugs work that is now being explored using recently developed novel small molecules and peptides. This symposium will showcase the work of four leaders in the field who are using these new tools to better understand the molecular mechanisms underlying METH's actions both *in vitro* and *in vivo*. The aim of this symposium is to inform attendees about the new mechanisms of METH's actions that are being revealed using recently developed small molecules and peptides.

## SYMPOSIA

### XIV. *This is your brain before drugs: Neuroimaging high-risk youth*

Chairs: Leslie Hulvershorn and Joanna Jacobus

A large body of research in human brain imaging and animal models has confirmed that, across the brain, drugs of abuse negatively impact neural structures and functioning. However, neurobiological characterization of youth determined to be at high genetic and/or phenotypic risk for the development of substance use disorders (SUDs) suggests that functional and structural deficits may also *precede* substance use and may have value in predicting addiction course. In this symposium, we aim to introduce the audience to the emerging field of addiction risk neuroimaging. Data will be presented from three recent neuroimaging studies of youth considered to be at increased risk for the eventual development of SUDs. Speakers will address functional circuitry underlying addiction-relevant psychological impairments, including deficient reward processing, emotion regulation and impulse control. Brain structure (i.e., structural volumes, white matter integrity) as a predictor of later substance use will also be addressed. Implications for linking this neuroscience perspective on addictions risk to preventive and treatment interventions will be discussed.

### XV. *Use it AND lose it: Impact of a pharmacological pot pourri on the developing brain*

Chairs: Scott Lukas and Staci Gruber

Adolescence is a time of neuromaturation during which the brain is *more* vulnerable to the effects of drugs and alcohol than the adult brain. This symposium offers insights on the impact of early onset substance use on brain structure and function, and brings together findings from the most commonly used substances among adolescents and emerging adults. Recent work showing that that regular use of marijuana prior to age 16 results in both increased frequency and magnitude of regular use in adulthood, as well as neurocognitive, structural and functional brain differences (relative to those who begin smoking later) will be compared and contrasted with data showing that earlier age of onset of alcohol drinking is associated with significantly poorer visual memory in emerging adult binge drinkers, even after controlling for confounding variables. Data will be presented demonstrating that prefrontal cortical activity during the performance of an inhibitory control task and risky decision-making is related to indices of smoking behavior and nicotine dependence in late adolescent/early adult smokers, suggesting that nicotine use during adolescence may influence the trajectory of brain development. Collectively, these data provide clear evidence of how early exposure to drugs and alcohol impact the developing brain and underscore the need for increased efforts to engage in early interventions aimed at delaying the onset of drug use beyond the developmental years. Future challenges will be to integrate these imaging and neurocognitive results into a “package” that can be used by clinicians for individualized therapy.



## SYMPOSIA

Thursday, June 20

### XVI. *Brain functional connectivity as a biomarker for stimulant abuse*

Chairs: Leonard Howell and Anna Rose Childress

There is growing interest in functional connectivity magnetic resonance imaging (fcMRI) to provide biomarkers for psychiatric and neurological diseases and to predict individual responses to treatment. However, few fcMRI studies have been performed in the context of drug addiction. Technical and analytical procedures to examine functional brain networks in nonhuman primates will be described. The results indicate that brain network integrity and spatial extent of brain networks predict cocaine self-administration and drug consumption. Brain network changes that occur during drug abstinence in human cocaine users provide important information about prognosis and should guide new approaches for intervention. Current studies that employ interleaved Transcranial Magnetic Stimulation (TMS) and BOLD fMRI to quantify mesolimbic and mesocortical connectivity in cocaine-dependent subjects suggest that cocaine users have selective dysfunction in mesolimbic circuitry while mesocortical circuitry appears to be intact. Resting-state functional connectivity data from a large sample of healthy human subjects, evaluating the functional connectivity of dopaminergic regions, and data suggesting hypo-connectivity in dopaminergic pathways in cocaine addiction will be presented. The effects of methylphenidate on these networks will be evaluated. These findings hold significant promise for fcMRI with important implications for future treatment approaches in stimulant abuse.

### XVII. *Cannabis: From plants to rats, monkeys and humans*

Chairs: Iain McGregor and Margaret Haney

This symposium will highlight key preclinical and clinical research developments in cannabis use disorders and highlight clinically relevant issues in treating cannabis users. Topics discussed will include the cannabis plant and how differences in the type of cannabis consumed may affect clinical outcomes; the clinical significance of “reintoxication” whereby THC can be released from fat stores by exercise, fasting or stress, causing a spike in blood THC levels; the effects of early and heavy cannabis on brain volume and connectivity, as well as its effects on memory and discuss the relationship of cannabis use to the development of psychotic symptoms; effects of cannabis on adolescent brain function; the use of exercise as an adjunct in the treatment of persons with cannabis use disorders. The utility of DSM 5 in diagnosing and treating cannabis use disorders and psychosocial interventions for cannabis dependence will be reviewed. Results from recent clinical trials (including the cannabis buccal spray nabiximols and an exercise study) will be reported. The pharmacological treatment of cannabis dependence and the effects of a range of medications on cannabis intoxication, withdrawal and relapse will be discussed.

## WORKSHOPS

Sunday, June 16

### *I. The intertwining epidemics of drug use and HIV/AIDS: The HIV/AIDS workgroup*

Chairs: Don Des Jarlais and James Sorensen

Groundbreaking randomized controlled trials have demonstrated that expanded access to anti-retroviral therapy (ART) can decrease HIV incidence. Because drug users were excluded in many of these trials, there is a critical need for research to inform the integration of biological and behavioral approaches to HIV/AIDS prevention with drug users. The overarching goal of the workshop is to provide a forum to examine how clinical and translational drug use research can inform the development of bio-behavioral HIV/AIDS prevention interventions. Specifically, we will highlight clinical research to examine methods of optimizing health outcomes and decreasing HIV transmission risk among HIV-positive drug users. We will also examine cutting-edge bio-behavioral approaches to prevent HIV seroconversion in both injection and non-injection drug users. Ultimately, this workgroup represents a critical opportunity to begin to bridge the boundaries that have divided substance use research and HIV/AIDS prevention research in order to optimize bio-behavioral HIV/AIDS prevention efforts with drug users.

### *II. Assessment of abuse-deterrent and tamper-resistant technologies*

#### *Part II: New directions*

Chairs: Marta Sokolowska and Kerri Schoedel

Prescription drug abuse is a multidimensional problem and one of the major public health concerns in the United States today. Formulation tampering has been recognized as an important contributing factor. This is particularly problematic for extended-release opioid medications, where the drug release mechanism of the pill can be circumvented enabling immediate access to a large dose of medication, suitable for administration via unintended routes. Abuse-deterrent formulations (ADFs) are being developed with the goal of decreasing the public health risk of prescription opioid abuse by altering medication tampering behaviors. Recently policy and regulatory initiatives have been proposed to assist ADFs development including introduction of the Stop Tampering of Prescription Pills Act of 2013, or STOPP Act or the FDA Draft Guidance for Industry: Abuse Deterrent Opioids – Evaluation and Labeling. It is anticipated that the latest developments will have a widespread impact on the development and scientific assessment of ADFs thus the objectives of this session are to: a) discuss the most recent recommendations; b) compare the recommendations with the current approaches for assessing abuse deterrence focusing on in vitro, clinical and epidemiological studies; c) examine strengths and limitations of these approaches; d) highlight the policy and regulatory initiatives that may impact ADF developments in the near future.

## WORKSHOPS

### III. *Animal models of sex differences and drug abuse: Mind the gaps*

Chairs: Suzette Evans and Cora Lee Wetherington

The goal of this workshop is to bring together pioneering investigators in the field to engage in a dialogue among basic, preclinical, human laboratory, and clinical researchers with the goal of improving animal models and treatment and prevention strategies, with an emphasis on sex/gender, other phenotypic characteristics, environmental factors and their interaction with each other. The session will begin with a dynamic keynote speaker who will lay the groundwork for why studying sex differences in neuroscience matters. Speakers will then review selected topics for which we have the best knowledge related to sex differences and drug abuse. While broad, these topics will include 1) triggers to relapse, 2) social and environmental factors, 3) phenotypic variables and 4) correspondence and bi-directionality of human and animal laboratory models. Each speaker will review the available animal model(s) for that topic, and highlight key findings from their laboratory, as well as others. Each talk will not simply extol our progress, but will critically examine what these models have contributed to the field in general and specifically to sex differences. Each speaker will challenge the current prevailing framework and conclude with 1) where improvements can be made to the existing models and 2) where there is a lack of appropriate paradigms “modeling” relevant clinical conditions. Time for an interactive discussion with the speakers and audience will follow to further discuss how to improve the translational value of laboratory models.

### IV. *How are we doing? Measuring quality of care for adolescent abuse treatment*

Chairs: Beth Ann Griffin and Rajeev Ramchand

Drug treatment programs for youth have a history of low rates of success and many youth in treatment do not improve. Quality of care provided by these programs must get better. Federal policy, including the Affordable Care Act and SAMHSA’s Framework for Quality Improvement in Behavioral Health Care, have called for establishment of a strategic plan for improving delivery of health care services and achieving better client outcomes using quality indicators to monitor programs and drive reform. In spite of increased attention being placed on performance measurement for the types of treatment programs most youths enter in this country, few practices or processes have been shown to reliably predict client outcomes. Whereas other sectors of the healthcare system have fully developed systems measuring provider performance, such systems are in the development phase for alcohol and drug treatment services generally and for adolescent services in particular. This workshop aims to advance performance measurement for substance abuse treatment for adolescents by (i) identifying good candidates for measuring quality of care for adolescents, (ii) describing which measures have actually been linked to superior outcomes, (iii) summarizing availability and receipt of quality treatment components in community programs, and (iv) delineating what gaps exist in

## WORKSHOPS

measuring quality of care for this particular subgroup. It is critical to identify good quality indicators for adolescents to ensure that parents, policymakers, and payers have the information necessary to ensure adolescent clients are being provided with effective treatments and to drive market forces to encourage adoption of these practices.

### *V. Epidemiology and public health research methods*

Chairs: J. Anthony and Georgiy Bobashev

This workshop is geared towards those doing research in epidemiology, prevention and public health. Included among the topics will be methods of analysis of complex data, a discussion of the National Addiction & HIV Data Archive Program, methods of research on cannabis smoking, and how to access data from the U.S. National Survey on Drug Use and Health.

Monday, June 17

### *VI. The 19th Annual Contingency Management Working Group*

Chairs: Kelly Dunn and Kathryn Saulsgiver

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the dissemination and discussion of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 19th Annual Meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

### *VII. Take-home naloxone to address opioid overdose: State of the evidence and methods*

Chairs: Alexander Walley and Phillip Coffin

Substantial annual increases in opioid-related overdose deaths in the United States since the early 1990s have resulted in drug poisoning becoming the leading cause of injury death. Many communities have responded by providing overdose prevention education and distributing naloxone for lay administration (“take-home naloxone” or THN) to opioid users and their social networks. Naloxone is an opioid antagonist and the standard antidote to an opioid overdose. THN has been recognized by the American Medical Association and the World Health Organization as a promising intervention to address the overdose epidemic. Existing research has demonstrated the acceptability, feasibility, and successful implementation of THN, and ecologic studies have observed short-term community-level reductions in mortality after implementation of THN. However, important research questions remain, including outcomes in randomized controlled trials,

## WORKSHOPS

long-term impact, implementation among different groups of opioid users, and identification of the key components of THN interventions. While implementation expands, the methods for studying THN as an intervention to reduce overdose fatalities are at an early stage. The aim of this session is to describe the current state of the evidence and research methods for THN. We will present the findings and methodological approaches from the latest THN research studies underway, including randomized trials to determine effectiveness, ecological analyses of the population impact, a feasibility study assessing individual intervention components and outcome measure development, and mathematical modeling of cost-effectiveness and population outcomes.

VIII. *The interplay of the juvenile justice and adolescent treatment systems and how to use evidenced-based assessment, treatment and implementation practices to improve outcomes*

Chairs: Michael Dennis and Redonna Chandler

Over two-thirds of the youths in the juvenile justice system report three or more major clinical problems related to addiction, mental health, crime, violence, victimization, homelessness, or HIV-risk behaviors. Moreover, almost half of the adolescents entering treatment were referred by the justice system and over two-thirds are involved in it to some degree. This workshop will focus on the interplay of the juvenile justice and adolescent treatment systems and examine how to use evidenced-based assessment, treatment and implementation practices to improve outcomes.

IX. *Evaluating and minimizing the risk, misuse and diversion of prescription drug use in youth*

Chairs: Linda Cottler and Sidney Schnoll

This workshop will focus on the use, misuse, diversion and etiology of prescription stimulant and opioid use among youth as young as 10 years of age. Risk factors ranging from gender, age, geographic location, parental behaviors, grades, other illicit drug use, ADHD, depressed mood and other factors will be explored. Outcomes assessed will include recent use, misuse (comprehensively described), and incoming and outgoing diversion from national samples of youth. In addition to a discussion on methods for data collection among this age cohort, we will detail specific ideas from teens on how we can prevent misuse and diversion at this time of the epidemic. Experts in post-marketing surveillance, as well as epidemiological methods will be involved. Attendees will be exposed to state-of-the-art methods of signal detection and assessment of factors that are associated with these outcomes.

## WORKSHOPS

Tuesday, June 18

### *X. How to get your addiction research manuscripts published:*

#### *Guidelines for emerging investigators*

Chairs: James Sorensen and Carmen Masson

With the rapid expansion of the Internet and electronic communication options, the addiction research field needs increasingly productive investigators who create high-quality scientific reports. This practical workshop focuses on development of manuscripts for publication. Presenters include productive junior and senior investigators spanning both preclinical and clinical research and the editors of two of the prominent addiction research journals. All presenters suggest both conceptual and practical guidelines. While the workshop is aimed at assisting young investigators, seasoned colleagues can also benefit and provide their perspective. In this interactive workshop, one third of the time is reserved for audience questions, comments, and discussion.

### *XI. Findings from introduction of reformulated opioid analgesics on patterns of abuse and diversion of prescription opioids and their surveillance*

Chairs: Edward Sellers and Paul Coplan

The workshop will explore what has been learned about surveillance systems of substance abuse when an abuse-deterrent formulation of extended-release oxycodone was introduced. Extended-release oxycodone was used widely to treat pain, but was also abused, particularly through non-oral routes that required manipulation of the tablets. . The rapid transition to a formulation with physicochemical barriers to crushing and dissolving to be more difficult to manipulate for abuse provides an opportunity to understand the measurement characteristics of the six surveillance systems that were in place to measure the effects of the transition. Presentation 1 describes findings from a national surveillance system of poison centers, including the persistence of adverse events due to the old formulation that were reported to poison centers and concordance of trends between different types of poison center mentions affecting those who abused, as well as those using the drug therapeutically. The presentations summarize findings from a national surveillance system of substance abuse treatment centers, including duration of continued abuse of the original formulation, changes in source of acquiring ER oxycodone, and evidence of switching from one opioid to another, describe findings from national studies of diversion events and doctor-shopping and discuss using epidemiologic studies to validate forensic and behavioral pharmacologic research.



## WORKSHOPS

### XII. *Early Career Research and Secondary Data Analysis*

Chairs: Amy Pienta and Kaye Marz

Early career investigators (junior faculty, postdoctoral fellows and graduate students) are invited to attend an evening workshop providing information about the use of secondary data in one's research. Research addressing problems related to drug dependence and abuse using secondary data is more viable than before given the availability archived data through the University of Michigan's National Addiction and HIV Data Archive Program (NAHDAP) funded by the National Institute of Drug Abuse. This workshop will provide an overview of the benefits and challenges associated with secondary data use for the substance abuse research community including cost-effectiveness, availability of various types of secondary data, sample size and issues of representativeness, breadth and depth of secondary datasets, common analytic techniques, understanding disclosure risk, access to secondary data sources containing identifiers (direct and/or indirect) of study participants, and preparing a restricted data use agreement (RDU). The workshop will also provide a dynamic presentation of the NAHDAP website including: searching for secondary data sources, locating sources of data outside NAHDAP, variable searching, variable comparisons across studies, related bibliographic search, and online data analysis. The wealth of data and related resources of NAHDAP have considerable potential to benefit the early career scientist working in the area of substance abuse research. This workshop will help those interested in gaining access to these kinds of resources.

### XIII. *Novel tobacco and nicotine products and regulatory science*

Chairs: Dorothy Hatsukami and Stacey Sigmon

The tobacco market is evolving with the availability of a plethora of new tobacco and nicotine products of varying types and degrees of abuse liability and harm. These products range from oral tobacco products to electronic nicotine delivery cigarettes to pure nicotine inhalation devices. These products are advertised for use in situations when a smoker cannot smoke or as a product to use instead of cigarettes. As a result, the distinction between a product to be used for recreational purposes and for cessation is becoming blurred. The major challenge is determining how best to evaluate and regulate these products. The goal of this symposium is to describe the current Family Smoking Prevention and Tobacco Control Act, the current and future tobacco/nicotine market, the research priorities of the FDA Center for Tobacco Products and how CPDD researchers can contribute to tobacco regulatory science.

## WORKSHOPS

### *XIV. Are we missing the mark with gender differences, women substance users, and social determinants for HIV risk? Lessons from around the globe*

Chairs: Wendee Wechsberg and Steffanie Strathdee

Reaching vulnerable women who use drugs and alcohol and their partners in different global settings offers many lessons. In some settings they are very hidden and often stigmatized if they try to seek help. In other settings, they are more open about their drug use, and often use with partners. Most of these women are of childbearing age, many engage in sex work, and many use both injection and non-injection drugs and alcohol. Intersecting risks include STI and HIV in addition to gender-based violence; other social determinants vary by setting. This workshop will examine gender differences in the social determinants of substance use and HIV risk including stigma, structural and cultural barriers to treatment, and the influence of intimate partnerships and opportunities for effective interventions, particularly those related to gender equity and access to HIV prevention and treatment. Presenters will challenge prevailing wisdom and explore new avenues for research by offering lessons learned from different regions of the world.

### *XV. Approaches for screening and treating risky drug using patients in community health centers*

Chairs: Lillian Gelberg and Ronald Andersen

Use of illegal drugs and prescription medications with addictive potential are leading causes of disability, crime, and socioeconomic impoverishment. This adverse health behavior is as common and costly as coronary artery disease and depression. Early detection and management of casual or regular drug use can be a feasible and effective way to interrupt progression to dependence. Primary care settings offer an important opportunity for intervening on risky drug use. The NIDA-funded UCLA Quit Using Drugs Intervention Trial (QUIT) is the first US RCT that is powered to detect the effect of a primary care clinician delivered very brief intervention protocol (adapted from the W.H.O. ASSIST Trial) for reducing ‘at risk’ drug use and drug-related harm among diverse, low-income adult patients at federally qualified health centers (FQHCs) in Los Angeles. We have screened 2,600 patients for drug use and enrolled 400 in the trial (goal of 480). This workshop presents methods and findings from this important study, focusing on (1) conceptual model; (2) prevalence of risky drug use in FQHCs; (3) patients’ barriers to reducing drug use; (4) effectiveness of QUIT for reducing risky drug use; and (5) finally, we present an approach for applying the ASSIST/QUIT model for an international collaborative study aimed at reducing risky drug use of primary care patients on both sides of the Mexico-US border, funded by the State Department and NIDA as part of the 9th Bi-National Mexico-US Drug Demand Reduction Meetings.

## **Acknowledgements and Advertisements**

The following organizations have financially supported the work  
of the CPDD organization during the past year

**Collegium Pharmaceutical, Inc.**

**CSAT (Center for Substance Abuse Treatment)**

**Grunenthal USA, Inc**

**NIDA (National Institute on Drug Abuse)**

**The Harris Family Foundation**

**Vince & Associates Clinical Research**

Funding for this conference was made possible (in part) by  
Grant Agreement # R13 DA 013192 from NIDA.

The views expressed in written conference materials or publications and by  
speakers and moderators do not necessarily reflect the official policies of the  
Department of Health and Human Services; nor does mention of trade names,  
commercial practices, or organizations imply endorsement by the U.S.  
Government